

**A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab for the treatment in patients with unresectable or metastatic BRAF V600 mutant melanoma**

**Name(s) of the test product(s):** Cobimetinib, Vemurafenib, Atezolizumab

**Indication:** Unresectable or metastatic BRAF V600 mutant melanoma

**Clinical trial phase:** Phase II

**Short Title / Acronym:** ImmunoCobiVem

**Protocol number:** ImmunoCobiVem\_2015

**EudraCT Number:** 2015-005097-37

**Study start date – Study end date / data cut-off date**

[REDACTED] 2016 (date first patient enrolled) – [REDACTED] 2024 (date 48 months after the last patient was randomized) / 09 July 2024

## **Clinical Study Report**

### **Sponsor's Responsible Medical Officer:**

University Hospital Essen, Hufelandstraße 55, D-45122 Essen, Germany

Represented by [REDACTED]

Department of Dermatology, Skin Cancer Center, Comprehensive Cancer Center Essen, [REDACTED], Germany

Phone: [REDACTED] / Fax: [REDACTED]

E-Mail: [REDACTED]

### **Principal / Coordinating Investigator:**

[REDACTED], Department of Dermatology, Skin Cancer Center  
Comprehensive Cancer Center Essen, [REDACTED], Germany

The study was performed in compliance with International Council for Harmonisation (ICH) guideline on Good Clinical Practices (GCP), including the archiving of essential documents.

**Version / Date:** Final 1.0 / 10 March 2025

<Confidential>

## SYNOPSIS

<b>Name of Sponsor:</b> University Hospital Essen, Hufelandstraße 55, D-45122 Essen, Germany Represented by [REDACTED]	
<b>Name of Finished product:</b> Cobimetinib (Cotellic®), Vemurafenib (Zelboraf®), Atezolizumab (Tecentriq®)	
<b>Active Ingredient:</b> Cobimetinib (Cotellic®), Vemurafenib (Zelboraf®), Atezolizumab (Tecentriq®)	
<b>Study title:</b> A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab for the treatment in patients with unresectable or metastatic BRAF V600 mutant melanoma <b>Trial registry name and number:</b> Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma; ClinicalTrials.gov ID NCT02902029 <b>Protocol number:</b> ImmunoCobiVem_2015	
<b>Principal / Coordinating Investigator:</b> [REDACTED] Department of Dermatology, Skin Cancer Center Comprehensive Cancer Center Essen [REDACTED], Germany	
<b>Study sites:</b> 22 sites in Germany, 5 sites in France, 1 site in Greece, 1 site in Serbia	
<b>Publication:</b> [REDACTED] et al. Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF V600-positive melanoma: Interim analysis of the ImmunoCobiVem study. 2022 ASCO Annual Meeting. Abstract 9548. [REDACTED]. Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAF V600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial. Eur J Cancer. 2023 Sep;190:112941 [REDACTED]. Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial. 2024 ESMO Annual Meeting. LBA45 [REDACTED], et al. Adjuvant treatment of patients with stage III melanoma: 4-year follow-up time of multicenter real-world study. 2024 ESMO Annual Meeting. 1124P [REDACTED]. Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: Final results of the randomized phase II ImmunoCobiVem trial. <i>In preparation</i>	
<b>Study Period:</b> [REDACTED] 2016 (date first patient enrolled) – [REDACTED] 2024 (date 48 months after the last patient was randomized) <b>First patient in:</b> [REDACTED] 2016 <b>Last patient out:</b> [REDACTED] 2024 / <b>Data cut-off date:</b> 09 July 2024	<b>Phase of development: II</b>
<b>Result analysis stage:</b> final stage, date of global end of the study: [REDACTED] 2024	

**Background and rationale for the study:** Cutaneous malignant melanoma is the most aggressive form of skin cancer that once it has spread to distant organs rapidly becomes life-threatening. If detected in an early-stage, surgical excision is curative in > 90% of cases. For advanced melanoma, the relative 5-year survival rate for stage IV is 41% for women and 40% for men in Germany. Approximately 60% of advanced melanoma harbor a mutation in the gene encoding the serine/threonine protein kinase BRAF, with V600E mutations accounting for the majority of 70-80% of all cases.

Targeted therapy with selective BRAF inhibitors in combination with MEK inhibitors has improved patient outcomes in patients with unresectable or metastatic BRAF-mutant melanoma, especially in those with rapid disease progression. However, even with high response rates, some patients remained unresponsive to targeted therapy. Among patients with good responses, some patients were refractory due to the emergence of resistance, as evident by disease relapse after partial or complete remission. Immunotherapy using antibody-mediated blockade of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) with ipilimumab or inhibition of the immune checkpoint programmed cell death protein 1 (PD-1) with nivolumab or pembrolizumab has further improved patient outcomes.

In recent years, the treatment of advanced melanoma has been transformed by the emergence of immunotherapy (use of immune checkpoint inhibitors) and targeted therapies. The complementary response kinetic of such treatment approaches, supported by mechanistic evidence that targeted therapy affects immune aspects of the tumor microenvironment, suggests that an optimal combination or sequencing of immune checkpoint inhibitors and targeted therapy may provide additional clinical benefit. Sequencing the two clinically effective approaches, i.e., targeting the mutant BRAF pathway and the immunological checkpoint, should prolong tumor control, PFS, and OS even further. However, the best sequencing strategy was unclear.

This prospective, open-label, multi-center clinical trial addressed efficacy and safety of the superior sequencing strategy for sequentially targeting the BRAF/MEK pathway with a combination of vemurafenib and cobimetinib and targeting immune checkpoint control with an antibody against PD-L1 (MPL3280A, atezolizumab) in patients with unresectable or metastatic BRAF V600 mutant melanoma. After a 3-month run-in phase in which all patients were treated with vemurafenib + cobimetinib, all patients without tumor progression were randomized to one of two treatment arms. It was analyzed whether continuation of the BRAFi/MEKi combination until tumor progression and subsequent crossover to PD-L1 antibody atezolizumab or whether an immediate start with PD-L1 antibody atezolizumab after the run-in phase and treatment until disease progression with subsequent crossing back to vemurafenib + cobimetinib was more efficient in controlling tumor progression in patients with BRAF mutant melanoma.

**Objectives:** The objective of the study was to assess if an early switch (i.e. switch at 3 months) from targeting the Ras/Raf signaling pathway by BRAF and MEK inhibition to immunologic checkpoint inhibition with an anti-PD-L1 antibody led to prolongation of progression-free and overall survival outcomes in patients with unresectable or metastatic BRAFV600 mutant melanoma. Furthermore, the safety of the study treatment was assessed.


**Methodology:** Patients were screened according to the eligibility criteria. Patients fulfilling all inclusion and exclusion criteria were enrolled and treated with cobimetinib (oral 60 mg once daily on days 1-21, q28d) and vemurafenib (oral 960 mg twice daily on days 1-28) during the 3-months run-in phase. Patients without PD, treatment interruption for more than 28 days, withdrawal of informed consent, or death during run-in phase were block-randomized in a 1:1 ratio

- either to proceed vemurafenib and cobimetinib (Arm A)
- or to switch to receive the anti-PD-L1 antibody atezolizumab (intravenous infusion of 1200 mg on day 1, q21d) (Arm B).

Randomization was stratified according to serum LDH at enrollment (elevated vs. within normal limits at enrollment), metastatic stage (IV M1c yes/no), and previous adjuvant therapy (yes/no).

In both treatment arms, patients were treated until first documented PD (PD1), unacceptable toxicity, withdrawal of informed consent or death, whichever occurred first and, if applicable,

subsequently cross-over to atezolizumab treatment (Arm A) or combination therapy with cobimetinib and vemurafenib (Arm B). In case of second documented PD (PD<sub>2</sub>), unacceptable toxicity, withdrawal of informed consent or death in the cross-over phase, whichever occurred first, study therapy was discontinued, and patients entered the follow-up phase, if applicable. In the follow-up phase, patients were followed for survival and disease status including documentation of subsequent lines of therapy and treatment response. The end of study was defined as 48 months after the last patient was randomized.



\*The Follow-up Period for this study is 48 months after the last patient is randomized. Therefore, the patients are followed up until this timepoint.

\*\*After the registration, run-in treatment with vemurafenib and cobimetinib can be instituted within a maximum interval of 14 days.

30 days after discontinuation of study treatment, a safety evaluation was performed. During the first year of the follow-up, visits were conducted every 3 months, thereafter every 6 months.

Standardized and study-specific patient questionnaires had to be completed by the patients at predefined time points either as paper version or electronically according to his/her preference: EORTC QLQ C-30, HADS-D, GSE (German: SWE), Brief-IPQ, SES ladder, study-specific list of questions.

During cobimetinib and vemurafenib treatment, patients had to fill in a medication diary to document the medication intake. They could choose whether to complete a paper version or use a personalized web-based electronic medication adherence reminder system (Alcedis eMARS).

Quality of life (QoL) was assessed by means of QLQ-C30 questionnaires. The other questionnaires were used to characterize the patient groups that opt for electronic vs. paper-based documentation of medication adherence.

Tumor tissue and blood samples of enrolled patients who agreed to participate in the translational research project were sent to the central laboratory of the University Essen. Analyses of tumor tissue, blood plasma and peripheral blood were performed to evaluate the biologic effects of treatment sequence on the molecular profile and biomarker expression in tissue and plasma.

**Number of patients (planned and analyzed):** It was planned to enrol approximately 176 patients in the run-in phase of this study, in order to randomize 141 patients.

**Actual:** 244 patients were screened; of these, 59 patients were not eligible to participate in the study.

185 patients started the 3-month run-in phase, of which 50 patients stopped study treatment prior to randomization due to adverse events (n=28), disease progression (n=11), death events (n=3), patients' own decision / withdrawal of their informed consent (n=6), or investigator decision (n=2). 135 patients completed the run-in phase and were randomized either to Arm A (n=66) or Arm B (n=69).

**Diagnosis and main criteria for inclusion and exclusion:** Histologically confirmed diagnosis of locally advanced, unresectable or metastatic melanoma AJCC 7th edition (unresectable stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c) without active or untreated brain metastases.

Inclusion criteria:

Patients were **included** in the study only if they met **all** the following criteria:

- Willing and able to provide written informed consent for the trial.
- Male or female patient  $\geq 18$  years of age on day of signing informed consent.
- Histologically confirmed diagnosis of locally advanced, unresectable or metastatic melanoma AJCC 7<sup>th</sup> edition (unresectable stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c) without active or untreated brain metastases; all known CNS lesions must have been treated with stereotactic therapy or surgery at least 4 weeks prior to the first dose of trial treatment AND the patient must be without evidence of clinical or radiographic disease progression in the CNS for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms must have returned to baseline, the patient must have no evidence of new or enlarging brain metastases, and the patient must not have used steroids in dosing exceeding 10 mg daily of prednisone equivalent for at least 3 weeks prior to trial treatment
- No previous therapy for the advanced or metastatic stage. Prior adjuvant therapy is permitted (e.g. IFN, IL-2-therapy, chemo- or radiotherapy). Prior adjuvant therapy had to be terminated (last dose) at least 28 days before enrolment. Patients who are in follow-up period of a clinical trial in adjuvant setting and progressing may be enrolled / randomized.
- Measurable disease, i.e., present with at least one measurable lesion per RECIST, version 1.1, for the definition of a measurable lesion.
- Presence of BRAF mutation (V600) in tumor tissue from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion prior to enrolment.
- Have provided tissue from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion.
- Performance status of 0 or 1 on the ECOG Performance Scale.
- Adequate organ and cardiac function.
- All prior treatment-related toxicities (except alopecia) following adjuvant therapy must be  $\leq$  Grade 1 according to the CTCAE (version 4.03) at the time of randomization.
- Note: Subjects with  $\leq$  Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
- Able to take oral medications.
- Patient is deemed by the investigator to have the initiative and means to be compliant with the protocol.
- Female subject of childbearing potential should have a negative urine pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use a highly effective form of contraception according to CTFG during the course of this study and for at least 6 months after completion of study therapy.

Exclusion criteria:

Patients were excluded from the study for **any** of the following reasons:

- Use of any investigational or non-registered product within 30 days before registration.
- Diagnosis of immunodeficiency or receiving systemic steroid therapy in dosing exceeding 10 mg daily of prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior to study Day 1.
- Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) also in an adjuvant setting.

- Prior therapy with a BRAF inhibitor (including but not limited to vemurafenib, dabrafenib, encorafenib and / or MEK inhibitor (including but not limited to trametinib, AZD6244, binimetinib, cobimetinib) also in an adjuvant setting.
- Prior major surgery. Note: Subjects may be included if they have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
- Known additional malignancy that is progressing or requires active treatment within 3 years prior to the study. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy without evidence or recurrence.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Note: Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 3 weeks prior to trial treatment.
- History of leptomeningeal metastases
- History or current evidence of central serous retinopathy (CSR) or retinal vein occlusion (RVO) or predisposing factors to RVO or CSR (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled diabetes mellitus, history of hyperviscosity or hypercoagulability syndromes).
- History of retinal degenerative disease.
- History of allogenic bone marrow transplantation or organ transplantation.
- History of Gilbert's syndrome
- Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following: (a) History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) < 6 months prior to screening, (b) symptomatic chronic heart failure, history or current evidence of clinically significant cardiac arrhythmia and / or conduction abnormality < 6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia, (c) history of congenital long QT syndrome or mean (average of triplicate measurements) QTc measured using Fridericia's method > 450 ms at baseline or uncorrectable abnormalities in serum electrolytes (sodium, potassium, calcium, magnesium, phosphorus).
- Uncontrolled arterial hypertension despite medical treatment.
- Patients who have neuromuscular disorders which are associated with elevated CK (e. g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
- Impairment of gastrointestinal function or gastrointestinal disease (e.g. ulcerative disease, uncontrolled nausea, vomiting, malabsorption syndrome, small bowel resection).
- Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids in dosing exceeding 10 mg daily of prednisone equivalent or immunosuppressive agents.
- Note: Subjects with vitiligo or controlled asthma/atopy would be an exception to this rule.
- Note: Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study.
- Note: Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study.
- Evidence of interstitial lung disease or active, non-infectious pneumonitis.
- Active infection requiring systemic therapy.
- Pregnancy or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through at least 6 months after the last dose of trial treatment.
- Positive test for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

- Positive test for Hepatitis B (e.g., HbsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- Known hypersensitivity reaction to any of the components of study treatment.
- Medical, psychiatric, cognitive or other conditions, including known alcohol or drug abuse that would not permit the subject to complete the study or sign informed consent.
- Patients taking non-topical medication known to be a strong inhibitor of CYP3A4. However, patients who either discontinue their treatment or switch to another medication at least three days prior to registration / randomization are eligible.
- Patients having received a live, attenuated vaccine within 4 weeks prior to the first dose of trial treatment.
- Legal incapacity or limited legal capacity.
- Presence of uveal melanoma.

**Test product (dosage, method of administration, batch number(s))**

Cobimetinib:

Cobimetinib was supplied as 20 mg film-coated tablets. Cobimetinib was taken orally at a dose of 60 mg (3 tablets) once daily for 21 days, followed by a 7-day break.

Batch numbers: 1152310, 1153347, 1153878, 1154442, 1156020, 1153127, 1158966, 1159929, 1161779, 1174487, 1175137

Vemurafenib:

Vemurafenib was supplied as 240 mg film-coated tablets. During each 28-day cycle, vemurafenib was taken orally at a dose of 960 mg (4 tablets) twice daily.

Batch numbers: 1152629, 1153516, 1154058, 1154531, 1155049, 1156835, 1157801, 1161777, 1171015, 1171317, 1174486, 1175585

Atezolizumab:

Atezolizumab was supplied as a concentrate for solution for infusion. Each 20 mL vial contained 1200 mg of atezolizumab.

Atezolizumab dose was 1,200 mg (equivalent to an average body weight-based dose of 15 mg/kg) administered by i.v. infusion on day 1 every 3 weeks (21  $\pm$  3] days). The initial dose of atezolizumab was delivered over 60 ( $\pm$  15) minutes. If the first infusion was tolerated without infusion-associated adverse events and cytokine release syndrome, the second infusion could be delivered over 30 ( $\pm$  10) minutes. If the 30-minute infusion was well tolerated, all subsequent infusions could be delivered over 30 ( $\pm$  10) minutes. At all infusions, the patient's vital signs (heart rate, respiratory rate, blood pressures, and temperature) should be determined within 60 minutes before and 30 ( $\pm$  10) minutes after the infusion. Vital signs had also to be collected during the first infusion (every 15  $\pm$  5] minutes). During subsequent infusions, vital signs were collected if clinically indicated.

Batch numbers: 1153708, 1153375, 1153048, 1154613, 1156592, 1161810, 1164255, 1165191, 1167909, 1175838, 1177286

**Duration of treatment:** Each enrolled patient received cobimetinib + vemurafenib combination therapy for a maximum of 3 months (run-in phase). Patients with PD, unacceptable toxicity, withdrawal of informed consent or death during the run-in phase, whichever occurred first, did not receive further study treatment and entered the follow-up phase as appropriate.

All other patients were randomized. Treatment in each arm was administered until PD, unacceptable toxicity, withdrawal of informed consent or death, whichever occurred first. Upon documented first PD after randomization, patients in Arm A and B cross over to receive the respective other treatment. Treatment after cross-over was continued until PD, unacceptable toxicity, withdrawal of informed consent or death, whichever occurred first. In the case of second documented PD after randomization, patients entered the follow-up phase.

**Reference product (dosage, method of administration, batch number(s)):** Not applicable

**Endpoints:**

**Efficacy:**

- Progression free survival (PFS) 1, defined as time from start of run-in phase (date of first intake of study drug) to first documented tumor progression date according to RECIST v. 1.1 (PD<sub>1</sub>) or death by any cause, whichever occurred first.
- Time to Second Objective Disease Progression (PFS2), defined as time from start of run-in phase (date of first intake of study drug) to second documented disease progression according to RECIST v. 1.1 (PD2) following randomization or death by any cause.
- Overall Survival (OS) of patients, defined as the time from start of run-in phase (date of first intake of study drug) until documented date of death, for any cause.
- OS rates at 12 months, 24 months, 36 months, and 48 months, defined as the rate of patients alive 12 months, 24 months, 36 months, and 48 months, respectively after start of run-in phase (date of first intake of study drug).
- 12-months and 24-months disease control rate (DCR), best overall objective response rate (OORR), time to overall objective response (OOR) and duration of OOR.
- Rate of patients with progressive disease (PD) who could not cross-over to subsequent line of therapy due to deterioration of ECOG status or multiple and/or symptomatic brain metastasis and/or leptomeningeal disease
  - From vemurafenib + cobimetinib to atezolizumab (Arm A)
  - From atezolizumab to vemurafenib + cobimetinib (Arm B)
- PFS3, defined as time from the first documented tumor progression date (PD1) until the second documented tumor progression date (PD2) after randomization or death by any cause, whichever occurs first.

**Safety:**

Special attention to all adverse events (AEs) ≥ Grade 3 according to CTCAE, Version 4.03 criteria, and all serious AEs (SAEs) regardless of causal relationship to the administration of the investigational agents.

**Other endpoints (not part of the CSR):**

- Addressed by the translational research project:
  - To evaluate the relationship of the tumor immune and signaling biomarker landscape and efficacy.
  - To evaluate non-inherited genetic alterations of circulating free tumor-specific DNA in plasma.
  - To assess and monitor the immunophenotype in peripheral blood mononuclear cells.
- Addressed by patient questionnaires:
  - To characterize the patient groups that opt for eMARS vs. paper-based documentation and to assess reasons for not participating in the eMARS program.
  - To assess the user-friendliness and practicality of eMARS and the user satisfaction.
  - To compare medication adherence between patients using eMARS and paper-based documentation.
  - To assess quality of life using the EORTC QLQ C-30 questionnaire.
  - To characterize the patient groups that opt for electronic vs. paper-based documentation of medication adherence using a study-specific questionnaire and standardized questionnaires (HADS-D, GSE Scale, Brief-IPQ, SES-Ladder).

**Statistical methods:** In general summary statistics (n, mean, standard deviation, median, minimum and maximum for continuous variables, and number of patients and percentage in each category for categorical variables) were provided.

All main analyses of the efficacy endpoints (OS and response-related endpoints, except for PFS1) were performed on the intent to treat (ITT) population using the ITT principle: randomized patients were considered as in the treatment group as indicated at randomization, all non-randomized patients (i.e. who dropped out during run-in phase) formed an extra group. For PFS1 analysis, all patients with an intake of at least one study drug after randomization and who did not have major



disqualifying protocol violations were analyzed (Primary Endpoint Population). OS was analyzed for patients in Arm A and Arm B regardless of whether a cross-over has occurred or not.

The Kaplan-Meier technique was used to obtain estimates of the survival-type distributions (PFS1/2/3, OS, time to OR, duration of OR). In addition, based on the Kaplan-Meier curves, estimates at given time-points were provided (e.g. 12-, 24-, 36- and 48-month OS rates), along with their standard errors, computed using the Greenwood formula. Medians - if reached - were presented with a 95% confidence interval (CI) based on the non-parametric method of Brookmeyer and Crowley. The comparison of the time-to-event distributions (PFS, OS, time to OR) between the different treatment groups was done using the log-rank test for ITT and subgroups by LDH (elevated vs. within normal limits at enrollment), metastatic stage (IV M1c yes/no), previous adjuvant therapy (yes/no) as indicated at enrollment. These comparisons were purely descriptive. All p-values generated in the analysis were of descriptive manner and were not corrected for multiple testing.

The HR of Arm B: Arm A, and its 2-sided 95% confidence interval, was estimated using a Cox proportional hazards (PH) model (using Efron's tie-handling method) with treatment group as a single covariate.

In each treatment arm, the rates of CR and OORR were summarized with their corresponding 2-sided 95% CI.

Subgroup analyses: In addition to LDH (elevated vs. within normal limits at enrollment) at baseline, metastatic stage (IV M1c yes/no), and previous adjuvant therapy (yes/no) as indicated at enrollment, the following variables were considered for the prognostic/predictive factors for the efficacy endpoints (PFS, OS):

- Sex (male vs. female)
- Age at enrollment
- Asymptomatic brain metastases at enrollment (no, yes)
- ECOG status at enrollment (0 vs  $\geq 1$ )
- Number of organ sites with metastases ( $< 3$  sites vs  $\geq 3$  sites) at enrollment
- Sum of lesion diameter ( $< \text{median}$  vs  $\geq \text{median}$ ) at enrollment
- Tumor response after run-in phase (SD vs. PR vs CR)
- Prior radiotherapy before enrollment (no, yes)
- Prior therapy before enrollment ANY (no, yes)

To avoid a possible treatment influence on the prognostic importance of these factors, univariate analyses (Kaplan-Meier curves, log rank test, Cox model) were done in each treatment group, separately. Thereafter, a multivariable Cox model was fitted using both treatment groups, including as covariates randomized treatment group and all factors which appeared of prognostic importance (at a 2-sided  $\alpha=20\%$ ) in univariate analyses in at least one treatment group, and of the variable LDH (elevated vs. within normal limits at enrolment), metastatic stage (IV M1c yes/no), previous adjuvant therapy (yes/no) as indicated at enrolment. A step down was used for the multivariable Cox model selection at the 2-sided 10% significance level, and forcing treatment arm to stay in the model. The model with the lowest Akaike information criterion (AIC) was retained. The assumption of proportional hazards was checked using a procedure derived from cumulative sums of martingale-based residuals over follow-up time (method of Lin, Wei, and Ying). In case one of the strong prognostic factors violated the PH assumption, a Cox model stratified by this factor was considered.

Safety analyses were performed on the safety population (SP), that were all patients of the ITT set who received at least one dose of the investigational agent. All safety analyses were done separately for each treatment step: a) the run-in phase, b) the randomized phase, c) the switch phase. For the randomized phase and the switch phase, the analyses were done separately for treatment Arm A and Arm B. All AEs were tabulated using worst grade per NCI CTCAE v 4.03 criteria by system organ class (SOC) and preferred term (PT).

### **Summary of results and Conclusion:**

**Subject Disposition:** Between [REDACTED] 2016 and [REDACTED] 2019, 185 patients started the run-in phase, of which 50 patients stopped study treatment due to toxicity (n=28), disease progression (n=11), death (n=3), withdrawal of informed consent (n=6) or decision by the investigator (n=2). The remaining 135 patients (ITT population) were randomly assigned to receive vemurafenib in combination with cobimetinib (Arm A, n=69) or atezolizumab (Arm B, n=66) until the first disease progression (PD1) (randomized phase). After PD1, 21 patients in Arm A switched to treatment with atezolizumab and 35 patients in Arm B switched to treatment with vemurafenib in combination with cobimetinib until second disease progression (PD2) (crossover phase), with one patient in Arm B not receiving the assigned treatment. At the final data cut-off (09 JUL 2024) and a median follow-up of 57.83 months (IQR 22.66 - 65.43) in Arm A and 55.79 months (27.34 - 62.34) in Arm B, 5 patients in Arm A and 4 patients in Arm B were still under first treatment of the randomized phase and 2 patients in each treatment arm were still under treatment in the crossover phase. 48 patients in Arm A and 49 patients in Arm B prematurely discontinued the clinical trial due to death, withdrawal of informed consent or lost to follow up.

**Demographic and baseline characteristics:** Patient demographics for the total intention-to-treat (ITT) population, as well as for patients of Arm A, patients for Arm B and for the 50 patients who stopped study treatment prior to randomization were well balanced. Key patient characteristics of the 21 and 35 patients undergoing crossover in Arm A and in Arm B, respectively, did not differ substantially except for baseline LDH. While 23.81% of patients in Arm A had an LDH of 2x upper limit of normal or higher, almost twice as many (42.42%) patients in Arm B had elevated LDH at baseline.

**Efficacy results:** For the initial treatment course, Arm A showed statistically superior outcomes for PFS1 with a median of 12.96 months (95% CI 9.87-15.59) compared to 5.94 months (95% CI 5.46-8.29) for Arm B. Descriptive subgroup analyses for potentially prognostic/predictive factors of PFS1 did not reveal a specific subgroup to particularly benefit from an early switch to atezolizumab (Arm B).

The median OS of all patients entering the randomized phase was improved with 49.64 months in the early-switch Arm B compared to 40.23 months in Arm A; HR=1.17. Subgroup analyses did not indicate a relevant benefit for any group, but patients with SD after the run-in phase seemed to benefit more from a treatment switch to atezolizumab (Arm B). Long-term OS rates at 36, 48 and 60 months were 54.56%, 42.43% and 40.08%, respectively in Arm A and 55.01%, 52.62% and 44.97%, respectively, in Arm B. After crossover, a significant proportion of patients both in Arm A and Arm B had rapid further disease progression. Second-line atezolizumab (Arm A) did not show a clinically meaningful PFS3 benefit, i.e., median time to second disease progression (PFS3) was shorter for patients in Arm A than for patients in Arm B who received vemurafenib + cobimetinib (2.83 months vs. 6.02 months; HR=1.72, 95% CI 0.93-3.20). As a result, PFS2 (PFS1 + PFS3) of the 35 patients with crossover in Arm B was slightly better compared with the 21 patients of Arm A (14.61 months vs. 12.57 months, HR=1.29, 95% CI 0.70-2.38) despite the very short PFS1 of patients in Arm B.

During the run-in phase, 17 (24.64%) patients in Arm A and 16 (24.24%) patients in Arm B had a SD as BOR. After randomization, tumor control was lost rapidly in 50.00% of the patients (n=33) in Arm B who experienced PD as BOR compared to 12 (17.39%) patients of Arm A. However, 14 (20.29%) patients in Arm A and 12 (18.18%) patients in Arm B achieved a CR as BOR during the randomized phase. Resulting BORR for the run-in phase and randomized phase combined were 81.16% for Arm A and 83.33% for Arm B. After switching, three (14.29%) patients of Arm A and four (11.43%) patients of Arm B achieved a CR. In total, the absolute BORR across the whole treatment sequence increased to 89.39% in Arm B, but remained 81.16% in Arm A. The median duration of response, including responses achieved during the run-in phase, was significantly longer in Arm compared to Arm B (11.32 months vs. Arm B 3.09 months, HR=0.48, 95% CI 0.30-0.78).

**Safety results:** Treatment related AEs of any CTCAE grade, along all trial phases combined, were reported for 68 (98.55%) patients in Arm A and for all 66 patients in Arm B as well as for 45 (95.74%) patients who stopped treatment before the randomized phase (not randomized group). The most common treatment-related AE of any CTCAE grade across all study phases was

diarrhea, which occurred in 36 (52.17%) patients in Arm A, in 35 (53.03%) patients in Arm B, and in 22 (46.81%) patients not randomized. Treatment-related AEs of CTCAE grade 3/4 were reported for 29 (42.03%) patients in Arm A, for 32 (48.48%) patients in Arm B, and for 27 (57.45%) patients not randomized. The most common treatment-related AE of CTCAE grade 3/4, which occurred in at least 10% of patients across all study phases combined, included increased lipase levels (Arm A: 12 (17.39%) patients, Arm B: 8 (12.1%) patients) and increased blood creatine phosphokinase levels (reported for 8 (12.12%) patients in Arm B). Following randomization, well-known immune checkpoint inhibitor-specific treatment-related AEs observed in Arm B included hyperthyroidism reported for 10 (15.15%) patients (including 1 patient with CTCAE grade 3) and hypothyroidism reported for 9 (13.64%) patients. In Arm A, treatment with vemurafenib + cobimetinib resulted in new or ongoing, class-specific photosensitivity reactions of any grade in 11 (15.94%) patients (including 1 patient with CTCAE grade 3). Immune-related AEs of any CTCAE grade were reported for 44 (66.67%) patients in Arm B, including seven (10.61%) patients with CTCAE grade 3/4, and for 11 (15.94%) patients in Arm A. Treatment discontinuation due to any kind of toxicity was very frequent during the run-in phase with the reported 22 cases to represent a significant portion of the 28 patients leaving the study prior to randomization. Treatment discontinuation due to treatment-related AEs across all study phases was reported for 5 (7.25%) patients in Arm A, for 6 (9.09%) patients in Arm B and for 21 (44.68%) of patients who left the study prior to randomization. The investigator could not rule out a relationship to the study medication for one treatment-related death (i.e., intracranial hemorrhage) reported in Arm B (after randomization). No additional CTCAE grade 5 treatment-related AEs were reported during the overall 56.97 months of median follow-up.

Other results: Not applicable.

Post-hoc results: Not applicable.

Conclusion(s): Early switch to the immune checkpoint inhibitor atezolizumab after BRAF/MEK inhibitor therapy with vemurafenib in combination with cobimetinib during the run-in phase (Arm B) improved, although not statistically significant, long-term OS compared to continued treatment with vemurafenib + cobimetinib (Arm A) and thus demonstrated a lasting landmark survival benefit. Additionally, early switch to atezolizumab resulted in higher overall BORR and thus suggests improved tumor control and response kinetics. Safety outcomes were consistent, and patterns of treatment-related AEs were indicative for each drug (atezolizumab or vemurafenib/cobimetinib) used during each treatment phase. In conclusion, the ImmunoCobiVem clinical trial showed that switch to immune checkpoint inhibitor therapy with atezolizumab before disease progression after a short (3-months) initial run-in therapy with the BRAF/MEK inhibitors vemurafenib/cobimetinib is clinically superior in terms of OS and overall BORR in BRAF V600 mutation-positive patients with advanced melanoma, but small and it remains to be determined which patients will benefit from a TT run-in and which patients will develop rapid tumor progression when switched from TT to ICI.

**Date and version of report:** 10 March 2025 – Final v1.0

### 3 TABLE OF CONTENTS

	Page
SYNOPSIS.....	2
3 TABLE OF CONTENTS .....	12
4 LIST OF ACRONYMS & ABBREVIATIONS AND DEFINITIONS .....	16
5 ETHICS .....	19
5.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB) .....	19
5.2 Ethical Conduct of the Study .....	21
5.3 Patient Information and Consent.....	22
5.4 Funding.....	22
6 INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE .....	22
7 INTRODUCTION .....	23
8 STUDY OBJECTIVES AND ENDPOINTS.....	25
8.1 Objectives .....	25
8.2 Endpoints.....	26
9 INVESTIGATIONAL PLAN.....	27
9.1 Overall Study Plan / Study Design .....	27
9.2 Discussion of Study Design, Including the Choice of Control Groups.....	28
9.3 Selection of Study Population .....	29
9.3.1 Inclusion Criteria .....	30
9.3.2 Exclusion Criteria .....	31
9.3.3 Removal of Patients from Therapy or Analysis.....	33
9.3.4 Stopping or Suspending the Study .....	34
9.4 Treatments.....	34
9.4.1 Treatments administered.....	34
9.4.2 Identity of Investigational Products .....	35
9.4.3 Method of Assigning Patients to Treatment groups.....	37
9.4.4 Dose Selection .....	37
9.4.5 Selection and Timing of Dose for Each Patient .....	37
9.4.6 Blinding.....	37
9.4.7 Prior and Concomitant Therapy.....	38
9.4.8 Treatment Compliance .....	39
9.5 Efficacy and Safety Variables.....	39
9.5.1 Efficacy and Safety Measurements Assessed and Schedule of Assessment.....	39
9.5.2 Appropriateness of Measurements.....	49
9.5.3 Pharmacokinetic and Pharmacodynamic Measurements .....	49
9.5.4 Other Measures .....	49

9.6	Data Quality Assurance .....	49
9.7	Statistical Methods Planned in the Protocol and Determination of Sample Size .....	49
9.7.1	Statistical Analysis Plan.....	49
9.7.2	Determination of Sample Size .....	54
9.8	Changes in the Conduct of the Study or Planned Analyses .....	55
10	STUDY PATIENTS .....	56
10.1	Disposition of Patients.....	56
10.2	Recruitment .....	58
10.3	Protocol Deviations .....	58
11	EFFICACY EVALUATION.....	59
11.1	Data Sets Analyzed .....	59
11.2	Demographic and Other Baseline Characteristics .....	59
11.3	Measurements of Treatment Compliance.....	61
11.4	Efficacy Results .....	61
11.4.1	Primary Efficacy endpoint.....	61
11.4.2	Secondary Efficacy Endpoints .....	63
11.4.3	Other Efficacy Endpoints.....	71
11.4.4	Post-hoc Analyses.....	71
11.5	Statistical / Analytical Issues .....	72
11.5.1	Adjustments for Covariates .....	74
11.5.2	Handling of Dropouts or Missing Data.....	74
11.5.3	Interim Analyses and Data Monitoring.....	75
11.5.4	Multicenter Trials.....	75
11.5.5	Multiple Comparison / Multiplicity.....	75
11.5.6	Use of an "Efficacy Subset" of Patients (e.g. Per Protocol Analysis).....	75
11.5.7	Active-Control Studies Intended to Show Equivalence .....	75
11.5.8	Examination of Subgroups.....	75
11.5.9	Tabulation of Individual Response Data.....	75
11.6	Pharmacokinetic, Pharmacodynamic and other analyses results .....	76
11.6.1	Drug Dose, Drug Concentration, and Relationships to Response .....	76
11.6.2	Drug-Drug and Drug-Disease Interactions.....	76
11.6.3	Other Endpoints .....	76
11.7	By Patient Displays .....	76
11.8	Efficacy Result Summary .....	76
12	SAFETY EVALUATION .....	76
12.1	Extent of Exposure.....	77
12.2	Adverse Events.....	81
12.2.1	Brief Summary of Adverse Events.....	81

12.2.2	Display of Adverse Events .....	81
12.2.3	Analysis of Adverse Events .....	85
12.2.4	Listing of Adverse Events by Patient .....	85
12.3	Deaths, Other Serious Adverse Events, and Other Significant Adverse Events .....	85
12.3.1	Listing of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events .....	85
12.3.2	Narratives of Deaths, Other SAEs, and Certain Other Significant AEs .....	86
12.3.3	Analysis and Discussion of Deaths, Other SAEs, and Other Significant AEs.....	86
12.4	Clinical Laboratory Evaluation.....	86
12.4.1	Individual Laboratory Measurements by Patient and Abnormal Laboratory Value.....	86
12.4.2	Evaluation of Laboratory Values .....	86
12.5	Vital Signs, Physical Findings, and Other Observations Related to Safety .....	86
12.6	Safety Result Summary .....	86
13	DISCUSSION AND OVERALL CONCLUSIONS .....	87
14	TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT .....	90
14.1	Demographic Data .....	90
14.2	Efficacy Data.....	94
14.3	Safety Data .....	97
14.3.1	Display of AEs.....	97
14.3.2	Listings of Deaths, SAEs, Other Significant AEs .....	104
14.3.3	Narratives of Deaths, SAEs, Other Significant AEs.....	112
14.3.4	Abnormal Clinically Meaningful Laboratory Values (by-patient listing) .....	112
14.4	Other data .....	112
15	LIST OF REFERENCES .....	112
16	APPENDICES.....	115
16.1	Study Information.....	115
16.1.1	Study Protocol and Amendments .....	115
16.1.2	Sample CRF .....	115
16.1.3	List of Ethics Committees.....	115
16.1.4	List of Investigators and Other Important Participants in the Trial.....	116
16.1.5	Signatures of the Principal or Coordinating Investigator(s), the Sponsor's Responsible Medical Officer, and the Biostatistician, and, if applicable, of Other Authors.....	118
16.1.6	Listing of Investigational Product(s) Batch Numbers .....	119
16.1.7	Randomization Scheme and Codes.....	120
16.1.8	Audit Certificates (if available) .....	123
16.1.9	Documentation of Statistical Methods .....	123
16.1.10	Documentation of Inter-laboratory Standardization Methods and Quality Assurance Procedures .....	123

16.1.11 Publications Based on the Clinical Trial.....	123
16.1.12 Important Publications Cited in This Report (Copies).....	123
16.1.13 Optional Appendix .....	123
16.2 Patient Data Listings .....	124
16.2.1 Dropouts, Discontinued Patients .....	124
16.2.2 Protocol Deviations .....	128
16.2.3 Patients Excluded from the Efficacy Analysis .....	129
16.2.4 Demographic Data.....	129
16.2.5 Compliance Data and / or Drug Concentration data (if available).....	129
16.2.6 Individual Efficacy and Response Data .....	129
16.2.7 AE Listings (by patient).....	130
16.2.8 Listing of Individual Laboratory Measurements (by patient), if required by regulatory authorities .....	435
16.3 Case Report Forms.....	435
16.3.1 CRFs of Deaths, Other SAEs, and Withdrawals for AEs .....	435
16.3.2 Other CRFs .....	435

## 4 LIST OF ACRONYMS & ABBREVIATIONS AND DEFINITIONS

AE	Adverse Event
AESI	Adverse Event of Special Interest
AIC	Akaike Information Criterion
AJCC	American Joint Committee on Cancer
ALT (SGPT)	Alanine transaminase
AMG	German Medicinal Products Act
ANC	Absolute Neutrophil Count
ANOVA	Analysis of Variance
β-hCG	Human Chorionic Gonadotropin
aPTT	activated Partial Thromboplastin Time
AST	Aspartate transaminase
BID	Bi-Daily
BRAF	v-Raf murine sarcoma viral oncogene homolog B
BUN	Blood Urea Nitrogen
CD4+	Cluster of Differentiation 4-positive
CD8+	Cluster of Differentiation 8-positive
CI	Confidence Interval
CNS	Central Nervous System
CR	Complete Remission
CRF	Case Report Form
CRO	Contract Research Organization
CSR	Central Serous Retinopathy
CT	Computed Tomography
CTCAE	Common Terminology Criteria for Adverse Events
CTFG	Clinical Trial Facilitation Group
CTLA-4	Cytotoxic T-Lymphocyte Associated Protein 4
CYP3A4	Cytochrome P450 3A4
DCR	Disease Control Rate
DILI	Drug-Induced Liver Injury
DMP	Data Management Plan
DVP	Data Validation Plan
ECG	Electrocardiography
ECHO	Echocardiography
ECOG	Eastern Cooperative Oncology Group
eCRF	Electronic Case Report Form
EMA	European Medicines Agency,
eMARS	Electronic Major Accident Reporting System
EORTC	European Organization for Research and Treatment of Cancer
EORTC QLQ C-30	European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire
FDA	Food and Drug Administration
FFPE	Formalin-Fixed Paraffin Embedded
FSH	Follicle-Stimulating Hormone
GCP	Good Clinical Practice
GFR	Glomerular Filtration Rate
GGT	Gamma-Glutamyl Transferase
GSE	General Self-Efficacy Scale (German: SWE – Skala zur Allgemeinen Selbstwirksamkeitserwartung)
HADS-D	Hospital Anxiety and Depression Scale – Deutsche Version
HbsAg	surface Antigen of the Hepatitis B virus
HCV	Hepatitis C Virus
HIV	Human Immunodeficiency Virus



HR	Hazard Ratio
IB	Investigator Brochure
ICH GCP	International Conference on Harmonization - Good Clinical Practice
IEC	Independent Ethics Committee
IFN	Interferon
IL-2	Interleukin 2
IMP	Investigational Medicinal Product
IRB	Institutional Review Board
ITT	Intent-to-treat (population)
LDH	Lactate dehydrogenase
LLN	Lower Level Normal
LVEF	Left Ventricular Ejection Fraction
MAPK	Mitogen-activated Protein Kinase
MedDRA	Medical Dictionary for Drug Regulatory Affairs
MEK1/2	Mitogen-activated Protein Kinase Kinases 1/2
MRI	Magnetic Resonance Imaging
MRT	Magnetic Resonance Tomography
MUGA	Multigated Acquisition
NaCl	Sodium Chloride
NCI	National Cancer Institute
NSCLC	Non-small Cell Lung Cancer
OCT	Optical Coherence Tomography
OOR	Overall Objective Response
OORR	Overall Objective Response Rate
ORR	Overall Response Rate
OS	Overall Survival
OTC	Over the Counter
PD	Progressive disease
PD-1	Programmed cell death protein 1
PD-L1/2	Programmed Cell Death 1 Ligands 1/2
PEP	Primary Endpoint Population
PFS	Progression Free Survival
PH	Proportional Hazard
PT	Preferred Term
PVC	Polyvinyl Chloride
QLQ	Quality of Life Questionnaire
QoL	Quality of Life
QTc	QT-Interval
RAS	Rat Sarcoma Virus
RCC	Renal Cell Carcinoma
RECIST	Response Evaluation Criteria in Solid Tumors
RNA	Ribonucleic acid
RP	Randomized Population
RVO	Retinal Vein Occlusion
SAE	Serious Adverse Event
SAP	Statistical Analysis Plan
SCC	Squamous Cell Carcinoma
SD	Stable Disease
SGOT	Serum Glutamic Oxaloacetic Transaminase
SGPT	Serum Glutamate-Pyruvate Transaminase
SOC	System Organ Class
SP	Safety Population
SUSAR	Suspected Unexpected Serious Adverse Reaction
T3	Total Triiodothyronine
T4	Free Thyroxine

TRAE	Treatment-related adverse event
TSH	Thyroid Stimulating Hormone
ULN	Upper Limit of Normal
USP	United States Pharmacopeia
WBC	White Blood Cell
WBDC	Web-Based Validated Software
WBRT	Whole Brain Radiotherapy
WHO	World Health Organization

## 5 ETHICS

### 5.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB)

Approval of the German leading ethics committee of the coordinating investigator (Ethics Committee of the Faculty of Medicine of the University of Duisburg-Essen) was obtained on August 25, 2016 for protocol version 1.3 (dated July 12, 2016).

During the study conduct, there have been 9 substantial amendments affecting the study protocol.

With Amendment No 1, questionnaires for patients regarding medication adherence and quality of life became part of the study. New exploratory objectives addressed by patient questionnaires were specified. Furthermore, the amendment includes corrections and specification of wording throughout the protocol. Amendment No 1 was submitted to the Paul-Ehrlich-Institute (PEI) and the Ethics Committees on August 5, 2016. The amendment and the revised protocol version 1.3 (dated July 12, 2016) were approved by the leading Ethics Committee on August 31, 2016, and by the PEI on September 8, 2016. Amendment 1 became effective on October 1, 2016.

Amendment No 2 included specification of inclusion and exclusion criteria and an update of risks associated with the study treatment. Moreover, the specification of the BRAF mutation was deleted. A reference for (S)AE documentation and new Adverse Events of Special Interest (AESI) were included and assessment schedules updated. The amendment was submitted to the PEI and ethics committees on 20 December 2016. The amendment and the revised protocol version 1.4 (dated December 15, 2016) were approved by the PEI on January 24, 2017, and by the leading ethics committee on January 09, 2017. Amendment No 2 became effective on February 28, 2017.

With Amendment No 3, changes regarding medication adherence questionnaires have been made. Amendment 3 was submitted to the PEI and ethics committees on 02 August 2017. The amendment and the revised protocol version 1.5 (dated May 18, 2017) were approved by the leading ethics committee on August 24, 2017, and by the PEI on August 31, 2017. Amendment No 3 became effective on September 26, 2017.

With Amendment No 4 timelines were updated, and clinical examination schedules were changed. Moreover, based on the updated atezolizumab Investigator Brochure (IB, version 10 from Jul 2017), changes regarding clinical experience and risks associated with atezolizumab were updated. Amendment No 4 was submitted to the PEI and the leading ethics committee on December 22, 2017, and to all other involved ethics committees on February 01, 2018. The amendment and the revised protocol version 1.6 (dated December 12, 2017) were approved on December 29, 2017 by the PEI, and on February 15, 2018 by the leading ethics committee. Amendment No 4 became effective on April 18, 2018.

Protocol version 1.6 was submitted to French, Greek, and Serbian competent authorities and ethics committees. It was approved by Serbian competent authority on August 09, 2018, and by the Serbian ethics committee on April 26, 2018. In Greece, protocol version 1.6 was approved by the competent authority on September 27, 2018, and by the central ethics committee on September 24, 2018, any by the lead ethics committee on November 15, 2018. Due to requests of French competent authority, the protocol was updated to country-specific version 1.7 (dated March 21, 2018), which was approved by French competent authority on March 23, 2018, and by the ethics committee on April 17, 2018.

Amendment No 5 changes included update to the study timelines, change of marketing authorization holder, adaptation of schedules of study visits and examinations. Furthermore, clinical experience and risks associated with atezolizumab were updated due to the release of revised IBs for cobimetinib (version 11, dated September 25, 2018), for vemurafenib (version 16, dated December 13, 2018) and for atezolizumab (version 14, dated October 24, 2018), and corresponding addendum 1 (dated December 05, 2018). Amendment No 5 was submitted to the PEI, the leading ethics committee and to all other involved ethics committees in Germany on May 17, 2019. The amendment and the revised protocol version 1.8 (dated April 29, 2019) were

approved on June 07, 2019 by the PEI, and on June 12, 2019 by the leading ethics committee. Amendment No 5 became effective on June 21, 2019 in Germany.

Protocol version 1.8 was submitted to French competent authority and ethics committee on May 29, 2019, and approved by the ethics committee on June 11, 2019, and by the competent authority on August 07, 2019. Protocol version 1.8 was submitted to the Serbian ethics committee on May 27, 2019 and approved on June 25, 2019, and submitted to the competent authority on May 29, 2019, and approved on July 02, 2019. In Greece, protocol version 1.8 was submitted to the competent authority on July 03, 2019 and approved on August 05, 2019, and submitted to the central and local ethics committees on July 05, 2019 and approved on July 29, 2019.

With Amendment No 6 the primary endpoint was changed. The previous secondary endpoint progression-free survival (PFS) 1 is now analyzed as primary endpoint, and the previous primary endpoint PFS2 is now analyzed as secondary endpoint. During regular data review, it was noticed that there were patients not switching therapy after their first progress as planned according to protocol. These patients were previously not included in the primary endpoint population even though they received other therapies. In addition, the follow-up period was extended by two years, to collect further data for overall survival (OS). Moreover, an interim analysis was added in order to gain knowledge on the impact of an early switch from BRAF/MEK inhibition to PD-L1 inhibition on PFS1. This analysis was conducted after 80% of patients have reached PFS1 or prematurely discontinued the study. Furthermore, the protocol was updated according to the release of revised IBs for cobimetinib (version 12, dated September 2019 with new addendum), for vemurafenib (version 17, dated December 2019), and for atezolizumab (version 15, dated December 2019 with corresponding addendum 2). According to the sponsor, these revised documents did not affect the benefit-risk assessment for patients undergoing treatment within the study. Amendment No 6 was submitted to the PEI, the leading ethics committee and to all other involved ethics committees in Germany on July 15, 2020. The amendment and the revised protocol version 2.0 (dated June 09, 2020) were approved on July 28, 2020 by the PEI, and on August 04, 2020 by the leading ethics committee. Amendment No 6 became effective on August 08, 2020 in Germany.

Protocol version 2.0 was submitted to the French competent authority and ethics committee on August 10, 2020, and approved by the ethics committee on December 17, 2020, and by the competent authority on August 14, 2020. Protocol version 2.0 was submitted to the Serbian central and local ethics committee on August 17, 2020, and approved by the central ethics committee on October 30, 2020, and by the local ethics committee on November 19, 2020. It was submitted to the Serbian competent authority on August 17, 2020, and approved on December 25, 2020. In Greece, protocol version 2.0 was submitted to the competent authority on July 31, 2020 and approved on September 17, 2020, and submitted to the central and local ethics committees on July 31, 2020 and approved on September 11, 2020 (central ethics committee) and on September 14, 2020 (local ethics committee).

Amendment No 7 included changes regarding safety and approved indications of atezolizumab based on the release of revised IBs for cobimetinib (version 13, dated September 2020), for vemurafenib (version 18, dated May 2020), and for atezolizumab (version 17, dated September 2020; version 16 was withdrawn from the marketing authorization holder and did not become effective). According to the sponsor, the revision of these documents did not affect the benefit-risk assessment for patients undergoing treatment within the study. Amendment No 7 was submitted to the PEI, the leading ethics committee and to all other involved ethics committees in Germany on June 15, 2021. The amendment and the revised protocol version 3.0 (dated May 11, 2021) were approved on June 28, 2021 by the leading ethics committee, and on July 05, 2021 by the PEI. Amendment No 7 became effective in Germany on July 14, 2021.

Protocol version 3.0 was submitted to the French competent authority and ethics committee on June 07, 2021. Competent authority approval was received on June 07, 2021, ethics committee approval was issued on June 08, 2021. In Greece, protocol version 3.0 was submitted to the competent authority and central ethics committee on June 25, 2021, and to the local ethics committee on July 08, 2021. It was approved by the central ethics committee on July 16, 2021 and by the competent authority on July 27, 2021, local ethics committee approval was issued on

September 06, 2021. Protocol version 3.0 was submitted to the Serbian competent authority as well as the central and local ethics committee on July 02, 2021, ethics committee approval was received on November 03, 2021, competent authority approval on April 05, 2022.

Amendment No 8 included changes regarding new risks of vemurafenib and atezolizumab based on the release of revised IBs for vemurafenib (version 19, dated May 2021), and for atezolizumab (version 18 and Addendum 1, dated Jul and Aug 2021, respectively). Furthermore, changes in the management of atezolizumab-specific adverse events were issued. Updates on clinical trials were implemented in chapters 2.2, 2.3, 2.5 and 2.6. According to the sponsor, the revision of these documents did not affect the benefit-risk assessment for patients undergoing treatment within the study. Amendment No 8 was submitted to the PEI, the leading ethics committee and to all other involved ethics committees in Germany on May 10, 2022. The amendment and the revised protocol version 4.0 (dated April 26, 2022) were approved on May 11, 2022 by the PEI, and on May 23, 2022 by the leading ethics committee. Amendment No 8 became effective on June 09, 2022 in Germany. Protocol version 4.0, dated April 26, 2022, was submitted to the German competent authority and Ethics Committee on May 10, 2022. The approval by the Ethics Committee was received on May 23, 2022, the approval by the competent authority was received on May 11, 2022. In France, protocol version 4.0 was submitted to the French competent authority and the Ethics Committee on May 6, 2022. The approval by the competent authority was received on May 10, 2022, and the approval by the Ethics Committee approval was received on June 16, 2022. In Greece, protocol version 4.0 was submitted to the competent authority and to the central and the local Ethics Committee on June 14, 2022. It was approved by the central Ethics Committee on June 17, 2022, with a silent approval after 30 days by the local Ethics Committee, and by the competent authority on June 29, 2022. The protocol version 4.0 was submitted to the Serbian competent authority and the central and local Ethics Committee on July 29, 2022. Approval of protocol version 4.0 was granted by the central and local Ethics Committee on October 5, 2022, and by the competent authority on October 13, 2022.

Amendment No 9 included changes regarding safety and approved indications of cobimetinib and vemurafenib based on the release of revised IBs for vemurafenib (versions 20 and 21, dated May 2022 and May 2023, respectively), cobimetinib (version 15, Sep 2022) and for atezolizumab (version 19, dated Aug 2022). Risks associated with atezolizumab and cobimetinib as well as dose modifications and treatment alterations of study treatment were updated. Further, specification for cardiac evaluation was included in the 'schedule of visits and assessments'.

The amendment and the revised protocol version 5.0, dated 24 May 2023, were approved on 14 Jul 2023 by the German lead ethics committee.

Protocol version 5.0 was submitted to the French, Greek, and Serbian competent authorities and ethics committees. It was approved by the French ethics committee on June 13, 2023, by the Greek ethics committee on September 11, 2023, and by the Serbian ethics committee on November 28, 2023.

A list of all Ethics Committees involved is available in the Appendix (16.1.3).

## 5.2 Ethical Conduct of the Study

The regulatory basis of the conduct of this study consisted of the Declaration of Helsinki (in its current version), the AMG [German Medicinal Products Act] / Regulation EU No 536/2014 (Clinical Trials Regulation), Regulation (EU) 2016/679 (General Data Protection Regulation), and the principles of the proper conduct of clinical trials (ICH GCP).

The sponsor had taken out insurance for all subjects who gave consent to participation in the clinical trial.

### 5.3 Patient Information and Consent

An unconditional prerequisite for a patient participating in the study was his/her written informed consent. Adequate information was given to the subject by the investigator before informed consent was obtained. A person designated by the investigator gave the information, if permitted by local regulations. A patient information sheet in the local language was provided to inform the patients in writing about relevant information on the study (drugs used and their possible adverse effects, nature and objectives of the study, expected advantages of the participation, possible hazards of the study and alternatives of treatment, trial-specific insurance, data protection). Each patient was given enough time and opportunity to decide to participate in the study and to clarify open questions before the institution of any study procedures. Each patient was also informed that participation in the study was completely voluntary, and that participation could be withdrawn at any time without giving any reasons and without disadvantage for the respective patient.

The written informed consent of the patient to participate in the clinical study was given before any study-related activities were carried out. It was signed and personally dated by the patient and by the investigator/person designated by the investigator to conduct the informed consent discussion. In addition to this written information, the investigator or his designate informed the patient verbally. In doing so, the wording used was chosen so that the information could be fully and readily understood by laypersons. Patients were also asked to give consent to additional analysis of tumor material. This approval was not a precondition for participation in the study.

Provision of consent was confirmed in the electronic case report form (eCRF) by the investigator. The signed and dated declaration of informed consent remained at the investigator's site and was safely archived by the investigator so that the forms were retrieved at any time for monitoring, auditing and inspection purposes. A copy of the signed and dated information and consent was provided to the subject prior to participation.

The patient informed consent was presented in duplicate. One copy remained with the investigator and the other was given to the patient. The patient information sheet was submitted to the ethics committee and approved before use. It was revised whenever important new information became available that was relevant to the consent of patients. The revised version was also submitted to the Ethics Committee. This approved version was signed once again by already enrolled patients.

### 5.4 Funding

Third party funds were provided by F. Hoffmann-La Roche for study co-ordination, documentation, monitoring and analysis. Vemurafenib, cobimetinib and atezolizumab were provided free of charge for this study by F. Hoffmann-La Roche Ltd., Basel, Switzerland.

## 6 INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE

This study was an investigator-initiated multinational trial conducted in Germany, France, Greece and Serbia.

Initiator and German Coordinating Investigator was [REDACTED] (Department of Dermatology, Skin Cancer Center, Comprehensive Cancer Center Essen, [REDACTED], Germany).

The Sponsor was the University Hospital Essen, represented by [REDACTED], Germany.

The French Coordinating Investigator was [REDACTED].

The Greek Coordinating Investigator was [REDACTED].

The Serbian Coordinating Investigator was [REDACTED].

At each trial site a principal investigator and at least one representative were designated who were responsible for the conduct of all aspects of the trial at the trial site.

A list of principal investigators with their site affiliations is provided in Appendix 16.1.4.

The Contract Research Organization (CRO), Alcedis GmbH, Gießen, Germany, was responsible for site management, development, and hosting of the study database and eCRF. Additionally, the CRO was responsible for data management, statistical analysis and preparation of the statistical and clinical study report. A list of the author of the Clinical Study Report, including the responsible biostatistician is provided in Appendix 16.1.4.

Alcedis GmbH contracted local CROs that were responsible for submission of the study documents to competent authority and ethics committee and for management of study sites in the respective participating countries:

- Responsible in France:
  - C2R, 66 Rue de Provence, 75009 Paris
- Ascopharm group Novasco, 56 Rue de Londres, 75008 Paris
- Responsible in Greece:
  - CORONIS Research S.A., 2 Nikitara Street, 152 32 Chalandri, Athens
- Responsible in Serbia:
  - Hungaro Trail CRO, Bulevar oslobodjenja 149/2, 11000 Belgrade
  - former CRO: Dokumeds, Katrīnas dambis 20, Ziemeļu rajons, Rīga, LV-1045, Lettland

Within this study a risk-based monitoring was performed. On-site monitoring was performed by clinical research associates appointed by Alcedis GmbH or by the respective contracted national CRO.

Cobimetinib, vemurafenib and atezolizumab were supplied by the Global Clinical Distribution Team F. Hoffmann-La Roche Ltd., Global Investigational Product Supply (PTDS), 4303 Kaiseraugst, Switzerland. The medication was labelled and sent to the study sites by Roche Pharma AG, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany.

A research laboratory at the University of Essen, Department of Dermatology, was responsible for analyzing blood samples and tumor samples of registered patients within the translational research project. Samples were collected only from German patients who agreed to participate in translational research.

Signatures from the Principal Investigator / Coordinating Investigator, sponsor's medical representative and biostatistician are provided in the Appendix 16.1.5.

## 7 INTRODUCTION

Cutaneous malignant melanoma is the most aggressive form of skin cancer that once it has spread to distant organs rapidly becomes life-threatening, causing ~59,000 deaths annually worldwide [1, 2]. If detected in an early stage surgical excision is curative in > 90% of patients [3]. In the advanced stage (stage IV), the relative 5-year survival rate is 41% for women and 40% for men in Germany [4].

After a stagnant period of years, when chemotherapeutic agents were the preferred systemic treatment of advanced malignant melanoma, the development of novel agents and therapy options resulted in significant improvement in response rates and survival. Molecular analysis of malignant melanoma cells led to detection of mutations which are used as therapeutic targets. Approximately 60% of melanomas harbor a mutation in the gene encoding the serine/threonine protein kinase BRAF [5]. Most of the BRAF mutations are transversion mutations in exon 15, which result in a V600 E/D/K amino acid substitution [6]. 70-80% of all BRAF mutations are indeed V600E mutations. Mutated BRAF has an approximately 10-fold increased activity compared to the wild type form [5]. Mutations in BRAF result in constitutive activation of the Mitogen-Activated Protein

Kinase (MAPK) pathway, causing an increase in proliferation and angiogenesis, while preventing apoptosis, thus enhancing the oncogenic activity of melanoma. Inhibition of BRAF by selective BRAF inhibitors has been shown to have clinical benefit in patients with V600-mutated melanoma [7, 8] compared to the alkylating agent dacarbazine. Despite prolongation of PFS and OS, disease recurrence occurs in almost all patients treated with BRAF inhibitors [9]. The mechanisms of resistance leading to disease progression are varied and include activation of alternative signaling pathways as well as reactivation of the MAPK pathway through new mutations [10].

In addition to direct inhibition of BRAF, MEK inhibitors have emerged as a therapeutic option for the treatment of BRAF-mutated melanoma. MEK as the only known phosphorylation substrate of BRAF is a downstream component of the BRAF/MEK/ERK signaling pathway and is upregulated in response to BRAF-inhibition [11]. Upregulation of MEK constitute one mechanism by which tumors develop resistance to BRAF inhibitors [12]. Activation of the Ras GTPase promotes the kinase activity of the Raf serine/threonine protein kinases. Activated Raf kinases promote the sequential phosphorylation and activation of the MEK and ERK kinases. ERK proteins translocate in the nucleus to stimulate the translation of proteins and the activation of transcription factors. This leads to a series of gene expression changes that promote cell proliferation and survival. This pathway can be targeted by inhibition of the mutated BRAF kinase by specific BRAF inhibitors and by inhibition of the MEK kinase by specific MEK inhibitors.

Proposed to delay or overcome resistance and thereby exerting additive or synergistic effects upon progression-free survival, a combined approach involving BRAF and MEK inhibition provided a greater clinical benefit compared with BRAF inhibitor monotherapy as well as reduced BRAF inhibition-associated side effects [13, 14].

Vemurafenib (Zelboraf<sup>®</sup>, also known as RO5185426 and PLX4032) was the first specific BRAF inhibitor approved by the FDA (2011) and the EMA (2012) for the treatment of adult patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. The combination of vemurafenib with cobimetinib (also known as Cotellic<sup>®</sup>, GDC-0973, XL518 or RO5514041) is approved in approximately 83 countries, including the United States and the European Union, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation. Cobimetinib is also approved in combination with vemurafenib and atezolizumab in the US and in several other countries for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is not approved in the EU.

Besides targeting the BRAF/MEK/ERK signaling pathway, the modulation of the immunological checkpoint is another target for therapy. Independent of the genetic background of the tumor, specific antibodies are used to block critical molecules for the regulation of the immune system, including cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligand PD-L1. Tumor cells can circumvent host immunity by expressing PD-L1 and other immunoinhibitory ligands, thus preventing the effects of anti-tumor cytotoxic T cells, and by blocking production of important immune-modulating cytokines [15]. The presence of tumor-related antigens on the surface of a tumor cell triggers an immune cascade, resulting in the proliferation and activation of T-lymphocytes, which leads to elimination of the tumor cell. The PD-1 related pathway is a co-inhibitory mechanism involved in the suppression of T-cell activation and regulating peripheral tolerance [16]. Some tumor cells and some other cells in the tumor microenvironment express PD-1 ligands (PD-L1 and PD-L2), which protect the tumor cell from immune destruction [17, 18]. The primary PD-1 ligand is PD-L1, which is upregulated in solid tumors where it can inhibit cytokine production and the cytolytic activity of PD-1+, tumor infiltrating CD4+ and CD8+ T cells [19, 20]. High expression of PD-L1 on tumor cells has been found to correlate with poor prognosis and survival in various types of cancer [21, 22]. Healthy organs express only little if any PD-L1. Drugs blocking the PD-1/PD-L1 pathway restore anti-tumor immunity [23]. Anti-PD-1 and anti-PD-L1 agents are shown to have impressive antitumor effects in several malignancies, especially in melanoma (reviewed in [24]). In September 2014, pembrolizumab (KEYTRUDA<sup>®</sup>) was the first antibody targeting the PD-1/PD-L1 interaction approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if the patient had a BRAF V600 mutation, after treatment with a BRAF inhibitor. On December 2014,



the FDA approved nivolumab (Opdivo®), the second PD-1 inhibitor for the treatment of patients with unresectable or metastatic melanoma and disease progression following treatment with ipilimumab and, if the patient was positive for a BRAF V600 mutation, after treatment with a BRAF inhibitor. In 2015, ipilimumab/nivolumab combination was approved by the FDA. In the CheckMate 067 trial, combination of ipilimumab with nivolumab has shown unprecedented survival results, reaching a mOS of more than 6 years [25]. On July 30, 2020, the FDA granted approval for the combination of atezolizumab (Tecentriq®, also known as RO5541267) plus vemurafenib and cobimetinib (triplet therapy) for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is not approved in the EU.

## Study Rationale

Targeting BRAF mutant metastatic melanoma using selective BRAF inhibitors or MEK inhibitors has shown PFS and OS benefit in treated patients. The major limitation of these monotherapies was the early appearance of resistance leading to tumor progression with a median PFS of 6 months. Clinical phase III data combining BRAF and MEK inhibitors improved clinical outcomes in patients with unresectable or metastatic BRAF-mutant melanoma, especially in those with rapid disease progression [26, 27]. However, even with high response rates, some patients remained unresponsive to targeted therapy. Among patients with good responses, some patients were refractory due to the emergence of resistance, as evident by disease relapse after partial or complete remission. Immunotherapy using antibody-mediated blockade of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) with ipilimumab [28, 29] or inhibition of the immune checkpoint programmed cell death protein 1 (PD-1) with nivolumab or pembrolizumab has further improved patient outcomes [18, 30-32].

In recent years, the treatment of advanced melanoma has been transformed by the emergence of immunotherapy (use of immune checkpoint inhibitors) and targeted therapies. The complementary response kinetic of such treatment approaches, supported by mechanistic evidence that targeted therapy affects immune aspects of the tumor microenvironment, suggests that an optimal combination or sequencing of immune checkpoint inhibitors and targeted therapy may provide additional clinical benefit. Sequencing the two clinically effective approaches, i.e., targeting the mutant BRAF pathway and the immunological checkpoint, should prolong tumor control, PFS, and OS even further. However, the best sequencing strategy was unclear. This prospective, open-label, multi-center clinical trial addressed the superior sequencing strategy for sequentially targeting the BRAF/MEK pathway with a combination of vemurafenib and cobimetinib and targeting immune checkpoint control with an antibody against PD-L1 (MPL3280A). After a 3-month run-in phase in which all patients were treated with vemurafenib + cobimetinib, all patients without tumor progression were randomized to one of two treatment arms. It was analyzed whether continuation of the BRAFi/MEKi combination until tumor progression and subsequent crossover to PD-L1 antibody atezolizumab or whether an immediate start with PD-L1 antibody atezolizumab after the run-in phase and treatment until disease progression with subsequent crossing back to vemurafenib + cobimetinib was more efficient in controlling tumor progression in patients with BRAF mutant melanoma.

## 8 STUDY OBJECTIVES AND ENDPOINTS

### 8.1 Objectives

The objective of the study was to assess if an early switch (i.e. switch at 3 months) from targeting the Ras/Raf signaling pathway by BRAF and MEK inhibition to immunologic checkpoint inhibition with an anti-PD-L1 antibody leads to prolongation of progression-free and overall survival outcomes in patients with unresectable or metastatic BRAFV600 mutant melanoma. Furthermore, the safety of the study treatment was assessed.

## 8.2 Endpoints

### Primary Endpoint

PFS 1 defined as time from start of run-in phase (date of first intake of study drug) to first documented tumor progression date according to RECIST v. 1.1 (PD<sub>1</sub>) or death by any cause, whichever occurred first. PFS1 was based on the disease assessment or date of death provided by the local investigator. For patients who remained alive and whose disease had not progressed, PFS1 was censored on the date of last visit/contact when a disease assessment was performed

### Secondary Endpoints:

- Time to Second Objective Disease Progression (PFS2), defined as time from start of run-in phase (date of first intake of study drug) to second documented disease progression according to RECIST v. 1.1 (PD<sub>2</sub>) following randomization or death by any cause. PFS2 was based on the disease assessment or date of death provided by the local investigator. For patients who remained alive and whose disease had not progressed, PFS2 was censored on the date of last visit/contact when a disease assessment was performed.
- Safety, Special attention was paid to all adverse events (AEs) ≥ Grade 3 according to CTCAE, Version 4.03 criteria, and all serious AEs (SAEs), regardless of causal relationship to the administration of the investigational agents.
- Overall Survival (OS) of patients, defined as the time from start of run-in phase (date of first intake of study drug) until documented date of death, for any cause. Patients still alive were censored at the time of last visit/contact.
- Overall survival rates at 12 months, 24 months, 36 months, and 48 months, defined as the rate of patients alive 12 months, 24 months, 36 months, and 48 months, respectively after start of run-in phase (date of first intake of study drug).
- 12-months and 24-months disease control rate (DCR), best overall objective response rate (OORR), time to overall objective response (OOR) and duration of OOR. DCR was defined as the rate of patients showing complete response (CR) or partial response (PR) or stable disease (SD) at 12 months and at 24 months after the start of run-in phase (date of first intake of study drug), OORR was defined as the rate of patients showing complete response (CR) or partial response (PR). CR, PR, and SD were defined according to RECIST v1.1 Criteria.
- Rate of patients with progressive disease (PD) who could not cross-over to subsequent line of therapy due to deterioration of ECOG status or multiple and/or symptomatic brain metastasis and/or leptomeningeal disease
  - from vemurafenib + cobimetinib to atezolizumab (Arm A)
  - from atezolizumab to vemurafenib + cobimetinib (Arm B)
- PFS3 defined as time from the first documented tumor progression date (PD<sub>1</sub>) until the second documented tumor progression date (PD<sub>2</sub>) after randomization or death by any cause, whichever occurs first. PFS3 was based on the disease assessment or date of death provided by the local investigator. For patients who remained alive and whose disease had not progressed, PFS3 was censored on the date of last visit/contact when a disease assessment was performed.

### Exploratory objectives (addressed by the translational research project, not part of the CSR):

- To evaluate the relationship of the tumor immune and signaling biomarker landscape and efficacy.
- To evaluate non-inherited genetic alterations of circulating free tumor-specific DNA in plasma.
- To assess and monitor the immunophenotype in peripheral blood mononuclear cells.

**Exploratory objectives (addressed by patient questionnaires, not part of the CSR):**

- To characterize the patient groups that opt for eMARS vs. paper-based documentation and to assess reasons for not participating in the eMARS program.
- To assess the user-friendliness and practicality of eMARS and the user satisfaction.
- To compare medication adherence between patients using eMARS and paper-based documentation.
- To assess quality of life using the EORTC QLQ C-30 questionnaire.
- To characterize the patient groups that opt for electronic vs. paper-based documentation of medication adherence using a study-specific questionnaire and standardized questionnaires (HADS-D, GSE Scale, Brief-IPQ, SES-Ladder).

## **9 INVESTIGATIONAL PLAN**

### **9.1 Overall Study Plan / Study Design**


This was a prospective, open, multicenter, randomized phase II study in patients with unresectable or metastatic BRAF V600 mutant melanoma. In this study the scheduling of the treatment with a combined BRAF/MEK inhibition and the treatment with a PD-L1 antibody were assessed.

After signing the informed consent, patients underwent screening procedures. All eligible patients entered the 3-month run-in phase with vemurafenib and cobimetinib. Vemurafenib (starting dose 960 mg/BID) was taken on day 1 to day 28 of each 28-day treatment cycle (in total, three 28-day cycles). The first dose of vemurafenib was taken in the morning, and the second dose in the evening. Cobimetinib (starting dose 60 mg/QD) was taken once daily, starting on day 1 to day 21 of each 28-day treatment cycle, approximately at the same time, preferably in the morning with the vemurafenib dose.

Patients showing disease progression during the run-in phase stopped study treatment and were not randomized to one of the two treatment arms. These patients entered the follow-up phase and were followed for survival and disease status, including documentation of subsequent lines of therapy and treatment response.

After the 3-month run-in phase, all patients who did not show disease progression or treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days were randomized in a 1:1 ratio either to proceed vemurafenib and cobimetinib treatment (Arm A) or to cross-over to receive atezolizumab treatment (Arm B). Patients were stratified according to serum LDH at enrolment, metastatic stage (IV M1c yes/no) and previous adjuvant therapy (yes/no). After randomization to the respective treatment arm, patients were treated with vemurafenib and cobimetinib (Arm A) or atezolizumab (Arm B) until the (next) progression of the disease. Vemurafenib and cobimetinib were given in the same dosing as in the run-in-phase. If a patient required a dose reduction of cobimetinib/ and or vemurafenib during the run-in phase due to toxicity, cobimetinib and vemurafenib were administered for this patient with the reduced dose during the randomized phase. Atezolizumab was administered intravenously at a fixed dose of 1,200 mg on day 1 of each 21-day treatment-cycle. Vemurafenib + cobimetinib (Arm A) or atezolizumab (Arm B) treatment in the randomized phase was given until disease progression (PD1). After disease progression, patients were subsequently crossed-over to atezolizumab treatment (1,200 mg/ q3w, arm A) or crossed back to vemurafenib + cobimetinib treatment (same dosing as in the run-in phase, arm B) until further disease progression (PD2). Patients showing unacceptable toxicities during the randomized phase stopped study treatment. These patients entered the follow-up phase and were followed for survival and disease status, including documentation of subsequent lines of therapy and treatment response.

After the treatment period, patients were followed for survival and disease status, including the status of subsequent lines of therapy and treatment response until the end of study. The individual follow-up time for this study was defined as time from 1<sup>st</sup> administration of study drug to end of study (48 months after the last patient was randomized (follow-up period)) (**Figure 1**).



\*The Follow-up Period for this study is 48 months after the last patient is randomized. Therefore, the patients are followed up until this timepoint.

\*\*After the registration, run-in treatment with vemurafenib and cobimetinib can be instituted within a maximum interval of 14 days.

**Figure 1 Study Flow Chart**

At any time, treatment could be discontinued at the discretion of the investigator or by patient refusal (withdrawal of consent). In case of toxicities attributable to one component of the therapy scheme, this component was stopped while continuing giving the other medications. However, due to the limited efficacy of cobimetinib alone, patients had to discontinue treatment with cobimetinib if vemurafenib treatment was discontinued.

All patients were closely monitored for safety and tolerability during all cycles of therapy, at the end-of-study treatment visit, and during the follow-up period. Patients were assessed for AEs every 2 weeks during the first 2 cycles of the run-in period, then prior to each subsequent cycle, and as necessary throughout the study. Tumor response was evaluated according to RECIST v1.1. Any evaluable and measurable disease was documented at screening and reassessed at each subsequent tumor evaluation. Response was assessed by the investigator at 12-weeks intervals. At the investigator's discretion, CT/MRI scans were repeated at any time if PD was suspected. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03 was used to characterize the toxicity profile of the study treatment on all patients. ECG assessment, dermatologic assessment, ophthalmologic examination was evaluated at baseline assessment and throughout the study. Left-ventricular function evaluation by echocardiogram or multigated acquisition (MUGA) was conducted during baseline assessment and throughout the study.

The Protocol and any Amendments as well as a sample CRF are provided as stand-alone documents on request (Appendix 16.1.1 and 16.1.2).

## 9.2 Discussion of Study Design, Including the Choice of Control Groups

Although considerable progress occurred in understanding the biological characteristics of cancer as well as the development of more effective treatment regimens, most patients with locally advanced or metastatic tumors succumb to their disease. Thus, there was a substantial need for novel therapeutic strategies to improve the outcome for patients with advanced or metastatic melanoma [33].

Targeting the BRAF/MEK/ERK pathway with the BRAF inhibitor vemurafenib in BRAF V600 mutation positive advanced melanoma in a phase III study (BRIM-3) was shown to prolong PFS and OS compared to dacarbazine. However, a median PFS of 6-7 months for vemurafenib-treated patients was not satisfying [7, 34].

Since the addition of a MEK inhibitor to vemurafenib abrogated vemurafenib resistance in preclinical findings, the combination of vemurafenib with the MEK inhibitor cobimetinib was evaluated in a Phase Ib study (BRIM-7) [35]. The BRIM-7 study identified the proposed investigational dose of the present study (vemurafenib 960 mg on day 1-28, cobimetinib 60 mg on day 1-21, in 28-day treatment cycles) as safe and well tolerated. The combination of vemurafenib and cobimetinib was investigated in the Phase III coBrim study [36, 37].

Targeting immunological checkpoint via the PD-1/PD-L1 axis emerged as breakthrough for the treatment of melanoma, showing high response rates with long duration of response. Atezolizumab is an antibody against PDL1. Objective responses were observed in a broad range of malignancies, including NSLLC, RCC, melanoma, bladder cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, and sarcoma in a Phase Ia study (study PCD4989g). Although atezolizumab was generally well tolerated, adverse events with potentially immune-mediated causes, including rash, hypothyroidism, hepatitis/transaminitis, colitis, and myasthenia gravis were observed in study PCD4989g. These events were monitorable and treatable.

This study was designed as a randomised cross-over study. Randomization ensured that the baseline characteristics of the patients were balanced between the two study arms. Only patients with previously untreated unresectable or metastatic BRAF V600 mutant melanoma were enrolled to prevent an influence of prior treatment lines on the study results. The risks associated with the combined vemurafenib and cobimetinib therapy and the immunological approach with the anti-PD-L1 antibody atezolizumab were reduced through a safety plan that incorporated into the eligibility criteria to exclude patients at unacceptable risk, enhanced monitoring of all patients, specific risk mitigation plans, and in case of the combined vemurafenib + cobimetinib therapy dose modification guidelines. In addition, safety data from the study were reviewed by the sponsor on a regular and ongoing basis in order to ensure the safety of the patients.

Taking into account, the efficacy and safety data of the combined vemurafenib + cobimetinib therapy observed in the BRIM-7, coBRIM and ML29741 studies, and of the atezolizumab therapy observed in the PCD4989g study, the potential benefits of this sequential therapeutic approaches outweighed the potential risks.

The combined vemurafenib + cobimetinib therapy is an approved therapy for the treatment of unresectable or metastatic BRAF V600-mutated melanoma. The dosing and dosing regimen was according to approved status. The potential risks of this treatment were therefore known. To further reduce risks for the patients, randomization was performed only after a run-in period during which patients were treated with the approved vemurafenib + cobimetinib combination therapy. Only patients without disease progression and who were well tolerating the combination therapy were randomized to continue combination therapy or to receive atezolizumab therapy. After randomization, a cross-over to the other treatment took place only in the case of PD.

### 9.3 Selection of Study Population

The selection of patients occurred through the investigator according to the inclusion and exclusion criteria after informing the patient written and orally about the study and after the patient has signed the informed consent. There was no preferred enrollment of men or women within this study. However, pregnant or breast-feeding women were excluded from participation. Within this clinical trial, no sex specific differences were expected concerning the efficacy and safety of the used trial medication. Thus, it was not necessary to consider the sex during recruitment and evaluation or conception of this clinical trial. Therefore, reasons according to §7 Abs. 2 Nr. 12 GCP-V did not apply.

Patients were screened to ensure that they meet the inclusion and exclusion criteria and were enrolled by online registration. After the registration, run-in treatment with vemurafenib and cobimetinib was instituted within a maximum interval of 14 days. Patients who were registered but who were not treated within 14 days were treated under the same patient number after a further screening examination if all inclusion and exclusion criteria were met. All patients who did not show progression of disease, who had not withdrawn their informed consent and who did not show unacceptable adverse reactions preventing study treatment during run-in phase for more than 28

days, were randomized to one of the treatment arms. Online randomization was possible 24 hours a day. The randomization result was notified immediately by an automatically generated fax to the investigator. The randomization list was kept in safe and confidential custody at Alcedis GmbH. After randomization, treatment was instituted within a maximum interval of 14 days. Patients who were not randomized to Arm A or Arm B after the run-in phase ("drop-out" during run-in phase) were not replaced.

### 9.3.1 Inclusion Criteria

Patients were **included** in the study only if they met **all** the following criteria:

1. Be willing and able to provide written informed consent for the trial.
2. Male or female patient being  $\geq 18$  years of age on day of signing informed consent.
3. Histologically confirmed diagnosis of locally advanced, unresectable or metastatic melanoma AJCC 7th edition (unresectable stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c) without active or untreated brain metastases; all known CNS lesions must have been treated with stereotactic therapy or surgery at least 4 weeks prior to the first dose of trial treatment AND the patient must be without evidence of clinical or radiographic disease progression in the CNS for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms must have returned to baseline, the patient must have no evidence of new or enlarging brain metastases, and the patient must not have used steroids in dosing exceeding 10 mg daily of prednisone equivalent for at least 3 weeks prior to trial treatment.
4. No previous therapy for the advanced or metastatic stage. Prior adjuvant therapy is permitted (e.g. IFN, IL-2-therapy, chemo- or radiotherapy). Prior adjuvant therapy has to be terminated (last dose) at least 28 days before enrollment. Patients who are in follow-up period of a clinical trial in adjuvant setting and progressing may be enrolled / randomized.
5. Measurable disease, i.e., present with at least one measurable lesion per RECIST, version 1.1, for the definition of a measurable lesion.
6. Presence of BRAF mutation (V600) in tumor tissue from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion prior to enrollment.
7. Have provided tissue from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion.
8. Have a performance status of 0 or 1 on the ECOG Performance Scale.
9. Demonstrate adequate organ function as defined in the following table. All screening labs should be performed within 28 days of treatment initiation.

**Table 1 Laboratory parameter to assess organ function**

System	Laboratory Value
<b>Hematological</b>	
Absolute neutrophil count (ANC)	$\geq 1,500$ /mcL
Platelets	$\geq 100,000$ / mcL
Hemoglobin	$\geq 9$ g/dL <b>OR</b> $\geq 5.6$ mmol/L
<b>Coagulation</b>	
INR and aPTT	$\leq 1.5 \times$ ULN
<b>Renal</b>	
Serum creatinine <b>OR</b> Measured or calculated <sup>a</sup> creatinine clearance (GFR can also be used in place of creatinine or CrCl)	$\leq 1.5 \times$ upper limit of normal (ULN) <b>OR</b> $\geq 50$ mL/min for subject with creatinine levels $> 1.5$ $\times$ institutional ULN
<b>Hepatic</b>	
Serum total bilirubin	$\leq 1.5 \times$ ULN
AST (SGOT) and ALT (SGPT)	$\leq 2.5 \times$ ULN <b>OR</b> $\leq 5 \times$ ULN for subjects with liver metastases
<sup>a</sup> Creatinine clearance should be calculated per institutional standard.	

10. Adequate cardiac function:
  - Left ventricular ejection fraction (LVEF)  $\geq 50\%$  as determined by multigated acquisition (MUGA) scan or echocardiogram
  - QTc interval  $\leq 450\text{ms}$
11. All prior treatment-related toxicities (except alopecia) following adjuvant therapy must be  $\leq$  Grade 1 according to the CTCAE (version 4.03) at the time of randomization.  
Note: Subjects with  $\leq$  Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
12. Able to take oral medications.
13. Patient is deemed by the investigator to have the initiative and means to be compliant with the protocol.
14. Female subject of childbearing potential should have a negative urine pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
15. Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use a highly effective form of contraception according to CTFG during the course of this study and for at least 6 months after completion of study therapy. Birth control methods which may be considered as highly effective can achieve a failure rate of less than 1% per year when used consistently and correctly.
  - Females of childbearing potential are defined as sexually mature women without prior oophorectomy or hysterectomy who have had menses within the last 12 months.
  - Females are not considered to be of childbearing potential if amenorrheic for  $> 12$  months and follicle-stimulating hormone (FSH) levels  $\geq 40$  IU/L.
  - For females who have been amenorrheic for  $\geq 2$  years, the requirement for FSH measurement at screening will be waived.
  - Highly effective forms of contraception include hormonal contraception (combined or progesterone-only) associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomy (must have received medical assessment of the surgical process) and sexual abstinence (complete avoidance of heterosexual intercourse), according to the CTFGs "Recommendations related to contraception and pregnancy testing in clinical trials". Please note that potential interactions between vemurafenib and hormonal contraceptives may decrease the effectiveness of hormonal contraceptives.

### 9.3.2 Exclusion Criteria

Patients were excluded from the study for **any** of the following reasons:

1. Use of any investigational or non-registered product within 30 days before registration.
2. Diagnosis of immunodeficiency or receiving systemic steroid therapy in dosing exceeding 10 mg daily of prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior to study Day 1.
3. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) also in an adjuvant setting.
4. Prior therapy with a BRAF inhibitor (including but not limited to vemurafenib, dabrafenib, encorafenib and / or MEK inhibitor (including but not limited to trametinib, AZD6244, binimetinib, cobimetinib) also in an adjuvant setting.
5. Prior major surgery.  
Note: Subjects may be included if they have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
6. Known additional malignancy that is progressing or requires active treatment within 3 years prior to the study. Exceptions include adequately treated basal cell carcinoma of

- the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy without evidence or recurrence.
7. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
    - Note: Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 3 weeks prior to trial treatment.
  8. History of leptomeningeal metastases.
  9. History or current evidence of central serous retinopathy (CSR) or retinal vein occlusion (RVO) or predisposing factors to RVO or CSR (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled diabetes mellitus, history of hyperviscosity or hypercoagulability syndromes).
  10. History of retinal degenerative disease.
  11. History of allogenic bone marrow transplantation or organ transplantation.
  12. History of Gilbert's syndrome.
  13. Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:
    - History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) < 6 months prior to screening.
    - Symptomatic chronic heart failure, history or current evidence of clinically significant cardiac arrhythmia and / or conduction abnormality < 6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia.
    - History of congenital long QT syndrome or mean (average of triplicate measurements) QTc measured using Fridericia's method > 450 ms at baseline or uncorrectable abnormalities in serum electrolytes (sodium, potassium, calcium, magnesium, phosphorus).
  14. Uncontrolled arterial hypertension despite medical treatment.
  15. Patients who have neuromuscular disorders which are associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
  16. Impairment of gastrointestinal function or gastrointestinal disease (e.g. ulcerative disease, uncontrolled nausea, vomiting, malabsorption syndrome, small bowel resection).
  17. Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids in dosing exceeding 10 mg daily of prednisone equivalent or immunosuppressive agents.
    - Note: Subjects with vitiligo or controlled asthma/atopy would be an exception to this rule.
    - Note: Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study.
    - Note: Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study.
  18. Evidence of interstitial lung disease or active, non-infectious pneumonitis.
  19. Active infection requiring systemic therapy.
  20. Pregnancy or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through at least 6 months after the last dose of trial treatment.
  21. Positive test for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).



22. Positive test for Hepatitis B (e.g., HbsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
23. Known hypersensitivity reaction to any of the components of study treatment.
24. Medical, psychiatric, cognitive or other conditions, including known alcohol or drug abuse that would not permit the subject to complete the study or sign informed consent.
25. Patients taking non-topical medication known to be a strong inhibitor of CYP3A4. However, patients who either discontinue their treatment or switch to another medication at least three days prior to registration / randomization are eligible.
26. Patients having received a live, attenuated vaccine within 4 weeks prior to the first dose of trial treatment.
27. Legal incapacity or limited legal capacity.
28. Presence of uveal melanoma.

### 9.3.3 Removal of Patients from Therapy or Analysis

Each patient remained in the study until the criteria defined below were met or until either the patient or the investigator determined discontinuation to patient's best interest.

Patients who discontinued participation in the clinical study on their own by withdrawal of informed consent (at any time) or patients who were withdrawn by the investigator were defined as premature withdrawals. Patients who did not start the study treatment in the run-in phase but signed informed consent and underwent at least some of the screening procedures were considered screening failures. A record of these patients was maintained in the eCRF

If patients had PD, permanent treatment discontinuation (e.g., due to unacceptable toxicity) or a treatment interruption for more than 28 days during the run-in phase, patients were not randomized to one of the two treatment arms and did not receive further study therapy. These patients entered the follow-up phase and were also included in the analyses.

Patients received study treatment until any of the following occurred:

- Subject experienced unacceptable toxicities or an adverse experience that would, in the investigator's or sponsor's judgement, make continued administration of the study regimen an unacceptable risk.
- Situations requiring a therapeutic intervention that was not permitted by the treatment plan.
- Development of an intercurrent illness or situation which could, in the judgement of the investigator, affect assessments of clinical status and study endpoints to a significant degree.
- In case of pregnancy.
- Request by the patient to stop the treatment.
- Study was closed or terminated.
- Investigator's decision.
- At the specific request of the sponsor.

In case of prolongation of the treatment-free interval beyond 28 days as a result of delayed hematological recovery or/and non-hematological side effects, permanent treatment discontinuation was decided after consultation with the coordinating investigator (Prof. Dr. med. Schandendorf, UK Essen).

The reason for discontinuing the investigational product was clearly documented in the patient's medical record and recorded on the electronic case report forms (eCRF). Subjects for whom the investigational product was permanently discontinued continued in the study follow-up unless they met the criteria for study withdrawal.

**Note:** A temporary interruption in study medication of  $\leq 28$  days due to an AE was not considered to be permanent discontinuation from investigational product.

Patients with identified violations of inclusion or exclusion criteria after enrolment were excluded from the final analysis.

### 9.3.4 Stopping or Suspending the Study

The sponsor was able to discontinue the study upon thirty (30) days prior written notice. Study discontinuation was at the discretion of the sponsor in any of the following events:

- Medical or ethical reasons affecting the continued performance of the study
- Difficulties in the recruitment of subjects

In addition, the study could have been discontinued at the discretion of the sponsor at any time in the event of any or all of the following:

- Inefficacy of the investigational product
- Occurrence of AEs previously unknown in respect of their nature, severity and duration, or unexpected incidence of known AEs

Safety data from the study was reviewed by the sponsor on a regular and ongoing basis in order to ensure the safety of the patients.

## 9.4 Treatments

### 9.4.1 Treatments administered

Cobimetinib, vemurafenib and atezolizumab were the investigational medicinal products (IMPs) in this study. It was possible that sites had more than one clinical study on the same drugs ongoing at the same time. It was imperative that only drug products designated for this protocol were used for this study. The investigator was responsible for ensuring that the investigational product was stored under appropriate environmental conditions (temperature, light, humidity). If concerns regarding the quality or appearance of the investigational product arose, the investigational product was not dispensed and F. Hoffmann-La Roche Ltd and Alcedis GmbH were contacted immediately. The investigator or a designated person delivered vemurafenib and cobimetinib to patients in the run-in phase and after randomization during treatment with these drugs. At each study visit these patients received enough vemurafenib/cobimetinib medication for the time period between two study visits.

Detailed information on storage, handling, and reconstitution was given in the respective Investigator's Brochure and the Medication Handling Manual as presented in the Pharmacy File.

During the run-in phase, all patients were treated with cobimetinib and vemurafenib combination therapy. A study cycle was defined by the 28-day dosing cycle during cobimetinib + vemurafenib treatment. After randomization, cobimetinib and vemurafenib combination therapy was continued with the same dose and dosage schedule (Arm A) or patients were treated with atezolizumab monotherapy (Arm B).

Atezolizumab was supplied as a concentrate for solution for infusion. Each 20 mL vial contained 1,200 mg atezolizumab. Atezolizumab dose was 1,200 mg (equivalent to an average body weight-based dose of 15 mg/kg) administered by i.v. infusion on day 1 every 3 weeks (21 [± 3] days). The initial dose of atezolizumab was delivered over 60 (± 15) minutes. During the first infusion, the patient's vital signs (heart rate, respiratory rate, blood pressures, and temperature) were collected within 60 minutes before, every 15 [± 5] minutes during the infusion and 30 (± 10) minutes after the infusion. If the first infusion was tolerated without infusion-associated adverse events and cytokine release syndrome, the second infusion was delivered over 30 (± 10) minutes. If the 30-minute infusion was well tolerated, all subsequent infusions were delivered over 30 (± 10) minutes. From the second infusion onwards, the patient's vital signs were recorded within 60 minutes before and 30 (± 10) minutes after the infusion. No premedication was allowed for the first dose of atezolizumab. Premedication could be administered for cycles ≥ 2 at the discretion of the treating physician.

For the cross-over treatment, cobimetinib + vemurafenib combination and atezolizumab monotherapy were administered as described above. Dose modifications were allowed for cobimetinib and vemurafenib independently. Cobimetinib dose was not reduced to < 20 mg once daily, and vemurafenib dose was not reduced to < 480 mg twice daily. Due to the limited efficacy

of cobimetinib alone, the treatment with cobimetinib was stopped if a patient discontinued treatment with vemurafenib. Dose modifications (reductions or escalations) were not allowed for atezolizumab. Atezolizumab doses were withheld for drug-related AEs until improvement to NCI grade  $\leq 1$ . In the case of grade 4 toxicities, atezolizumab treatment was permanently discontinued, except for endocrinopathies that were controlled by hormone-replacement therapy.

#### 9.4.2 Identity of Investigational Products

**Cobimetinib:** The 20 mg cobimetinib drug product was a film-coated, immediate release tablet. The white tablet was round with either the engraving “ROCHE” or the engraving “COBI” on one side. Cobimetinib was packaged in blister packs.

The inactive ingredients in cobimetinib were as follows: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate for the tablet core. The tablet coating consists of polyvinyl alcohol-part hydrolyzed, titanium dioxide, polyethylene glycol 3350, and talc.

Cobimetinib was not stored above 25°C (77°F). If cobimetinib was stored outside of the permitted temperature ranges, the affected supply was quarantined, and the monitor contacted.

Patients recorded the time and the date they took each dose in a medication diary. Missed doses were also recorded. Patients were instructed to bring all unused study drugs and their study drug diaries to each study visit for assessment of compliance. If a dose of study drug was missed (i.e. not taken within 4 hours after the scheduled dosing time), the patient resumed dosing with the next scheduled dose. Missed or vomited doses were not made up.

Cobimetinib was taken orally with a dose of 60 mg (3 tablets) once daily (QD). Cobimetinib was taken once daily at approximately the same time each day with the morning vemurafenib dose, and not later than 4 hours after the scheduled time.

Cobimetinib could be taken with or without a meal. Cobimetinib tablets were not to be chewed, cut, or crushed.

Each study cycle was defined by the 28-day dosing cycle during vemurafenib + cobimetinib treatment phase. At least 7 days off cobimetinib was required prior to starting a new treatment cycle. Therefore, cobimetinib was taken during the first 21 days of each 28-day cycle (21 days on, 7 days off) during the cobimetinib + vemurafenib treatment period.

Batch numbers: 1152310, 1153347, 1153878, 1154442, 1156020, 1153127, 1158966, 1159929, 1161779, 1174487, 1175137

**Vemurafenib:** The 240 mg vemurafenib drug product was a film-coated tablet light pink in color, oval shaped. Vemurafenib was packaged in bottles.

The inactive ingredients in vemurafenib tablets were as follows: croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, hydroxypropyl cellulose (tablet core), polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc, and iron oxide red (tablet coating).

Vemurafenib was stored at room temperature 20°C-25°C (68°F-77°F); excursions between 15°C and 30°C (59°F and 86°F) were permitted. If vemurafenib was stored outside of the permitted temperature ranges, the affected supply was quarantined, and the monitor contacted.

Patients recorded the time and the date they took each dose in a medication diary. Missed doses were also recorded. Patients were instructed to bring all unused study drugs and their study drug diaries to each study visit for assessment of compliance. If a dose of study drug was missed (i.e. not taken within 4 hours after the scheduled dosing time), the patient resumed dosing with the next scheduled dose. Missed or vomited doses were not made up.

Vemurafenib was taken orally, with a dose of 960 mg (4 tablets) twice daily (BID). The first dose of vemurafenib was taken in the morning, and the second dose was taken in the evening, at least 8 hours after the first dose (the ideal interval between the doses was 12 hours).

Vemurafenib could be taken with or without a meal and had to be taken with a glass of water. The vemurafenib tablets were not to be chewed, cut, or crushed.

During the combined vemurafenib + cobimetinib treatment periods vemurafenib was administered in 28-day cycles. Vemurafenib was taken continuously during each 28-day cycle.

Batch numbers: 1152629, 1153516, 1154058, 1154531, 1155049, 1156835, 1157801, 1161777, 1171015, 1171317, 1174486, 1175585

**Atezolizumab:** The atezolizumab drug product was provided in a single-use, 20-cc USP/Ph. Eur. Type 1 glass vial as a colorless to slightly yellow, sterile, preservative-free clear liquid solution intended for i.v. administration. The vial was designed to deliver 20.0 mL (1,200 mg) of atezolizumab solution but could contain more than the stated volume to enable delivery of the entire 20.0 mL volume. The atezolizumab drug product was formulated as 60 mg/mL atezolizumab in 20 mM histidine acetate, 120 mM sucrose, 0.04% polysorbate 20, pH 5.8.

Atezolizumab was to be refrigerated at 2°C-8°C upon receipt until use. Atezolizumab vials were not allowed to be used beyond the expiration date provided by the manufacturer.

No preservative was used in the atezolizumab drug product; therefore, each vial was intended for single use only. Vial contents were not frozen or shaken and must have been protected from direct light by keeping the vial in the outer carton.

The dose level of atezolizumab tested in this study was 1,200 mg (equivalent to an average body weight-based dose of 15 mg/kg) administered by IV infusion on day 1 every 3 weeks (q3w) (21 [± 3] days), according to the FDA-approved prescribing information for atezolizumab (FDA reference ID: 3933242).

Administration of atezolizumab was performed in a setting with emergency medical facilities and staff who were trained to monitor for and respond to medical emergencies.

Atezolizumab was delivered in IV infusion bags containing 0.9% sodium chloride (NaCl) and infusion lines equipped with 0.2 or 0.22 µm in-line filters. The IV bag could have been constructed of polyvinyl chloride (PVC), polyolefin, polyethylene or polypropylene. The IV infusion line could have been constructed of polyvinyl chloride, polyethylenene, or polybutadiene and the 0.2 or 0.22 µm in-line filter could have been constructed of polyethersulfone or polysulfone. Atezolizumab could have been diluted to concentrations between 3.2 mg/mL and 16.8 mg/mL in IV bags containing 0.9% NaCl.

The use of administration supplies composed of materials other than those listed was avoided if possible. Atezolizumab was prepared/diluted under appropriate aseptic conditions as it did not contain antimicrobial preservatives. The prepared solution for infusion was used immediately to limit microbial growth in case of potential accidental contamination.

The initial dose of atezolizumab was delivered over 60 (± 15) minutes. If the first infusion was tolerated without infusion-associated adverse events and cytokine release syndrome, the second infusion was delivered over 30 (± 10) minutes. If the 30-minute infusion was well tolerated, all subsequent infusions were delivered over 30 (± 10) minutes. At all infusions, the patient's vital signs (heart rate, respiratory rate, blood pressures, and temperature) were determined within 60 minutes before and 30 (± 10) minutes after the infusion. Vital signs were also collected during the first infusion (every 15 [± 5] minutes). During subsequent infusions, vital signs were collected if clinically indicated. Patients were informed about the possibility of delayed post-infusion symptoms and instructed to contact their study physician if they developed such symptoms.

No premedication was allowed for the first dose of atezolizumab. Premedication could have been administered for Cycles ≥ 2 at the discretion of the treating physician.

Batch numbers: 1153708, 1153375, 1153048, 1154613, 1156592, 1161810, 1164255, 1165191, 1167909, 1175838, 1177286

For storage of the IMP at the study sites, a temperature log was maintained daily. In the event of a deviation, Roche provided a response on how to handle the drug.

### 9.4.3 Method of Assigning Patients to Treatment groups

All enrolled patients received the same study treatment comprising vemurafenib (960 mg BID; day 1-28 of each cycle) in combination with cobimetinib (60 mg QD, day 1-21 of each cycle) during the 3-month run-in phase (comprising three 28-day cycles). During the run-in phase, monitoring of drop-out rate was conducted by the Coordinating Investigator in a constant manner. All patients who did not show disease progression, permanent treatment discontinuation (e.g. due to unacceptable toxicity) or treatment interruption for more than 28 days, were block-randomized in a 1:1 ratio to one of two treatment arms. Randomization was stratified by LDH serum level (normal institutional level vs. elevated level by institutional standard), metastatic stage (IV M1c yes/no) and previous adjuvant therapy for underlying disease (yes/no). Patients in treatment Arm A continued treatment with cobimetinib and vemurafenib until disease progression. As during the run-in phase, vemurafenib (960 mg BID, day 1-28 of each cycle) + cobimetinib (60 mg QD, day 1-21 of each cycle) were administered in 28-day cycles. After disease progression according to RECIST v.1.1. and proof of eligibility ("Cross-over" check) patients were then subsequently (within an interval  $\leq$  14 days) crossed over to atezolizumab treatment until the next progression of the disease. Atezolizumab was administered IV in 21-day cycles (day 1 of each 21-day cycle) in a dose of 1,200 mg. Patients in treatment Arm B crossed-over within an interval of  $\leq$  14 days to atezolizumab treatment until progression of disease. Atezolizumab (1,200 mg) was administered IV in 21-day cycles (day 1 of each 21-day cycle) until progression of disease according to RECIST v.1.1. After a proof of eligibility ("Cross-over" check) patients were then subsequently (within an interval  $\leq$  14 days) crossed-back to vemurafenib (960 mg BID; day 1-28 of each 28-day cycle) + cobimetinib (60 mg QD, day 1-21 of each 28-day cycle). Combined vemurafenib + cobimetinib treatment was administered until the next progression of disease.

A description of the randomization method and a table for identification of subjects is provided in the Appendix 16.1.7.

### 9.4.4 Dose Selection

Cobimetinib and vemurafenib were administered according to the approved dose and dosing schedule as detailed in the SmPC.

For atezolizumab monotherapy, a flat dose of 1,200 mg (corresponding to an average body weight-based dose of 15 mg/kg) administered intravenously every 3 weeks was chosen.

### 9.4.5 Selection and Timing of Dose for Each Patient

Vemurafenib was taken with a glass of water, without chewing, cutting or crushing with the first dose administered in the morning and the second dose in the evening – ideally within a 12-hour interval (or at least 8 hours after the first dose). The administration of vemurafenib was not dependent on taking a meal.

Cobimetinib was taken once daily approximately with the morning dose of vemurafenib, but no later than 4 hours after the morning dose of vemurafenib. The administration of cobimetinib was not dependent on taking a meal. Tablets were not to be chewed, cut or crushed.

Atezolizumab was administered in a setting with emergency medical facilities by trained staff to monitor and respond to medical emergencies. The initial dose was delivered over 60 ( $\pm$  15) minutes and vital signs of the patient were determined every 15 ( $\pm$  5) minutes. The second dose was delivered over 30 ( $\pm$  10) minutes with determination of patient's vital signs within 60 minutes before the infusion and 30 ( $\pm$  10) minutes after the infusion. Upon well tolerance (e.g., no infusion-associated adverse events and cytokine release syndrome), all subsequent doses were delivered over 30 ( $\pm$  10) minutes. Vital signs were collected if clinically relevant.

### 9.4.6 Blinding

No blinding of study medication was necessary as study treatment was administered in an open-label manner during all study phases.

#### 9.4.7 Prior and Concomitant Therapy

All treatments that the investigator considered necessary for a subject's welfare were at the discretion of the investigator in keeping with the community standards of medical care. Relevant prior and concomitant medications received within 28 days before the first dose of trial treatment and 30 days after the last dose of trial treatment were recorded in the eCRF, including all prescription, over the counter (OTC), herbal supplements, and IV medications and fluids. If changes occurred during the trial period, documentation of drug dosage, frequency, route, and date were also included in the eCRF. The patient notified the investigational site about any new medications he/she took after the start of the study drug. Patients taking concomitant medications chronically had to maintain the same dose and dose schedule throughout the study if medically feasible.

Anti-emetics and anti-diarrheal medications were not administered prophylactically, before initial treatment with the study drugs. At the discretion of the investigator, prophylactic anti-emetic and anti-diarrheal medication(s) could have been used per standard clinical practice before subsequent doses of study drugs.

Patients who experienced infusion associated symptoms during atezolizumab therapy were managed symptomatically. Serious infusion-related events manifested by dyspnea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation, or respiratory distress were managed with supportive therapies as clinically indicated.

Systemic corticosteroids and TNF-alpha (TNF- $\alpha$ ) inhibitors could potentially attenuate beneficial immunologic effects of treatment with atezolizumab but were allowed to be administered at the discretion of the treating physician. During atezolizumab therapy alternatives to corticosteroids were considered, if feasible, but premedication could have been administered for Cycles  $\geq 2$  of the atezolizumab treatment phase. The use of inhaled corticosteroids and mineralocorticoids was allowed. Megastrol administered as an appetite stimulant was acceptable during study participation.

Patients who used hormonal therapy such as oral contraceptives, hormone-replacement therapy, prophylactic or therapeutic anticoagulation therapy (such as low-molecular weight heparin or warfarin at a stable dose level), or other allowed ongoing therapies or medications continued their use. Males and females of reproductive potential had to use highly effective methods of contraception. Potential interactions between vemurafenib and hormonal contraceptives potentially decreased the effectiveness of hormonal contraceptives.

Use of the following therapies was prohibited during the screening and the treatment phase of this study:

- Any concomitant therapy intended for the treatment of advanced melanoma, either approved by health authorities or experimental, including chemotherapy, radiation therapy, immunotherapy, hormonal therapy, biologic therapy, or investigational agents was prohibited. Stereotactic radiation therapy of single brain metastases that occurred due to disease progression during the study was allowed after discussion with and approval by the coordinating investigator.
- Prior adjuvant therapy (e.g. IFN, IL-2 therapy, chemo- or radiotherapy). Prior adjuvant therapy had to be terminated (last dose) at least 28 days before enrollment.
- Systemic steroids in dosing exceeding 10 mg daily of prednisone equivalent (unless utilized to treat a drug-related adverse event).
- Systemic immunosuppressive medication, including but not limited to, cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil, and thalidomide (unless utilized to treat a drug-related adverse event). These agents potentially altered the activity and the safety of atezolizumab. Patients who were in follow-up period of a clinical trial in adjuvant setting could have been enrolled.

No premedication was allowed for the initial (first) dose of atezolizumab. Premedication could have been administered for subsequent cycles (cycle  $\geq 2$ ) at the discretion of the treating physician.

Use of the following foods was prohibited during the study and for at least 7 days prior to initiation of study treatment, unless otherwise specified below:

- St John's wort or hyperforin (potent CYP3A4 enzyme inducer)
- Grapefruit Juice (potent CYP3A4 enzyme inhibitor)

Patients who required the use of any of these agents were discontinued from study treatment and followed for safety outcomes for 30 days after the last dose of study medication. These patients were also continued to be followed for survival.

#### 9.4.8 Treatment Compliance

Vemurafenib and cobimetinib were taken orally and atezolizumab was administered as intravenous infusions at the respective site. The date of the atezolizumab infusion was recorded in the eCRF.

### 9.5 Efficacy and Safety Variables

#### 9.5.1 Efficacy and Safety Measurements Assessed and Schedule of Assessment

Patients who provided written informed consent were further evaluated to confirm that the patients met all inclusion and none of the exclusion criteria of the clinical trial.

#### Clinical examinations prior to therapy (pre-/screening phase)

All clinical examinations were performed within 28 days before registration (administration of the first study treatment), including:

- Medical history
- Demographics (year of birth, sex, race, height, and weight)
- Prior and concomitant medications
- Physical examination and imaging to document stage of melanoma at baseline according to AJCC (v. 7.0) classification; furthermore, BRAF mutational status in tumor tissue was assessed
- Tumor assessment<sup>1</sup> by CT or MRI scan of thorax, abdomen, and brain to document baseline tumor status and response evaluation per RECIST v1.1.
- Transfer of tumor tissue (formalin-fixed paraffin-embedded (FFPE) tumor sample aliquots) to the central biobank laboratory (Essen) for analysis of BRAF mutational status and for the Translational Research Project, if available
- Complete physical examination
- Vital signs (including temperature, heart rate, respiratory rate, systolic and diastolic blood pressure)
- Eastern Cooperative Oncology Group (ECOG) performance status
- Ophthalmologic examination by a qualified ophthalmologist
- Cardiac evaluation (including ECG and LVEF<sup>2</sup> evaluation)
- Baseline dermatologic examination by a dermatologist or a qualified equivalent medical specialist for cuSCC surveillance
- Blood samples for Translational Research Project
- Laboratory assessments
  - Hematology: Hematocrit, hemoglobin, platelet count, white blood cell count (WBC) (total and differential), red blood cell count, absolute neutrophile count
  - Serum chemistry: Albumin, sodium, potassium, total protein, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), S-100, gamma-glutamyl transferase (GGT), CPK, bilirubin (total, direct and indirect), blood urea nitrogen (BUN) or urea, serum creatinine OR measured or calculated creatinine clearance
  - Thyroid: total triiodothyronine (T3), free thyroxine (FT4), thyroid stimulating hormone (TSH)

<sup>1</sup> at discretion of the investigator, the assessment method /technique used for evaluation at baseline had to be the same throughout the study and performed by the same investigator or radiologist

<sup>2</sup> by the same method, laboratory and operator for each patient

- Test for HIV, hepatitis B and hepatitis C
- Coagulation: INR, aPTT
- Pregnancy test (within 72 hours prior to the start of the first cycle)<sup>3</sup>: urine or serum  $\beta$ -hCG test
- Urine: pH, protein, glucose, blood, ketones, leukocytes
- Patients Questionnaires: EORTC QLQ C-30, HADS-D, GSE (German: SWE), Brief-IPQ, SES ladder, project specific list of questions (a)

### Clinical examinations during the study

Clinical examinations scheduled on the day of drug administration were performed prior to the study drug dosing, unless otherwise specified. Clinical examinations, which were conducted every 4 weeks (during treatment with vemurafenib + cobimetinib in both the run-in phase and the randomized phase) or every 3 weeks (during treatment with atezolizumab) were conducted within a window of  $\pm 3$  days.

#### Within 72 hours prior to the start of each cycle:

- Pregnancy test

#### At day 1 of each study cycle (prior to administration of study drug)

- Vital signs (body temperature, heart rate, respiratory rate, systolic and diastolic blood pressure)<sup>4</sup>
- Physical examination (head and neck evaluation by visual inspection of the oral cavity and by lymph node palpitation to monitor for non-cutaneous SCC (ncSCC))<sup>5</sup>
- Weight
- Laboratory assessments<sup>6</sup>:
  - Hematology: Hematocrit, hemoglobin, platelet count, white blood cell count (WBC) (total and differential), red blood cell count, absolute neutrophil count
  - Urine, if clinically indicated: pH, protein, glucose, blood, ketones, leukocytes (if clinically indicated)
  - Serum chemistry<sup>7</sup>: Albumin, sodium, potassium, total protein, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), S-100, gamma-glutamyl transferase (GGT), CPK, bilirubin (total, direct and indirect), blood urea nitrogen (BUN) or urea, serum creatinine OR measured or calculated creatinine clearance
  - Thyroid: T3, FT4, TSH
- Interval medical history including documentation of new or worsening AEs and concomitant medications
- ECOG performance status
- If available, transfer of FFPE tumor tissue sample aliquots to the central biobank laboratory (Essen) for Translational Research Project. Ophthalmologic examination, if clinically indicated by a qualified ophthalmologist: Patients were questioned at each visit for symptoms of visual disturbances, and any patients with symptoms of visual disturbance underwent ophthalmological examination including optical coherence tomography (OCT)

<sup>3</sup> If urine pregnancy results could not have been confirmed as negative, a serum pregnancy test was required. Female patients of childbearing potential as well as all men must have been informed that they were obliged to practice medically accepted contraception throughout the study, as defined in the Inclusion/Exclusion criteria section

<sup>4</sup> If the examination was performed within 7 days of cycle 1 – day 1 visit, a repeat examination on day 1 was not necessary

<sup>5</sup> If the examination was performed within 7 days of cycle 1 – day 1 visit, a repeat examination on day 1 was not necessary

<sup>6</sup> If specimens for laboratory assessment were collected within 7 days of cycle 1 – day 1 visit, a repeat collection on day 1 was not necessary

<sup>7</sup> If the examination was performed within 7 days of cycle 1 – day 1 visit, a repeat examination on day 1 was not necessary



At week 2 / at randomization / at week 2 and week 12 of secondary treatment / at PD before crossing-over (PD1) / at week 2 and 12 after crossing-over / at PD after crossing-over (PD2)

- Blood samples for Translational Research Project

Monthly after treatment initiation for the duration of the run-in phase

- Cardiac evaluation (ECG)

Once monthly after treatment initiation of the run-in phase

- Cardiac evaluation (LVEF)

At week 12 after 1<sup>st</sup> dose of study medication in run-in phase

- Patient's Questionnaires: EORTC QLQ C-30, Brief-IPQ, project-specific list of questions (b)

At week 12 after 1<sup>st</sup> dose of study medication in randomized phase

- Patient's Questionnaires: EORTC QLQ C-30, Brief-IPQ)

Every 9 weeks

- Serum chemistry: T3, T4, TSH

Every 12 weeks

- Physical examination (head and neck evaluation by visual inspection of the oral cavity and by lymph node palpitation to monitor for ncSCC)

Every 3 months ( $\pm$  1 week)

- Tumor assessment by CT or MRI scan of thorax/ abdomen, MRT/CT scan of the brain was repeated only in case of specific symptoms or in case of pre-existing brain metastases
- Dermatologic examination by a dermatologist or a qualified equivalent medical specialist for surveillance of cuSCC and of new primary melanoma or other cutaneous neoplasms
- Cardiac evaluation (ECG and LVEF measurement) during vemurafenib and cobimetinib treatment<sup>8</sup>

### **Clinical examinations at the end of the study treatment visit (end of treatment)**

Clinical examinations at the end of the study were conducted within 7 days of discontinuation.

- Interval medical history including documentation of new or worsening AEs according to NCI CTCAE version 4.03
- Physical examination (head and neck evaluation by visual inspection of the oral cavity and by lymph node palpitation, including pelvic (women) and anal examination to monitor for ncSCC)
- Vital signs (body temperature, heart rate, blood pressure)
- ECOG performance status
- Pregnancy test: Urine or serum  $\beta$ -HCG
- Laboratory assessments:
  - Hematology: Hematocrit, hemoglobin, platelet count, white blood cell count (WBC) (total and differential), red blood cell count, absolute neutrophile count
  - Serum chemistry: Albumin, sodium, potassium, total protein, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), S-100, gamma-glutamyl transferase (GGT), CPK, bilirubin (total, direct and indirect), blood urea nitrogen (BUN) or urea, serum creatinine OR measured or calculated creatinine clearance
  - Pregnancy urine or serum  $\beta$ -hCG test
- Ophthalmologic examination by a qualified ophthalmologist<sup>9</sup>

<sup>1</sup> at discretion of the investigator, the assessment method /technique used for evaluation at baseline had to be the same throughout the study and performed by the same investigator or radiologist

<sup>2</sup> by the same method, laboratory and operator for each patient

<sup>8</sup> Patients on treatment for  $\geq$  24 months without decrease of LVEF by  $>$  10% compared to baseline and LVEF  $<$  LLN at any time while on study, cardiac evaluation was only performed every 24 weeks (or more frequently if clinically indicated)

<sup>9</sup> Only if not performed within the last 12 weeks

- Dermatologic examination by a dermatologist or a qualified equivalent medical specialist for surveillance of cuSCC and of new primary melanoma or other cutaneous neoplasms
- Tumor assessment<sup>1</sup> by CT or MRI scan of thorax, abdomen, and pelvis; MRT/CT scan of the brain was only performed in case of specific symptoms or in case of pre-existing brain metastases and response evaluation per RECIST v1.1.

### Clinical examinations during the safety follow-up (post-treatment)

Clinical examinations during the safety follow-up (post-treatment) were conducted 30 ( $\pm$  3) days after discontinuation, including:

- Documentation of new or worsening AEs according to NCI CTCAE version 4.03
- Physical examination (head and neck evaluation by visual inspection of the oral cavity and by lymph node palpitation to monitor for ncSCC)
- Vital signs (body temperature, heart rate, blood pressure)
- ECOG performance status
- Cardiac evaluation (ECG and LVEF<sup>2</sup>), if it was clinically indicated
- Laboratory assessments:
  - Hematology: Hematocrit, hemoglobin, platelet count, white blood cell count (WBC) (total and differential), red blood cell count, absolute neutrophile count
  - Serum chemistry: Albumin, sodium, potassium, total protein, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), S-100, gamma-glutamyl transferase (GGT), CPK, bilirubin (total, direct and indirect), blood urea nitrogen (BUN) or urea, serum creatinine OR measured or calculated creatinine clearance
  - Thyroid: T3, FT4, TSH
  - Coagulation: PT / INR, aPTT
- Subsequent therapies
- Survival status

### Clinical examinations during the follow-up visits (post-treatment)

- Clinical examinations during the follow-up visits (post-treatment) were conducted every 3 months for 1 year and thereafter every 6 months ( $\pm$  7 days) until Last Patient Last Visit (LPLV), including: Head and neck examination including: to monitor for non-cutaneous SCC consisting of a visual inspection of the oral mucosa and lymph node palpation (every 12 weeks for a minimum of 6 months after study drug discontinuation)
- Documentation of new or worsening (S)AEs according to NCI CTCAE version 4.03: all (S)AEs that occurred within 90 days of discontinuation of the investigational product must have been reported. After this time period, SAEs that were believed to be related to vemurafenib/cobimetinib/atezolizumab should also have been reported
- ECOG performance status
- Dermatologic examination by a dermatologist or a qualified equivalent medical specialist for surveillance of cuSCC and of new primary melanoma or other cutaneous neoplasms had to be done once at 6 months after the end of treatment visit
- Tumor assessment<sup>1</sup> by CT or MRI scan of thorax, abdomen, and pelvis. MRT/CT scan of the brain was only performed in case of specific symptoms or in case of pre-existing brain metastases
- Subsequent therapies
- Survival status<sup>10</sup>

<sup>1</sup> at discretion of the investigator, the assessment method /technique used for evaluation at baseline had to be the same throughout the study and performed by the same investigator or radiologist

<sup>2</sup> by the same method, laboratory and operator for each patient

<sup>10</sup> Survival status was assessed until death via visits, phone calls or letters. A patient was considered as lost to follow up if no contact could have been established for 3 consecutive time points.

Routine laboratory assessments were performed at the site-specific local laboratory. In patients who consented to the Translational Research Program, an additional 18 ml of blood sample were obtained at baseline, at week 2 and at randomization, at week 2 and week 12 of the secondary treatment, at tumor progression before crossing-over (PD1) and at week 2 and week 12 after crossing-over, as well as at second progression after randomization (PD2). These blood samples were sent to the central laboratory at the University of Essen, Department of Dermatology, for analysis.

For all patients, BRAF V600 mutation status was analyzed at the central biobank laboratory of the University of Essen, Department of Dermatology, on FFPE tumor sample aliquots (either primary tumor or metastasis). Further analyses in specialized biomarker laboratories were performed on tumor samples of patients who consented to the Translational Research Program.

Tumor assessment was performed according to RECIST 1.1 at the trial site [38]. CT or MRI scans of the chest, abdomen, and pelvis – and of the brain in subjects with known brain metastases – were performed within 28 days prior to registration / enrollment to establish a baseline tumor assessment and re-assessed in 3-months intervals during the run-in phase, the randomization phase and during the first year of the follow-up phase. Thereafter, tumor assessment was performed every 6 months until end of study or more frequently as clinically indicated. The method of the tumor assessment was the same as at baseline and was performed by the same investigator or radiologist.

A complete history of prior dermatologic interventions and cuSCC risk factors (i.e., radiation therapy, sun exposure, immunosuppression, prior SCC, use of tanning beds, precursor lesions, and phototherapy for psoriasis) was collected at baseline. Regular skin examinations to monitor for cuSCC, BCC, actinic keratosis, keratoacanthoma and second primary melanomas were performed in 3 months intervals during the treatment phase and 6 months after the end of treatment.

All patients underwent baseline ophthalmologic examination to evaluate for evidence of retinal pathology that is considered a risk factor for neurosensory retinal detachment, RVO or neovascular macular degeneration. Patients were questioned at each visit for symptoms of visual disturbances, and patients with symptoms of visual disturbance underwent ophthalmologic examination, including OCT by a qualified ophthalmologist.

Cardiac examinations were conducted by ECG monitoring during screening phase and monthly after treatment initiation with vemurafenib and cobimetinib for 3 months and then every third month while on vemurafenib and cobimetinib treatment. Single ECG recordings were obtained within approximately 2-5 minutes at each specified timepoint. The average of the 3 readings were used to determine ECG intervals (e.g., PR interval, QT interval). ECGs for each patient were obtained from the same machine whenever possible. To minimize variability, it was important that patients were in a resting position for  $\geq 10$  minutes prior to each ECG evaluation. Body position was consistently maintained for each ECG evaluation to prevent changes in the heart rate. Environmental distractions (e.g., television, radio, conversation) were avoided during the pre-ECG resting period and during ECG recordings. In addition, LVEF was evaluated by echocardiography (ECHO) or multiple gated ejection acquisition scan (MUGA) before initiation of treatment to establish baseline values, then after the first month vemurafenib and cobimetinib treatment and at least every 3 months or as clinically indicated until while on vemurafenib and cobimetinib treatment. Evaluation of LVEF was performed by the same method for each patient, and for ECHO by the same laboratory and operator for each individual patient. Any patient who developed clinical signs or symptoms suspicious of cardiac failure underwent an LVEF assessment.

**Table 2 Overview of Study Examinations**

Trial Period:		Pre-/ Screening Phase	Treatment Cycles <sup>a</sup>	End of Treatment	Post-Treatment	
Treatment Cycle/Title:			Day 1 of each cycle	End of Study treatment visit	Safety Follow-up	Follow Up Visits
Scheduling Window (Days):		- 28 to -1	± 3	Within 7 days of discontinuation	30 days after discontinuation ± 3 days	Every 3 months for 1 year, thereafter every 6 months till Last Patient Last Visit ± 7 days
<b>Administrative Procedures</b>						
Informed Consent		X				
Inclusion/Exclusion Criteria		X				
Tumor status (BRAF mutation)		X				
Demographics and Medical History		X				
Prior and Concomitant Medication Review		X				
Post-study anticancer therapy status					X	X
Survival Follow-up					X	X
<b>Clinical Procedures/Assessments</b>						
Adverse Events (AEs) / Serious adverse Events (SAEs)*		X	X	X	X	X
Full Physical Examination <sup>l, m</sup>		X	X	X	X	
Ophthalmologic examination		X	If clinically indicated	X**		
Vital Signs		X	X	X	X	
ECOG Performance Status		X	X	X	X	X
Cardiac Evaluation		X <sup>b</sup>	X <sup>b</sup>		X <sup>b</sup>	
Dermatologic Evaluation		X	X <sup>c</sup>	X		X <sup>d</sup>
<b>Laboratory Procedures/Assessments</b>						
Pregnancy Test – Urine or Serum β-HCG <sup>e</sup>		X	X	X		
PT/INR and aPTT		X			X	
Hematological assessment <sup>f</sup>		X	X	X	X	
Comprehensive Serum Chemistry Panel <sup>g</sup>		X	X	X	X	
Urine analysis		X	Urine dipstick if clinically indicated			
T3, FT4 and TSH		X	X <sup>h</sup>		X	

Trial Period:	Pre-/ Screening Phase	Treatment Cycles <sup>a</sup>	End of Treatment	Post-Treatment	
				Safety Follow-up	Follow Up Visits
Treatment Cycle/Title:		Day 1 of each cycle	End of Study treatment visit		
Scheduling Window (Days):	- 28 to -1	± 3	Within 7 days of discontinuation	30 days after discontinuation ± 3 days	Every 3 months for 1 year, thereafter every 6 months till Last Patient Last Visit ± 7 days
HIV Test	X				
Hepatitis B and C Test	X				
<b>Efficacy Measurements</b>					
Tumor and response evaluation	X	X <sup>i</sup>	X		X
<b>Tumor Biopsies/Archival Tissue Collection/Correlative Studies Blood</b>					
Tumor tissue	X <sup>j</sup>	X <sup>j</sup>			
Blood plasma collection and blood cell collection	X <sup>k</sup>	X <sup>k</sup>	X <sup>k</sup>		
<b>Questionnaires for Patients and Study sites, Compliance request</b>					
Questionnaire for Study site	X <sup>n</sup>	X <sup>o</sup>			
Questionnaires for patients	X <sup>p</sup>	X <sup>q</sup>			
Documentation of medication intake		daily, in case of cobimetinib / vemurafenib treatment			

a: Treatment cycle duration during run-in phase with vemurafenib +cobimetinib and during treatment with vemurafenib + cobimetinib in randomized phase was 28 days. Duration of treatment cycles of atezolizumab treatment during randomized phase was 21 days.

b: Cardiac evaluation, including ECG and LVEF measurement was performed at baseline. After treatment initiation with vemurafenib and cobimetinib ECG was monitored monthly for 3 months and then every third month while on vemurafenib and cobimetinib treatment. LVEF was evaluated after the first month of vemurafenib and cobimetinib treatment and then at least every 3 months or as clinically indicated while on vemurafenib and cobimetinib treatment. For patients who had been on-treatment for ≥ 24 months without decreases of >10% in LVEF compared to baseline and LVEF < LLN at any time while on study, cardiac imaging was performed every 24 weeks (or more frequently if clinically indicated). If clinically indicated, cardiac evaluation was performed at safety follow-up visit.

c: Dermatologic Examination during treatment period was performed in 3 months intervals.

d: Dermatologic Examination had to be performed 6 months after the End of Treatment Visit.

e: Pregnancy test had to be conducted within 72 hours prior to the start of each cycle.

f: Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential (total neutrophil count including bands, lymphocyte, monocyte, eosinophil and basophil counts), platelet.

g: BUN or urea, serum creatinine OR measured or calculated creatinine clearance, sodium, potassium, total protein, albumin, S-100, LDH, AST, ALT, GGT, alkaline phosphatase, CPK, bilirubin.

h: Thyroid panel was conducted every 9 weeks during treatment phase.

- i: Tumor response evaluation during run-in and randomized phase was conducted by CT/ MRT thorax/abdomen in 3-month intervals ( $\pm$  1 week) from the date of first study drug administration. MRT/CT evaluation of brain was only performed at study entry and repeated only in case of specific symptoms or in case of preexisting brain metastases in 3-month intervals.
- j: After local confirmation of the BRAFV600 mutation status at the study sites, aliquots of the FFPE samples were sent to the central biobank laboratory (Essen) for analysis in the translational research program. If sequential tumor samples were available under therapy, aliquots of these FFPE samples should also be sent to the central biobank laboratory (Essen) for analysis in the translational research program.
- k: For analysis of circulating free tumor-specific DNA in blood plasma, a blood sample (additional 18 ml) was obtained at baseline, at week 2 and at randomization, at week 2 and week 12 of secondary treatment, at tumor progression before crossing-over (PD1), at week 2 and week 12 after crossing-over, and at second progression after randomization (PD2). Blood samples for isolation of peripheral blood mononuclear cells (additional 45 ml) were collected in all German sites at baseline, at week 2 and at randomization, at week 2 and week 12 of secondary treatment, at tumor progression before crossing-over (PD1), at week 2 and week 12 after crossing-over, and at second progression after randomization (PD2).
- l: Head and neck examination was performed at screening, every 12 weeks while on study treatment and every 12 weeks for a minimum of 6 months after discontinuation of study treatment or until death, withdrawal of consent or loss to follow up.
- m: Pelvic (for women) and anal examination was conducted at baseline visit and at End of Study treatment visit.
- n: At Initiation of site
- o: After the end of run-in phase of all patients at each site
- p: EORTC QLQ C-30, HADS-D, GSE (German: SWE), Brief-IPQ, SES ladder, project-specific list of questions (a)
- q: At week 12 after 1<sup>st</sup> dose of study medication in run-in-phase [EORTC QLQ C-30, Brief-IPQ, project-specific list of questions (b)]. At week 12 after 1<sup>st</sup> dose of study medication in randomized phase (EORTC QLQ C-30, Brief-IPQ)
- \*: Following the subject's written consent to participate in the study, all (S)AEs that occurred within 90 days of discontinuation of dosing of the investigational product were reported (after this time period SAE that were considered related to vemurafenib/ cobimetinib/ atezolizumab were also reported as described in the protocol chapter 12: Adverse Event Reporting). All adverse events were followed until resolution.
- \*\*: Ophthalmologic examination was performed at end-of-Study treatment visit if it had been performed within the last 12 weeks

### 9.5.1.1 Safety – Adverse Events

All patients who received at least one dose of study treatment with vemurafenib and cobimetinib during the run-in phase of the study were considered evaluable for safety parameters.

Safety assessments were based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests or elicited during open-ended questioning. All side effects that occurred with the study therapy were entered on the Adverse Event page of the eCRF. Following the subject's written consent, all (S)AEs that occurred until 90 days of discontinuation of dosing of the investigational product were collected. Before first administration of study medication only (S)AEs were documented which occurred during study specific procedures or investigations. Results of investigations were documented as pre-existing conditions, not as AE or SAE. If known, the diagnosis of the underlying illness or disorder was recorded, rather than its individual symptoms. The following information were captured for all AEs: onset, duration, intensity, seriousness, relationship to investigational product, action taken, and treatment required. If treatment for the AE was administered, it was recorded in the medical record. All SAEs were followed to resolution or stabilization. The assessment of an adverse event was made on the basis of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 (<http://ctep.cancer.gov>).

All entries in patient questionnaires and electronic medication diaries were checked routinely at fixed time points for any hidden potential AE by the Pharmacovigilance of Alcedis. If there was suspicion that an AE mentioned by a patient was not entered into the eCRF by the study center, the investigator was contacted and asked for clarification and documentation. In case the patient documents medication adherence on paper diary the investigator was encouraged to check the patient's entries for suspicious AEs, to clarify any findings with the patient and to document proven (S)AEs into the respective eCRF form.

All cases of potential drug-induced liver injury (DILI) that included an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law, were reported as adverse events of special interest (AESIs). Potential DILI was defined as follows:

- Treatment-emergent ALT or AST elevation  $> 3 \times$  baseline value in combination with total bilirubin  $> 2 \times$  upper limit of normal (ULN) (of which  $\geq 35\%$  was direct bilirubin)
- Treatment-emergent ALT or AST elevation  $> 3 \times$  baseline value in combination with clinical jaundice
- No other immediately apparent possible causes of AT elevation and hyperbilirubinemia, including, but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, liver metastases or the administration of other drug(s) known to be hepatotoxic.

Suspected transmission of an infectious agent by the study treatment was considered as follows:

- Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform encephalopathy), pathogenic or non-pathogenic, was considered an infectious agent. A transmission of an infectious agent might have been suspected from clinical symptoms or laboratory findings that indicated an infection in a patient exposed to a medicinal product. This term applied only when a contamination of study treatment was suspected.

For the combined treatment of vemurafenib and cobimetinib the following AEs were defined as AESIs:

- Grade 1-4 serous retinopathy
- Retinal vein occlusion (any Grade)
- Grade  $\geq 2$  left ventricular dysfunction
- Rhabdomyolysis (including elevations of CPK-MM in conjunction with other laboratory evidence (aldolase and urine myoglobin), and clinical feature consistent with rhabdomyolysis (such as muscle pain, signs of renal failure, dark red or brown urine)
- Grade  $\geq 3$  hemorrhage event, or any Grade cerebral hemorrhage
- Grade  $\geq 3$  rash

- Grade  $\geq 3$  photosensitivity
- Events suggestive of drug-Induced liver or other Grade  $\geq 3$  hepatotoxicity
- AEs potentially associated with prolongation of cardiac repolarization
- Any new or worsening malignancy including progression of RAS-mutant malignancy, cuSCC, new primary melanoma, basal cell carcinoma

For atezolizumab the following AEs were defined as AESIs:

- Pneumonitis Grade  $\geq 2$
- Colitis
- Endocrinopathies: Diabetes mellitus, pancreatitis, adrenal insufficiency, hyperthyroidism and hypophysitis
- Hepatitis, including AST or ALT  $> 10 \times$  ULN
- Neurological events: Guillain-Barré syndrome, myasthenic syndrome or myasthenia gravis, meningoencephalitis
- Nephritis
- Events suggestive of hypersensitivity, cytokine release, influenza-like illness, systemic inflammatory response syndrome, systemic inflammatory activation, infusion reactions syndrome
- Ocular toxicities (e.g., uveitis, retinitis)
- Myositis
- Myopathies, including rhabdomyolysis
- Grade  $\geq 2$  cardiac disorders (e.g., atrial fibrillation, myocarditis, pericarditis)
- Vasculitis

*The following SAEs (hospitalizations) were excluded from compulsory notification:*

A visit to the emergency room or other hospital department lasting less than 24 hours that did not result in admission (unless considered an “important medical event” or a life-threatening event)

- Elective surgery planned before signing consent
- Hospitalizations associated with therapeutic measures (administration of the trial substances, blood transfusions, elective procedures and surgery for tumor removal). Hospitalizations for therapeutic measures for an AE were not excluded from SAE reporting requirements.
- Admissions as per protocol for a planned medical/surgical procedure
- Routine health assessment requiring admission for baseline/trending of health status (e.g., routine colonoscopy)
- Medical/surgical admission for purposes other than remedying ill health state that was planned before study entry. Appropriate documentation was required in these cases.
- Admission encountered for another life circumstance that carried no bearing on health status and required no medical/surgical intervention (e.g., lack of housing, economic inadequacy, caregiver respite, family circumstances, administrative).
- Overnight hospitalizations that occurred exclusively for logistical reasons (e.g., no transportation available for the patient to return home on the same day).
- Deaths due solely to progression of underlying disease, and other events that were solely attributed to progression of the underlying disease, were not reported as AEs/SAEs in this study. If there was any uncertainty whether the death or event was due solely to the underlying disease, it was reported as an AE/SAE.

Suspected Unexpected Serious Adverse Reactions (SUSARS) were reported by the sponsor to the relevant authorities as well as listed in the EudraVigilance database (<http://eudravigilance.ema.europa.eu/highres.htm>).

Pregnancies of female study participants were reported immediately within 24 hours of becoming aware of the event and were recorded on the Clinical Trial Pregnancy Reporting Form. Likewise, pregnancy of a female partner of a male study participant were reported and collected on the



Pregnancy Surveillance Form. Follow-up information regarding the course of the pregnancy, including perinatal and neonatal outcome was reported. Infants were followed for a minimum of eight weeks.

Causal relationships between AEs and each investigational drug were determined by a physician using the following categories:

- Related: Reasonable causal relationship to the investigational product administration and the AE.
- Not Related: No reasonable causal relationship to the investigational product administration and the AE.

The degree of certainty of the relationship between AE and drug was determined by how well the event was explained by the following factors: (1) known pharmacological properties, (2) comparable reactions observed previously with the drug or another member of its class, (3) an event with comparable substances commonly described in the literature as drug-related, (4) a chronological relationship between the event and drug intake, disappearance on withdrawal or recurrence on re-institution of the drug.

All SAEs and AESIs, whether related or unrelated to the study drug(s), were reported within 24 hours of becoming aware of the event by using the electronically available “Serious adverse events report” form. All SAEs and AESIs were followed to resolution or stabilization.

### 9.5.2 Appropriateness of Measurements

There was no efficacy or safety measures used which were not standard or not widely used.

### 9.5.3 Pharmacokinetic and Pharmacodynamic Measurements

Not applicable.

### 9.5.4 Other Measures

Not applicable.

## 9.6 Data Quality Assurance

The investigator and the respective representative(s) signed the study protocol and thereby confirmed that they read and understood the protocol and worked according to the protocol.

At each participating site, an on-site initiation visit was performed by a clinical monitor appointed by Alcedis GmbH or a representative CRO, and study personnel were trained about study procedures, medication handling and medication order, as well as documentation.

Data for this clinical trial was collected, processed and stored using AlcedisTRIAL, a web-based validated software (WBDC) provided by Alcedis GmbH. Data were entered at the study site into a validated eCRF, which enabled rapid processing and fast communication between trial site (investigator and study nurse), monitor, data manager and sponsor. Data validation was performed automatically during data entry by electronic system-based plausibility checks (e.g., checks on range, plausibility and type mismatch) and by a formal query process to resolve inconsistencies in AE data. The Data Management Plan (DMP) and the Data Validation Plan (DVP) are available on request.

## 9.7 Statistical Methods Planned in the Protocol and Determination of Sample Size

### 9.7.1 Statistical Analysis Plan

The statistical analysis was performed by Alcedis GmbH using SAS statistical software (version 9.4). All analyses defined in the protocol were described in detail in the statistical analysis plan

(SAP) v2.0, dated June 4, 2024, which is available on request. The analysis of the translational research project was not part of the study analysis and therefore no specifications were included in the study protocol.

### **Analysis populations**

The following analysis populations were defined:

**Intention-to-Treat population (ITT):** All patients with informed consent who were enrolled in the study. ITT was used for the efficacy endpoints (OS and response-related endpoints) except for PFS1 whenever a population of the run-in phase was included.

**Safety population (SP):** All patients of the ITT set who received at least one dose of the investigational agent.

**Randomized population (RP):** All patients of the ITT set who underwent randomization. RP was used for the efficacy endpoints whenever only populations from the randomized phase were assessed.

**Primary endpoint population (PEP):** All patients of the ITT set who had at least one dose of the scheduled treatment in the randomized phase and who did not have had major disqualifying protocol violations. PEP was the main analysis population for the primary endpoint PFS1.

The following list of protocol violations that could have potentially impacted the scientific integrity of the primary endpoint led to exclusion from the PEP:

#### ***At entrance:***

- Patients without locally advanced, unresectable or metastatic melanoma AJCC 7th edition (unresectable stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c) with a measurable lesion per RECIST 1.1 documented/confirmed at baseline
- Subject with baseline ECOG performance status > 1
- Baseline staging was more than 6 weeks before the first drug intake in the run-in phase
- Previous therapy in the advanced or metastatic setting
- Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) also in an adjuvant setting
- Prior therapy with a BRAF inhibitor (including but not limited to vemurafenib, dabrafenib, encorafenib and / or MEK inhibitor (including but not limited to trametinib, AZD6244, cobimetinib, binimetinib) also in an adjuvant setting
- Subjects with uveal melanoma
- BRAF wildtype tumor
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- History of leptomeningeal metastases

#### ***On Study:***

- Subjects who received anti-cancer therapy (chemotherapy, hormonal therapy, immunotherapy, standard or investigational agents for treatment of cancer) while on study therapy
- At randomization: patients with confirmed disease progression per RECIST 1.1
- For randomized phase: Time between randomization and first treatment within randomized phase >21 days
- Subjects treated differently than as randomized (subjects who received the wrong treatment, excluding the never treated)

All randomized patients were analyzed in the arm they were allocated by randomization. For the safety analyses, patients were analyzed according to the treatment they actually received. E.g., if a patient was randomized to arm A (vemurafenib plus cobimetinib) but mistakenly received

atezolizumab, he/she was evaluated in the atezolizumab group. Safety data was presented separately for the run-in phase, the first phase after randomisation, and the phase after the switch.

### Protocol violations/deviations

The following programmable deviations were considered as major protocol violations/deviations and were summarized by treatment arm and overall for the ITT population.

#### *At entrance:*

- Patients without locally advanced, unresectable or metastatic melanoma AJCC 7th edition (unresectable stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c) with a measurable lesion per RECIST 1.1 documented/confirmed at baseline
- Subject with baseline ECOG performance status > 1
- Baseline staging was more than 4 weeks before the first drug intake in the run-in phase
- Previous therapy in the advanced or metastatic setting
- Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or antiCytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways) also in an adjuvant setting
- Prior therapy with a BRAF inhibitor (including but not limited to vemurafenib, dabrafenib, encorafenib and / or MEK inhibitor (including but not limited to trametinib, AZD6244, cobimetinib, binimetinib) also in an adjuvant setting
- Subjects with uveal melanoma
- BRAF wildtype tumour
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- History of leptomeningeal metastases
- Prior adjuvant treatment has not been completed at least 28 days before enrolment

#### *On Study:*

- Subjects who received anti-cancer therapy (chemotherapy, hormonal therapy, immunotherapy, standard or investigational agents for treatment of cancer) while on study therapy
- At randomization: patients with confirmed disease progression per RECIST 1.1
- For randomized phase: Time between randomization and first treatment within randomized phase >14 days
- For cross-over:
  - Patients with brain metastases who required whole brain radiotherapy (WBRT)
  - Patients who did not perform cross-over per protocol
  - Patients with multiple and/or symptomatic brain metastasis and/or leptomeningeal disease
  - ECOG >2 or rapid deterioration of general state
  - Time between disease progression in randomized phase (PD1) and cross-over to other treatment (atezolizumab in case of prior treatment with cobimetinib/vemurafenib or cobimetinib/vemurafenib in case of prior treatment with atezolizumab) >14 days unless results of the clinical and laboratory assessments as outlined for the examinations during the treatment cycles did not preclude treatment with the next therapy
  - Subjects treated differently than as randomized (subjects who received the wrong treatment, excluding the never treated)

### **Statistical methods**

A CONSORT diagram was used to document the flow of patients through the various stages of the study.

The number of patients in the various analysis populations were presented in a table, and reasons for exclusions were given.

In general, summary statistics (N, mean, standard deviation, median, minimum and maximum for continuous variables, and number of patients and percentage in each category for categorical variables) were provided. In addition, 95% confidence intervals (CI) and p-values were given for some analyses. However, they were of purely explorative character.

All main analyses of the efficacy endpoints (OS and response-related endpoints) were performed on the ITT population for analyses, including patient groups that did not undergo randomization and on the RP for analyses, referring to randomized patients only: randomized patients were considered as in the treatment group as indicated at randomization, all non-randomized patients (i.e., who dropped out during run-in phase) formed an extra group. For PFS1 analysis, all patients with an administration of at least one study drug after randomization and who did not have major disqualifying protocol violation were analyzed (PEP). OS was analyzed for patients in Arm A and Arm B regardless of whether a switch had occurred or not.

In the case of  $\geq 10\%$  major protocol violations in one arm, all main analyses of the efficacy endpoints were analyzed post hoc using the per protocol principle, i.e., only patients without major protocol violations were considered.

The Kaplan-Meier technique was used to obtain estimates of the survival-type distributions (PFS1/2/3, OS, time to OR, duration of OR). In addition, based on the Kaplan-Meier curves, estimates at given time-points were provided (e.g. 12-, 24-, 36 and 48-month OS rates), along with their standard errors. Medians – if reached – were presented with a 95% CI. The comparison of the time-to-event distributions (PFS, OS, time to OR) between the different treatment groups was done using the log-rank test for ITT and RP stratified by LDH (elevated vs. within normal limits at enrollment), metastatic stage (IV M1c yes/no) and previous adjuvant therapy (yes/no) as indicated at enrollment. These comparisons were in a purely descriptive manner.

All p-values generated in the analysis were of descriptive manner and were not corrected for multiple testing.

The HR and its 2-sided 95% CI was estimated using a Cox proportional hazards (PH) model (using Efron's tie-handling method) using treatment group as a single covariate. Subgroup analyses were conducted for LDH (elevated vs. within normal limits at enrollment), metastatic stage (IV M1c yes/no), previous adjuvant therapy (yes/no) as indicated at enrollment, with treatment as the single covariate.

In each treatment arm, the rate of CR and the OORR as well as the corresponding rates after randomization and switch were summarized with their corresponding 2-sided 95% CI. Since the incidences of CR rate were not expected to be very high in both groups, and since this phase II study had a relatively low sample size, no statistical inference was done. Idem for the OORRs.

In order to assess a possible influence on the efficacy endpoints, the following prognostic / predictive factors were investigated in univariate analyses (Kaplan-Meier curves, log rank test, Cox model) in each treatment group, separately:

- Sex (male vs. female)
- Age at enrollment (< 65 vs.  $\geq 65$  years)
- Asymptomatic brain metastases at enrollment (no vs. yes)
- ECOG status at enrollment (0 vs.  $\geq 1$ )
- Number of organ sites with metastases (<3 sites v.  $\geq 3$  sites) at enrollment
- Sum of lesion diameter (<median vs.  $\geq$ median) at enrollment
- Prior radiotherapy before enrollment (no vs. yes)
- Prior therapy before enrollment ANY (no vs. yes)
- Tumor response after run-in phase (SD vs. PR vs. CR)

Thereafter, a multivariable Cox model was fitted using both treatment groups, including as covariates randomized treatment group and all factors which appeared of prognostic importance (at a 2-sided  $\alpha = 20\%$ ) in univariate analyses adjusted for LDH (elevated vs. within normal limits at enrollment), metastatic stage (IV M1c yes/no), previous adjuvant therapy (yes/no) as indicated at enrollment. A step down was used for the multivariable Cox model selection at the 2-sided 10 % significance level, and forcing treatment arm to stay in the model. The model with the

lowest Akaike information criterion (AIC) was retained. The assumption of proportional hazards was checked using a procedure derived from cumulative sums of martingale-based residuals over follow-up time (method of Lin, Wei, and Ying). In case one of the strong prognostic factors violated the PH assumption, a Cox model stratified by this factor was considered. Hazard ratios for disease progression or death among the following subgroups LDH at baseline (elevated vs. within normal limits), metastatic stage (IV M1c no vs. yes), prior adjuvant therapy before enrollment (no vs. yes), sex (male vs. female), age at enrollment (<65 vs.  $\geq 65$  years), asymptomatic brain metastases at enrollment (no vs. yes), ECOG status at enrollment (0 vs.  $\geq 1$ ) by treatment, number of organ sites with metastases (<3 sites v.  $\geq 3$  sites) at enrollment by treatment, sum of lesion diameter (<median vs.  $\geq$  median) at enrollment by treatment, prior radiotherapy before enrollment (no vs. yes), prior therapy before enrollment ANY (no vs. yes) and tumor response after run-in phase (SD vs. PR vs. CR) were evaluated and displayed in a forest plot.

Outcome variables (questionnaires, sociodemographic) were compared between user, mixed user and non-user of eMARS using ANOVA (with posthoc analyses for significant mean differences using Tukey's test) and corresponding Kruskal-Wallis test, the non-parametric tests (with posthoc analyses for significant mean differences using Dwass-Steel-Critchlow-Flinger test) as well as chisquare test.

The SP set was used for the analyses of the safety variables. All safety analyses were done separately for each treatment step: a) the run-in phase, b) the randomized phase, c) the switch phase. For the randomized phase and the switch phase, the analyses were done separately for treatment Arm A and Arm B. All AEs were tabulated using worst grade per NCI CTCAE v 4.03 criteria by system organ class and preferred term.

#### Safety analysis included:

- System Organ Class (SOC) and Preferred Term (PT) according to the Medical Dictionary for Regulatory Activities (MedDRA) classification
- Severity of AE
- Causality of AE
- Outcome of AE
- SAEs
- AESIs
- All AEs leading to discontinuation of study treatment
- All AE-related deaths

#### Treatment exposure

Frequency tables and summary statistics (median, range, interquartile range) of the following parameters were provided for the different treatment periods:

In the run-in phase, treatment Arm A and in treatment Arm B after switch:

- Number of treatment days with vemurafenib and cobimetinib during run-in phase, from randomization to switch or end of treatment, whatever occurred first and from switch to end of treatment
- Mean cumulative dose of vemurafenib and cobimetinib of the starting doses (vemurafenib: 960 mg BID; cobimetinib: 60 mg QD for 21 days followed by a 7-day rest period in each 28-day cycle)
- For vemurafenib and cobimetinib: Ratio between the total dose given and expected dose during the period these treatments were administered
- If administration of vemurafenib and cobimetinib was delayed and/or skipped: reason
- Reason to stop vemurafenib and cobimetinib
- Duration of treatment breaks (number of days that treatment was not taken since randomization to switch or end of treatment, whatever occurred first)
- Medication adherence in the run-in phase for patients using eMARS and non-users: (determined by dividing number of taken tablets (cobimetinib / vemurafenib) by number of

envisaged tablets. Patients with adherence took at least 80% of envisaged tablets of each cobimetinib or vemurafenib)

In treatment Arm B and in treatment arm A after switch:

- Number of infusions of atezolizumab from randomization to switch or end of treatment, whatever occurred first, or from switch to end of treatment
- Mean cumulative dose of atezolizumab of the starting dose (atezolizumab (1200 mg/ q3w)
- Ratio between the total number of atezolizumab infusions given and expected during the period these treatments were administered
- If atezolizumab was delayed and/or skipped: reason
- Reason to stop atezolizumab

All exploratory variables were analyzed in a descriptive manner with the appropriate summary statistics and considering the applying manuals (for standardized questionnaires), if applicable. Baseline measures were summarized using descriptive statistics for each scale by treatment group or eMARS group, respectively. For the comparison of eMARS users versus non-users, the ITT population was assessed for the comparison of the treatment arms, the RP was assessed. Change from baseline was summarized using descriptive statistics (N, mean, standard deviation, median, first and third quartiles, minimum, maximum) for each scale at each assessment time point by treatment group / eMARS user vs. non-user group. This analysis was performed in the ITT population who had an assessment at baseline and at the time point of interest.

Non-parametric rank-order tests were performed using a 2-sided significance level of 5% to test for significant differences between the treatment arms at each point in time.

The Global Health Status scale was used as the primary outcome of interest for this study. A difference of 10 points on the 100-point QLQ-C30 scale between the two arms was considered clinically relevant.

### 9.7.2 Determination of Sample Size

It was supposed that after a 3-month run-in phase with cobimetinib and vemurafenib an earlier switch to atezolizumab (treatment Arm B) will lead to a prolongation of progression-free survival 2 (PFS2) compared to switch to atezolizumab after first progression (treatment Arm A). A direct effect size was not known and therefore could not have been predicted. With 120 patients, the 95% CI of HR = 0.647 had a total width of 0.557 [0.426- 0.983]. A HR of 0.647 was achieved if the median PFS2 in treatment Arm B was prolonged to 17 months compared to a median PFS2 of 11 months in treatment Arm A.

With an assumed drop-out rate of 15% during the randomization phase, 141 patients were needed to yield the desired number of 120 eligible patients.

Since the median PFS under vemurafenib + cobimetinib therapy of metastatic melanoma patients in the phase 1b BRIM-7 study amounted to 13.7 months [35] (other data were not available when the protocol was initiated), 86% of patients were expected to be event-free after the 3-month run-in phase. Since only event-free patients with no therapy interruption of more than 28 days were randomized after the run-in phase, the drop-out rate was assumed to be 20% during the run-in phase. Thus, 176 patients were needed to enter the run-in phase of this study.

It was unclear how patients benefit from an early change from targeted therapy with BRAF/MEK inhibition to immune checkpoint inhibitor therapy. In a retrospective data analysis by Reijers et al., 74 patients were examined who received immune checkpoint inhibitor therapy either while still responding to the targeted therapy (n = 37 sDR group) or during progress (also n = 37 sPD group) [39]. The OR to immune checkpoint inhibitor therapy was 27.0% in the sDR group and 24.3% in the sPD group (p = 0.790), the median PFS time after switch was 2.5 months versus 1.2 months (p = 0.145). Overall, there was no difference in PFS between an early switch and a switch at progress, but OS of patients with an early switch was significantly better even after adjustment for baseline and prognostic factors (HR 0.48, p = 0.055).

As of April 2020, the effect of an early switch to atezolizumab before disease progression after a run-in phase with cobimetinib / vemurafenib was unknown. Data derived from the phase 3 CoBrim study [36] showed that the median PFS for patients with unresectable stage IIIC or stage IV melanoma treated with cobimetinib/vemurafenib amounted to 12.3 months. Considering a median PFS of 12.3 months in Arm A, a two-sided alpha of 0.05 and 140 randomized patients, Table 3 depict the power when observing median PFS1 values between 7.3 and 20.8 months in Arm B.

**Table 3 Power calculation**

PFS1 Arm B	Total number of events	Power [%]
7.3	124	81.6
7.5	124	77.5
10.0	121	20.6
12.5	135	5.1
15.0	118	18.9
17.5	116	47.0
20.0	114	72.8
20.8	113	78.9

With 140 patients randomized and a two-sided alpha of 0.05, a power of approximately 80% were to be achieved, if the median PFS1 was improved to 20.8 months (HR=0.59) or decreased to 7.3 months (HR=1.68) when switching to atezolizumab after the run-in phase.

However, the analysis was no longer confirmatory but descriptive only.

## 9.8 Changes in the Conduct of the Study or Planned Analyses

There were nine substantial amendments to the protocol with implications in the study design and statistical analysis. Respective changes included the following:

With Amendment No 1 (and protocol version 1.3), questionnaires for patients regarding medication adherence and quality of life were implemented in the study. New exploratory objectives addressed by patient questionnaires were specified.

With Amendment No 2 (and protocol version 1.4), inclusion and exclusion criteria were specified, risk assessment was updated, and former specification of BRAF mutation was deleted. In addition, a reference for AE / SAE documentation and new AESIs were included, and assessment schedules were updated.

With Amendment No 3 (and protocol version 1.5), changes regarding medication adherence questionnaires have been made.

With Amendment No 4 (and protocol version 1.6), timelines were updated, and clinical examination schedules were changed. Moreover, changes regarding clinical experience and risks associated with atezolizumab were updated.

With Amendment No 5 (and protocol version 1.8), the study timelines were updated, and schedules of study visits and examinations were adapted. In addition, clinical experience and risks associated with atezolizumab were updated due to the release of revised IB for atezolizumab (version 14, dated October 24, 2018) and corresponding addendum 1 (dated December 05, 2018).

With Amendment No 6 (and protocol version 2.0), the primary endpoint was changed. The previous secondary endpoint progression-free survival (PFS) 1 was now analyzed as primary endpoint, and the previous primary endpoint PFS2 was now analyzed as secondary endpoint. During regular data review, it was noticed that there were patients not switching therapy after their first progress as planned according to protocol. These patients were previously not included in the primary endpoint population even though they received other therapies. In addition, the follow-up period was extended by two years to collect further data for overall survival (OS). Moreover, an interim analysis was added in order to gain knowledge on the impact of an early switch from BRAF/MEK inhibition to PD-L1 inhibition on PFS1. This analysis was conducted after 80% of patients had reached PFS1 or prematurely discontinued the study. Furthermore, the protocol was updated according to the release of revised IBs for cobimetinib (version 12, dated September 2019 with new addendum), for

vemurafenib (version 17, dated December 2019), and for atezolizumab (version 15, dated December 2019 with corresponding addendum 2).

With Amendment No 7 (and protocol version 3.0), changes regarding safety were included and approved indications of atezolizumab based on the release of revised IBs for cobimetinib (version 13, dated September 2020), for vemurafenib (version 18, dated May 2020), and for atezolizumab (version 17, dated September 2020; version 16 was withdrawn from the marketing authorization holder and did not become effective) were changed.

With Amendment No 8 (and protocol version 4.0), changes regarding new risks of vemurafenib and atezolizumab based on the release of revised IBs for vemurafenib (version 19, dated May 2021), and for atezolizumab (version 18 and Addendum 1, dated July and August 2021, respectively) were included. Furthermore, changes in the management of atezolizumab-specific adverse events were issued.

With Amendment No 9 (and protocol version 5.0), changes regarding safety were included and approved indications of cobimetinib and vemurafenib based on the release of revised IBs for vemurafenib (versions 20 and 21, dated May 2022 and May 2023, respectively), cobimetinib (version 15, September 2022) and for atezolizumab (version 19, dated August 2022) were changed. Risks associated with atezolizumab and cobimetinib as well as dose modifications and treatment alterations of study treatment were updated. Furthermore, specifications for cardiac evaluation were included in the 'schedule of visits and assessments'.

During the regular data review, it was found that after the first disease progression during the randomized phase (PD1) many patients did not switch study therapy as planned in the protocol (Arm A: from cobimetinib/vemurafenib to atezolizumab, Arm B: from atezolizumab to cobimetinib/vemurafenib) but discontinued study treatment and entered the follow-up phase of the study. As the therapies administered to these patients after initial progression were at the discretion of the treating physician, these patients were not included in the PEP according to protocol version 1.8. Therefore, with protocol version 2.0, dated after the completion of the recruitment period, the primary endpoint was changed from PFS2 to PFS1 (time from start of run-in phase to PD1).

## 10 STUDY PATIENTS

### 10.1 Disposition of Patients


Between [REDACTED], 2016 and [REDACTED], 2019, 244 patients were assessed for eligibility, including 59 screening failures. Hence, 185 patients were enrolled in the run-in phase and were treated with a combination of vemurafenib and cobimetinib. Of these, 50 patients discontinued study treatment during the run-in phase, i.e., prior to randomization, predominantly due to AE (N=28). Other reasons for prematurely discontinuing study treatment during the run-in phase included disease progression (N=11), patient's wish (N=4), death (N=3), withdrawal of informed consent (N=2), or decision taken by the investigator (N=2). A total of 135 patients completed the run-in phase. Of these, 69 patients were randomly assigned to continue treatment with vemurafenib/cobimetinib (Arm A) and 66 patients were randomly assigned to receive atezolizumab (Arm B) until first disease progression (PD1) (randomization phase). Sixty-four patients in Arm A and 62 patients in Arm B discontinued treatment during the randomization phase, mainly due to progression of the primary disease (Arm A: N=30, Arm B: N=43), AE (Arm A: N=12, Arm B: N=4) or brain metastases (Arm A: N=7, Arm B: N=7). Following PD1, 21 patients in Arm A switched to treatment with atezolizumab until disease progression 2 (PD2). The majority of these patients (N= 19) discontinued treatment due to disease progression (N=18, 94.7%) or death (N=1, 5.3%). In Arm B, 35 patients switched to treatment with vemurafenib/cobimetinib until PD2 with 34 patients receiving vemurafenib/cobimetinib. Of these, 32 patients discontinued treatment due to disease progression (N=20; 62.5%), death (N=2; 6.25%) or other reasons (N=10; 31.25%).

After a median follow-up of 57.83 months (IQR 22.66 – 65.43 months) in Arm A and 55.79 months (IQR 27.34 – 62.34 months) in Arm B (each calculated using the reverse Kaplan Meier method), five patients in Arm A and four patients in Arm B were still under study treatment in the randomized



phase and had therefore not switched therapy. In addition, two patients each in Arm A and Arm B were still receiving study treatment in the crossover phase (**Figure 2, Table 6**).

All patients in Arm A (N=69) and Arm B (N=66) were included in the randomized population (RP) as well as in the safety population (SP). However, the primary endpoint population (PEP) consisted of 68 patients of Arm A and 65 patients of Arm B.



**Figure 2 CONSORT Flow Diagram**

Data source: Figure 1 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

For 142 patients of the ITT, a premature end of study was documented, including 48 (70.59%) patients in Arm A, 49 (76.56%) patients in Arm B, and 45 (90.00%) patients who stopped treatment during the run-in phase and who therefore were not randomized to either treatment Arm A or Arm B. The main reasons for study discontinuation among the treatment arms were death, withdrawal of informed consent or lost to follow up (**Table 4**).

A listing of all patients discontinued from the study after enrolment is provided in **Table 45** in the Appendix 16.2.1.

**Table 4 Premature End of Study (ITT)**

<i>Premature end of study</i>	<b>Arm A</b>	<b>Arm B</b>	<b>Not randomized</b>	<b>Total</b>
Number of patients with documented end of study	68 (100.00)	64 (100.00)	50 (100.00)	182 (100.00)
Premature end of study				
No	20 (29.41)	15 (23.44)	5 (10.00)	40 (21.98)
Yes	48 (70.59)	49 (76.56)	45 (90.00)	142 (78.02)
Death				
Yes	35 (51.47)	29 (45.31)	24 (48.00)	88 (48.35)
No	30 (44.12)	32 (50.00)	25 (50.00)	87 (47.80)
Unknown	3 (4.41)	3 (4.69)	1 (2.00)	7 (3.85)
Patient died- Cause of death				
Disease progression	34 (50.00)	24 (37.50)	21 (42.00)	79 (43.41)
Therapeutic reason	0 (0.00)	1 (1.56)	0 (0.00)	1 (0.55)
No therapeutic reason or basic disease	0 (0.00)	2 (3.13)	3 (6.00)	5 (2.75)
Unknown	1 (1.47)	2 (3.13)	0 (0.00)	3 (1.65)
Cause of death: treatment-related- Adverse events leading to death				
Haemorrhage intracranial	0 (0.00)	1 (1.56)	0 (0.00)	1 (0.55)
Cause of death: treatment-related- If cause of death is related to study therapy, to which one?				
a causality to all three medications is possible but not known for sure	0 (0.00)	1 (1.56)	0 (0.00)	1 (0.55)
Cause of death according to ICD10				
Cardiac arrest, unspecified	0 (0.00)	0 (0.00)	1 (2.00)	1 (0.55)
Intracranial haemorrhage (nontraumatic), unspecified	0 (0.00)	2 (3.13)	0 (0.00)	2 (1.10)
Sepsis, unspecified	0 (0.00)	0 (0.00)	1 (2.00)	1 (0.55)
Septic shock	0 (0.00)	0 (0.00)	1 (2.00)	1 (0.55)
Stroke, not specified as haemorrhage or infarction	0 (0.00)	1 (1.56)	0 (0.00)	1 (0.55)
Withdrawals of informed consent (total)	5 (7.35)	12 (18.75)	11 (22.00)	28 (15.38)
Lost to follow up (total)	8 (11.76)	2 (3.13)	2 (4.00)	12 (6.59)

Data source: Table 141 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

## 10.2 Recruitment

The patients' written consents were provided between [REDACTED], 2016, and [REDACTED], 2019. The last patient last visit (LPLV) was on [REDACTED], 2024, which was also defined as the end of the study (EoS).

## 10.3 Protocol Deviations

A total of 18 protocol violations were identified in 17 patients – eight protocol violations in Arm A and ten protocol violations in Arm B. In seven cases of protocol violations (Arm A: N=4; Arm B: N=3), the time between disease progression during the randomized phase (PD1) and cross-over to the other treatment regimen extended 14 days unless the results of the clinical and laboratory assessments as outlined for the examinations during the treatment cycles did not preclude treatment with the next therapy. For one patient in Arm A and four patients in Arm B, the sponsor granted an exception for crossing-over, despite the presence of multiple brain metastasis. For three patients (Arm A: N=2; Arm B: N=1), cross-over was not performed as per protocol: Crossover without progress was performed for two patients in Arm A, who were clinically assessed as having a progress by the site, however, radiologically no progress was confirmed. Moreover, no switch

despite progress was performed for one patient in Arm B. In this case, the tumor board decided to not take the patient to the crossover despite showing disease progression, i.e. this patient continued treatment with atezolizumab after disease progression and did not cross over to treatment with cobimetinib in combination with vemurafenib. In addition, two patients (one patient each treatment arm) had a confirmed disease progression per RECIST 1.1. at randomization but were allowed to continue trial treatment by the sponsor as the only site of progression was a small asymptomatic brain metastasis. In addition, one patient in Arm B had an ECOG performance status >2 or rapid deterioration of the general status (**Table 5**).

The listing of patients with protocol deviations broken down by site is provided in **Table 46** in the Appendix 16.2.2.

**Table 5 Protocol deviations on study (ITT)**

<b>Protocol violations</b>	<b>Arm A</b>	<b>Arm B</b>	<b>Total</b>
Number of patients	69 (100.00)	66 (100.00)	185 (100.00)
At randomization: patients with confirmed disease progression per RECIST 1.1*	1 (1.45)	1 (1.52)	2 (1.08)
For cross-over: patients who did not perform cross-over per protocol**	2 (2.90)	1 (1.52)	3 (1.62)
For cross-over: patients with multiple and/or symptomatic brain metastasis and/or leptomeningeal disease	1 (1.45)	4 (6.06)	5 (2.70)
For cross-over: ECOG >2 or rapid deterioration of general state	0 (0.00)	1 (1.52)	1 (0.54)
For cross-over: Time between disease progression in randomized phase (PD1) and cross-over to other treatment (atezolizumab in case of prior treatment with cobimetinib/vemurafenib or cobimetinib/vemurafenib in case of prior treatment with atezolizumab) >14 days unless results of the clinical and laboratory assessments as outlined for the examinations during the treatment cycles do not preclude treatment with the next therapy	4 (5.80)	3 (4.55)	7 (3.78)

\* Decision by sponsor representative: Patient may remain in study

\*\* Switch without progress. Radiologically no progress, clinically assessed as progress by site.; No switch despite progress. The patient was not taken to the crossover. Was decided by tumor board.

Data source: Table 10 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

## 11 EFFICACY EVALUATION

### 11.1 Data Sets Analyzed

The intention-to-treat (ITT) population set comprised 185 patients (69 patients in Arm A, 66 patients in Arm B, and 50 patients not randomized to any treatment arm due to discontinuation of study treatment during the run-in phase). Hence, the randomized patient population (RP) set comprised 135 patients (69 patients in Arm A and 66 patients in Arm B). The primary endpoint population (PEP) set comprised 133 patients (68 patients in Arm A and 65 patients in Arm B), and the safety population (SP) set comprised 182 patients (69 patients in Arm A, 66 patients in Arm B, 47 patients not randomized) (**Figure 2**).

Information on patients excluded from efficacy analysis and reasons for their exclusions over time is provided in the Appendix 16.2.3.

### 11.2 Demographic and Other Baseline Characteristics

Patient demographics are shown in **Table 6** for the total ITT set, as well as for patients of Arm A, patients for Arm B and for the 50 patients who stopped study treatment prior to randomization (not randomized). In addition to the protocol-defined stratification factors for randomization (serum lactate dehydrogenase (LDH) (elevated vs. within normal limits at enrolment), metastatic stage (IV M1c yes/no) and previous adjuvant therapy (yes/no)) – both treatment arms were well-balanced.

Key patient characteristics of the 21 and 35 patients undergoing crossover in Arm A and in Arm B, respectively, did not differ substantially except for baseline LDH. While 23.81% of patients in Arm

A had an LDH of 2x upper limit of normal or higher, almost twice as many (42.42%) patients in Arm B had elevated LDH at baseline. Additional baseline characteristics for these patients undergoing crossover, as for the further 16 patients in Arm A and 15 patients in Arm B not crossing-over despite disease progression under initial therapy (PD1), are provided in (Table 30 in section 14.1).

**Table 6 Patient demographics (ITT)**

<i><b>Patient characteristics</b></i>	<i><b>Total</b></i>	<i><b>Arm A</b></i>	<i><b>Arm B</b></i>	<i><b>Not randomized</b></i>
Number of patients	185 (100.00)	69 (100.00)	66 (100.00)	50 (100.00)
Median follow-up time [months] (IQR)	20.28 (8.49 - 54.80)	19.84 (11.28 - 55.63)	25.58 (10.00 - 54.08)	12.96 (4.61 - 54.61)
Follow up (using reverse Kaplan Meier method)				
N	182	69	66	47
Median (months)	56.97	57.83	55.79	55.79
IQR of median (months)	22.66 - 62.99	22.66 - 65.43	27.34 - 62.34	16.91 - 60.16
Sex				
Female	68 (36.76)	21 (30.43)	26 (39.39)	21 (42.00)
Male	117 (63.24)	48 (69.57)	40 (60.61)	29 (58.00)
Age [years]				
N	185	69	66	50
Mean	59.09	59.23	56.58	62.20
STD	14.46	14.79	12.41	16.07
Median	58.00	58.00	56.00	64.50
Min	19.00	19.00	31.00	21.00
Max	91.00	89.00	82.00	91.00
Nmiss	0	0	0	0
Age [years]- categorical				
<65 years	112 (60.54)	39 (56.52)	48 (72.73)	25 (50.00)
≥65 years	73 (39.46)	30 (43.48)	18 (27.27)	25 (50.00)
Body mass index				
Underweight <18.5	2 (1.08)	1 (1.45)	0 (0.00)	1 (2.00)
Normal BMI 18.5-24.9	57 (30.81)	17 (24.64)	24 (36.36)	16 (32.00)
Overweight ≥25	126 (68.11)	51 (73.91)	42 (63.64)	33 (66.00)
ECOG baseline				
Grade 0	157 (84.86)	58 (84.06)	55 (83.33)	44 (88.00)
Grade 1	28 (15.14)	11 (15.94)	11 (16.67)	6 (12.00)
Ulceration				
No	73 (39.46)	25 (36.23)	30 (45.45)	18 (36.00)
Yes	77 (41.62)	33 (47.83)	21 (31.82)	23 (46.00)
Unknown	35 (18.92)	11 (15.94)	15 (22.73)	9 (18.00)
Histological subtype				
Superficial Spreading Melanoma (SSM)	62 (33.51)	23 (33.33)	24 (36.36)	15 (30.00)
Nodular malignant melanoma	55 (29.73)	22 (31.88)	16 (24.24)	17 (34.00)
Acral lentiginous melanoma (ALM)	5 (2.70)	2 (2.90)	1 (1.52)	2 (4.00)
Other	56 (30.27)	19 (27.54)	23 (34.85)	14 (28.00)
Missing	7 (3.78)	3 (4.35)	2 (3.03)	2 (4.00)
Tumor stage (AJCC 2010)				
Stage IIIB	5 (2.70)	4 (5.80)	1 (1.52)	0 (0.00)
Stage IIIC	8 (4.32)	2 (2.90)	1 (1.52)	5 (10.00)
Stage IV	172 (92.97)	63 (91.30)	64 (96.97)	45 (90.00)
M substage of stage IV patients (AJCC 2010)				
M1a	41 (22.16)	16 (23.19)	14 (21.21)	11 (22.00)
M1b	40 (21.62)	14 (20.29)	18 (27.27)	8 (16.00)
M1a+b	81 (43.78)	30 (43.48)	32 (48.48)	19 (38.00)
M1c (total)	91 (49.19)	33 (47.83)	32 (48.48)	26 (52.00)
No of disease sites				
<3	37 (20.00)	12 (17.39)	12 (18.18)	13 (26.00)
≥3	54 (29.19)	21 (30.43)	20 (30.30)	13 (26.00)
No data	94 (50.81)	36 (52.17)	34 (51.52)	24 (48.00)
Sum of lesion diameters				
N	185	69	66	50
Mean	68.01	65.00	64.96	76.19
STD	54.74	46.05	57.34	62.07
Median	54.00	50.00	51.50	59.50
Min	10.00	10.00	10.23	10.00
Max	310.30	183.00	310.30	233.50

<i><b>Patient characteristics</b></i>	<i><b>Total</b></i>	<i><b>Arm A</b></i>	<i><b>Arm B</b></i>	<i><b>Not randomized</b></i>
Nmiss	0	0	0	0
LDH baseline				
Within normal limits	94 (50.81)	35 (50.72)	34 (51.52)	25 (50.00)
Elevated	69 (37.30)	24 (34.78)	28 (42.42)	17 (34.00)
2x the upper limit of norm or higher	22 (11.89)	10 (14.49)	4 (6.06)	8 (16.00)
Prior adjuvant therapy				
No	161 (87.03)	62 (89.86)	54 (81.82)	45 (90.00)
Yes	24 (12.97)	7 (10.14)	12 (18.18)	5 (10.00)
Type of prior adjuvant therapy				
IFN	19 (10.27)	7 (10.14)	7 (10.61)	5 (10.00)
Chemotherapy	2 (1.08)	0 (0.00)	2 (3.03)	0 (0.00)
Radiotherapy	8 (4.32)	3 (4.35)	5 (7.58)	0 (0.00)
Other	1 (0.54)	1 (1.45)	0 (0.00)	0 (0.00)
Prior radiotherapy				
No	166 (89.73)	63 (91.30)	57 (86.36)	46 (92.00)
Yes	19 (10.27)	6 (8.70)	9 (13.64)	4 (8.00)
Intention of prior radiotherapy (multiple answers possible)				
Adjuvant	8 (4.32)	3 (4.35)	5 (7.58)	0 (0.00)
Not adjuvant	12 (6.49)	4 (5.80)	4 (6.06)	4 (8.00)
Irradiated location of prior radiotherapy				
Cerebral	1 (0.54)	0 (0.00)	1 (1.52)	0 (0.00)
Extracerebral	20 (10.81)	7 (10.14)	9 (13.64)	4 (8.00)
Type of prior radio therapy				
Conventional radiotherapy	16 (8.65)	5 (7.25)	8 (12.12)	3 (6.00)
Stereotaxy	2 (1.08)	0 (0.00)	1 (1.52)	1 (2.00)
Other	1 (0.54)	1 (1.45)	0 (0.00)	0 (0.00)
Radiological response to treatment in run-in phase				
CR	8 (4.32)	3 (4.35)	5 (7.58)	0 (0.00)
PR	96 (51.89)	48 (69.57)	44 (66.67)	4 (8.00)
SD	34 (18.38)	17 (24.64)	16 (24.24)	1 (2.00)
PD	14 (7.57)	1 (1.45)	1 (1.52)	12 (24.00)
Missing	33 (17.84)	0 (0.00)	0 (0.00)	33 (66.00)

Data source: Table 2 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

## 11.3 Measurements of Treatment Compliance

The dates of atezolizumab infusions, including dose modifications, were documented in the eCRF. For vemurafenib and cobimetinib, drug administration times (hh:mm) were recorded in a medical diary.

## 11.4 Efficacy Results

### 11.4.1 Primary Efficacy endpoint

Progression-free survival 1 (PFS1), defined as time from start of run-in phase (i.e., date of first intake of the study drug) to first documented tumor progression date according to RECIST v. 1.1 (PD1) or death by any cause, was defined as the primary endpoint of the ImmunoCobiVem clinical trial.

In the primary endpoint population (PEP) set, PFS1 rates at 6 months were higher in Arm A (81.22%, 95% CI 69.30–88.87) compared to Arm B (48.39%, 95% CI 35.54–60.08). At 12 months, PFS1 rates were still higher in Arm A (52.61%, 95% CI 39.36–64.24) compared to Arm B (29.03%, 95% CI 18.38–40.54) (**Table 7**). This resulted in a median PFS1 of 12.96 months (95% CI 9.87–15.59) in Arm A, compared to a median PFS1 of 5.94 months (95% CI 5.46–8.29) in Arm B (**Table 8, Figure 3**).

**Table 7 Progression-free Survival 1 (PFS1) rate at 6 and 12 months (PEP)**


		PFS1 rate at 6 months							PFS1 rate at 12 months				
	N	N <sub>cens</sub>	%	CI 95%	Event	%		N	N <sub>cens</sub>	%	CI 95%	Event	%
Arm A	68	56	81.22	69.30- 88.87	12	18.78		68	39	52.61	39.36- 64.24	29	47.39
Arm B	65	33	48.39	35.54- 60.08	32	51.61		65	21	29.03	18.38- 40.54	44	70.97

Data source: Table 12 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v0.1\_2024AUG07

**Table 8 Progression-free Survival 1 (PFS1) (PEP)**

PFS1	N	N <sub>cens</sub>	%	Event	%	Mean	Median	95% CI for median	p <sub>Log-rank</sub>	p <sub>stratified</sub>	HR	CI <sub>HR</sub>	p <sub>HR</sub>
Arm A	68	21	30.88	47	69.12	20.45	12.96	9.87- 15.59	0.0141	0.0055	0.61	0.41-0.91	0.0154
Arm B	65	13	20.00	52	80.00	12.52	5.94	5.46- 8.29	.	.	.	.	.

Data source: Table 11 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05



**Figure 3 Kaplan-Meier Estimates of Progression-free Survival 1 (PFS1) (PEP)**

Data source: Figure 2 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

PFS1 rates for the initial course of treatment after randomization were compared for potentially prognostic/predictive factors for PFS1, including LDH levels at enrolment, metastatic stage IV M1c, prior adjuvant therapy before enrolment, sex, age at enrolment, asymptomatic brain metastases at enrolment, ECOG performance status at enrolment, number of organ sites with metastases at enrolment, sum of lesion diameter at enrolment, prior radiotherapy before enrolment, and tumor response after run-in phase (**Table 31** in section 14.2). Hazard ratios (HRs) for PFS1, shown as a forest plot for Arm A vs Arm B, among the above mentioned prespecified subgroups are shown in **Figure 8** in section 14.2. Overall, these descriptive subgroup analyses did not reveal any subgroup to particularly benefit from an early switch to atezolizumab (Arm B).

11.4.2 Secondary Efficacy Endpoints

11.4.2.1 Progression-free Survival 3 (PFS3)

Progression-free survival 3 (PFS3), defined as time from the first documented tumor progression date (PD1) until the second documented tumor progression date (PD2) after randomization or death by any cause, was defined as a secondary endpoint.

After crossover, a significant number of patients in both treatment arms had rapid further disease progression. Overall, the median PFS3 was longer for patients in Arm B (6.02 months, 95% CI 2.14–8.75 than for patients in Arm A (2.83 months, 95% CI 2.14–3.32) (**Table 9, Figure 4**). PFS3 rates at 6 and 12 months were 14.29% (95% CI 3.57–32.12) and 9.52% (95% CI 1.63–26.12), respectively, for Arm A and 52.01% (95% CI 33.29–67.81) and 32.20% (95% CI 16.00–49.62), respectively, for Arm B (**Table 10**).

Table 9 PFS3 [months] (RP)


PFS3	N	N <sub>cens</sub>	%	Event	%	Mean	Median	95% CI for median	p <sub>Log-rank</sub>	p <sub>stratified</sub>	HR	CI <sub>HR</sub>	p <sub>HR</sub>
Arm A with switch	21	2	9.52	19	90.48	3.42	2.83	2.14- 3.32	0.0801	0.0157	1.72	0.93-3.20	0.0848
Arm B with switch	35	12	34.29	23	65.71	9.82	6.02	2.14- 8.75	.	.	.	.	.

Data source: Table 29 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

Table 10 PFS3 rate at 6 and 12 months (RP)

	PFS3 rate at 6 months						PFS3 rate at 12 months					
	N	N <sub>cens</sub>	%	CI 95%	Event	%	N	N <sub>cens</sub>	%	CI 95%	Event	%
Arm A with switch	21	3	14.29	3.57- 32.12	18	85.71	21	2	9.52	1.63- 26.12	19	90.48
Arm B with switch	35	20	52.01	33.29- 67.81	15	47.99	35	15	32.20	16.00- 49.62	20	67.80

Data source: Table 30 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

**Figure 4 Kaplan-Meier estimates of PFS3 (RP)**

Data source: Figure 10 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

#### 11.4.2.2 Progression-free Survival 2 (PFS2)

Another secondary endpoint of the ImmunoCobiVem clinical trial was progression-free survival 2, defined as time from start of run-in phase (i.e., the date of first intake of the study drug) to second documented disease progression according to RECIST v. 1.1 (PD2) following randomization or death by any cause.


PFS2 was better for the 35 patients in Arm B who switched to treatment with vemurafenib/cobimetinib after completing the randomized phase compared to the 21 patients in Arm A who switched to atezolizumab, although statistical significance was not reached. Median PFS2 was 12.57 months (95% CI 8.32–17.01) for Arm A vs. 14.61 months (95% CI 8.55–25.56) for Arm B (Table 11, Figure 5).

**Table 11 PFS2 [months] (RP)**

PFS2	N	N <sub>cens</sub>	%	Event	%	Mean	Median	95% CI for median	p <sub>Log-rank</sub>	p <sub>stratified</sub>	HR	CI <sub>HR</sub>	p <sub>HR</sub>
Arm A with switch	21	2	9.52	19	90.48	18.72	12.57	8.32- 17.01	0.4069	0.7568	1.29	0.70-2.38	0.4093
Arm B with switch	35	12	34.29	23	65.71	17.32	14.61	8.55- 25.56	.	.	.	.	.

Data source: Table 21 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05





**Figure 5 Kaplan-Meier estimates of PFS2 (RP)**

Data source: Figure 6 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

PFS2 rates at 6 and 12 months were 95.24% (95% CI 70.72–99.32) and 52.38% (95% CI 29.67–70.88), respectively, for Arm A and 91.43% (95% CI 75.73–97.15) and 59.48% (95% CI 41.30–73.69), respectively, for Arm B (**Table 12**). At 18 and 24 months, PFS rates remained higher in Arm B (43.09% (95% CI 25.97–59.11) and 34.82% (95% CI 34.82–51.70), respectively) compared to Arm A (28.57% (95% CI 11.66–48.18) and 14.29% (95% CI 3.57–32.12), respectively) (**Table 13**).

**Table 12 PFS2 rate at 6 and 12 months (RP)**

	PFS2 rate at 6 months						PFS2 rate at 12 months					
	N	N <sub>cens</sub>	%	CI 95%	Event	%	N	N <sub>cens</sub>	%	CI 95%	Event	%
Arm A with switch	21	20	95.24	70.72- 99.32	1	4.76	21	11	52.38	29.67- 70.88	10	47.62
Arm B with switch	35	32	91.43	75.73- 97.15	3	8.57	35	21	59.48	41.30- 73.69	14	40.52

Data source: Table 22 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

**Table 13 PFS2 rate at 18 and 24 months (RP)**

	PFS2 rate at 18 months						PFS2 rate at 24 months					
	N	N <sub>cens</sub>	%	CI 95%	Event	%	N	N <sub>cens</sub>	%	CI 95%	Event	%
Arm A with switch	21	6	28.57	11.66- 48.18	15	71.43	21	3	14.29	3.57- 32.12	18	85.71
Arm B with switch	35	16	43.09	25.97- 59.11	19	56.91	35	14	34.82	18.50- 51.70	21	65.18

Data source: Table 23 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

### 11.4.2.3 Overall Survival (OS)

Overall survival (OS), defined as the time from start of run-in phase (i.e., the date of first intake of the study drug) until documented date of death, for any cause was defined as a further secondary endpoint of the ImmunoCobiVem clinical trial.


The median OS (mOS) of patients in Arm B was improved compared to mOS of patients in Arm A (HR=1.16, 95% CI 0.71-1.90) (**Figure 6**). Median OS was 40.23 months (95% CI 18.88–NE) in Arm A and 49.64 months (95% CI 26.05–NE) in Arm B. Median OS of patients who stopped treatment during the run-in phase was 17.96 months (95% CI 10.89–NE) (**Table 14**).

**Table 14 OS [months] (ITT)**

OS	N	N <sub>cens</sub>	%	Event	%	Mean	Median	95% CI for median	p <sub>Log-rank</sub>	p <sub>stratified</sub>	HR	CI <sub>HR</sub>	p <sub>HR</sub>
Total	182	94	51.65	88	48.35	38.52	39.01	25.16-64.77	.	.	.	.-.	.
Patients who stopped treatment during run-in phase	47	23	48.94	24	51.06	33.89	17.96	10.89	.	.	.	.-.	.
Patients who stopped treatment during run-in phase due to PD	11	3	27.27	8	72.73	18.44	10.89	3.39	0.0876	0.1885	2.09	0.88-4.97	0.0951
Patients who stopped treatment during run-in phase due to other reason	36	20	55.56	16	44.44	37.49	64.77	12.99	.	.	.	.-.	.
Arm A total	69	34	49.28	35	50.72	34.84	40.23	18.88	0.5339	0.9424	1.17	0.71-1.91	0.5344
Arm B total	66	37	56.06	29	43.94	36.56	49.64	26.05	.	.	.	.-.	.
Arm A with switch	21	10	47.62	11	52.38	28.53	37.53	16.78	0.8133	0.7072	1.10	0.51-2.37	0.8136
Arm B with switch	35	19	54.29	16	45.71	35.25	37.17	23.55	.	.	.	.	.
Arm A without switch	16	6	37.50	10	62.50	25.49	35.13	12.14-40.63	0.7323	0.8588	0.86	0.35-2.08	0.7326
Arm B without switch	15	5	33.33	10	66.67	26.27	25.16	10.03-33.82	.	.	.	.	.

3 patients were excluded because of missing start of treatment

Data source: Table 36 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05



**Figure 6 Kaplan-Meier estimates of OS for Arm A vs Arm B vs non-randomized patients (ITT)**

Data source: Figure 19 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

OS rates at 12 and 24 months were 78.69% (95% CI 66.67–86.79) and 58.39% (95% CI 45.05–69.56), respectively, for Arm A compared to 79.05% (95% CI 66.66–87.27) and 68.02% (95% CI 54.40–78.36), respectively, for Arm B (**Table 15**). Over the long-term, OS rates remained higher in Arm B compared to Arm A. OS rates at 36 months, 48 months and 60 months in Arm B were 55.01% (95% CI 40.57–67.32), 52.62% (95% CI 38.12–65.22) and 44.97% (95% CI 30.51–58.39), respectively. Those for Arm A were 54.56% (95% CI 41.14–66.14), 42.43% (95% CI 29.33–54.93) and 40.08% (95% CI 27.05–52.75), respectively (**Table 16**).

Subgroup analyses did not indicate a relevant benefit for any particular group, but patients in Arm B with stable disease (SD) after the run-in phase seemed to benefit more from an early treatment with atezolizumab (**Figure 9** in section 14.2).

**Table 15 OS rate at 12 and 24 months (RP)**

	OS rate at 12 months						OS rate at 24 months					
	N	N <sub>cens</sub>	%	CI 95%	Event	%	N	N <sub>cens</sub>	%	CI 95%	Event	%
Arm A	69	55	78.69	66.67- 86.79	14	21.31	69	43	58.39	45.05- 69.56	26	41.61
Arm B	66	53	79.05	66.66- 87.27	13	20.95	66	47	68.02	54.40- 78.36	19	31.98

Data source: Table 47 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

**Table 16 OS rate at 36, 48 and 60 months (RP)**

OS rate at 36 months							OS rate at 48 months						
	<i>N</i>	<i>N<sub>cens</sub></i>	%	<i>CI</i> 95%	<i>Event</i>	%	<i>N</i>	<i>N<sub>cens</sub></i>	%	<i>CI</i> 95%	<i>Event</i>	%	
Arm A	69	41	54.56	41.14- 66.14	28	45.44	69	35	42.43	29.33- 54.93	34	57.57	
Arm B	66	41	55.01	40.57- 67.32	25	44.99	66	40	52.62	38.12- 65.22	26	47.38	
OS rate at 60 months													
	<i>N</i>	<i>N<sub>cens</sub></i>	%	<i>CI</i> 95%	<i>Event</i>	%							
Arm A	69	34	40.08	27.05- 52.75	35	59.92							
Arm B	66	37	44.97	30.51- 58.39	29	55.03							

Data source: Table 48 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05 (modified)

#### 11.4.2.4 Rate of Patients with PD Who Could Not Cross-Over to Subsequent Line of Therapy Due to Deterioration of ECOG Status or Multiple and/or Symptomatic Brain Metastasis and/or Leptomeningeal Disease

The rate of patients with PD who were not able to cross over to subsequent line of therapy due to either deterioration of the ECOG performance status or due to multiple and/or symptomatic brain metastases and/or leptomeningeal disease was defined as a further secondary endpoint of the ImmunoCobiVem clinical trial. Thirty-seven patients in Arm A and 50 patients in Arm B had a progressive disease before end of treatment (EoT). Cross-over/switch to subsequent line of therapy was not possible for 16 (43.24%) patients in Arm A and 15 (30.00%) patients in Arm B, predominantly because of multiple and/or symptomatic brain metastases and/or leptomeningeal disease (**Table 17**).

**Table 17 Rate of disease progression preventing cross-over/switch to subsequent therapy within the protocol (RP)**

	<b>Arm A</b>	<b>Arm B</b>	<b>Total</b>
Patients with progressive disease before end of treatment	37 (100.00)	50 (100.00)	87 (100.00)
Crossover/Switch to subsequent line of therapy possible?			
No	16 (43.24)	15 (30.00)	31 (35.63)
Yes	21 (56.76)	35 (70.00)	56 (64.37)
Reason for no crossover/switch			
Due to multiple and/or symptomatic brain metastasis and/or leptomeningeal disease	7 (18.92)	7 (14.00)	14 (16.09)
Death	0 (0.00)	1 (2.00)*	1 (1.15)
Patient's wish	1 (2.70)	1 (2.00)	2 (2.30)
Physician's decision	5 (13.51)	1 (2.00)	6 (6.90)
Rapid progression	1 (2.70)	0 (0.00)	1 (1.15)
Unknown	0 (0.00)	2 (4.00)	2 (2.30)
withdrawn informed consent	1 (2.70)	0 (0.00)	1 (1.15)
Deterioration of ECOG	0 (0.00)	1 (2.00)	1 (1.15)
Toxicity	0 (0.00)	2 (4.00)	2 (2.30)
Other	1 (2.70)	0 (0.00)	1 (1.15)

\* The patient died because of disease progression.

Data source: Table 82 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

#### 11.4.2.5 Response and Progression Patterns

Overall objective response rate (OORR), defined as the proportion of patients with partial response (PR) or complete response (CR) to study treatment, was a further secondary endpoint of the ImmunoCobiVem clinical trial. At the end of the run-in phase, i.e., at time of randomization, a total of eight patients (three patients in Arm A and five patients in Arm B) achieved a complete response (CR). About one in four patients (33 patients in total, 17 patients in Arm A and 16 patients in Arm B) had a stable disease (SD) and more than half of all patients (48 patients in Arm A and 44 patients in Arm B) had partial response (PR) as best overall response (BOR) during the run-in phase. One patient each in Arm A and Arm B had a progressive disease (PD) (**Table 18**). Resulting overall objective response rate (ORR), defined as the rate of patients showing CR or PR, after the run-in phase was 73.91% (95% CI 62.49–82.81) for Arm A and 74.24% (95% CI 62.57–83.25) for Arm B.

Resulting disease control rate (DCR) was similarly high in both treatment arms (Arm A: 98.55% (95% CI 92.24–99.74) vs. Arm B: 98.48% (95% CI 91.90–99.73)) (**Table 18**).

After randomization, half of patients in Arm B (N=33) had disease progression (PD) as BOR compared to 17.39% of patients in Arm A (N=12). Four patients in Arm A (5.80%) and four patients in Arm B (6.06%) had a SD as BOR after randomization phase. PR was achieved in almost half of patients in Arm A (46.38%) and for 18.18% of patients in Arm B. Almost one in five patients in both treatment arms achieved a CR as BOR at the end of randomization (14 patients in Arm A (20.29%) and 12 patients in Arm B (18.18%)). Resulting ORR after randomization was 66.67% (95% CI 54.93–76.65) for Arm A and 36.36% (95% CI 25.81–48.42) for Arm B. Resulting DCR was similarly high in both treatment arms (Arm A: 98.55% (95% CI 92.24–99.74) vs. Arm B: 98.48% (95% CI 91.90–99.73)) (**Table 18**).

Following progression and crossover, three patients in Arm A (14.29%) and four patients of Arm B (11.43%) achieved a CR as BOR. However, almost three of four patients in Arm A (71.43%) had disease progression (PD) compared to 28.57% of patients in Arm A. One patient in Arm A (4.76%) and four patients in Arm B (11.43%) had a SD after crossover. Resulting ORR after crossover was higher in Arm A (66.67%, 95% CI 54.93–76.65) compared to Arm B (36.36%, 95% CI 25.81–48.42). However, DCR was similar among both treatment arms (Arm A: 98.55% (95% CI 92.24–99.74) vs. Arm B: 98.48% (95% CI 91.90–99.73)) (**Table 18**).

**Table 18 RECIST response (RP)**

		<i>Arm A</i>	<i>Arm B</i>	<i>Total</i>
<b>At the end of run-in phase</b>	Number of patients	69 (100.00)	66 (100.00)	135 (100.00)
	Tumor response			
	CR	3 (4.35)	5 (7.58)	8 (5.93)
	PR	48 (69.57)	44 (66.67)	92 (68.15)
	SD	17 (24.64)	16 (24.24)	33 (24.44)
	PD	1 (1.45)	1 (1.52)	2 (1.48)
	ORR (CR+PR), n(%) [95% CI]	51 (73.91) [62.49 - 82.81]	49 (74.24) [62.57 - 83.25]	100 (74.07) [66.09 - 80.73]
	DCR (CR+PR+SD), n(%) [95% CI]	68 (98.55) [92.24 - 99.74]	65 (98.48) [91.90 - 99.73]	133 (98.52) [94.76 - 99.59]
<b>Randomized phase before crossover</b>	Number of patients	69 (100.00)	66 (100.00)	135 (100.00)
	Tumor response			
	CR n(%)	14 (20.29)	12 (18.18)	26 (19.26)
	(n')*	(11)	(10)	(21)
	PR n(%)	32 (46.38)	12 (18.18)	44 (32.59)
	(n')*	(4)	(5)	(9)
	SD n(%)	4 (5.80)	4 (6.06)	8 (5.93)
	(n')*	(0)	(0)	(0)
	PD n(%)	12 (17.39)	33 (50.00)	45 (33.33)
	(n')*	(12)	(33)	(45)
	Missing n(%)	7 (10.14)	5 (7.58)	12 (8.89)
	(n')*	(7)	(5)	(12)
<b>After crossover</b>	ORR (CR+PR), n(%) [95% CI]	46 (66.67) [54.93 - 76.65]	24 (36.36) [25.81 - 48.42]	70 (51.85) [43.49 - 60.11]
	DCR (CR+PR+SD), n(%) [95% CI]	50 (72.46) [60.95 - 81.61]	28 (42.42) [31.24 - 54.44]	78 (57.78) [49.34 - 65.78]
	Number of patients	21 (100.00)	35 (100.00)	56 (100.00)
	Tumor response			
	CR	3 (14.29)	4 (11.43)	7 (12.50)
	PR	0 (0.00)	11 (31.43)	11 (19.64)
	SD	1 (4.76)	4 (11.43)	5 (8.93)
	PD	15 (71.43)	10 (28.57)	25 (44.64)
	Missing	2 (9.52)	6 (17.14)	8 (14.29)
	ORR (CR+PR), n(%) [95% CI]	3 (14.29) [4.98 - 34.64]	15 (42.86) [27.98 - 59.14]	18 (32.14) [21.40 - 45.18]

	Arm A	Arm B	Total
DCR (CR+PR+SD), n(%) [95% CI]	4 (19.05) [7.67 - 40.00]	19 (54.29) [38.19 - 69.53]	23 (41.07) [29.17 - 54.12]

Data source: Table 71 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

Resulting best objective response rate (BORR) before crossover, i.e., during the run-in phase or the randomized phase, were 81.16% (95% CI 70.39–88.65) for Arm A and 83.33% (95% CI 72.57–90.43) for Arm B (**Table 19**). The absolute BORR was 81.16% (95% CI 70.39–88.65) for Arm A and 89.39% (95% CI 79.69–94.77) for Arm B (**Table 20**).

**Table 19 Overall objective response rate (OORR) (ITT)**

OORR	N	Pat. with CR	Rate	95% CI for CR	Pat. with CR or PR	Rate	95% CI for OORR
Arm A	69	14	20.29	12.49 - 31.22	56	81.16	70.39 - 88.65
Arm B	66	15	22.73	14.29 - 34.17	55	83.33	72.57 - 90.43

This table shows the rate of patients with CR or PR during run-in or the randomized phase before crossover.

Data source: Table 72A of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

**Table 20: Overall objective response rate absolute (OORRa) (ITT)**

OORRa	N	Pat. with CR	Rate	95% CI for CR	Pat. with CR or PR	Rate	95% CI for OORR
Arm A	69	15	21.74	13.64 - 32.82	56	81.16	70.39 - 88.65
Arm B	66	19	28.79	19.27 - 40.64	59	89.39	79.69 - 94.77

This table shows the rate of patients with CR or PR during run-in or the randomized phase or after crossover

Data source: Table 72B of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

Time to OOR was similar for both treatment arms (HR=0.95, 95% CI 0.65–1.38). Median time to OOR for Arm A was 2.76 (95% CI 2.63–2.80), for Arm B median time to OOR was 2.73 (95% CI 2.60–2.80) (**Table 21**).

**Table 21 Time to overall objective response (OOR) [months] (RP)**

OOR	N	N <sub>cens</sub>	%	Event	%	Mean	Median	95% CI for median	p <sub>Log-rank</sub>	p <sub>stratified</sub>	HR	CI <sub>HR</sub>	p <sub>HR</sub>
Arm A	69	13	18.84	56	81.16	8.41	2.76	2.63- 2.80	0.7746	0.9800	0.95	0.65-1.38	0.7862
Arm B	66	11	16.67	55	83.33	5.07	2.73	2.60- 2.80	.	.	.	.	.

Data source: Table 76 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

Disease control rate (DCR), defined as the percentage of patients with complete response (CR), partial response (PR), or stable disease (SD) as a result of their therapy, was a further secondary endpoint of the ImmunoCobiVem clinical trial. At 12 months, two patients each in Arm A and Arm B had a CR. A PR was achieved in 24 and 8 patients in Arm A and Arm B, respectively, and five patients in Arm A and six patients in Arm B had a SD. At 24 months, one patient in Arm A as well as one patient in Arm B had a CR. PR was achieved by ten patients in Arm A and four patients in Arm B. Four patients in Arm B and two patients in Arm B had a SD at 24 months after randomization (**Table 22**).

**Table 22 Disease control rate (DCR) at 12 and 24 months by overall response at start of randomized phase (RP)**

DCR		DCR at 12 months						DCR at 24 months					
		N	N <sub>cens</sub>	%	Event	%		N	N <sub>cens</sub>	%	Event	%	
CR	Arm A	3	1	33.33	2	66.67		3	2	66.67	1	33.33	
	Arm B	5	3	60.00	2	40.00		5	4	80.00	1	20.00	
PR	Arm A	48	24	50.00	24	50.00		48	38	79.17	10	20.83	
	Arm B	44	36	81.82	8	18.18		44	40	90.91	4	9.09	
SD	Arm A	17	12	70.59	5	29.41		17	15	88.24	2	11.76	
	Arm B	16	10	62.50	6	37.50		16	12	75.00	4	25.00	

DCR		DCR at 12 months					DCR at 24 months				
		N	N <sub>cens</sub>	%	Event	%	N	N <sub>cens</sub>	%	Event	%
Total	Arm A	69	38	55.07	31	44.93	69	56	81.16	13	18.84
	Arm B	66	50	75.76	16	24.24	66	57	86.36	9	13.64


Data source: Table 75 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

The median duration of objective overall response, including responses achieved during the run-in phase, was significantly longer in Arm A (11.32 months, 95% CI 8.32–14.84 months) compared to Arm B 3.09 months (95% CI 2.83–6.25 months) in Arm B (HR = 0.48 (95% CI 0.30–0.78) (**Table 23, Figure 7**).

**Table 23 Duration of OOR [months] (RP)**

Duration of OOR	N	N <sub>cens</sub>	%	Event	%	Mean	Median	95% CI for median	p <sub>Log-rank</sub>	p <sub>stratified</sub>	HR	CI <sub>HR</sub>	p <sub>HR</sub>
Arm A	56	23	41.07	33	58.93	20.93	11.32	8.32- 14.84	0.0090	0.0040	0.55	0.35-0.87	0.0103
Arm B	55	14	25.45	41	74.55	9.94	3.09	2.83- 6.25	.	.	.	.	.

Data source: Table 79 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05



**Figure 7 Kaplan-Meier estimates of duration of OOR (RP)**

Data source: Figure 35 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

### 11.4.3 Other Efficacy Endpoints

Not applicable.

### 11.4.4 Post-hoc Analyses

Not applicable.

## 11.5 Statistical / Analytical Issues

A CONSORT diagram was used to document the flow of patients through the various stages of the study.

The number of patients in the various analysis populations was presented in a table, and reasons for exclusions were given.

There were no formal hypotheses. All analyses were of purely descriptive character.

In general summary statistics (n, mean, standard deviation, median, minimum and maximum for continuous variables, and number of patients and percentage in each category for categorical variables) were provided. In addition, 95% CI and p-values were given for some analyses. However, they were of purely explorative character.

All main analyses of the efficacy endpoints (OS and response-related endpoints) were performed on the intention to treat (ITT) population for analyses, including patient groups that did not undergo randomization and on the randomized population (RP) for analyses referring to randomized patients only: randomized patients were considered as in the treatment group as indicated at randomization, all non-randomized patients (i.e., who dropped out during the run-in phase) formed an extra group. For the analysis of the primary endpoint PFS1, all patients with an intake of at least one study drug after randomization and who did not have had major disqualifying protocol violation were analyzed (Primary Endpoint Population, PEP). The major protocol violations were given in section 10.3. OS was analyzed for patients in Arm A and Arm B regardless of whether a cross-over has occurred or not. In case of  $\geq 10\%$  major protocol violations in one arm, all main analyses of the efficacy endpoints were analyzed post hoc using the per protocol principle, i.e. only patients without major protocol violations were considered.

The Kaplan-Meier technique was used to obtain estimates of the survival-type distributions (PFS1/2/3, OS, time to OR, duration of OR). In addition, based on the Kaplan-Meier curves, estimates at given time-points were provided (e.g. 12-, 24-, 36 and 48-month OS rates), along with their standard errors. Medians – if reached – were presented with a 95% confidence interval (CI). The comparison of the time-to-event distributions (PFS, OS, time to OR) between the different treatment groups were done using the log-rank test for ITT and RP stratified by LDH (elevated vs. within normal limits at enrollment), metastatic stage (IV M1c yes/no), previous adjuvant therapy (yes/no) as indicated at enrolment. These comparisons were in a purely descriptive manner.

All p-values were of descriptive manner and were not corrected for multiple testing.

The HR and its 2-sided 95% confidence interval, were estimated using a Cox proportional hazards (PH) model (using Efron's tie-handling method) using treatment group as a single covariate. Subgroup analyses were done for LDH (elevated vs. within normal limits at enrolment), metastatic stage (IV M1c yes/no), previous adjuvant therapy (yes/no) as indicated at enrolment, with treatment as the single covariate.

In each treatment arm, the rate of CR and the OORR as well as the corresponding rates after randomization and switch were summarized with their corresponding 2-sided 95% CI. Since one did not expect the incidences of CR rate to be very high in both groups, and since this phase II study has a relatively low sample size, no statistical inference was done. Idem for the OORRs.

In order to assess a possible influence on the efficacy endpoints the following prognostic/predictive factors

- Sex (male vs. female)
- Age at enrollment (<65 vs.  $\geq 65$  years)
- Asymptomatic brain metastases at enrolment (no vs. yes)
- ECOG status at enrolment (0 vs.  $\geq 1$ )
- Number of organ sites with metastases (<3 sites v.  $\geq 3$  sites) at enrolment
- Sum of lesion diameter (<median vs.  $\geq$ median) at enrolment
- Prior radiotherapy before enrolment (no vs. yes)
- Prior therapy before enrolment ANY (no vs. yes)
- Tumor response after run-in phase (SD vs. PR vs. CR)



were investigated in univariate analyses (Kaplan-Meier curves, logrank test, Cox model) in each treatment group, separately.

Thereafter, a multivariable Cox model was fitted using both treatment groups, including as covariates randomized treatment group and all factors which appeared of prognostic importance (at a 2-sided  $\alpha=20\%$ ) in univariate analyses adjusted for LDH (elevated vs. within normal limits at enrollment), metastatic stage (IV M1c yes/no), previous adjuvant therapy (yes/no) as indicated at enrollment. A step down was used for the multivariable Cox model selection at the 2-sided 10% significance level, and forcing treatment arm to stay in the model. The model with the lowest Akaike information criterion (AIC) was retained. The assumption of proportional hazards was checked using a procedure derived from cumulative sums of martingale-based residuals over follow-up time (method of Lin, Wei, and Ying). In case one of the strong prognostic factors violated the PH assumption, a Cox model stratified by this factor was considered. Hazard ratios for disease progression or death among the following subgroups LDH at baseline (elevated vs. within normal limits), metastatic stage (IV M1c no vs. yes), prior adjuvant therapy before enrollment (no vs. yes), sex (male vs. female), age at enrollment ( $<65$  vs.  $\geq 65$  years), asymptomatic brain metastases at enrollment (no vs. yes), ECOG status at enrollment (0 vs.  $\geq 1$ ) by treatment, number of organ sites with metastases ( $<3$  sites v.  $\geq 3$  sites) at enrollment by treatment, sum of lesion diameter ( $<$ median vs.  $\geq$ median) at enrollment by treatment, prior radiotherapy before enrollment (no vs. yes), prior therapy before enrollment ANY (no vs. yes) and tumor response after run-in phase (SD vs. PR vs. CR) was evaluated and displayed in a forest plot.

Outcome variables (questionnaires, sociodemographics) were compared between user, mixed user and non-user of eMARS using ANOVA (with posthoc analyses for significant mean differences using Tukey's test) and corresponding Kruskal-Wallis test, the non-parametric tests (with posthoc analyses for significant mean differences using Dwass-Steel-Critchlow-Flinger test) as well as chisquare test.

The SP set was used for the analyses of the safety variables. All safety analyses were also done separately for each treatment step: a) the run-in phase, b) the randomized phase, c) the switch phase. For the randomized phase and the switch phase, the analyses were also done separately for treatment arm A and B. All AEs were tabulated using worst grade per NCI CTCAE v 4.03 criteria by system organ class and preferred term.

Safety analysis included:

- System Organ Class (SOC) and Preferred Terms (PT) according to the Medical Dictionary for Regulatory Activities (MedDRA) classification
- Severity of AE
- Causality of AE
- Outcome of AE
- SAEs
- AESIs
- All AEs leading to discontinuation of study treatment
- All AE-related deaths

### Treatment exposure

Frequency tables and summary statistics (median, range, interquartile range) of the following parameters were provided for the different treatment periods:

In the run-in phase, treatment Arm A and in treatment Arm B after switch:

- Number of treatment days with vemurafenib and cobimetinib during run-in phase, from randomization to switch or end of treatment, whatever occurred first and from switch to end of treatment
- Mean cumulative dose of vemurafenib and cobimetinib of the starting doses (vemurafenib: 960 mg BID; cobimetinib: 60 mg QD for 21 days followed by a 7-day rest period in each 28-day cycle)
- For vemurafenib and cobimetinib: Ratio between the total dose given and expected dose during the period these treatments were administered

- If administration of vemurafenib and cobimetinib was delayed and/or skipped: reason
- Reason to stop vemurafenib and cobimetinib
- Duration of treatment breaks (number of days that treatment was not taken since randomization to switch or end of treatment, whatever occurred first)
- Medication adherence in the run-in phase for patients using eMARS and non-users: (determined by dividing number of taken tablets (cobimetinib / vemurafenib) by number of envisaged tablets. Patients with adherence have taken at least 80% of envisaged tablets of each cobimetinib or vemurafenib)

In treatment Arm B and in treatment arm A after switch:

- Number of infusions of atezolizumab from randomization to switch or end of treatment, whatever occurred first, or from switch to end of treatment
- Mean cumulative dose of atezolizumab of the starting dose (atezolizumab (1,00 mg/ q3w)
- Ratio between the total number of atezolizumab infusions given and expected during the period these treatments were administered
- If atezolizumab was delayed and/or skipped: reason
- Reason to stop atezolizumab

All exploratory variables were analyzed in a descriptive manner with the appropriate summary statistics and considering the applying manuals (for standardized questionnaires), if applicable. Baseline measures were summarized using descriptive statistics for each scale by treatment group or eMARS group, respectively. For the comparison of eMARS users versus non-users, the ITT population was assessed, for the comparison of the treatment arms, the RP was assessed. Change from baseline was summarized using descriptive statistics (N, mean, standard deviation, median, first and third quartiles, minimum, maximum) for each scale at each assessment time point by treatment group/eMARS user vs. non-user group. This analysis was performed in the ITT population who had an assessment at baseline and at the time point of interest.

Non-parametric rank-order tests were performed using a 2-sided significance level of 5% to test for significant differences between the treatment arms at each point in time. The Global Health Status scale was used as the primary outcome of interest for this study. A difference of 10 points on the 100-point QLQ-C30 scale between the two arms was considered clinically relevant.

### 11.5.1 Adjustments for Covariates

Usage of eMARS was used for ANOVA/Kruskal-Wallis test of:

- EORTC QLQ-C30 questionnaire Score changes from baseline to end of run-in
- HADS Baseline Anxiety and depression score
- General Self Efficacy scale
- Brief-IPQ questionnaire Score changes from baseline to end of run-in
- Brief-IPQ questionnaire Score changes from baseline to week 12 of randomized phase
- Scale of Subjective Social Status

The following variables were used for Cox regression of PFS1, PFS2, PFS3 and OS:

- LDH at enrollment (elevated vs. within normal limits),
- Metastatic stage IV M1c (yes/no),
- Prior adjuvant therapy (yes/no)

### 11.5.2 Handling of Dropouts or Missing Data

All randomized patients were included in the ITT analysis. Missing values were not imputed.

### 11.5.3 Interim Analyses and Data Monitoring

One interim analysis was conducted on November 26, 2021 (data cutoff: November 18, 2021). At this time point 80% of the patients reached PFS1 or prematurely discontinued the study. No SAEs that would lead to discontinuation of the study occurred.

### 11.5.4 Multicenter Trials

Patients from all study sites were pooled and tabulated as a single treatment group.

### 11.5.5 Multiple Comparison / Multiplicity

All p-values generated in the analysis were of descriptive manner and were not corrected for multiple testing.

### 11.5.6 Use of an "Efficacy Subset" of Patients (e.g. Per Protocol Analysis)

Not applicable

### 11.5.7 Active-Control Studies Intended to Show Equivalence

Not applicable.

### 11.5.8 Examination of Subgroups

Prespecified subgroup analyses for the primary endpoint are detailed in section **Error! Reference source not found..**

Hazard ratios (HR) for disease progression (PD) or death among the following subgroups LDH at baseline (elevated vs. within normal limits), metastatic stage (IV M1c no vs. yes), prior adjuvant therapy before enrolment (no vs. yes), sex (male vs. female), age at enrolment (<65 vs. ≥ 65 years), asymptomatic brain metastases at enrolment (no vs. yes), ECOG status at enrolment (0 vs. ≥1) by treatment, number of organ sites with metastases (<3 sites v. ≥3 sites) at enrolment by treatment, sum of lesion diameter (<median vs. ≥median) at enrolment by treatment, prior radiotherapy before enrolment (no vs. yes), prior therapy before enrolment ANY (no vs. yes) and tumor response after run-in phase (SD vs. PR vs. CR) were evaluated and displayed in a forest plot.

Analyses of PFS1 were done for the following subgroup of the PEP or the RP: (a) treatment: Arm A vs. Arm B. All main analyses of OS, PFS2 and PFS3 were also done for the following subgroup of the RP: (a) Arm A with switch vs. Arm B with switch, (b) Arm A with brain metastasis at switch vs. Arm A without brain metastasis at switch vs. Arm B with brain metastasis at switch vs. Arm B without brain metastasis at switch, (c) Arm A with brain metastasis at any time vs. Arm A without brain metastasis at any time vs. Arm B with brain metastasis at any time vs. Arm B without brain metastasis at any time. Analyses of OS was additionally done for the following subgroups of the ITT or the RP, as appropriate: (a) Treatment: Arm A vs. Arm B, (b) Patients who dropped out in run-in phase (ITT), (c) Arm A without switch (RP) v. Arm B without switch (RP), (d) Arm A with crossover vs. Arm A without crossover vs. Arm B with crossover vs. Arm B without crossover.

All analysis of the exploratory objectives (addressed by patient questionnaires) were done for the following subgroup of the ITT: Usage of eMARS: user vs. non-user vs. mixed user (i.e., patients who were user and non-user during the run-in phase of the study). Analysis of global quality of life (QoL) was additionally done for the following subgroups of the RP: treatment: Arm A vs. Arm B.

All safety analyses will be done for the following subgroups of the SP, if applicable: (a) treatment: Arm A vs. Arm B, (b) non-randomized, (c) usage of eMars: user vs. non-user vs. mixed user.

### 11.5.9 Tabulation of Individual Response Data

Not applicable.

## 11.6 Pharmacokinetic, Pharmacodynamic and other analyses results

### 11.6.1 Drug Dose, Drug Concentration, and Relationships to Response

Not applicable.

### 11.6.2 Drug-Drug and Drug-Disease Interactions

Not applicable.

### 11.6.3 Other Endpoints

Not applicable.

## 11.7 By Patient Displays

Not applicable.

## 11.8 Efficacy Result Summary

Median PFS1 was statistically significantly better in patients in Arm A continuing treatment with vemurafenib/cobimetinib after completing the run-in phase compared to patients in Arm B who switched to treatment with atezolizumab after the run-in phase (12.96 months in Arm A vs. 5.94 months in Arm B). After crossover upon first disease progression (PD1), patients in Arm B who were re-challenged with vemurafenib/cobimetinib had a longer time to second progression (PD2), while in Arm A the use of second-line atezolizumab did not result in a clinically meaningful PFS3 benefit (2.83 months in Arm B vs. 6.02 months in Arm A). As a result, PFS2 of the patients with crossover in Arm B was slightly better compared to PFS2 of the patients with crossover in Arm A (14.6 months in Arm B vs. 12.6 months in Arm A) despite the very short PFS1 of patients in Arm B.

OS rates at 12-, 24-, 36-, 48- and 60 months were higher in patients in Arm B compared to patients in Arm A. As a result, median OS of all patients entering the randomized phase was superior with 49.6 months in Arm B compared to 40.2 months in Arm A. Subgroup analyses did not indicate a relevant benefit for any particular group, but patients with SD after completing the run-in phase seemed to benefit more from a treatment switch to atezolizumab (Arm B).

At randomization (i.e, at the end of the run-in phase), 17 patients in Arm A (24.64%) and 16 patients in Arm B (24.24%) had SD as BOR during run-in. After randomization, tumor control was lost rapidly in 33 patients (50.00%) in Arm B who experienced disease progression as BOR compared with 12 patients (17.39%) of Arm A. However, 14 patients in Arm A (20.29%) and 12 patients in Arm B (18.18%) achieved a CR as BOR in the randomized phase. Resulting BORR for the run-in phase and randomized phase combined were 81.16% (95% CI 70.39-88.65) for Arm A and 83.33% (95% CI 72.57-90.43) for Arm B. Following progression and crossover, 3 patients in Arm A (14.29%) and 4 patients of Arm B (11.43%) achieved a CR as BOR. In total, due to *de novo* PR arising from patients with SD as BOR in the randomized phase, the BORR across the whole treatment sequence increased to 89.39% in Arm B, but remained 81.16% in Arm A. The median duration of objective overall response (DOOR), including responses achieved in the run-in phase, was significantly longer in Arm A (11.32 months (95% CI 8.32-14.84)) compared to Arm B (3.09 months (95% CI 2.83-6.25)) (HR = 0.48 (95% CI 0.30-0.78)).

## 12 SAFETY EVALUATION

The safety population (SP) comprised a total of 182 patients, who received at least one dose of the investigational agent(s). All AEs were documented in reference to NCI CTCAE Version v4.03.

Following the patient's written consent to participate in the study, all (S)AEs that occurred until 90 days of discontinuation of dosing of the investigational product had to be reported. Before the first

administration of study medication, only (S)AEs had to be documented, which occurred during study specific procedures or investigations. Results of investigations had to be documented as pre-existing conditions, not as (S)AEs.

AEs  $\geq$  grade 3 according to CTCAE, Version v4.03 criteria, and all SAEs regardless of causal relationship to the administration of the investigational agents were analyzed as a secondary endpoint.

## 12.1 Extent of Exposure

During the 3-month run-in phase, patients in Arm A were treated on average (median) on 81 days with vemurafenib and on 61 days with cobimetinib. Patients in Arm B were treated for approximately five days less with vemurafenib (76.50 days) and cobimetinib (56.50 days). The number of study drug doses administered during the run-in phase was similar between the treatment arms. Patients in Arm A received a median of 160.00 doses of vemurafenib (IQR 144.00-167.00), and 61.00 doses of cobimetinib (IQR 54.00-63.00), patients in Arm B were administered with a median of 151.50 doses of vemurafenib (IQR 127.50-164.00) and 56.50 doses of cobimetinib (IQR 48.00-62.00). This corresponded to a cumulative dose of vemurafenib of 137,233.5 mg for patients in Arm A and 125,703.8 mg for patients in Arm B. The cumulative dose of cobimetinib was 3,158.39 mg in Arm A and 2,935.31 mg in Arm B. The median time on treatment with vemurafenib and cobimetinib was 84.00 days (IQR 83.00-84.00) for Arm A and Arm B.

A total of 37 patients in Arm A (53.62%) and 36 patients in Arm B (54.55%) interrupted treatment with vemurafenib and cobimetinib during the run-in phase, mostly because of side effects (Arm A: 31 patients, Arm B: 33 patients). The median duration of treatment breaks was 4.50 days (IQR 2.00-12.00) in Arm A and 5.00 days (IQR 2.50-11.50) in Arm B. Fifty patients prematurely discontinued study treatment during the 3-month run-in phase, including three patients who have not started study treatment (patient decision, decision by the investigator, and withdrawal of informed consent, each one patient). Reasons for premature discontinuation included toxicity/adverse event (N=28), disease progression/relapse (N=11, death (N=3), patient's decision (N=4), withdrawal of informed consent (N=2) and decision of the investigator (N=2) (**Table 24**).

**Table 24 Trial treatment administration run-in phase (ITT)**

	<b>Arm A</b>	<b>Arm B</b>	<b>Not randomized</b>
Number of patients	69 (100.00)	66 (100.00)	50 (100.00)
Number treatment days vemurafenib			
Median	81.00	76.50	40.50
IQR	(74.00-84.00)	(66.00-83.00)	(12.00-56.00)
Number treatment days cobimetinib			
Median	61.00	56.50	28.50
IQR	(54.00-63.00)	(48.00-62.00)	(11.00-45.00)
Number of doses vemurafenib			
Median	160.00	151.50	70.00
IQR	(144.00-167.00)	(127.50-164.00)	(23.00-111.00)
Number of doses cobimetinib			
Median	61.00	56.50	28.50
IQR	(54.00-63.00)	(48.00-62.00)	(12.00-45.00)
Cumulative dose of vemurafenib			
Mean	137233.5	125703.8	70205.71
Cumulative dose of cobimetinib			
Mean	3158.39	2935.31	1775.71
Ratio between the total dose given and expected dose			
Vemurafenib	0.84	0.81	0.76
Cobimetinib	0.82	0.82	0.78
Time on treatment vemurafenib and cobimetinib (days)			
Median	84.00	84.00	54.50
IQR	(83.00-84.00)	(83.00-84.00)	(21.00-83.00)
Duration of treatment breaks (days)			
Median	4.50	5.00	4.00
IQR	(2.00-12.00)	(2.50-11.50)	(2.00-9.00)
Medication adherence*			
Yes	38 (55.07)	36 (54.55)	21 (42.00)

	<b>Arm A</b>	<b>Arm B</b>	<b>Not randomized</b>
No	24 (34.78)	28 (42.42)	21 (42.00)
Unknown	7 (10.14)	2 (3.03)	8 (16.00)
Reason for interruption of study therapy			
Adverse event	31 (44.93)	33 (50.00)	34 (68.00)
Other	6 (8.70)	3 (4.55)	6 (12.00)
Missing	0 (0.00)	0 (0.00)	1 (2.00)
Premature termination			
Yes	0 (0.00)	0 (0.00)	47 (94.00)
No (Treatment not started)	69 (100.00)	66 (100.00)	3 (6.00)
Cause for premature termination of study therapy			
Disease progression/relapse	0 (0.00)	0 (0.00)	11 (22.00)
Toxicity/adverse event	0 (0.00)	0 (0.00)	28 (56.00)
Withdrawal of informed consent	0 (0.00)	0 (0.00)	2 (4.00)
Patient request	0 (0.00)	0 (0.00)	4 (8.00)
Investigator decision	0 (0.00)	0 (0.00)	2 (4.00)
Death	0 (0.00)	0 (0.00)	3 (6.00)
Study is closed or terminated	2 (2.90)	2 (3.03)	0 (0.00)
Cause for not performed restaging visit 1			
Death before week 12	0 (0.00)	0 (0.00)	1 (2.00)
Progress before week 12	0 (0.00)	1 (1.52)	5 (10.00)
Due to AE/SAE	0 (0.00)	0 (0.00)	17 (34.00)
Withdrawal of informed consent form before week 12	0 (0.00)	0 (0.00)	1 (2.00)

\* Patients with adherence have taken at least 80% of envisaged tablets of each cobimetinib or vemurafenib

Data source: Table 126 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

Following randomization until cross-over/end of study treatment, patients in Arm A were treated on a median for 144.00 days with vemurafenib and for 114.00 days with cobimetinib. The median number of applied doses of vemurafenib was 289.00 (IQR 112.00-632.00), corresponding to a cumulative dose of vemurafenib of 540,166.8 mg. The number of applied doses of cobimetinib was 116.00 (IQR 60.00-239.00) with a cumulative dose of cobimetinib of 121,38.60 mg. Patients in Arm B received on average (median) five infusion of atezolizumab (IQR 3.00-13.00) with a cumulative dose of atezolizumab of 6,000.00 mg (IQR 3600.00-15600.00). The median time on treatment was 174.00 days (IQR 81.00-365.00) for patients in Arm A receiving vemurafenib in combination with cobimetinib and 89.50 days (IQR 44.00-316.00) for patients in Arm B receiving atezolizumab. Forty-eight patients in Arm A and nine patients in Arm B interrupted study treatment for a median of eight days, due to adverse events or other reasons.

In total, 64 (92.75%) patients in Arm A and 62 (93.94%) patients in Arm B prematurely discontinued study treatment following randomization and prior to cross-over. In Arm A, six (8.70%) patients discontinued study treatment already after one treatment cycle, five patients (7.25%) after treatment cycles and eight patients (11.59%) after three treatment cycles. Main reason for premature termination of study treatment in both treatment arms was progression of the primary disease. Other reasons included toxicity, death, occurrence of brain metastases, patient's wish or decision by the investigator. One patient in Arm B withdrew the informed consent and three patients in Arm A discontinued study treatment due to other reasons (**Table 25**).

**Table 25 Trial treatment administration randomized phase until switch/end of treatment (RP)**

	<b>Arm A</b>	<b>Arm B</b>
Number of patients	69 (100.00)	66 (100.00)
Number treatment days vemurafenib		
Median	144.00	.
IQR	(56.00-320.00)	.
Number treatment days cobimetinib		
Median	114.00	.
IQR	(60.00-239.00)	.
Number of doses vemurafenib		
Median	289.00	.
IQR	(112.00-632.00)	.
Number of doses cobimetinib		
Median	116.00	.

	<b>Arm A</b>	<b>Arm B</b>
IQR	(60.00-239.00)	
Cumulative dose of vemurafenib		
Mean	540166.8	.
Cumulative dose of cobimetinib		
Mean	12138.60	.
Ratio between the total dose given and expected dose		
Vemurafenib	0.79	.
Cobimetinib	0.76	.
Time on treatment vemurafenib and cobimetinib (days)		
Median	174.00	.
IQR	(81.00-365.00)	
Duration of treatment breaks (days)		
Median	8.00	.
IQR	(3.00-16.00)	
Reason for interruption of study therapy		
Adverse event	27 (39.13)	4 (6.06)
Other	21 (30.43)	5 (7.58)
Number of infusions		
Median	.	5.00
IQR		(3.00-13.00)
Cumulative dose of atezolizumab		
Median	.	6000.00
IQR		(3600.00-15600.00)
Ratio between the total infusions given and expected infusions		
Skipped one infusion	0	8 (12.12)
Skipped more than one infusion	0	5 (7.58)
Time on treatment atezolizumab (days)		
Median	.	89.50
IQR		(44.00-316.00)
Premature termination		
Yes	64 (92.75)	62 (93.94)
After 1 treatment cycle	6 (8.70)	
After 2 treatment cycles	5 (7.25)	0
After 3 treatment cycles	8 (11.59)	0
Cause for premature termination of study therapy		
Progression of primary disease	30 (43.48)	43 (65.15)
Toxicity	12 (17.39)	4 (6.06)
Death	2 (2.90)	2 (3.03)
Brain metastasis	7 (10.14)	7 (10.60)
Patient's wish	7 (10.14)	3 (4.55)
Lost to follow up	0 (0.00)	0 (0.00)
Withdrawn informed consent	0 (0.00)	1 (1.52)
Protocol violation	0 (0.00)	0 (0.00)
Investigator decision	3 (4.35)	2 (3.03)
Specific request of the sponsor	0 (0.00)	0 (0.00)
Other	3 (4.35)	0 (0.00)
Cause for not performed restaging visits		
Death before restaging visits	2 (2.90)	3 (4.55)
Due to AE/SAE	12 (17.39)	5 (7.58)
Withdrawal of informed consent form	0 (0.00)	1 (1.52)

Data source: Table 127 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

After switching, i.e, following first disease progression (PD1), patients in Arm A received on average (median) four infusion of atezolizumab (IQR 2.00-5.00) with a cumulative dose of 4,800.00 mg (IQR 2400.00-6000.00). The median time on treatment with atezolizumab in Arm A was 64.00 days (IQR 22.00-86.00). Patients in Arm B were treated on average (median) for 121 days (IQR 41.00-227.00) with vemurafenib (with a median number of 240 doses administered (cumulative dose 33,8524.1 mg) and for 94 days (IQR 32.00-174.00) with cobimetinib (with 95 doses administered (cumulative dose 7,655.17 mg). The median time on treatment with vemurafenib/cobimetinib in Arm B was 141.00 days (IQR 42.00-283.00). Twenty-four patients in Arm B interrupted study treatment for a median of six days (IQR 2.00-13.00), due to adverse events (51.43%) or other reasons (17.14%).

Nineteen (90.48%) patients in Arm A prematurely discontinued study treatment due to disease progression or death. In Arm B, 32 (91.43%) patients prematurely discontinued study treatment, including four (11.43%) patients who discontinued study treatment after three treatment cycles. The main reasons for premature termination in Arm B included disease progression (N=20), death (N=2) and other reasons (N=10). (**Table 26**).

**Table 26 Trial treatment administration after switch (RP)**

	<b>Arm A</b>	<b>Arm B</b>
Number of patients	21 (100.00)	35 (100.00)
Number treatment days vemurafenib		
Median		121.00
IQR		(41.00-227.00)
Number treatment days cobimetinib		
Median		94.00
IQR		(32.00-174.00)
Number of doses vemurafenib		
Median		240.00
IQR		(75.00-456.00)
Number of doses cobimetinib		
Median		95.00
IQR		(32.00-175.00)
Cumulative dose of vemurafenib		
Mean		338524.1
Cumulative dose of cobimetinib		
Mean		7655.17
Ratio between the total dose given and expected dose		
Vemurafenib		0.80
Cobimetinib		0.76
Time on treatment vemurafenib and cobimetinib (days)		
Median		141.00
IQR		(42.00-283.00)
Duration of treatment breaks (days)		
Median		6.00
IQR		(2.00-13.00)
Reason for interruption of study therapy		
Adverse event	0 (0.00)	18 (51.43)
Other	0 (0.00)	6 (17.14)
Number of infusions		
Median	4.00	.
IQR	(2.00-5.00)	
Cumulative dose of atezolizumab		
Median	4800.00	.
IQR	(2400.00-6000.00)	
Ratio between the total infusions given and expected infusions		
Skipped one infusion	1 (4.76)	0 (0.00)
Skipped more than one infusion	1 (4.76)	0 (0.00)
Time on treatment atezolizumab (days)		
Median	64.00	.
IQR	(22.00-86.00)	
Premature termination		
Yes	19 (90.48)	32 (91.43)
After 1 treatment cycle		1 (4.76)
After 2 treatment cycles		0 (0.00)
After 3 treatment cycles		4 (11.43)
Cause for premature termination of study therapy		
Progress	18 (85.71)	20 (57.14)
Death	1 (4.76)	2 (5.71)
Other reason	0 (0.00)	10 (28.57)
Cause for not performed restaging visits		
Death before restaging visits	2 (9.52)	3 (8.57)
Due to AE/SAE	0	7 (20.00)
Withdrawal of informed consent form	0	1 (2.86)

Data source: Table 128 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05



## 12.2 Adverse Events

### 12.2.1 Brief Summary of Adverse Events

Adverse events of any CTCAE grade were reported, along all trial phases combined, for 181 patients (99.45%) of the safety population (SP). AEs of any CTCAE grade occurred in 68 (98.55%) patients in Arm A, in 66 (100.00%) patients in Arm B and in 47 (100.00%) patients who prematurely discontinued study treatment during the 3-month run-in phase. Treatment-related AEs of any CTCAE grade were reported in 68 of 69 patients (98.55%) in Arm A, in 66 (100.00%) patients in Arm B and in 45 of 47 patients (95.74%) who prematurely discontinued study treatment during the 3-month run-in phase. The proportion of CTCAE grade 3/4 treatment-related AEs was similar among treatment Arm A and Arm B (42.03% vs. 48.48%), with one CTCAE grade 5 treatment-related AEs (haemorrhage intracranial) reported in Arm B for which the investigator could not rule out a causal relationship to the study treatment. Immune-related AEs of any CTCAE grade were reported for 11 (15.94%) patients in Arm A, all of which were of CTCAE grade < 3. In 44 (66.67%) patients in Arm B, immune-related AEs occurred, including seven (10.61%) cases of CTCAE grade 3/4 (**Table 27**).

Serious AEs (SAEs) of any CTCAE grade were reported for 30 (43.48%) patients in Arm A and for 33 (50.00%) patients in Arm B, including two cases of intracranial haemorrhage classified as CTCAE grade 5 in Arm B. Of the 47 patients who discontinued study treatment during the 3-month run-in phase, 33 (70.21%) cases were classified as SAEs. Forty-eight SAEs of any CTCAE grade in the SP were classified as treatment-related SAEs, including eight (11.59%) cases in Arm A and 18 (27.27%) cases in Arm B. The proportion of treatment-related SAEs of CTCAE grade 3 or 4 were slightly higher in Arm B (12.12%) than in Arm A (7.25%). The majority of 22 (46.81%) treatment-related SAEs, including those of CTCAE grade 3 or 4, were reported during the run-in phase in patients who discontinued study treatment thereafter (**Table 27**). A listing of SAEs is shown in **Table 39** in Appendix 14.3.2.

AEs occurring during all phases combined led to dose adjustment/interruption of study treatment in 17 (24.64%) patients in Arm A and 22 (33.33%) patients in Arm B. Seven (10.14%) patients in Arm A and seven (10.61%) patients in Arm B discontinued study treatment due to AEs of any kind (**Table 27**).

### 12.2.2 Display of Adverse Events

Diarrhea of any CTCAE grade was the most frequently reported treatment-related AE among all trial phases combined and occurred in 51.10% of all patients in the SP, including 36 (52.17%) patients in Arm A and 35 (53.03%) patients in Arm B. Other commonly reported treatment-related AEs of any CTCAE grade, reported in at least one in four patients, included rash maculo-papular, fatigue, photosensitivity reaction, and increased blood creatine phosphokinase. The proportion of patients with CTCAE grade 3/4 rash maculo-papular and increased blood creatine phosphokinase were higher in Arm B (9.09% and 12.12%, respectively) compared to Arm A (each 4.35%) (**Table 28**).

Treatment-related AEs, which occurred in at least 10% of the patients listed per study phase (run-in phase, post-randomization phase until crossover or end of treatment, post-crossover phase) are displayed in **Table 32**, **Table 33**, and **Table 34** in section 14.3.1. Following randomization, well-known, treatment-related AEs were observed in Arm B, including hyperthyroidism of any CTCAE grade in 10 (15.15%) patients (including one case of CTCAE grade 3) and hypothyroidism of any CTCAE grade in 9 (13.64%) patients. In Arm A, continuation of treatment with vemurafenib and cobimetinib resulted in new or ongoing, class-specific photosensitivity reactions of any CTCAE grade in 11 (15.94%) patients (including one case of CTCAE grade 3) (**Table 33** in Appendix 14.3.1). The incidence of immune-related AEs of any CTCAE grade, which occurred during all trial phases combined, was higher for Arm B (44 patients (66.67%)) compared to Arm A (11 patients (15.94%)). While none of the immune-related AE in Arm A was of CTCAE grade 3/4, seven (10.61%) cases were reported in Arm B, including immune-mediated hepatitis (N=2, 3.03%), colitis (N=1, 1.52%), hyperthyroidism (N=1, 1.52%), increased alanine aminotransferase (N=1, 1.52%),

abdominal pain (N=1, 1.52%), hypophysitis (N=1, 1.52%), and increased lipase (N=1, 1.52%) (**Table 35** in Appendix **14.3.1**).

Overall, treatment-related AEs obtained during all trial phases combined of any CTCAE grade led to discontinuation of study treatment for 32 (17.58%) patients of the SP, including five (7.25%) patients in Arm A and six (9.09%) patients in Arm B. The majority of 22 patients discontinued study treatment prior to randomization, i.e., during the 3-month run-in phase. In Arm A, reasons for treatment discontinuation included cardiac failure (CTCAE grade 3/4), diarrhea (CTCAE grade 3/4), injection fraction decreased, acute kidney injury, and pneumonitis. In Arm B, patients discontinued study treatment because of hyperthyroidism, retinopathy, drug-induced liver injury (CTCAE grade 3/4), immune-mediated hepatitis (CTCAE grade 3/4), encephalitis (CTCAE grade 3/4) and rash maculo-papular (CTCAE grade 3/4) (**Table 36** in Appendix **14.3.1**).

Table 27 Overview adverse events (all trial phases combined) (SP)

	Arm A						Arm B						Not randomized						Total					
	All Grades			Grade 3/4			Grade 5			All Grades			Grade 3/4			Grade 5			All Grades			Grade 3/4		
	N	%	N	N	%	N	N	%	N	N	%	N	N	%	N	N	%	N	N	%	N	N	%	N
Number of patients	69	100.00								66	100.00					47	100.00		182	100.00				
Any AE	68	98.55	37	53.62	0	0.00				66	100.00	42	63.64	2	3.03				181	99.45	112	61.54	4	2.20
Any treatment-related AE	68	98.55	29	42.03	0	0.00				66	100.00	32	48.48	1	1.52				179	98.35	88	48.35	1	0.55
Any immune-related AE	11	15.94	0	0.00	0	0.00				44	66.67	7	10.61	0	0.00				55	30.22	7	3.85	0	0.00
Serious AE	30	43.48	21	30.43	0	0.00				33	50.00	21	31.82	2	3.03				96	52.75	67	36.81	4	2.20
Treatment-related serious AE	8	11.59	5	7.25	0	0.00				18	27.27	8	12.12	1	1.52				48	26.37	32	17.58	1	0.55
AEs leading to discontinuation of any study drug	7	10.14	4	5.80	0	0.00				7	10.61	5	7.58	0	0.00				39	21.43	29	15.93	0	0.00
AEs leading to discontinuation of Vemurafenib + Cobimetinib																								
Vemurafenib only	6	8.70	4	5.80	0	0.00				5	7.58	5	7.58	0	0.00				35	19.23	28	15.38	0	0.00
Cobimetinib only	0	0.00	0	0.00	0	0.00				0	0.00	0	0.00	0	0.00				1	0.55	1	0.55	0	0.00
Atezolizumab only	1	1.45	0	0.00	0	0.00				1	1.52	0	0.00	0	0.00				3	1.65	1	0.55	0	0.00
AEs leading to dose adjustment/interruption of any study drug	0	0.00	0	0.00	0	0.00				2	3.03	1	1.52	0	0.00				2	1.10	1	0.55	0	0.00
AEs leading to dose adjustment/interruption of any study drug	17	24.64	11	15.94	0	0.00				22	33.33	16	24.24	1	1.52				45	24.73	31	17.03	1	0.55
AEs leading to dose adjustment/interruption of Vemurafenib + Cobimetinib																								
Vemurafenib only	13	18.84	7	10.14	0	0.00				19	28.79	15	22.73	0	0.00				36	19.78	25	13.74	0	0.00
Cobimetinib only	5	7.25	4	5.80	0	0.00				1	1.52	1	1.52	0	0.00				7	3.85	5	2.75	0	0.00
Atezolizumab only	2	2.90	0	0.00	0	0.00				1	1.52	0	0.00	0	0.00				5	2.75	1	0.55	0	0.00
Treatment related AEs leading to dose adjustment/interruption of any study drug	0	0.00	0	0.00	0	0.00				2	3.03	1	1.52	1	1.52				2	1.10	1	0.55	1	0.55
leading to dose adjustment/interruption of any study drug	10	14.49	7	10.14	0	0.00				15	22.73	9	13.64	1	1.52				28	15.38	18	9.89	1	0.55
Treatment related AEs leading to dose adjustment/interruption of Vemurafenib + Cobimetinib																								
Vemurafenib only	7	10.14	4	5.80	0	0.00				13	19.70	9	13.64	0	0.00				21	11.54	14	7.69	0	0.00
Cobimetinib only	3	4.35	3	4.35	0	0.00				0	0.00	0	0.00	0	0.00				4	2.20	3	1.65	0	0.00
Atezolizumab only	1	1.45	0	0.00	0	0.00				1	1.52	0	0.00	0	0.00				4	2.20	1	0.55	0	0.00
Treatment related AEs leading to dose adjustment/interruption of any study drug	0	0.00	0	0.00	0	0.00				1	1.52	0	0.00	1	1.52				1	0.55	0	0.00	1	0.55

Data source: Table 88 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

Table 28 Treatment-related AEs in at least 10% of the patients (patient based) (all trial phases combined) (SP)

	Arm A			Arm B			Not randomized			Total		
	All Grades	Grade 3/4		All Grades	Grade 3/4		All Grades	Grade 3/4		All Grades	Grade 3/4	
	N	%	N	N	%	N	N	%	N	N	%	N
Number of patients	69	100.00	.	66	100.00	.	47	100.00	.	182	100.00	.
Any AE	68	98.55	.	66	100.00	.	47	100.00	.	181	99.45	.
Any treatment-related AE	68	98.55	.	66	100.00	.	45	95.74	.	179	98.35	.
Diarrhoea	36	52.17	2	35	53.03	3	22	46.81	2	93	51.10	7
Rash maculo-papular	24	34.78	3	28	42.42	6	15	31.91	5	67	36.81	14
Fatigue	23	33.33	.	24	36.36	.	10	21.28	2	57	31.32	2
Photosensitivity reaction	29	42.03	1	20	30.30	.	7	14.89	.	56	30.77	1
Blood creatine phosphokinase increased	21	30.43	3	19	28.79	8	7	14.89	3	47	25.82	14
Nausea	15	21.74	.	21	31.82	1	9	19.15	.	45	24.73	1
Pyrexia	15	21.74	.	17	25.76	.	9	19.15	.	41	22.53	.
Aspartate aminotransferase increased	15	21.74	.	16	24.24	.	7	14.89	.	38	20.88	.
Lipase increased	18	26.09	12	14	21.21	8	4	8.51	1	36	19.78	21
Alanine aminotransferase increased	13	18.84	2	17	25.76	3	6	12.77	.	36	19.78	5
Blood creatinine increased	15	21.74	1	12	18.18	.	6	12.77	.	33	18.13	1
Gamma-glutamyltransferase increased	15	21.74	3	9	13.64	2	7	14.89	.	31	17.03	5
Arthralgia	15	21.74	.	13	19.70	.	3	6.38	.	31	17.03	.
Dermatitis acneiform	15	21.74	.	11	16.67	.	4	8.51	.	30	16.48	.
Vomiting	11	15.94	.	9	13.64	.	7	14.89	.	27	14.84	.
Sunburn	13	18.84	.	9	13.64	.	3	6.38	.	25	13.74	.
Blood alkaline phosphatase increased	11	15.94	.	9	13.64	1	2	4.26	.	22	12.09	1
Pruritus	9	13.04	.	7	10.61	.	3	6.38	.	19	10.44	.
Lymphocyte count decreased	8	11.59	3	6	9.09	.	5	10.64	1	19	10.44	4
Amylase increased	11	15.94	3	7	10.61	1	1	2.13	.	19	10.44	4
Hyperthyroidism	6	8.70	.	11	16.67	1	2	4.26	.	19	10.44	1
Hypothyroidism	6	8.70	.	11	16.67	.	1	2.13	1	18	9.89	1
Alopecia	11	15.94	.	7	10.61	.	.	.	.	18	9.89	.
Blood bilirubin increased	9	13.04	.	7	10.61	.	1	2.13	.	17	9.34	.
Anaemia	11	15.94	1	3	4.55	.	2	4.26	1	16	8.79	2
Pain in extremity	2	2.90	.	9	13.64	.	4	8.51	.	15	8.24	.
Electrocardiogram QT prolonged	8	11.59	1	7	10.61	.	.	.	.	15	8.24	1
Dry skin	8	11.59	.	5	7.58	.	2	4.26	.	15	8.24	.
Hypertension	3	4.35	1	8	12.12	4	2	4.26	2	13	7.14	7
Headache	3	4.35	.	8	12.12	.	1	2.13	.	12	6.59	.
Erythema multiforme	9	13.04	.	1	1.52	.	2	4.26	.	12	6.59	.
Vision blurred	8	11.59	.	2	3.03	.	2	4.26	.	12	6.59	.
Any AE leading to discontinuation	7	10.14	.	7	10.61	.	25	53.19	.	39	21.43	.
Treatment-related AE leading to discontinuation	5	7.25	.	6	9.09	.	21	44.68	.	32	17.58	.

Data source: Table 108 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

### 12.2.3 Analysis of Adverse Events

The median time to onset of treatment-related select AEs was, with few exceptions, equal or shorter in patients in Arm B compared to Arm A. The median time to resolution was similar in both groups. (Table 37 in Appendix 14.3.1).

### 12.2.4 Listing of Adverse Events by Patient

All AEs listed per patient are provided in Table 47 in Appendix 16.2.7.

## 12.3 Deaths, Other Serious Adverse Events, and Other Significant Adverse Events

### 12.3.1 Listing of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events

#### 12.3.1.1 Deaths

Eighty-eight deaths were reported (48.35% of 182 patients in the SP), including 35 (51.47%) patients in Arm A and 29 (45.31%) patients in Arm B.

Disease progression was the main cause of death for 79 (43.41%) patients. One patient in Arm B died due to intracranial hemorrhage for which the investigator could not rule out a causal relationship to the study treatment. The cause of death for five patients (two patients in Arm B and three patients who died during the run-in phase) was neither related to a therapeutic reason nor was the death caused by the underlying disease. For one patient in Arm A and two patients in Arm B the reason of death was unknown (Table 29).

A listing per patient is provided in Table 38 in Appendix 14.3.2.

**Table 29 Premature end of study (ITT)**

Premature end of study	Arm A	Arm B	Not randomized	Total
Number of patients with documented end of study	68 (100.00)	64 (100.00)	50 (100.00)	182 (100.00)
Premature end of study				
No	20 (29.41)	15 (23.44)	5 (10.00)	40 (21.98)
Yes	48 (70.59)	49 (76.56)	45 (90.00)	142 (78.02)
Death				
Yes	35 (51.47)	29 (45.31)	24 (48.00)	88 (48.35)
No	30 (44.12)	32 (50.00)	25 (50.00)	87 (47.80)
Unknown	3 (4.41)	3 (4.69)	1 (2.00)	7 (3.85)
Patient died- Cause of death				
Disease progression	34 (50.00)	24 (37.50)	21 (42.00)	79 (43.41)
Therapeutic reason	0 (0.00)	1 (1.56)	0 (0.00)	1 (0.55)
No therapeutic reason or basic disease	0 (0.00)	2 (3.13)	3 (6.00)	5 (2.75)
Unknown	1 (1.47)	2 (3.13)	0 (0.00)	3 (1.65)
Cause of death: treatment-related- Adverse events leading to death				
Haemorrhage intracranial	0 (0.00)	1 (1.56)	0 (0.00)	1 (0.55)
Cause of death: treatment-related- If cause of death is related to study therapy, to which one?				
a causality to all three medications is possible but not known for sure	0 (0.00)	1 (1.56)	0 (0.00)	1 (0.55)
Cause of death according to ICD10				
Cardiac arrest, unspecified	0 (0.00)	0 (0.00)	1 (2.00)	1 (0.55)
Intracranial haemorrhage (nontraumatic), unspecified	0 (0.00)	2 (3.13)	0 (0.00)	2 (1.10)
Sepsis, unspecified	0 (0.00)	0 (0.00)	1 (2.00)	1 (0.55)
Septic shock	0 (0.00)	0 (0.00)	1 (2.00)	1 (0.55)
Stroke, not specified as haemorrhage or infarction	0 (0.00)	1 (1.56)	0 (0.00)	1 (0.55)
Withdrawals of informed consent (total)	5 (7.35)	12 (18.75)	11 (22.00)	28 (15.38)
Lost to follow up (total)	8 (11.76)	2 (3.13)	2 (4.00)	12 (6.59)

Data source: Table 141 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

#### **12.3.1.2 Other SAEs**

All SAEs are provided in **Table 39** in section 14.3.2.

#### **12.3.1.3 Other Significant AEs**

Other significant AEs are provided in **Table 32** to **Table 37** in Appendix 14.3.1).

### **12.3.2 Narratives of Deaths, Other SAEs, and Certain Other Significant AEs**

Not applicable

### **12.3.3 Analysis and Discussion of Deaths, Other SAEs, and Other Significant AEs**

Discontinuation of the study due to treatment-related serious AEs (SAEs) was very frequent during the run-in phase: 22 patients left the study prior to randomization due to any kind of toxicity. Among all other phases of the ImmunoCobiVem clinical trial, treatment-related SAEs, including treatment-related SAEs of CTCAE grade 3/4, were more frequently reported in Arm A compared to Arm B. In total, 88 deaths were reported with disease progression to be the predominant cause of death. One treatment-related death (intracranial hemorrhage) was reported in one patient in Arm B, which occurred after randomization and for which the investigator could not rule out a relationship to study medication. No additional grade 5 treatment-related adverse event was reported. Five deaths were attributed to no therapeutic reason or underlying condition, and three deaths were attributed to an unknown cause.

## **12.4 Clinical Laboratory Evaluation**

### **12.4.1 Individual Laboratory Measurements by Patient and Abnormal Laboratory Value**

Not applicable

### **12.4.2 Evaluation of Laboratory Values**

Not applicable

#### **12.4.2.1 Laboratory Values Over Time**

Not applicable

#### **12.4.2.2 Individual Patient Changes in Laboratory Values**

Not applicable

#### **12.4.2.3 Individual Clinically Significant Abnormalities**

Not applicable

## **12.5 Vital Signs, Physical Findings, and Other Observations Related to Safety**

Not applicable

## **12.6 Safety Result Summary**

Treatment-related adverse events of any CTCAE grade, along all study phases, were reported with similar proportions of patients in Arm A (98.55%) and Arm B (100.00%). The proportion of CTCAE

grade 3-4 treatment-related AEs among all study phases combined was slightly higher in Arm B (48.5%) compared to Arm A (42.0%). Immune-related AEs, including those of CTCAE grade 3/4, were more frequently reported in Arm B (66.67%) compared to Arm A (15.94%). Twenty-five (53.19%) patients discontinued the study treatment during the run-in phase and therefore prior to randomization due to treatment-related AEs, including SAEs of CTCAE grade 3/4. In comparison, 10.14% and 10.61% of patients in Arm A and Arm B, respectively, discontinued study treatment due to treatment-related AEs.

## 13 DISCUSSION AND OVERALL CONCLUSIONS

The final results after a median follow-up 56.97 months of the phase 2 randomized clinical trial ImmunoCobiVem confirmed a longer PFS1 for continuous targeted therapy with the BRAF/MEK inhibitors vemurafenib and cobimetinib (i.e., in Arm A) compared to early switch to therapy with the immune checkpoint inhibitor atezolizumab (i.e., in Arm B) (HR=0.61; 95%CI 0.41-0.91, p=0.0055) in patients with BRAF V600-mutation-positive advanced melanoma. However, at crossover, i.e., after first disease progression (PD1), retreatment with vemurafenib in combination with cobimetinib (Arm B) resulted in higher PFS3 in comparison to second-line therapy with the immune checkpoint inhibitor atezolizumab (Arm A) (HR=1.72; 95%CI 0.93-3.20, p=0.0801). Importantly, early switching to therapy with the immune checkpoint inhibitor atezolizumab (Arm B) after the 3-month run-in phase with vemurafenib in combination with cobimetinib resulted in longer OS (descriptive HR 1.17, 95% CI 0.71-1.91). Early switch to therapy with the immune checkpoint inhibitor atezolizumab also improved absolute BORR to 89.39% (95%CI 79.69-94.77) compared to 81.16% (95%CI 70.39-88.65) in Arm A. A total of 15 (21.74%) patients in Arm A and 19 (28.79%) patients in Arm B achieved a CR at least once along each treatment sequence. No new safety signals were observed.

The ImmunoCobiVem clinical trial is – after the DREAMseq [40] and SECOMBIT [41, 42] clinical trials – the third randomized clinical trial which suggests that therapy with immune checkpoint inhibitors is superior in terms of OS when used early in BRAF V600 mutation-positive patients with advanced melanoma. Similar to the SECOMBIT clinical trial, the ImmunoCobiVem clinical trial explored the impact of a front-line BRAF/MEK targeted therapy (with vemurafenib in combination with cobimetinib) followed by a second-line like therapy with the immune checkpoint inhibitor atezolizumab with re-exposure to BRAF/MEK targeted therapy with vemurafenib in combination with cobimetinib after first disease progression (PD1) (referred to as 'sandwich approach'). Combination therapy with vemurafenib and cobimetinib as first-line cohort with a pre-defined cross-over to therapy with atezolizumab after initial progression (referred to as 'classical approach') was used as the study-specific internal control group. Both the DREAMseq and the SECOMBIT clinical trial showed an accentuated, characteristic crossing in their PFS and OS Kaplan-Meier curves, which was also observed in the ImmunoCobiVem trial. The initial clinical superiority of first-line targeted therapy with BRAF/MEK inhibitors until crossing of the PFS curve was around 6 months in the DREAMseq clinical trial [40] and around 12 months in the SECOMBIT clinical trial [42], and around 12 months until OS curve crossing for both clinical trials [40, 42]. The advantage of the first-line targeted therapy with BRAF/MEK inhibitors can be explained by the high response rate as well as the rapid time to (tumor) response [43]. In contrast, the response kinetics of immune checkpoint inhibitors are often delayed with numerically less responses, which result in an initially higher tumor progression and more early deaths. These differences in response kinetics supported the idea to join the rapid onset of response to targeted therapy with BRAF/MEK inhibitors and the durable responses achieved through therapy with immune checkpoint inhibitors by a strategy of an early switch to treatment with an immune checkpoint inhibitor, thus combining the best of both approaches with a well-known safety profile.

Similar to the SECOMBIT clinical trial, the ImmunoCobiVem clinical trial showed a superiority of front-line BRAF/MEK targeted therapy with vemurafenib in combination with cobimetinib followed by a second-line like therapy with the immune checkpoint inhibitor atezolizumab with re-exposure to BRAF/MEK targeted therapy after first disease progression (PD1) (Arm B, 'sandwich approach') over continued BRAF/MEK targeted therapy with a pre-defined cross-over to immune checkpoint inhibitor treatment with atezolizumab after initial progression (Arm A, 'classical approach') in terms of long-term OS. The OS rate at 2 years of the 'sandwich approach' (Arm B) in the ImmunoCobiVem

clinical trial was about 10% higher (2-year OS rate: 68.02%, 95% CI 54.40–78.36) compared to the ‘classical approach’ (Arm A) (2-year OS rate: 58.39%, 95% CI 45.05–69.56). In the SECOMBIT clinical trial, the OS rate at 2 years was 69% (95% CI, 59–80) for the ‘sandwich approach’ and 65% (95% CI, 54–76) for the ‘classical approach’ [41]. The 4-year OS rate were 52.62% (95% CI 38.12–65.22) for the ‘sandwich approach’ (Arm B), and 42.43% (95% CI 29.33–54.93) for the ‘classical approach’ (Arm A), which corresponds to a lasting landmark survival benefit in the range of ~ 11% for patients with BRAF V600 mutation-positive advanced melanoma. In the SECOMBIT clinical trial, the 4-year OS rates were similar with 59% (95% CI 47–71) for the ‘sandwich approach’ and 46% (95% CI 33–59) for the ‘classical approach’ [42], providing a clinically meaningful survival benefit in the range of ~ 13%.

The ImmunoCobiVem clinical trial indicated also that the sum of the absolute BORR calculated for the ‘sandwich approach’ (Arm B) was with 89.39% (95% CI 79.69–94.77) higher compared to the absolute BORR of 81.16% (95% CI 70.39–88.65) achieved by the ‘classical approach’ (Arm A). In the SECOMBIT clinical trial, the BORR of the first treatment (82.4%) and the second treatment (62.2%) were also higher for the ‘sandwich approach’ compared to 87.0% and 25.7%, respectively, obtained with the ‘classical approach’. This – at least partially – met the hypothesized rationale to improve tumor control by a sandwich approach based on the response kinetics. In contrast, in the DREAMseq clinical trial, the ORR for the first treatment was 46.0% for the ‘sandwich approach’ respectively 43.0% for the ‘classical approach’ and 47.8% and 29.6%, respectively, for the second treatment [40].

Recently presented results from the randomized phase II EBIN trial, testing another sandwich approach – a 3-month run-in with encorafenib and binimetinib followed by four cycles of combined checkpoint inhibition and subsequent nivolumab maintenance until progression with crossover to encorafenib plus binimetinib – versus combined checkpoint blockade plus nivolumab maintenance and investigator’s choice after progression – provided similar results. Overall tumor control was higher for the sandwich approach, but the PFS and OS curves crossed around 9 respectively 15 months also in this study, demonstrating better long-term benefit for the immune checkpoint inhibitor first-line study arm without BRAF-MEK induction [44].

The ImmunoCobiVem clinical trial is the first of the above-mentioned clinical trials, which elucidated the response and progression patterns along the treatment sequence in detail. In general, the design of crossover clinical trials is challenging [45], as real-world standards may change during the conduct of such fixed sequence trials [46]. Patients with SD after targeted therapy run-in seemed to benefit more from a treatment switch to immune checkpoint inhibitor therapy in terms of OS. After crossover, CRs could be re-induced in patients with previous RECIST-confirmed response. The response to immune checkpoint inhibitor therapy (atezolizumab) after disease progression on targeted therapy (vemurafenib in combination with cobimetinib) was poor, while several patients could benefit from re-challenge with targeted therapy.

Safety outcomes in ImmunoCobiVem were consistent with those previously reported [47]. Patterns of treatment-related AEs along each treatment arm were indicative either for atezolizumab or vemurafenib in combination with cobimetinib during each study phase. No CTCAE grade 3/4 treatment-related AE was reported for atezolizumab after crossover (Arm A). A total of four well-controllable CTCAE grade 3/4 treatment-related AEs, including diarrhea, nausea (each reported once) and increased creatine phosphokinase (reported twice), occurred upon re-challenge with vemurafenib and cobimetinib (Arm A).

The main limitation of the ImmunoCobiVem clinical trial is the lack of a third cohort investigating the impact of first-line therapy with immune checkpoint inhibitor. This, together with the crossover-design of a clinical trial that was recruiting at a time of rapidly emerging treatment options outside of clinical trials with a changing standard of care rendered the interpretation of the trial outcomes somehow difficult. Additionally, the trial was not blinded.

In conclusion, the ImmunoCobiVem clinical trial showed an improved, although not statistically significant, long-term OS and overall BORR after a short run-in with targeted therapy using vemurafenib and cobimetinib followed by a switch to therapy with the immune checkpoint inhibitor atezolizumab compared to continued treatment with vemurafenib and cobimetinib and treatment with atezolizumab only after first disease progression. However, the benefit was small, and it needs



to be determined which patients will benefit most from a targeted therapy run-in phase and which patients may develop a rapid tumor progression if switched from targeted therapy to therapy with immune-checkpoint inhibitors.

14 TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT

14.1 Demographic Data

Table 30 Demography of patients with and without switch (RP)

Patient characteristics	Arm A total	Arm A with switch at PD	Arm A without switch at PD	Arm A who stopped treatment for other reason than PD or death	Arm B total	Arm B with switch at PD	Arm B without switch at PD	Arm B who stopped treatment for other reason than PD or death
Number of patients	69 (100.00)	21 (100.00)	16 (100.00)	24 (100.00)	66 (100.00)	35 (100.00)	15 (100.00)	10 (100.00)
Median follow-up time [months] (IQR) (using reverse Kaplan Meier method)								
N	69	21	16	24	66	35	15	10
Median (months)	57.83	58.42	57.17	51.38	55.79	50.20	54.11	58.03
IQR (months)	22.66 - 65.43	21.28 - 62.99	14.51 - 73.78	22.66 - 66.25	27.34 - 62.34	21.28 - 59.77	20.76 - 54.11	28.39 - 63.59
Sex								
Female	21 (30.43)	8 (38.10)	6 (37.50)	6 (25.00)	26 (39.39)	12 (34.29)	8 (53.33)	5 (50.00)
Male	48 (69.57)	13 (61.90)	10 (62.50)	18 (75.00)	40 (60.61)	23 (65.71)	7 (46.67)	5 (50.00)
Age [years]								
N	69	21	16	24	66	35	15	10
Mean	59.23	57.76	57.69	62.17	56.58	57.00	60.73	56.10
STD	14.79	13.68	14.37	16.11	12.41	12.41	10.49	14.36
Median	58.00	54.00	57.50	62.50	56.00	57.00	59.00	50.00
Min	19.00	36.00	31.00	19.00	31.00	31.00	47.00	40.00
Max	89.00	80.00	85.00	89.00	82.00	78.00	79.00	82.00
Nmiss	0	0	0	0	0	0	0	0
Age [years]- categorical								
<65 years	39 (56.52)	13 (61.90)	9 (56.25)	13 (54.17)	48 (72.73)	24 (68.57)	10 (66.67)	8 (80.00)
≥65 years	30 (43.48)	8 (38.10)	7 (43.75)	11 (45.83)	18 (27.27)	11 (31.43)	5 (33.33)	2 (20.00)
Body mass index								
Underweight <18.5	1 (1.45)	0 (0.00)	0 (0.00)	1 (4.17)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
Normal BMI 18.5-24.9	17 (24.64)	6 (28.57)	5 (31.25)	4 (16.67)	24 (36.36)	12 (34.29)	5 (33.33)	5 (50.00)
Overweight ≥25	51 (73.91)	15 (71.43)	11 (68.75)	19 (79.17)	42 (63.64)	23 (65.71)	10 (66.67)	5 (50.00)
ECOG baseline								
Grade 0	58 (84.06)	20 (95.24)	14 (87.50)	18 (75.00)	55 (83.33)	27 (77.14)	14 (93.33)	8 (80.00)
Grade 1	11 (15.94)	1 (4.76)	2 (12.50)	6 (25.00)	11 (16.67)	8 (22.86)	1 (6.67)	2 (20.00)
Ulceration								
No	25 (36.23)	10 (47.62)	3 (18.75)	10 (41.67)	30 (45.45)	17 (48.57)	8 (53.33)	4 (40.00)


Patient characteristics	Arm A who stopped treatment for other reason than PD or death				Arm B who stopped treatment for other reason than PD or death			
	Arm A total	Arm A with switch at PD	Arm A without switch at PD	Arm A who stopped treatment for other reason than PD or death	Arm B total	Arm B with switch at PD	Arm B without switch at PD	Arm B who stopped treatment for other reason than PD or death
Yes	33 (47.83)	9 (42.86)	11 (68.75)	8 (33.33)	21 (31.82)	8 (22.86)	5 (33.33)	5 (50.00)
Unknown	11 (15.94)	2 (9.52)	2 (12.50)	6 (25.00)	15 (22.73)	10 (28.57)	2 (13.33)	1 (10.00)
Histological subtype								
Superficial Spreading Melanoma (SSM)	23 (33.33)	5 (23.81)	7 (43.75)	9 (37.50)	24 (36.36)	12 (34.29)	6 (40.00)	4 (40.00)
Nodular malignant melanoma	22 (31.88)	7 (33.33)	5 (31.25)	7 (29.17)	16 (24.24)	9 (25.71)	2 (13.33)	2 (20.00)
Acral lentiginous melanoma (ALM)	2 (2.90)	1 (4.76)	1 (6.25)	0 (0.00)	1 (1.52)	1 (2.86)	0 (0.00)	0 (0.00)
Other	19 (27.54)	8 (38.10)	2 (12.50)	8 (33.33)	23 (34.85)	12 (34.29)	7 (46.67)	3 (30.00)
Missing	3 (4.35)	0 (0.00)	1 (6.25)	0 (0.00)	2 (3.03)	1 (2.86)	0 (0.00)	1 (10.00)
Tumor stage (AJCC 2010)								
Stage IIIB	4 (5.80)	0 (0.00)	1 (6.25)	2 (8.33)	1 (1.52)	1 (2.86)	0 (0.00)	0 (0.00)
Stage IIIC	2 (2.90)	0 (0.00)	1 (6.25)	1 (4.17)	1 (1.52)	0 (0.00)	0 (0.00)	1 (10.00)
Stage IV	63 (91.30)	21 (100.00)	14 (87.50)	21 (87.50)	64 (96.97)	34 (97.14)	15 (100.00)	9 (90.00)
M substage of stage IV patients (AJCC 2010)								
M1a	16 (23.19)	3 (14.29)	5 (31.25)	8 (33.33)	14 (21.21)	5 (14.29)	3 (20.00)	4 (40.00)
M1b	14 (20.29)	6 (28.57)	2 (12.50)	4 (16.67)	18 (27.27)	9 (25.71)	7 (46.67)	1 (10.00)
M1a+b	30 (43.48)	9 (42.86)	7 (43.75)	12 (50.00)	32 (48.48)	14 (40.00)	10 (66.67)	5 (50.00)
M1c (total)	33 (47.83)	12 (57.14)	7 (43.75)	9 (37.50)	32 (48.48)	20 (57.14)	5 (33.33)	4 (40.00)
No of disease sites								
<3	12 (17.39)	4 (19.05)	2 (12.50)	6 (25.00)	12 (18.18)	6 (17.14)	2 (13.33)	4 (40.00)
≥3	21 (30.43)	8 (38.10)	5 (31.25)	3 (12.50)	20 (30.30)	14 (40.00)	3 (20.00)	0 (0.00)
No data	36 (52.17)	9 (42.86)	9 (56.25)	15 (62.50)	34 (51.52)	15 (42.86)	10 (66.67)	6 (60.00)
Sum of lesion diameters								
N	69	21	16	24	66	35	15	10
Mean	65.00	73.63	75.54	53.35	64.96	76.55	56.68	33.06
STD	46.05	47.60	50.45	40.84	57.34	69.92	34.26	28.34
Median	50.00	69.00	78.00	42.50	51.50	52.00	61.00	23.50
Min	10.00	10.40	10.00	10.00	10.23	10.23	15.00	10.60
Max	183.00	182.00	183.00	152.70	310.30	310.30	127.00	103.50
Nmiss	0	0	0	0	0	0	0	0
LDH baseline								
Within normal limits	35 (50.72)	12 (57.14)	8 (50.00)	12 (50.00)	34 (51.52)	17 (48.57)	8 (53.33)	7 (70.00)
Elevated	24 (34.78)	4 (19.05)	5 (31.25)	10 (41.67)	28 (42.42)	15 (42.86)	7 (46.67)	3 (30.00)
2x the upper limit of norm or higher	10 (14.49)	5 (23.81)	3 (18.75)	2 (8.33)	4 (6.06)	3 (8.57)	0 (0.00)	0 (0.00)

Patient characteristics	Arm A			Arm A who stopped treatment for other reason than PD or death			Arm B			Arm B who stopped treatment for other reason than PD or death		
	Arm A total	Arm A with switch at PD	Arm A without switch at PD	Arm A without switch at PD	Arm A who stopped treatment for other reason than PD or death	Arm B total	Arm B with switch at PD	Arm B without switch at PD	Arm B who stopped treatment for other reason than PD or death	Arm B total	Arm B with switch at PD	Arm B without switch at PD
Prior adjuvant therapy												
No	62 (89.86)	18 (85.71)	13 (81.25)	13 (81.25)	23 (95.83)	54 (81.82)	30 (85.71)	13 (86.67)	9 (90.00)			
Yes	7 (10.14)	3 (14.29)	3 (18.75)	3 (18.75)	1 (4.17)	12 (18.18)	5 (14.29)	2 (13.33)	1 (10.00)			
Type of prior adjuvant therapy												
IFN	7 (10.14)	3 (14.29)	3 (18.75)	3 (18.75)	1 (4.17)	7 (10.61)	3 (8.57)	1 (6.67)	0 (0.00)			
Chemotherapy	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	2 (3.03)	0 (0.00)	1 (6.67)	0 (0.00)			
Radiotherapy	3 (4.35)	0 (0.00)	2 (12.50)	2 (12.50)	1 (4.17)	5 (7.58)	3 (8.57)	0 (0.00)	1 (10.00)			
Other	1 (1.45)	0 (0.00)	1 (6.25)	1 (6.25)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)			
Prior radiotherapy												
No	63 (91.30)	21 (100.00)	13 (81.25)	13 (81.25)	22 (91.67)	57 (86.36)	31 (88.57)	14 (93.33)	8 (80.00)			
Yes	6 (8.70)	0 (0.00)	3 (18.75)	3 (18.75)	2 (8.33)	9 (13.64)	4 (11.43)	1 (6.67)	2 (20.00)			
Intention of prior radiotherapy (multiple answers possible)												
Adjuvant	3 (4.35)	0 (0.00)	2 (12.50)	2 (12.50)	1 (4.17)	5 (7.58)	3 (8.57)	0 (0.00)	1 (10.00)			
Not adjuvant	4 (5.80)	0 (0.00)	1 (6.25)	1 (6.25)	2 (8.33)	4 (6.06)	1 (2.86)	1 (6.67)	1 (10.00)			
Irradiated location of prior radiotherapy												
Cerebral	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (1.52)	0 (0.00)	0 (0.00)	1 (10.00)			
Extracerebral	7 (10.14)	0 (0.00)	3 (18.75)	3 (18.75)	3 (12.50)	9 (13.64)	4 (11.43)	2 (13.33)	1 (10.00)			
Type of prior radio therapy												
Conventional radiotherapy	5 (7.25)	0 (0.00)	3 (18.75)	3 (18.75)	1 (4.17)	8 (12.12)	4 (11.43)	1 (6.67)	1 (10.00)			
Stereotaxy	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (1.52)	0 (0.00)	0 (0.00)	1 (10.00)			
Other	1 (1.45)	0 (0.00)	0 (0.00)	0 (0.00)	1 (4.17)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)			
Radiological response to treatment in run-in phase												
CR	3 (4.35)	1 (4.76)	2 (12.50)	2 (12.50)	0 (0.00)	5 (7.58)	2 (5.71)	2 (13.33)	0 (0.00)			
PR	48 (69.57)	15 (71.43)	10 (62.50)	10 (62.50)	18 (75.00)	44 (66.67)	23 (65.71)	11 (73.33)	8 (80.00)			
SD	17 (24.64)	5 (23.81)	4 (25.00)	4 (25.00)	6 (25.00)	16 (24.24)	10 (28.57)	2 (13.33)	1 (10.00)			
PD	1 (1.45)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (1.52)	0 (0.00)	0 (0.00)	1 (10.00)			
At time of progression in randomized phase												
Site of progression (multiple answers possible)												
Abdominal wall	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	2 (3.03)	2 (5.71)	0 (0.00)	0 (0.00)			
Adrenal	2 (2.90)	1 (4.76)	0 (0.00)	0 (0.00)	1 (4.17)	1 (1.52)	1 (2.86)	0 (0.00)	0 (0.00)			
Bone	1 (1.45)	0 (0.00)	0 (0.00)	0 (0.00)	1 (4.17)	3 (4.55)	3 (8.57)	0 (0.00)	0 (0.00)			
Cerebral	15 (21.74)	6 (28.57)	8 (50.00)	8 (50.00)	0 (0.00)	19 (28.79)	10 (28.57)	8 (53.33)	1 (10.00)			

Patient characteristics	Arm A who stopped treatment for other reason than PD or death				Arm B who stopped treatment for other reason than PD or death			
	Arm A total	Arm A with switch at PD	Arm A without switch at PD	Arm A who stopped treatment for other reason than PD or death	Arm B total	Arm B with switch at PD	Arm B without switch at PD	Arm B who stopped treatment for other reason than PD or death
CNS	3 (4.35)	1 (4.76)	2 (12.50)	0 (0.00)	4 (6.06)	2 (5.71)	2 (13.33)	0 (0.00)
Dermal distance metastases	1 (1.45)	0 (0.00)	0 (0.00)	0 (0.00)	2 (3.03)	2 (5.71)	0 (0.00)	0 (0.00)
Diaphragm	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (1.52)	1 (2.86)	0 (0.00)	0 (0.00)
Gastric	1 (1.45)	0 (0.00)	1 (6.25)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
Intestinal	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (1.52)	1 (2.86)	0 (0.00)	0 (0.00)
Kidney	1 (1.45)	1 (4.76)	0 (0.00)	0 (0.00)	1 (1.52)	1 (2.86)	0 (0.00)	0 (0.00)
Liver	6 (8.70)	3 (14.29)	0 (0.00)	2 (8.33)	10 (15.15)	7 (20.00)	3 (20.00)	0 (0.00)
Lung	6 (8.70)	5 (23.81)	0 (0.00)	1 (4.17)	16 (24.24)	12 (34.29)	4 (26.67)	0 (0.00)
Lymph nodes	16 (23.19)	8 (38.10)	5 (31.25)	2 (8.33)	18 (27.27)	15 (42.86)	3 (20.00)	0 (0.00)
Musculature	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	2 (3.03)	2 (5.71)	0 (0.00)	0 (0.00)
Pancreas	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (1.52)	1 (2.86)	0 (0.00)	0 (0.00)
Pelvis	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (1.52)	0 (0.00)	1 (6.67)	0 (0.00)
Peritoneal	3 (4.35)	2 (9.52)	0 (0.00)	1 (4.17)	3 (4.55)	3 (8.57)	0 (0.00)	0 (0.00)
Skin	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	3 (4.55)	3 (8.57)	0 (0.00)	0 (0.00)
Soft tissues	1 (1.45)	1 (4.76)	0 (0.00)	0 (0.00)	3 (4.55)	3 (8.57)	0 (0.00)	0 (0.00)
Spleen	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (1.52)	1 (2.86)	0 (0.00)	0 (0.00)
Other	4 (5.80)	2 (9.52)	2 (12.50)	0 (0.00)	1 (1.52)	1 (2.86)	0 (0.00)	0 (0.00)
Missing	1 (1.45)	0 (0.00)	1 (6.25)	0 (0.00)	1 (1.52)	1 (2.86)	0 (0.00)	0 (0.00)
No of disease sites								
<3	11 (15.94)	4 (19.05)	5 (31.25)	2 (8.33)	13 (19.70)	7 (20.00)	6 (40.00)	0 (0.00)
≥3	32 (46.38)	17 (80.95)	11 (68.75)	2 (8.33)	38 (57.58)	28 (80.00)	9 (60.00)	1 (10.00)
Type of radiotherapy								
Conventional radiotherapy	4 (5.80)	2 (9.52)	2 (12.50)	0 (0.00)	3 (4.55)	2 (5.71)	1 (6.67)	0 (0.00)
Stereotaxy	6 (8.70)	4 (19.05)	1 (6.25)	1 (4.17)	9 (13.64)	5 (14.29)	3 (20.00)	1 (10.00)
Other	4 (5.80)	2 (9.52)	1 (6.25)	1 (4.17)	4 (6.06)	2 (5.71)	2 (13.33)	0 (0.00)
LDH at time of progression								
Elevated	21 (30.43)	11 (52.38)	6 (37.50)	2 (8.33)	17 (25.76)	10 (28.57)	7 (46.67)	0 (0.00)
Within normal limits	16 (23.19)	8 (38.10)	6 (37.50)	2 (8.33)	31 (46.97)	22 (62.86)	8 (53.33)	1 (10.00)
2x the upper limit of norm or higher	5 (7.25)	2 (9.52)	3 (18.75)	0 (0.00)	2 (3.03)	2 (5.71)	0 (0.00)	0 (0.00)
Missing	1 (1.45)	0 (0.00)	1 (6.25)	0 (0.00)	1 (1.52)	1 (2.86)	0 (0.00)	0 (0.00)

Data source: Table 6 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

14.2 Efficacy Data



\* P-Value is the test of interaction between treatment and each subgroup unadjusted for multiplicity.  
\*\* Hazard ratio can not be determined due to low patient count with this manifestation.

Figure 8 Hazard ratios for PFS1 as a forest plot: Arm A vs Arm B (PEP)

Data source: Figure 3 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

Table 31 PFS1- Univariate Cox regression (PEP)

PFS1- Univariate Cox regression		N	Progress/ Death	Censored	Parameter Estimate	Standard Error	Hazard ratio	95% CI	p-Value	p-Value (Effect)
Arm	Arm A	68	47	21	-0.49	0.20	0.61	0.41- 0.91	0.0154	.
LDH at enrollment	Arm B	65	52	13	.	.	.	.	.	0.0154
	Elevated	62	47	15	.	.	.	.	.	0.1299
Metastatic stage IV M1c	Within normal limits	71	52	19	-0.31	0.20	0.74	0.50- 1.09	0.1299	.
	No	70	51	19	-0.24	0.20	0.79	0.53- 1.17	0.2375	.
	Yes	63	48	15	.	.	.	.	.	0.2375
	No	114	85	29	.	.	.	.	.	0.6302
Prior adjuvant therapy before enrollment	Yes	19	14	5	-0.14	0.29	0.87	0.49- 1.53	0.6302	.
	Female	47	38	9	0.21	0.21	1.23	0.82- 1.85	0.3165	.
	Male	86	61	25	.	.	.	.	.	0.3165
Age at enrollment	<65	85	63	22	.	.	.	.	.	0.4832
	≥65	48	36	12	0.15	0.21	1.16	0.77- 1.75	0.4832	.
Asymptotic brain metastases at enrollment	No	132	98	34	.	.	.	.	.	0.7484
	Yes	1	1	0	-0.32	1.01	0.72	0.10- 5.20	0.7484	.
ECOG status at enrollment	0	111	84	27	.	.	.	.	.	0.5700
	≥1	22	15	7	0.16	0.28	1.17	0.68- 2.03	0.5700	.
Number of organ sites with metastases at enrollment	<3	75	52	23	.	.	.	.	.	0.2230
	≥3	58	47	11	0.25	0.20	1.28	0.86- 1.90	0.2230	.
Sum of lesion diameter at enrollment	<median	65	45	20	.	.	.	.	.	0.0685
	≥median	68	54	14	0.37	0.20	1.45	0.97- 2.15	0.0685	.
Prior radiotherapy before enrollment	No	118	90	28	.	.	.	.	.	0.1271
	Yes	15	9	6	-0.53	0.35	0.59	0.29- 1.16	0.1271	.
Tumor response after run-in phase	CR	8	8	0	0.22	0.41	1.24	0.56- 2.77	0.5983	.
	PR	92	67	25	-0.01	0.24	0.99	0.62- 1.59	0.9802	.
	SD	33	24	9	.	.	.	.	.	0.8375

Data source: Table 14 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05




Figure 9 Hazard ratios for OS as a forest plot: Arm A vs Arm B (RP)  
Data source: Figure 20 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05



## 14.3 Safety Data

### 14.3.1 Display of AEs

**Table 32 Treatment-related AEs during run-in phase in at least 10% of the patients (patient based) (SP)**

	<b>Arm A</b>				<b>Arm B</b>				<b>Not randomized</b>				<b>Total</b>			
	<i>All Grades</i>		<i>Grade 3/4</i>		<i>All Grades</i>		<i>Grade 3/4</i>		<i>All Grades</i>		<i>Grade 3/4</i>		<i>All Grades</i>		<i>Grade 3/4</i>	
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
Number of patients	69	100.00	.	.	66	100.00	.	.	47	100.00	.	.	182	100.00	.	.
Any AE	68	98.55	.	.	66	100.00	.	.	46	97.87	.	.	180	98.90	.	.
Any treatment-related AE	65	94.20	.	.	66	100.00	.	.	43	91.49	.	.	174	95.60	.	.
Diarrhoea	33	47.83	1	1.45	33	50.00	2	3.03	21	44.68	1	2.13	87	47.80	4	2.20
Rash maculo-papular	22	31.88	3	4.35	23	34.85	6	9.09	14	29.79	4	8.51	59	32.42	13	7.14
Fatigue	18	26.09	.	.	15	22.73	.	.	8	17.02	1	2.13	41	22.53	1	0.55
Photosensitivity reaction	22	31.88	.	.	11	16.67	.	.	7	14.89	.	.	40	21.98	.	.
Nausea	14	20.29	.	.	15	22.73	.	.	9	19.15	.	.	38	20.88	.	.
Blood creatine phosphokinase increased	14	20.29	2	2.90	13	19.70	5	7.58	5	10.64	2	4.26	32	17.58	9	4.95
Pyrexia	12	17.39	.	.	13	19.70	.	.	5	10.64	.	.	30	16.48	.	.
Blood creatinine increased	11	15.94	.	.	10	15.15	.	.	6	12.77	.	.	27	14.84	.	.
Aspartate aminotransferase increased	10	14.49	.	.	10	15.15	.	.	6	12.77	.	.	26	14.29	.	.
Vomiting	10	14.49	.	.	7	10.61	.	.	7	14.89	.	.	24	13.19	.	.
Dermatitis acneiform	11	15.94	.	.	9	13.64	.	.	3	6.38	.	.	23	12.64	.	.
Alanine aminotransferase increased	9	13.04	1	1.45	10	15.15	2	3.03	4	8.51	.	.	23	12.64	3	1.65
Lipase increased	13	18.84	9	13.04	8	12.12	6	9.09	1	2.13	.	.	22	12.09	15	8.24
Arthralgia	9	13.04	.	.	9	13.64	.	.	3	6.38	.	.	21	11.54	.	.
Sunburn	8	11.59	.	.	9	13.64	.	.	3	6.38	.	.	20	10.99	.	.
Gamma-glutamyltransferase increased	7	10.14	1	1.45	5	7.58	1	1.52	4	8.51	.	.	16	8.79	2	1.10
Pruritus	7	10.14	.	.	6	9.09	.	.	3	6.38	.	.	16	8.79	.	.
Blood alkaline phosphatase increased	8	11.59	.	.	6	9.09	.	.	1	2.13	.	.	15	8.24	.	.
Amylase increased	8	11.59	3	4.35	3	4.55	.	.	.	.	.	.	11	6.04	3	1.65
Any AE leading to discontinuation	2	2.90	.	.	1	1.52	.	.	14	29.79	.	.	17	9.34	.	.
Treatment-related AE leading to discontinuation	2	2.90	.	.	1	1.52	.	.	10	21.28	.	.	13	7.14	.	.

\*AE reported in at least 10% of the patients in at least one of the treatment groups  
Data source: Table 109 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

**Table 33 Treatment-related AEs after randomization until switch/end of treatment in at least 10% of the patients (patient based) (SP)**

	<b>Arm A</b>				<b>Arm B</b>				<b>Total</b>			
	<i>All Grades</i>		<i>Grade 3/4</i>		<i>All Grades</i>		<i>Grade 3/4</i>		<i>All Grades</i>		<i>Grade 3/4</i>	
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
Number of patients	69	100.00	.	.	66	100.00	.	.	135	100.00	.	.
Any AE	62	89.86	.	.	60	90.91	.	.	122	90.37	.	.
Any treatment-related AE	57	82.61	.	.	47	71.21	.	.	104	77.04	.	.
Diarrhoea	13	18.84	1	1.45	4	6.06	.	.	17	12.59	1	0.74
Fatigue	7	10.14	.	.	9	13.64	.	.	16	11.85	.	.
Blood creatine phosphokinase increased	12	17.39	1	1.45	3	4.55	1	1.52	15	11.11	2	1.48
Lipase increased	7	10.14	5	7.25	7	10.61	3	4.55	14	10.37	8	5.93
Gamma-glutamyltransferase increased	10	14.49	2	2.90	3	4.55	.	.	13	9.63	2	1.48
Alanine aminotransferase increased	7	10.14	1	1.45	6	9.09	1	1.52	13	9.63	2	1.48
Aspartate aminotransferase increased	7	10.14	.	.	5	7.58	.	.	12	8.89	.	.
Photosensitivity reaction	11	15.94	1	1.45	1	1.52	.	.	12	8.89	1	0.74
Hyperthyroidism	1	1.45	.	.	10	15.15	1	1.52	11	8.15	1	0.74
Alopecia	8	11.59	.	.	3	4.55	.	.	11	8.15	.	.
Hypothyroidism	1	1.45	.	.	9	13.64	.	.	10	7.41	.	.
Blood creatinine increased	8	11.59	1	1.45	2	3.03	.	.	10	7.41	1	0.74
Arthralgia	8	11.59	.	.	1	1.52	.	.	9	6.67	.	.
Anaemia	8	11.59	1	1.45	.	.	.	.	8	5.93	1	0.74
Any AE leading to discontinuation	4	5.80	.	.	1	1.52	.	.	5	3.70	.	.
Treatment-related AE leading to discontinuation	3	4.35	.	.	1	1.52	.	.	4	2.96	.	.

\*AE reported in at least 10% of the patients in at least one of the treatment groups  
 Data source: Table 110 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

**Table 34 Patients with switch- Treatment-related AEs after switch in at least 10% of the patients (patient based) (SP)**

	<b>Arm A</b>				<b>Arm B</b>				<b>Total</b>			
	<i>All Grades</i>		<i>Grade 3/4</i>		<i>All Grades</i>		<i>Grade 3/4</i>		<i>All Grades</i>		<i>Grade 3/4</i>	
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
Number of patients	21	100.00	.	.	35	100.00	.	.	56	100.00	.	.
Any AE	14	66.67	.	.	32	91.43	.	.	46	82.14	.	.
Any treatment-related AE	11	52.38	.	.	30	85.71	.	.	41	73.21	.	.
Diarrhoea	1	4.76	.	.	11	31.43	1	2.86	12	21.43	1	1.79
Photosensitivity reaction	.	.	.	.	10	28.57	.	.	10	17.86	.	.
Nausea	.	.	.	.	10	28.57	1	2.86	10	17.86	1	1.79
Fatigue	3	14.29	.	.	5	14.29	.	.	8	14.29	.	.
Blood creatine phosphokinase increased	.	.	.	.	8	22.86	2	5.71	8	14.29	2	3.57
Hyperthyroidism	4	19.05	.	.	1	2.86	.	.	5	8.93	.	.
Pyrexia	1	4.76	.	.	4	11.43	.	.	5	8.93	.	.
Hypothyroidism	3	14.29	.	.	2	5.71	.	.	5	8.93	.	.
Vomiting	.	.	.	.	4	11.43	.	.	4	7.14	.	.
Any AE leading to discontinuation	.	.	.	.	3	8.57	.	.	3	5.36	.	.
Treatment-related AE leading to discontinuation	.	.	.	.	2	5.71	.	.	2	3.57	.	.

\*AE reported in at least 10% of the patients in at least one of the treatment groups  
 Data source: Table 110 of ADO\_ImmunoCobiVem\_Final\_Part 1\_v1.0\_2025MAR05

Table 35 Immune-related AEs (all trial phases combined) (SP)

<i>irAE</i>	<b>Arm A</b>			<b>Arm B</b>			<b>Not randomized</b>			<b>Total</b>		
	<i>All Grades</i>	<i>N</i>	<i>%</i>	<i>All Grades</i>	<i>N</i>	<i>%</i>	<i>All Grades</i>	<i>N</i>	<i>%</i>	<i>All Grades</i>	<i>N</i>	<i>%</i>
<i>Respiratory, thoracic and mediastinal disorders</i>	<i>Cough</i>	1	1.45	.	.	.	.	.	.	1	0.55	.
	<i>Dyspnoea</i>	1	1.45	.	.	.	.	.	.	1	0.55	.
	<i>Pneumonitis</i>	.	.	3	4.55	.	.	.	.	3	1.65	.
	<i>Alopecia</i>	.	.	3	4.55	.	.	.	.	3	1.65	.
	<i>Dermatitis acneiform</i>	.	.	1	1.52	.	.	.	.	1	0.55	.
<i>Skin and subcutaneous tissue disorders</i>	<i>Hyperhidrosis</i>	.	.	1	1.52	.	.	.	.	1	0.55	.
	<i>Pruritus</i>	.	.	1	1.52	.	.	.	.	1	0.55	.
	<i>Psoriasis</i>	.	.	2	3.03	.	.	.	.	2	1.10	.
	<i>Rash maculo-papular</i>	.	.	1	1.52	.	.	.	.	1	0.55	.
	<i>Skin hypopigmentation</i>	.	.	3	4.55	.	.	.	.	3	1.65	.
	<i>Vitiligo</i>	1	1.45	1	1.52	.	.	.	.	2	1.10	.

Data source: Table 116 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

Table 36 Treatment-related AEs leading to discontinuation of at least one study medication (all trial phases combined) (SP)

	Arm A					Arm B					Not randomized					Total				
	All Grades			Grade 3/4		All Grades			Grade 3/4		All Grades			Grade 3/4		All Grades			Grade 3/4	
	N	%	N	N	%	N	%	N	N	%	N	%	N	N	%	N	%	N	N	%
Number of patients	69	100.00	.	.	.	66	100.00	.	.	.	47	100.00	.	.	.	182	100.00	.	.	.
Any AE	68	98.55	.	.	.	66	100.00	.	.	.	47	100.00	.	.	.	181	99.45	.	.	.
Any AE leading to discontinuation	5	7.25	2	2	2.90	6	9.09	4	6.06	.	21	44.68	18	38.30	.	32	17.58	24	13.19	.
Blood and lymphatic system disorders	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	1	0.55	1	0.55	.
Cardiac disorders	1	1.45	1	1	1.45	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.
Endocrine disorders	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	1	0.55	1	0.55	.
Eye disorders	.	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	1	0.55	.	.	.
Gastrointestinal disorders	1	1.45	1	1	1.45	.	.	.	.	.	1	2.13	1	2.13	.	2	1.10	1	0.55	.
Hepatobiliary disorders	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.
Infections and infestations	.	.	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	1	0.55	1	0.55	.
Investigations	.	.	.	.	.	1	1.52	1	1.52	.	1	2.13	1	2.13	.	1	0.55	1	0.55	.
Renal and urinary disorders	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.
Respiratory, thoracic and mediastinal disorders	1	1.45	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	1	0.55	1	0.55	.
Skin and subcutaneous tissue disorders	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.
Stevens-Johnson syndrome	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.
Erythema multiforme	.	.	.	.	.	.	.	.	.	.	1	2.13	.	.	.	1	0.55	1	0.55	.
Rash maculo-papular	.	.	.	.	.	1	1.52	1	1.52	.	5	10.64	4	8.51	.	6	3.30	5	2.75	.
Stevens-Johnson syndrome	.	.	.	.	.	.	.	.	.	.	3	6.38	3	6.38	.	3	1.65	3	1.65	.

Data source: Table 116 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

**Table 37 Time to onset and resolution of treatment-related select AEs (SP)**

<i>Time to onset and resolution</i>	<i>Arm A All Grades</i>	<i>Arm A Grade 3/4</i>	<i>Arm B All Grades</i>	<i>Arm B Grade 3/4</i>
Number of patients	69 (100.0)	69 (100.0)	66 (100.0)	66 (100.0)
Skin				
No. (%) patients with AE	63 (91.3)	5 (7.2)	61 (92.4)	8 (12.1)
Median time to onset, weeks (range)	3 (0-136)	2 (1-15)	2 (0-32)	1.5 (0-2)
No. (%) patients with resolution	47/63 (74.6)	5/5 (100)	49/61 (80.3)	8/8 (100)
Median time to resolution, weeks (range)	3.4 (0.3-153.3)	2.4 (0.3-8.7)	3 (0-115.1)	2.05 (0.3-35)
Gastrointestinal				
No. (%) patients with AE	43 (62.3)	3 (4.3)	46 (69.7)	5 (7.6)
Median time to onset, weeks (range)	1 (0-171)	5 (2-15)	1 (0-114)	75 (0-115)
No. (%) patients with resolution	34/43 (79.1)	2/3 (66.7)	41/46 (89.1)	3/5 (60)
Median time to resolution, weeks (range)	1.05 (0-103)	2 (0-4)	1.1 (0-14.3)	1 (0.9-2)
Hepatic				
No. (%) patients with AE	24 (34.8)	5 (7.2)	24 (36.4)	7 (10.6)
Median time to onset, weeks (range)	8.5 (2-45)	8 (2-25)	8 (2-199)	15 (4-139)
No. (%) patients with resolution	19/24 (79.2)	5/5 (100)	24/24 (100)	7/7 (100)
Median time to resolution, weeks (range)	4 (0.1-148)	4.7 (0.1-78.7)	3.85 (0.6-22.4)	9.4 (0.6-11)
Pancreatic				
No. (%) patients with AE	17 (24.6)	12 (17.4)	17 (25.8)	9 (13.6)
Median time to onset, weeks (range)	5 (4-175)	4 (4-64)	8 (4-81)	4 (4-81)
No. (%) patients with resolution	14/17 (82.4)	11/12 (91.7)	14/17 (82.4)	9/9 (100)
Median time to resolution, weeks (range)	2.35 (0.3-99.9)	2.6 (0.3-84)	2.5 (0.6-41.1)	1.1 (0.4-4)
Endocrine				
No. (%) patients with AE	13 (18.8)	0	22 (33.3)	3 (4.5)
Median time to onset, weeks (range)	30 (1-227)		18.5 (8-91)	23 (8-78)
No. (%) patients with resolution	4/13 (30.8)	0	11/22 (50)	0/3 (0)
Median time to resolution, weeks (range)	16.4 (3.9-28.6)		6 (0.3-18.4)	
Pulmonary				
No. (%) patients with AE	4 (5.8)	0	7 (10.6)	0
Median time to onset, weeks (range)	54 (6-76)		19 (2-60)	
No. (%) patients with resolution	2/4 (50)	0	6/7 (85.7)	0
Median time to resolution, weeks (range)	18.95 (7.6-30.3)		3.3 (0.4-16.7)	
Renal				
No. (%) patients with AE	22 (31.9)	2 (2.9)	19 (28.8)	0
Median time to onset, weeks (range)	4 (1-26)	22.5 (19-26)	4 (1-108)	
No. (%) patients with resolution	20/22 (90.9)	2/2 (100)	14/19 (73.7)	0
Median time to resolution, weeks (range)	3.95 (0.6-72)	2.3 (0.7-3.9)	10.15 (0.7-131.4)	
Hypersensitivity/infusion reaction				
No. (%) patients with AE	0	0	0	0
No. (%) patients with resolution	0	0	0	0
Neurological				
No. (%) patients with AE	17 (24.6)	0	21 (31.8)	1 (1.5)
Median time to onset, weeks (range)	10 (0-271)		19 (1-91)	39 (39-39)
No. (%) patients with resolution	13/17 (76.5)	0	13/21 (61.9)	1/1 (100)
Median time to resolution, weeks (range)	2.3 (0-21.3)		0.7 (0-18.7)	12.4 (12.4-12.4)
Musculoskeletal				
No. (%) patients with AE	35 (50.7)	3 (4.3)	35 (53)	8 (12.1)
Median time to onset, weeks (range)	6 (0-203)	2 (2-203)	4 (0-67)	5.5 (2-117)
No. (%) patients with resolution	27/35 (77.1)	3/3 (100)	29/35 (82.9)	8/8 (100)
Median time to resolution, weeks (range)	3.7 (0-40.4)	1.6 (0.7-8)	3 (0-70.7)	1.5 (0.3-10.7)
Cardiac				
No. (%) patients with AE	14 (20.3)	4 (5.8)	13 (19.7)	1 (1.5)
Median time to onset, weeks (range)	10.5 (3-47)	14.5 (3-19)	16 (1-87)	2 (2-2)
No. (%) patients with resolution	12/14 (85.7)	3/4 (75)	9/13 (69.2)	1/1 (100)
Median time to resolution, weeks (range)	4.7 (0-20)	20 (4.1-24)	7.9 (0-88.1)	15.7 (15.7-15.7)
Blood				
No. (%) patients with AE	25 (36.2)	4 (5.8)	18 (27.3)	1 (1.5)
Median time to onset, weeks (range)	11 (3-212)	21.5 (5-28)	4 (4-138)	32 (32-32)
No. (%) patients with resolution	16/25 (64)	3/4 (75)	14/18 (77.8)	1/1 (100)
Median time to resolution, weeks (range)	3.75 (0.3-20)	1.4 (1-2.4)	3 (1-11.6)	9.4 (9.4-9.4)
Biliary				
No. (%) patients with AE	0	0	1 (1.5)	0
Median time to onset, weeks (range)			20 (20-20)	
No. (%) patients with resolution	0	0	1/1 (100)	0
Median time to resolution, weeks (range)			8.6 (8.6-8.6)	
Ophthalmologic				

<i>Time to onset and resolution</i>	<i>Arm A</i> <i>All Grades</i>	<i>Arm A</i> <i>Grade 3/4</i>	<i>Arm B</i> <i>All Grades</i>	<i>Arm B</i> <i>Grade 3/4</i>
No. (%) patients with AE	9 (13)	0	5 (7.6)	0
Median time to onset, weeks (range)	14 (0-33)		13 (2-27)	
No. (%) patients with resolution	6/9 (66.7)	0	1/5 (20)	0
Median time to resolution, weeks (range)	0.9 (0.4-9.4)		0 (0-0)	

Data source: Table 120 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

### 14.3.2 Listings of Deaths, SAEs, Other Significant AEs

All deaths (n=88) are presented below (**Table 38**). All AEs listed per patient are provided in **Table 47** in section 16.2.7.

**Table 38: Listing of deaths (ITT)**

<i>Site</i>	<i>Patient no.</i>	<i>Arm</i>	<i>Year of birth</i>	<i>Sex</i>	<i>Cause of death</i>
Universitätsklinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Universitätsklinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Unknown
Universitätsklinikum Würzburg	[REDACTED]	Not randomized	[REDACTED]	Female	Disease progression
Universitätsklinikum Würzburg	[REDACTED]	Not randomized	[REDACTED]	Female	Disease progression
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Universitätsklinikum Essen	[REDACTED]	Not randomized	[REDACTED]	Male	Disease progression
HELIOS Klinikum Erfurt	[REDACTED]	Not randomized	[REDACTED]	Female	Disease progression
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Disease progression
Universitätsklinikum Schleswig-Holstein, Campus Kiel	[REDACTED]	Not randomized	[REDACTED]	Female	Disease progression
Universitätsklinikum Schleswig-Holstein, Campus Kiel	[REDACTED]	Not randomized	[REDACTED]	Male	Disease progression
Universitätsklinikum Schleswig-Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
Universitätsklinikum Schleswig-Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Disease progression
Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
Lübeck	[REDACTED]	Not randomized	[REDACTED]	Female	Disease progression
Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Unknown
Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Disease progression
Lübeck	[REDACTED]	Not randomized	[REDACTED]	Male	No therapeutic reason or basic disease
Lübeck	[REDACTED]	Not randomized	[REDACTED]	Male	Disease progression
Universitätsklinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
Universitätsklinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Universitätsklinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Universitätsklinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	No therapeutic reason or basic disease
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Johannes Wesling Klinikum Minden	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression



<b>Site</b>	<b>Patient no.</b>	<b>Arm</b>	<b>Year of birth</b>	<b>Sex</b>	<b>Cause of death</b>
Universitätsmedizin Mainz	[REDACTED]	Not randomized	[REDACTED]	Male	Disease progression
Universitätsmedizin Mainz	[REDACTED]	Not randomized	[REDACTED]	Male	Disease progression
Universitätsmedizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
Universitätsklinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Disease progression
Universitätsklinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
Universitätsklinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden	[REDACTED]	Not randomized	[REDACTED]	Male	Disease progression
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
Universitätsklinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Disease progression
Universitätsklinikum Tübingen	[REDACTED]	Not randomized	[REDACTED]	Female	Disease progression
Universitätsklinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Universitätsklinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
Universitätsklinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
Universitätsklinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
Charité - Universitätsmedizin Berlin	[REDACTED]	Arm B	[REDACTED]	Male	Therapeutic reason
Charité - Universitätsmedizin Berlin	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Charité - Universitätsmedizin Berlin	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
Charité - Universitätsmedizin Berlin	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Unknown
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Disease progression
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
CHU de Nantes	[REDACTED]	Not randomized	[REDACTED]	Male	Disease progression
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
SLK-Kliniken Heilbronn GmbH	[REDACTED]	Arm B	[REDACTED]	Female	Disease progression

<b>Site</b>	<b>Patient no.</b>	<b>Arm</b>	<b>Year of birth</b>	<b>Sex</b>	<b>Cause of death</b>
SLK-Kliniken Heilbronn GmbH	[REDACTED]	Not randomized	[REDACTED]	Female	Disease progression
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
Military Medical Academy, Belgrade	[REDACTED]	Not randomized	[REDACTED]	Male	No therapeutic reason or basic disease
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
Military Medical Academy, Belgrade	[REDACTED]	Not randomized	[REDACTED]	Male	Disease progression
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Not randomized	[REDACTED]	Female	No therapeutic reason or basic disease
"LAIKO" General Hospital of Athens	[REDACTED]	Not randomized	[REDACTED]	Male	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Not randomized	[REDACTED]	Male	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Not randomized	[REDACTED]	Female	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Not randomized	[REDACTED]	Female	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Not randomized	[REDACTED]	Female	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Disease progression
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	No therapeutic reason or basic disease
Centre Hospitalier Lyon Sud, Pierre- Bënite	[REDACTED]	Arm B	[REDACTED]	Male	Disease progression
Hospital Claude Huriez, Lille	[REDACTED]	Not randomized	[REDACTED]	Male	Disease progression

Data source: Listing 8 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

Table 39 SAEs (patient based) (all trial phases combined)

	Arm A						Arm B						Not randomized						Total														
	All Grades			Grade 3/4			All Grades			Grade 3/4			Grade 5			All Grades			Grade 3/4			Grade 5			All Grades			Grade 3/4			Grade 5		
	N	%		N	%		N	%		N	%		N	%		N	%		N	%		N	%		N	%		N	%				
Number of patients	69	100.00	.	.	66	100.00	.	.	.	.	47	100.00	.	.	.	182	100.00	.	.	.	.	.	.	.	.	.	.	.	.	.			
Any SAE	30	43.48	21	30.43	33	50.00	21	31.82	2	3.03	33	70.21	25	53.19	2	4.26	96	52.75	67	36.81	4	2.20											
Blood and lymphatic system disorders	2	2.90	1	1.45	.	.	.	.	.	.	3	6.38	1	2.13	.	.	5	2.75	2	1.10	.	.											
Eosinophilia	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	1	0.55	1	0.55	.	.											
Haemolytic anaemia	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.											
Angina pectoris	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.											
Aortic valve disease	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.											
Atrial fibrillation	.	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.											
Cardiac arrest	.	.	.	.	.	.	.	.	.	.	1	2.13	.	.	.	1	0.55	.	.	.	.	1	0.55										
Cardiac failure	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.											
Cardiopulmonary failure	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	1	0.55	1	0.55	.	.											
Left ventricular dysfunction	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	1	0.55	1	0.55	.	.											
Endocrine disorders	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.											
Eye disorders	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.											
Diplopia	.	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.											
Pterygium	.	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.											
Gastrointestinal disorders	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.											
Abdominal pain	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.											
Colitis	1	1.45	.	.	2	3.03	1	1.52	.	.	.	.	.	.	.	.	3	1.65	1	0.55	.	.											
Diarrhoea	2	2.90	2	2.90	3	4.55	1	1.52	.	.	2	4.26	1	2.13	.	.	7	3.85	4	2.20	.	.											
Gastritis	.	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.											
Ileus	.	.	.	.	2	3.03	.	.	.	.	.	.	.	.	.	.	2	1.10	.	.	.	.											
Intra-abdominal haemorrhage	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	1	0.55	1	0.55	.	.											

		Arm A						Arm B						Not randomized						Total					
		All Grades			Grade 3/4			All Grades			Grade 3/4			All Grades			Grade 3/4			All Grades			Grade 3/4		
		N	%		N	%		N	%		N	%		N	%		N	%		N	%		N	%	
General disorders and administration site conditions	Large intestinal haemorrhage	.	.	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	1	0.55	1	0.55	.	.
	Large intestine perforation	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.
	Lower gastrointestinal haemorrhage	.	.	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	1	0.55	1	0.55	.	.
	Pancreatitis	.	.	.	1	1.52	1	1.52	1	1.52	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.
	Vomiting	1	1.45	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	2	1.10	1	0.55	.	.
	General physical health deterioration	.	.	.	2	3.03	2	3.03	.	.	3	3.03	.	2	4.26	1	2.13	.	.	4	2.20	3	1.65	.	.
	Malaise	.	.	.	1	1.52	.	.	.	.	.	.	.	1	2.13	.	.	.	.	2	1.10	.	.	.	.
	Multiple organ dysfunction syndrome	.	.	.	.	.	.	.	.	.	.	.	.	1	2.13	.	.	.	.	1	0.55	.	1	0.55	.
	Pyrexia	.	.	.	3	4.55	2	3.03	.	.	1	1.52	.	1	2.13	.	.	.	.	4	2.20	2	1.10	.	.
	Bile duct stenosis	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.
Hepatobiliary disorders	Cholecystitis	.	.	.	1	1.52	.	1	1.52	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.
	Cholestasis	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.
	Drug-induced liver injury	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.
	Gallbladder obstruction	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.
	Immune-mediated hepatitis	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.
Immune system disorders	Autoimmune disorder	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.
	COVID-19	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.
	Cellulitis	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.
Infections and infestations	Cholecystitis infective	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.
	Encephalitis	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.
	Erysipelas	1	1.45	1	1.45	2	3.03	2	3.03	.	.	.	.	.	.	.	.	.	.	3	1.65	3	1.65	.	.

	Arm A						Arm B						Not randomized						Total							
	All Grades			Grade 3/4			All Grades			Grade 3/4			Grade 5			All Grades			Grade 3/4			Grade 5				
	N	%		N	%		N	%		N	%		N	%		N	%		N	%		N	%			
Herpes zoster	.	.	.	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.		
Infection	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.		
Lung abscess	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.		
Pneumocystis jirovecii pneumonia	.	.	.	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.		
Pneumonia	3	4.35	1	1.45	.	.	.	.	.	.	.	.	2	4.26	2	4.26	.	.	5	2.75	3	1.65	.	.		
Sepsis	3	4.35	3	4.35	3	4.55	3	4.55	3	4.55	.	.	1	2.13	1	2.13	.	.	7	3.85	7	3.85	.	.		
Skin infection	1	1.45	1	1.45	1	1.52	1	1.52	1	1.52	.	.	.	.	.	.	.	.	2	1.10	2	1.10	.	.		
Tonsillitis	.	.	.	.	.	.	.	.	.	.	.	.	1	2.13	.	.	.	.	1	0.55	.	.	.	.		
Urinary tract infection	.	.	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.		
Ankle fracture	2	2.90	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	1.10	.	.	.	.		
Brain radiation necrosis	.	.	.	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.		
Craniocerebral injury	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.		
Fall	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.		
Fracture	1	1.45	.	.	.	.	1	1.52	1	1.52	.	.	1	2.13	1	2.13	.	.	3	1.65	2	1.10	.	.		
Hip fracture	.	.	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	1	0.55	1	0.55	.	.		
Joint injury	.	.	.	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.		
Medication error	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.		
Overdose	.	.	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.		
Product administration error	.	.	.	.	.	.	.	.	.	.	.	.	1	2.13	.	.	.	.	1	0.55	.	.	.	.		
Splinter	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.		
Investigations	1	1.45	1	1.45	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	2	1.10	2	1.10	.	.		
Blood creatine phosphokinase increased																										

	Arm A						Arm B						Not randomized						Total														
	All Grades			Grade 3/4			All Grades			Grade 3/4			Grade 5			All Grades			Grade 3/4			Grade 5			All Grades			Grade 3/4			Grade 5		
	N	%		N	%		N	%		N	%		N	%		N	%		N	%		N	%		N	%		N	%				
Ejection fraction decreased	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	4.26	2	4.26	.	.	.	.	.	.	2	1.10	2	1.10	.	.		
Platelet count decreased	.	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.	.		
Troponin T increased	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	.	.	.	.	1	0.55	1	0.55	.	.		
Dehydration	2	2.90	2	2.90	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	1.10	2	1.10	.	.	.		
Hypokalaemia	.	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.	.		
Hyponatraemia	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	.	.	.	.	1	0.55	1	0.55	.	.		
Muscular weakness	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.	.		
Osteoarthritis	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.	.		
Osteoporosis	.	.	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.	.		
Pain in extremity	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.13	.	.	.	.	.	.	.	1	0.55	.	.	.	.	.		
Basal cell carcinoma	2	2.90	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	1.10	1	0.55	.	.	.		
Pituitary tumour benign	.	.	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.	.		
Cerebral ischaemia	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.	.		
Demyelination	.	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.	.		
Dizziness	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.	.		
Haemorrhage intracranial	1	1.45	1	1.45	2	3.03	.	.	.	2	3.03	.	.	.	.	.	.	.	.	.	.	.	.	.	3	1.65	1	0.55	2	1.10	.		
Monoparesis	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.	.		
Seizure	1	1.45	1	1.45	1	1.52	1	1.52	1	1.52	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	1.10	2	1.10	.	.	.		
Syncope	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	.	.	.	1	0.55	1	0.55	.	.	.		
Confusional state	.	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	1	2.13	.	.	.	.	.	.	.	2	1.10	.	.	.	.	.		
Acute kidney injury	2	2.90	1	1.45	3	4.55	2	3.03	.	.	.	.	5	10.64	4	8.51	.	.	.	.	.	.	.	.	10	5.49	7	3.85	.	.	.		
Hydronephrosis	.	.	.	.	.	1	1.52	1	1.52	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.	.		

	Arm A						Arm B						Not randomized						Total														
	All Grades			Grade 3/4			All Grades			Grade 3/4			Grade 5			All Grades			Grade 3/4			Grade 5			All Grades			Grade 3/4			Grade 5		
	N	%		N	%		N	%		N	%		N	%		N	%		N	%		N	%		N	%		N	%				
Respiratory, thoracic and mediastinal disorders	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	6.38	1	2.13	.	.	.	.	.	.	.	3	1.65	1	0.55	.	.	
	2	2.90	.	.	.	1	1.52	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	1.65	.	.	.	.	
Skin and subcutaneous tissue disorders	.	.	.	.	.	1	1.52	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.	
	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.	
Drug reaction with eosinophilia and systemic symptoms	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.13	1	2.13	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.	
	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	2.13	.	.	.	.	.	.	.	.	.	1	0.55	.	.	.	.	
Erythema multiforme	1	1.45	.	.	.	3	4.55	2	3.03	.	.	.	.	.	.	4	8.51	4	8.51	.	.	.	.	.	.	.	8	4.40	6	3.30	.	.	
Stevens-Johnson syndrome	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	4.26	2	4.26	.	.	.	.	.	.	.	2	1.10	2	1.10	.	.	
	1	1.45	1	1.45	2	3.03	1	1.52	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3	1.65	2	1.10	.	.	
Hypertension	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.	
Hypotension	1	1.45	1	1.45	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.55	1	0.55	.	.	

Data source: Table 96 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

### 14.3.3 Narratives of Deaths, SAEs, Other Significant AEs

Not applicable.

### 14.3.4 Abnormal Clinically Meaningful Laboratory Values (by-patient listing)

Not applicable.

### 14.4 Other data

Not applicable.

## 15 LIST OF REFERENCES

1. Bray, F., et al., *Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. CA Cancer J Clin, 2024. **74**(3): p. 229-263.
2. Schadendorf, D., et al., *Melanoma*. Lancet, 2018. **392**(10151): p. 971-984.
3. Tsao, H., M.B. Atkins, and A.J. Sober, *Management of cutaneous melanoma*. N Engl J Med, 2004. **351**(10): p. 998-1012.
4. Ronckers, C., et al., *Krebs in Deutschland für 2019/2020*. 2023, Robert Koch-Institut. p. 164.
5. Davies, H., et al., *Mutations of the BRAF gene in human cancer*. Nature, 2002. **417**(6892): p. 949-54.
6. Wellbrock, C., M. Karasarides, and R. Marais, *The RAF proteins take centre stage*. Nat Rev Mol Cell Biol, 2004. **5**(11): p. 875-85.
7. Chapman, P.B., et al., *Improved survival with vemurafenib in melanoma with BRAF V600E mutation*. N Engl J Med, 2011. **364**(26): p. 2507-16.
8. Hauschild, A., et al., *Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial*. Lancet, 2012. **380**(9839): p. 358-65.
9. Flaherty, K.T., et al., *Improved survival with MEK inhibition in BRAF-mutated melanoma*. N Engl J Med, 2012. **367**(2): p. 107-14.
10. Sullivan, R.J. and K. Flaherty, *MAP kinase signaling and inhibition in melanoma*. Oncogene, 2013. **32**(19): p. 2373-9.
11. Johannessen, C.M., et al., *COT drives resistance to RAF inhibition through MAP kinase pathway reactivation*. Nature, 2010. **468**(7326): p. 968-72.
12. Nazarian, R., et al., *Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation*. Nature, 2010. **468**(7326): p. 973-7.
13. Paraiso, K.H., et al., *Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy*. Br J Cancer, 2010. **102**(12): p. 1724-30.
14. Su, F., et al., *Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation*. Cancer Res, 2012. **72**(4): p. 969-78.
15. Harshman, L.C., et al., *Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer*. Cancer J, 2014. **20**(4): p. 272-80.
16. Dong, H., et al., *Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion*. Nat Med, 2002. **8**(8): p. 793-800.
17. Sullivan, R.J., P.M. Lorusso, and K.T. Flaherty, *The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be*. Clin Cancer Res, 2013. **19**(19): p. 5283-91.
18. Brahmer, J.R., et al., *Safety and activity of anti-PD-L1 antibody in patients with advanced cancer*. N Engl J Med, 2012. **366**(26): p. 2455-65.
19. Hino, R., et al., *Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma*. Cancer, 2010. **116**(7): p. 1757-66.



20. Taube, J.M., et al., *Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape*. Sci Transl Med, 2012. **4**(127): p. 127ra37.
21. Thompson, R.H., et al., *PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma*. Clin Cancer Res, 2007. **13**(6): p. 1757-61.
22. Gao, Q., et al., *Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma*. Clin Cancer Res, 2009. **15**(3): p. 971-9.
23. Dolan, D.E. and S. Gupta, *PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy*. Cancer Control, 2014. **21**(3): p. 231-7.
24. Mahoney, K.M., G.J. Freeman, and D.F. McDermott, *The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma*. Clin Ther, 2015. **37**(4): p. 764-82.
25. Wolchok, J.D., et al., *Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma*. J Clin Oncol, 2022. **40**(2): p. 127-137.
26. Larkin, J., et al., *Combined vemurafenib and cobimetinib in BRAF-mutated melanoma*. N Engl J Med, 2014. **371**(20): p. 1867-76.
27. Robert, C., et al., *Improved overall survival in melanoma with combined dabrafenib and trametinib*. N Engl J Med, 2015. **372**(1): p. 30-9.
28. Hodi, F.S., et al., *Improved survival with ipilimumab in patients with metastatic melanoma*. N Engl J Med, 2010. **363**(8): p. 711-23.
29. Schadendorf, D., et al., *Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma*. J Clin Oncol, 2015. **33**(17): p. 1889-94.
30. Hamid, O., et al., *Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM)*. Journal of Clinical Oncology, 2013. **31**(15\_suppl): p. 9010-9010.
31. Topalian, S.L., et al., *Safety, activity, and immune correlates of anti-PD-1 antibody in cancer*. N Engl J Med, 2012. **366**(26): p. 2443-54.
32. Robert, C., et al., *Nivolumab in previously untreated melanoma without BRAF mutation*. N Engl J Med, 2015. **372**(4): p. 320-30.
33. Schadendorf, D. and A. Hauschild, *Melanoma in 2013: Melanoma--the run of success continues*. Nat Rev Clin Oncol, 2014. **11**(2): p. 75-6.
34. McArthur, G.A., et al., *Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study*. Lancet Oncol, 2014. **15**(3): p. 323-32.
35. Ribas, A., et al., *Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study*. Lancet Oncol, 2014. **15**(9): p. 954-65.
36. Ascierto, P.A., et al., *Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial*. Lancet Oncol, 2016. **17**(9): p. 1248-60.
37. Larkin, J.M.G., et al., *Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced <i>BRAF</i>-mutated melanoma*. Journal of Clinical Oncology, 2015. **33**(15\_suppl): p. 9006-9006.
38. Eisenhauer, E.A., et al., *New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)*. Eur J Cancer, 2009. **45**(2): p. 228-47.
39. Reijers, I.L.M., et al., *Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in*

- patients with BRAF-mutated melanoma*. *Pigment Cell Melanoma Res*, 2020. **33**(3): p. 498-506.
40. Atkins, M.B., et al., *Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134*. *J Clin Oncol*, 2023. **41**(2): p. 186-197.
  41. Ascierto, P.A., et al., *Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial*. *J Clin Oncol*, 2023. **41**(2): p. 212-221.
  42. Ascierto, P.A., et al., *Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial*. *Nat Commun*, 2024. **15**(1): p. 146.
  43. Swetter, S.M., et al., *NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021*. *J Natl Compr Canc Netw*, 2021. **19**(4): p. 364-376.
  44. Robert, C., et al., *Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced <i>BRAF</i>-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN)*. *Journal of Clinical Oncology*, 2024. **42**(17\_suppl): p. LBA9503-LBA9503.
  45. Haslam, A. and V. Prasad, *When is crossover desirable in cancer drug trials and when is it problematic?* *Ann Oncol*, 2018. **29**(5): p. 1079-1081.
  46. Chandra, S., J.S. Choi, and J.A. Sosman, *Melanoma: Does Sequencing Really Matter?* *J Clin Oncol*, 2023. **41**(2): p. 167-169.
  47. Livingstone, E., et al., *Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial*. *Eur J Cancer*, 2023. **190**: p. 112941.

## 16 APPENDICES

### 16.1 Study Information

#### 16.1.1 Study Protocol and Amendments

Study protocol for Germany: MO29821\_ImmunoCobiVem\_V5.0final\_2023-05-24

There were nine amendments to the protocol:

Amendment 1 (dated 12 JUL 2016) led to protocol version 1.3 (approved on 25 AUG 2016)  
Amendment 2 (dated 15 DEC 2016) led to protocol version 1.4 (approved on 09 JAN 2017)  
Amendment 3 (dated 18 MAY 2017) led to protocol version 1.5 (approved on 24 AUG 2017)  
Amendment 4 (dated 12 DEC 2017) led to protocol version 1.6 (approved on 15 FEB 2018)  
Amendment 5 (dated 29 APR 2019) led to protocol version 1.8 (approved on 12 JUN 2019)  
Amendment 6 (dated 09 JUN 2020) led to protocol version 2.0 (approved on 04 AUG 2020)  
Amendment 7 (dated 11 MAY 2021) led to protocol version 3.0 (approved on 28 JUN 2021)  
Amendment 8 (dated 26 APR 2022) led to protocol version 4.0 (approved on 23 MAY 2022)  
Amendment 9 (dated 24 MAY 2023) led to protocol version 5.0 (approved on 14 JUL 2023)

Study protocol for France: MO29821\_ImmunoCobiVem\_V5.0\_2023-05-24

There were six amendments to the protocol:

Protocol version 1.7 of Amendment 4 (dated 21 MAR 2018) was approved on 17 APR 2018  
Protocol version 1.8 of Amendment 5 (dated 29 APR 2019) was approved on 11 JUN 2019  
Protocol version 2.0 of Amendment 6 (dated 09 JUN 2020) was approved on 17 DEC 2020  
Protocol version 3.0 of Amendment 7 (dated 11 MAY 2021) was approved on 08 JUN 2021  
Protocol version 4.0 of Amendment 8 (dated 26 APR 2022) was approved on 16 JUN 2022  
Protocol version 5.0 of Amendment 9 (dated 24 MAY 2023) was approved on 13 JUN 2023

Study protocol for Greece: MO29821\_ImmunoCobiVem\_V5.0\_2023-05-24

There were six amendments to the protocol:

Protocol version 1.6 of Amendment 4 (dated 12 DEC 2017) was approved on 24 SEP 2018  
Protocol version 1.8 of Amendment 5 (dated 29 APR 2019) was approved on 29 JUL 2019  
Protocol version 2.0 of Amendment 6 (dated 09 JUN 2020) was approved on 11 SEP 2020  
Protocol version 3.0 of Amendment 7 (dated 11 MAY 2021) was approved on 16 JUL 2021  
Protocol version 4.0 of Amendment 8 (dated 26 APR 2022) was approved on 17 JUN 2022  
Protocol version 5.0 of Amendment 9 (dated 24 MAY 2023) was approved on 11 SEP 2023

Study protocol for Serbia: MO29821\_ImmunoCobiVem\_V5.0\_2023-05-24

There were six amendments to the protocol:

Protocol version 1.6 of Amendment 4 (dated 12 DEC 2017) was approved on 26 APR 2018  
Protocol version 1.8 of Amendment 5 (dated 29 APR 2019) was approved on 25 JUN 2019  
Protocol version 2.0 of Amendment 6 (dated 09 JUN 2020) was approved on 30 OCT 2020  
Protocol version 3.0 of Amendment 7 (dated 11 MAY 2021) was approved on 03 NOV 2021  
Protocol version 4.0 of Amendment 8 (dated 26 APR 2022) was approved on 05 OCT 2022  
Protocol version 5.0 of Amendment 9 (dated 24 MAY 2023) was approved on 28 NOV 2023

The study protocols and amendments are available upon request.

#### 16.1.2 Sample CRF

A sample eCRF may be obtained upon request.

#### 16.1.3 List of Ethics Committees

The following ethics committees were involved in the study:

**Table 40 Ethics Committees**

<b>Ethics Committee</b>	<b>Address</b>	<b>Country</b>
Ethikkommission der Medizinischen Fakultät Heidelberg	Alte Glockengießerei 11/ 1 69115 Heidelberg (Baden-Württemberg)	Germany
Ethikkommission der Universität Tübingen	Gartenstraße 47 72074 Tübingen (Baden-Württemberg)	Germany
Ethik-Kommission bei der Medizinischen Fakultät der Universität Würzburg	Josef-Schneider-Straße 4 (Haus C12) 97080 Würzburg (Bayern)	Germany
Ethikkommission der Medizinischen Hochschule Hannover	Carl-Neuberg-Str. 1 30625 Hannover (Niedersachsen)	Germany
Ethikkommission der Medizinischen Fakultät der Universität Duisburg-Essen*	Robert-Koch-Straße 9-11 45147 Essen (Nordrhein-Westfalen)	Germany
Ethikkommission der Medizinischen Fakultät Köln	Kerpener Str. 62 50937 Köln (Nordrhein-Westfalen)	Germany
Ethikkommission bei der Landesärztekammer Rheinland-Pfalz	Deutschhausplatz 3 55116 Mainz (Rheinland-Pfalz)	Germany
Ethikkommission an der Medizinischen Fakultät der Universität Leipzig	Liebigstraße 18 04103 Leipzig (Sachsen)	Germany
Ethikkommission an der Technischen Universität Dresden	Fetscherstraße 74 01307 Dresden (Sachsen)	Germany
Ethikkommission der Med. Fakultät der Christian-Albrechts-Universität zu Kiel	Schwanenweg 20 24105 Kiel (Schleswig-Holstein)	Germany
Ethikkommission bei der Landesärztekammer Thüringen	Im Semmicht 33 07751 Jena (Thüringen)	Germany
The French National Agency for Medicines and Health Products Safety	143bd Anatole France 93200 Saint Denis Cedex	France
National Organization for Medicines	Leof. Mesogeion 284, 155 62 Chalandri	Greece
Ethics Committee of Medical Military Academy	Crnotravska 17 11000 Belgrade	Serbia

\*National leading ethics committee

**16.1.4 List of Investigators and Other Important Participants in the Trial**

The following principal investigators recruited patients:

**Table 41 By-center list of Investigators**

<b>Site ID</b>	<b>Principal investigator</b>	<b>Site</b>	<b>Address</b>	<b>N Enrolled patients</b>
294253	[REDACTED]	Universitätsklinikum Essen Hautklinik	[REDACTED] Essen	12
294247	[REDACTED]	Universitätsklinikum Würzburg Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie	[REDACTED] Würzburg	8
294250	[REDACTED]	Elbe Kliniken Stade - Buxtehude GmbH Klinik für Dermatologie	[REDACTED] Buxtehude	0
294265	[REDACTED]	HELIOS Klinikum Erfurt Dermatologie und Allergologie	[REDACTED] Erfurt	8
296880	[REDACTED]	Universitätsklinikum Schleswig-Holstein, Campus Kiel Hautklinik - Klinische Forschung	[REDACTED] Kiel	8
294254	[REDACTED]	Universitätsklinikum Köln Klinik und Poliklinik für Dermatologie und Venerologie	[REDACTED] Köln	1
294264	[REDACTED]	Universitätsklinikum Schleswig-Holstein, Campus Lübeck Klinik für Dermatologie, Allergologie und Venerologie (Hautklinik)	[REDACTED] Lübeck	9

294262	[REDACTED]	Universitätsklinikum Leipzig Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie	[REDACTED] Leipzig	10
294244	[REDACTED]	Universitätsklinikum Mannheim Klinik für Dermatologie, Venerologie und Allergologie	[REDACTED] Mannheim,	4
294257	[REDACTED]	Klinikum Ludwigshafen gGmbH Hautklinik	[REDACTED] Ludwigshafen	3
294256	[REDACTED]	Johannes Wesling Klinikum Minden Mühlenkreiskliniken Universitätsklinik für Dermatologie, Venerologie, Allergologie und Phlebologie	[REDACTED] Minden	3
294258	[REDACTED]	Universitätsmedizin Mainz Hautklinik und Poliklinik	[REDACTED] Mainz	3
294246	[REDACTED]	Klinikum der Universität München Klinik und Poliklinik für Dermatologie und Allergologie	[REDACTED] München	2
296861	[REDACTED]	Universitätsklinikum Heidelberg Hautklinik	[REDACTED] Heidelberg	4
294261	[REDACTED]	Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden Klinik und Poliklinik für Dermatologie	[REDACTED] Dresden	17
294245	[REDACTED]	Universitätsklinikum Tübingen Hautklinik	[REDACTED] Tübingen	13
294249	[REDACTED]	Charité - Universitätsmedizin Berlin Klinik für Dermatologie, Venerologie und Allergologie	[REDACTED] Berlin	5
294252	[REDACTED]	Medizinische Hochschule Hannover Klinik für Dermatologie, Allergologie und Venerologie	[REDACTED] Hannover	5
294243	[REDACTED]	SLK-Kliniken Heilbronn GmbH Medizinische Klinik III	[REDACTED] Heilbronn	2
295494	[REDACTED]	Hôpital de la Timone Service de Dermatologie et Cancérologie Cutanée	[REDACTED] Marseille Cedex 05	5
294791	[REDACTED]	CHU de Nantes Cancéro-dermatologie	[REDACTED] Nantes Cedex 1	3
295597	[REDACTED]	Centre Hospitalier Lyon Sud Dermatologie	[REDACTED] Pierre- Bënite	4
313501	[REDACTED]	Hospital Claude Huriez Clinique de Dermatologie	[REDACTED] Lille	4
313500	[REDACTED]	Hôpital Ambroise-Paré Dermatologie	[REDACTED] Boulogne- Billancourt	1
295408	[REDACTED]	Military Medical Academy Dermatology	[REDACTED] Belgrade	21*
313686	[REDACTED]	"LAIKO" General Hospital of Athens 1st Department of Medicine	[REDACTED] Athens	30

\*One patient moved during the study. The patient was allocated to a different site at the start of the study.

Other important participants in the trial:

**Table 42 Biostatistician and author of the report**

Role	Name	Address
Study Biostatistician	[REDACTED]	Alcedis GmbH Winchesterstr. 3, D-35394 Gießen
Author of the report	[REDACTED]	Alcedis GmbH Winchesterstr. 3, D-35394 Gießen

**16.1.5 Signatures of the Principal or Coordinating Investigator(s), the Sponsor’s Responsible Medical Officer, and the Biostatistician, and, if applicable, of Other Authors**

By signing this Clinical Study Report, the undersigned authors agree with the contents of this Clinical Study Report. The clinical trial reported here was conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice (GCP), and applicable legislation.

<b>Sponsor (Representative)</b>	<div>[REDACTED]</div>	<div>[REDACTED]</div> <div>12.03.2025   09:49 MEZ</div> <div>Place, date</div>
<b>Principal / Coordinating Investigator</b>	<div>[REDACTED]</div>	<div>[REDACTED]</div> <div>12.03.2025   09:49 MEZ</div> <div>Place, date</div>
<b>Biostatistician</b>	<div>[REDACTED]</div>	<div>[REDACTED]</div> <div>10.03.2025   14:42 MEZ</div> <div>Place, date</div>

### 16.1.6 Listing of Investigational Product(s) Batch Numbers

Table 43 Batch Numbers of Investigations Products

<i>Investigational Product</i>	<i>Batch Number</i>
<b>Atezolizumab</b>	1153708
	1153375
	1153048
	1154613
	1156592
	1161810
	1164255
	1165191
	1167909
	1175838
	1177286
<b>Cobimetinib</b>	1152310
	1153347
	1153878
	1154442
	1156020
	1153127
	1158966
	1159929
	1161779
	1174487
	1175137
<b>Vemurafenib</b>	1152629
	1153516
	1154058
	1154531
	1155049
	1156835
	1157801
	1161777
	1171015
	1171317
	1174486
	1175585

### 16.1.7 Randomization Scheme and Codes

After the 3-month run-in phase patients who did not show disease progression were randomized in an open label 2-arm design. Patients were block-randomized in a 1:1 ratio either to proceed on vemurafenib and cobimetinib treatment until disease progression and subsequently cross over to atezolizumab treatment until disease progression (Arm A) **or** to receive atezolizumab treatment until disease progression and subsequently cross back to vemurafenib and cobimetinib until disease progression (Arm B).

Stratification factors for randomization were LDH serum level (normal institutional level vs. elevated level by institutional standard) metastatic stage (IV M1c yes/no) and previous adjuvant therapy for underlying disease (yes/no).

**Table 44 Table for identification of subjects**

ID.	Randomization	Treatment
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED] 7	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase



10 March 2025

10 March 2025

ID.	Randomization	Treatment
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm B	Atezolizumab with switch to cobimetinib / vemurafenib
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Arm A	Cobimetinib / vemurafenib with switch to atezolizumab
[REDACTED]	Not randomized	Cobimetinib / vemurafenib during the run-in phase

**16.1.8 Audit Certificates (if available)**

Not applicable.

**16.1.9 Documentation of Statistical Methods**

Not applicable.

**16.1.10 Documentation of Inter-laboratory Standardization Methods and Quality Assurance Procedures**

Not applicable.

**16.1.11 Publications Based on the Clinical Trial**

[REDACTED] et al. Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF V600-positive melanoma: Interim analysis of the ImmunoCobiVem study. 2022 ASCO Annual Meeting. Abstract 9548.

[REDACTED] et al. Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAF V600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial. Eur J Cancer. 2023 Sep;190:112941

[REDACTED], et al. Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial. 2024 ESMO Annual Meeting. LBA45

[REDACTED] et al. Adjuvant treatment of patients with stage III melanoma: 4-year follow-up time of multicenter real-world study. 2024 ESMO Annual Meeting. 1124P

[REDACTED]. Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: Final results of the randomized phase II ImmunoCobiVem trial. *In preparation*

**16.1.12 Important Publications Cited in This Report (Copies)**

Please refer to section 15.

**16.1.13 Optional Appendix**

Not applicable.

16.2 Patient Data Listings

16.2.1 Dropouts, Discontinued Patients

The following patients prematurely discontinued the study (Table 45).

Table 45: Premature study discontinuation (ITT)

Site	Patient no.	Arm	Year of birth	Sex	Reason for premature study discontinuation
Universitätsklinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Death
Universitätsklinikum Würzburg		Arm B		Male	Death
Universitätsklinikum Würzburg		Arm B		Male	Withdrawal of informed consent
Universitätsklinikum Würzburg		Not randomized		Female	Death
Universitätsklinikum Würzburg		Arm A		Female	Withdrawal of informed consent
Universitätsklinikum Würzburg		Arm B		Male	Withdrawal of informed consent
Universitätsklinikum Würzburg		Not randomized		Female	Death
Universitätsklinikum Würzburg		Arm A		Male	Death
Universitätsklinikum Essen		Arm A		Male	Withdrawal of informed consent
Universitätsklinikum Essen		Arm B		Female	Lost to follow-up
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Death
Universitätsklinikum Essen		Arm B		Female	Withdrawal of informed consent
Universitätsklinikum Essen		Not randomized		Male	Death
Universitätsklinikum Essen		Not randomized		Female	Withdrawal of informed consent
Universitätsklinikum Essen		Not randomized		Female	Withdrawal of informed consent
HELIOS Klinikum Erfurt		Arm B		Female	Death
HELIOS Klinikum Erfurt		Arm A		Male	Death
HELIOS Klinikum Erfurt		Arm B		Male	Death
Universitätsklinikum Schleswig-Holstein, Campus Kiel		Not randomized		Female	Death
Universitätsklinikum Schleswig-Holstein, Campus Kiel		Not randomized		Male	Death
Universitätsklinikum Schleswig-Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Death
Universitätsklinikum Schleswig-Holstein, Campus Kiel		Arm A		Female	Death
Universitätsklinikum Schleswig-Holstein, Campus Lübeck		Arm B		Male	Withdrawal of informed consent
Universitätsklinikum Schleswig-Holstein, Campus Lübeck		Arm A		Male	Death
Universitätsklinikum Schleswig-Holstein, Campus Lübeck		Arm B		Female	Death
Universitätsklinikum Schleswig-Holstein, Campus Lübeck		Arm A		Female	Death
Universitätsklinikum Schleswig-Holstein, Campus Lübeck		Not randomized		Female	Death
Universitätsklinikum Schleswig-Holstein, Campus Lübeck		Arm B		Male	Death
Universitätsklinikum Schleswig-Holstein, Campus Lübeck		Not randomized		Male	Death
Universitätsklinikum Schleswig-Holstein, Campus Lübeck		Arm B		Female	Death
Universitätsklinikum Schleswig-Holstein, Campus Lübeck	[REDACTED]	Not randomized	[REDACTED]	Male	Death
Universitätsklinikum Leipzig		Arm B		Male	Withdrawal of informed consent

Site	Patient no.	Arm	Year of birth	Sex	Reason for premature study discontinuation
Universitätsklinikum Leipzig	[REDACTED]	Not randomized	[REDACTED]	Female	Withdrawal of informed consent
Universitätsklinikum Leipzig		Arm A		Male	Death
Universitätsklinikum Leipzig		Arm B		Female	Withdrawal of informed consent
Universitätsklinikum Leipzig		Arm A		Male	Death
Universitätsklinikum Leipzig		Arm B		Male	Death
Universitätsklinikum Leipzig		Arm A		Male	Withdrawal of informed consent
Universitätsklinikum Mannheim		Arm B		Male	Withdrawal of informed consent
Universitätsklinikum Mannheim		Arm A		Male	Withdrawal of informed consent
Universitätsklinikum Mannheim		Arm B		Female	Death
Klinikum Ludwigshafen gGmbH		Arm A		Male	Lost to follow-up
Klinikum Ludwigshafen gGmbH		Arm A		Male	Death
Johannes Wesling Klinikum Minden		Not randomized		Female	Withdrawal of informed consent
Johannes Wesling Klinikum Minden		Arm A		Male	Death
Johannes Wesling Klinikum Minden		Arm B		Female	Withdrawal of informed consent
Universitätsmedizin Mainz		Not randomized		Male	Death
Universitätsmedizin Mainz		Not randomized		Male	Death
Universitätsmedizin Mainz		Arm A		Female	Death
Klinikum der Universität München		Arm A		Male	Lost to follow-up
Universitätsklinikum Heidelberg		Arm A		Male	Death
Universitätsklinikum Heidelberg		Arm B		Female	Death
Universitätsklinikum Heidelberg		Arm B		Male	Death
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Death
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Arm B		Male	Withdrawal of informed consent
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Not randomized		Male	Death
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Arm A		Female	Death
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Not randomized		Male	Withdrawal of informed consent
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Arm B		Female	Withdrawal of informed consent
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Arm A		Male	Withdrawal of informed consent
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Arm A		Female	Withdrawal of informed consent
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Arm A		Female	Death
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Arm A		Male	Death
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Arm B		Male	Withdrawal of informed consent
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Arm B		Male	Death
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Not randomized		Male	Withdrawal of informed consent
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden		Arm B		Male	Withdrawal of informed consent
Universitätsklinikum Tübingen		Not randomized		Male	Withdrawal of informed consent
Universitätsklinikum Tübingen		Arm B		Female	Withdrawal of informed consent
Universitätsklinikum Tübingen		Arm B		Female	Death
Universitätsklinikum Tübingen		Arm B		Female	Death
Universitätsklinikum Tübingen		Arm A		Male	Death
Universitätsklinikum Tübingen		Arm B		Female	Death
Charité - Universitätsmedizin Berlin	[REDACTED]	Arm A	[REDACTED]	Female	Death
Charité - Universitätsmedizin Berlin		Not randomized		Male	Withdrawal of informed consent
Charité - Universitätsmedizin Berlin	[REDACTED]	Arm B	[REDACTED]	Male	Death
Charité - Universitätsmedizin Berlin		Arm B		Male	Death

Site	Patient no.	Arm	Year of birth	Sex	Reason for premature study discontinuation
Charité - Universitätsmedizin Berlin		Arm B		Male	Death
Charité - Universitätsmedizin Berlin		Arm A		Male	Death
Charité - Universitätsmedizin Berlin		Arm A		Female	Death
Medizinische Hochschule Hannover		Arm A		Female	Death
Medizinische Hochschule Hannover		Arm A		Male	Death
Medizinische Hochschule Hannover		Arm A		Male	Death
Medizinische Hochschule Hannover		Arm B		Male	Death
Medizinische Hochschule Hannover		Arm B		Male	Death
Hôpital de la Timone, Marseille Cedex 05		Arm B		Female	Death
Hôpital de la Timone, Marseille Cedex 05		Arm A		Male	Death
Hôpital de la Timone, Marseille Cedex 05		Arm B		Male	Death
Hôpital de la Timone, Marseille Cedex 05		Arm A		Male	Lost to follow-up
Hôpital de la Timone, Marseille Cedex 05		Not randomized		Male	Lost to follow-up
CHU de Nantes		Arm A		Female	Death
CHU de Nantes		Arm A		Female	Death
CHU de Nantes		Arm B		Female	Death
SLK-Kliniken Heilbronn GmbH		Not randomized		Female	Death
SLK-Kliniken Heilbronn GmbH		Not randomized		Female	Death
SLK-Kliniken Heilbronn GmbH		Not randomized		Female	Death
Military Medical Academy, Belgrade		Arm A		Male	Death
Military Medical Academy, Belgrade		Arm B		Male	Lost to follow-up
Military Medical Academy, Belgrade		Arm A		Female	Lost to follow-up
Military Medical Academy, Belgrade		Arm A		Male	Lost to follow-up
Military Medical Academy, Belgrade		Not randomized		Male	Lost to follow-up
Military Medical Academy, Belgrade		Not randomized		Female	Lost to follow-up
Military Medical Academy, Belgrade		Arm A		Female	Death
Military Medical Academy, Belgrade		Arm B		Female	Death
Military Medical Academy, Belgrade		Arm A		Male	Lost to follow-up
Military Medical Academy, Belgrade		Arm A		Male	Lost to follow-up
Military Medical Academy, Belgrade		Not randomized		Male	Death
Military Medical Academy, Belgrade		Not randomized		Male	Death
Military Medical Academy, Belgrade		Not randomized		Male	Lost to follow-up
Military Medical Academy, Belgrade		Arm B		Male	Death
Military Medical Academy, Belgrade		Arm A		Male	Lost to follow-up
Military Medical Academy, Belgrade		Not randomized		Male	Death
Military Medical Academy, Belgrade		Arm A		Male	Lost to follow-up
Military Medical Academy, Belgrade		Arm A		Male	Lost to follow-up
Military Medical Academy, Belgrade		Arm A		Male	Lost to follow-up
Military Medical Academy, Belgrade		Arm A		Male	Lost to follow-up
"LAIKO" General Hospital of Athens		Arm A		Female	Death
"LAIKO" General Hospital of Athens		Not randomized		Female	Death
"LAIKO" General Hospital of Athens		Not randomized		Male	Withdrawal of informed consent
"LAIKO" General Hospital of Athens		Not randomized		Male	Death
"LAIKO" General Hospital of Athens		Not randomized		Male	Withdrawal of informed consent
"LAIKO" General Hospital of Athens		Arm A		Male	Death
"LAIKO" General Hospital of Athens		Not randomized		Male	Death
"LAIKO" General Hospital of Athens		Not randomized		Female	Death
"LAIKO" General Hospital of Athens		Arm A		Male	Death
"LAIKO" General Hospital of Athens		Arm B		Male	Death
"LAIKO" General Hospital of Athens		Not randomized		Female	Death
"LAIKO" General Hospital of Athens		Not randomized		Female	Death

Site	Patient no.	Arm	Year of birth	Sex	Reason for premature study discontinuation
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Death
"LAIKO" General Hospital of Athens		Not randomized		Male	Withdrawal of informed consent
"LAIKO" General Hospital of Athens		Arm A		Male	Death
"LAIKO" General Hospital of Athens		Arm B		Male	Death
"LAIKO" General Hospital of Athens		Not randomized		Male	Withdrawal of informed consent
"LAIKO" General Hospital of Athens		Not randomized		Female	Withdrawal of informed consent
"LAIKO" General Hospital of Athens		Arm B		Female	Death
"LAIKO" General Hospital of Athens		Arm A		Female	Death
"LAIKO" General Hospital of Athens		Arm A		Male	Death
"LAIKO" General Hospital of Athens		Not randomized		Female	Death
"LAIKO" General Hospital of Athens		Arm B		Female	Death
"LAIKO" General Hospital of Athens		Arm B		Female	Death
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Death
Hospital Claude Huriez, Lille		Not randomized		Male	Death

Data source: Listing 4 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

16.2.2 Protocol Deviations

The following randomized patients showed relevant protocol deviations (Table 46).

Table 46: Protocol deviations per patient (ITT)

Site	Patient no.	Arm	Year of birth	Sex	Relevant protocol deviation
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	For cross-over: Time between disease progression in randomized phase (PD1) and cross-over to other treatment (atezolizumab in case of prior treatment with cobimetinib/vemurafenib or cobimetinib/vemurafenib in case of prior treatment with atezolizumab) >14
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	For cross-over: patients with multiple and/or symptomatic brain metastasis and/or leptomeningeal disease
Universitätsklinikum Schleswig-Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	For cross-over: patients who did not perform cross-over per protocol
	[REDACTED]	Arm A	[REDACTED]	Male	For cross-over: patients who did not perform cross-over per protocol
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Prior adjuvant treatment has not been completed at least 28 days before enrolment
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	For cross-over: Time between disease progression in randomized phase (PD1) and cross-over to other treatment (atezolizumab in case of prior treatment with cobimetinib/vemurafenib or cobimetinib/vemurafenib in case of prior treatment with atezolizumab) >14
Universitätsklinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	For cross-over: patients with multiple and/or symptomatic brain metastasis and/or leptomeningeal disease
Universitätsklinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	For cross-over: Time between disease progression in randomized phase (PD1) and cross-over to other treatment (atezolizumab in case of prior treatment with cobimetinib/vemurafenib or cobimetinib/vemurafenib in case of prior treatment with atezolizumab) >14
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden	[REDACTED]	Arm B	[REDACTED]	Male	For cross-over: ECOG >2 or rapid deterioration of general state
	[REDACTED]	Arm B	[REDACTED]	Male	At randomization: patients with confirmed disease progression per RECIST 1.1*
Universitätsklinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	At randomization: patients with confirmed disease progression per RECIST 1.1*
Universitätsklinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	For cross-over: patients with multiple and/or symptomatic brain metastasis and/or leptomeningeal disease
Universitätsklinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	For cross-over: patients who did not perform cross-over per protocol
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	For cross-over: patients with multiple and/or symptomatic brain metastasis and/or leptomeningeal disease



Site	Patient no.	Arm	Year of birth	Sex	Relevant protocol deviation
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	For cross-over: Time between disease progression in randomized phase (PD1) and cross-over to other treatment (atezolizumab in case of prior treatment with cobimetinib/vemurafenib or cobimetinib/vemurafenib in case of prior treatment with atezolizumab) >14
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	For cross-over: Time between disease progression in randomized phase (PD1) and cross-over to other treatment (atezolizumab in case of prior treatment with cobimetinib/vemurafenib or cobimetinib/vemurafenib in case of prior treatment with atezolizumab) >14
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	For cross-over: patients with multiple and/or symptomatic brain metastasis and/or leptomeningeal disease
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	For cross-over: Time between disease progression in randomized phase (PD1) and cross-over to other treatment (atezolizumab in case of prior treatment with cobimetinib/vemurafenib or cobimetinib/vemurafenib in case of prior treatment with atezolizumab) >14
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	For cross-over: Time between disease progression in randomized phase (PD1) and cross-over to other treatment (atezolizumab in case of prior treatment with cobimetinib/vemurafenib or cobimetinib/vemurafenib in case of prior treatment with atezolizumab) >14

Data source: Listing 6 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

16.2.3 Patients Excluded from the Efficacy Analysis

All randomized patients were included in the efficacy analysis (ITT analysis).

16.2.4 Demographic Data

All demographic data are displayed in section 11.2.

16.2.5 Compliance Data and / or Drug Concentration data (if available)

Not applicable.

16.2.6 Individual Efficacy and Response Data

Not applicable.

**16.2.7 AE Listings (by patient)**

**Table 47 AE Listing (SAF)**

Site	Patient ID.	Arm	of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotrans- ferase increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Tooth disorder	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No,	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Rash	2	2019	2019	No	No	No	[REDACTED]	Atezo: No Cobi: No, Vem: No,	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Rash	2	2019	2019	No	No	No	[REDACTED]	Atezo: No Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Prostatic obstruction	2			No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Pleural effusion	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Pleural effusion	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	2	2020		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Hyperuricaemia	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Hyperuricaemia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-gluta- myltransferase increased	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Enanthema	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Enanthema	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Electrocardiogram QT prolonged	1	2019		No	No	No		Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Electrocardiogram QT prolonged	1	2019	2019	No	No	No		Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Ejection fraction decreased	1	2019	2019	No	No	Yes		Cobi: Yes, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: None
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Dysphagia	2	2019	2019	No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	2			No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2019		No	No	No		Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2019	2019	No	No	No		Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Cough	1			No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	C-reactive protein increased	2			No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Bundle branch block left	1	2019		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	2	2020		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2019	2020	No	No	No		Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	1	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2020-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Atrioventricular block	1	2020-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotransferase increased	1	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Aortic valve disease	3	2019-01-01	2019-01-01	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Not applicable, Vem: Not applicable
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Angina pectoris	2	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2020-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	2	2020-01-01	2020-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2019-01-01	2020-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	2	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Abnormal faeces	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	White blood cell count decreased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	White blood cell count decreased	1	2018-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	3	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Troponin increased	1	2018-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Tooth fracture	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Tooth extraction	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Solar dermatitis	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Platelet count decreased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Platelet count decreased	1	2018-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2018-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Lymphocyte count decreased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Lymphocyte count decreased	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hyperuricaemia	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hyperuricaemia	1	2018-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hyperglycaemia	2	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Gastritis	3	2018-	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltransferase increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltransferase increased	1	2018-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019-	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Electrocardiogram QT prolonged	1	2018-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	3	2018-	2018	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem:

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Dehydration	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Temporarily interrupted
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatinine increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatinine increased	2	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phosphokinase increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Anaemia	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Acute kidney injury	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]			Female	Alanine amino-transferase increased	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]			Female	Urinary tract infection	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]			Female	Rash maculo-papular	1	2019		No	No	No	[REDACTED]	Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]			Female	Rash maculo-papular	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]			Female	Purpura	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]			Female	Platelet count decreased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Nausea	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Gamma- glutamyltransferase increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Fatigue	1	[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Diarrhoea	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Diarrhoea	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: None
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Dehydration	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Blood pressure diastolic increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Blood creatinine increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Atrial fibrillation	3	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Aspartate aminotransferase increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Actinic keratosis	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Weight decreased	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Vulvovaginal inflammation	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Vision blurred	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Viral acanthoma	2		2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Viral acanthoma	2		2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Urinary tract infection	2	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Toxic nodular goitre	2	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Toothache	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Tongue eruption	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Proteinuria	2	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Postoperative wound infection	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Photosensitivity reaction	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Photosensitivity reaction	1			No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Lymphocyte count decreased	1	2019-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Lymphocyte count decreased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Lymphocyte count decreased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Lymphocyte count decreased	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Lipase increased	1	2018-	-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Lipase increased	3	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Hypoaacusis	1	2018-	-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Hyperuricaemia	1	2019-	-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Hyperthyroidism	1	2018-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Hyperkalaemia	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Hyperkalaemia	1	2017-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Hyperkalaemia	2	2017-	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Gamma-glutamyltransferase increased	1	2017	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Eczema	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	2			No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Cough	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Conjunctivitis	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatinine increased	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatine phosphokinase increased	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatine phosphokinase increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Basal cell carcinoma	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Basal cell carcinoma	2		[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Basal cell carcinoma	3		[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Basal cell carcinoma	2		[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Arthritis	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Arthritis	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Arthralgia	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Arthralgia	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm A	[REDACTED]	Female	Amylase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Abdominal pain	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	White blood cell count decreased	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Weight decreased	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Vision blurred	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Skin fissures	1	[REDACTED]	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Pain of skin	1	[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Pain in extremity	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Non-cardiac chest pain	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Mucosal infection	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Localised oedema	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hypoventilation	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hyperuricaemia	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hyperkalaemia	1	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hyperkalaemia	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2017-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Flatulence	1	2017-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Fall	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Faeces discoloured	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Eye pain	1	2017-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Epistaxis	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Dry skin	1	2017-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2017-	2017-	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: None
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	2	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	3	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Dermatitis acneiform	2	2017-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Dermatitis acneiform	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Depression	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Bronchitis	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phosphokinase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Basal cell carcinoma	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Atrial flutter	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Arthralgia	1	[REDACTED]	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Anaemia	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Acute kidney injury	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Acute kidney injury	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Acute kidney injury	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Urinary tract infection	3	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Syncope	3	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Skin erosion	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Skin erosion	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Rash maculo- papular	3	2017	[REDACTED]	No	No	Yes	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	Cobi: Not changed, Vem: Not changed
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Pyrexia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Photosensitivity reaction	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Pain in extremity	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Nausea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Lipase increased	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Lipase increased	3	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Large intestinal haemorrhage	3	2017	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Intertrigo	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Hyponatraemia	4	2017	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted,

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Hyponatraemia	3	2017	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Vem: Temporarily interrupted
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Hypoalbuminaemia	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Hyperuricaemia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Hypernatraemia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Gastritis	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Gamma- glutamyltransferase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Dyspnoea	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Dry skin	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Diverticulum intestinal	3	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Diarrhoea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	[REDACTED]	[REDACTED]	Female	Diarrhoea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Blood creatine phosphokinase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Blood bilirubin increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Aspartate aminotransferase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Anaemia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Alanine aminotransferase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Female	Agitation	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Actinic keratosis	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Upper limb fracture	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Sinus bradycardia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Restless legs syndrome	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Pruritus	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Platelet count decreased	1	2017	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Photosensitivity reaction	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Lymphocyte count decreased	1	2018	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	1	2017	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Intertrigo	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hypothyroidism	1	2018	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hypotension	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hypotension	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	3	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Gastrointestinal pain	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltransferase increased	1	2017	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltransferase increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltransferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Dyspnoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Dysgeusia	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Dry mouth	1	2018		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Constipation	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Cataract	3		2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Blood lactate dehydrogenase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatinine increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phosphokinase increased	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phosphokinase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phosphokinase increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Atrioventricular block first degree	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotransferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Arthritis	2	2018		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitätsklinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Anaphylactic reaction	3	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotransferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Acute kidney injury	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Acute kidney injury	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]	Arm B	[REDACTED]	Male	Anaemia	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Vomiting	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Vision blurred	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Vertigo	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Tremor	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Product administration error	2	2018-	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Overdose	2	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Myalgia	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Lymphocyte count decreased	2	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Lymphadenopathy	1	2018-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Hypotension	2	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Haemoglobin decreased	1	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Flatulence	1	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Dry mouth	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Würzburg	[REDACTED]		[REDACTED]	Male	Diplopia	1	2018-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Male	Conjunctivitis	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Male	Confusional state	2	2018-	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Male	Blood potassium increased	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Male	Blood creatinine increased	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Würzburg	[REDACTED]		[REDACTED]	Male	Blood alkaline phosphatase increased	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Abdominal pain	2	2019-	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Tinea pedis	1	2020-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Solar dermatitis	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Solar dermatitis	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Solar dermatitis	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- sklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Small intestinal obstruction	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo- papular	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Rash	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Rash	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Rash	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Pneumonitis	2	2020	[REDACTED]	Yes	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Photosensitivity reaction	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Oedema peripheral	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	N-terminal prohormone brain natriuretic peptide increased	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Lymphocyte count decreased	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Lymphocyte count decreased	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Localised oedema	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Ketonuria	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Ileus	2	2020	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Hypothyroidism	1	2020		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Hypokalaemia	3	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Hypokalaemia	1	2019	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Hypocalcaemia	3	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Hyperthyroidism	2	2020		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Helicobacter infection	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Helicobacter gastritis	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Haematuria	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Gastroenteritis	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Gastritis	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltransferase increased	2	2020		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Fungal disease carrier	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Ejection fraction decreased	2	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Dysgeusia	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Dysbiosis	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Dry mouth	1	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Dry mouth	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Constipation	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Colitis	2	2020		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Carbohydrate metabolism disorder	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Candida infection	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phosphokinase increased	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phosphokinase increased	2	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phosphokinase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Anaemia	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Anaemia	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Alanine ami-notransferase increased	1	2019	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Male	Abdominal pain upper	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]			Female	Alanine ami-notransferase increased	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]			Female	Stevens-Johnson syndrome	3	2017		No	Yes	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitätsklinikum Essen	[REDACTED]			Female	Rash	3	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]			Female	Pyrexia	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]		[REDACTED]	Female	Lipase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]		[REDACTED]	Female	Haematoma	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]		[REDACTED]	Female	Gastrooesophageal reflux disease	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]		[REDACTED]	Female	Gastritis	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]		[REDACTED]	Female	Gamma-glutamyltransferase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]		[REDACTED]	Female	Blood alkaline phosphatase increased	1		2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]		[REDACTED]	Female	Amylase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotransferase increased	3	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Vision blurred	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Vision blurred	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Scleral disorder	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Sarcoidosis	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Rash	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Rash	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Radiation skin injury	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Proteinuria	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Proteinuria	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Photosensitivity reaction	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Nausea	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	3	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	2	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Localised oedema	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	3	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Hypophosphataemia	3	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Hyperuricaemia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Hyperuricaemia	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Gastroenteritis	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-gluta- myltransferase increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-gluta- myltransferase increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-gluta- myltransferase increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Follicular eczema	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Dysgeusia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Dry eye	2	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis psoriasiform	1	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Conjunctivitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Conjunctivitis	2	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotransferase increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotransferase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Amylase increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotransferase increased	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotransferase increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Aminotransferase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]			Male	Blood bilirubin increased	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]			Male	Urinary tract infection	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]			Male	Stevens-Johnson syndrome	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitätsklinikum Essen	[REDACTED]			Male	Pyrexia	2	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]		[REDACTED]	Male	Hypothyroidism	3	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]		[REDACTED]	Male	Dyspnoea	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]		[REDACTED]	Male	Diarrhoea	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]		[REDACTED]	Male	Conjunctivitis	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]		[REDACTED]	Male	Chronic kidney disease	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Abdominal discomfort	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Visual impairment	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Visual impairment	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Sinusitis	2	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Pruritus	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Pruritus	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Pruritus	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Pharyngitis	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Paraesthesia	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Pain in extremity	1			No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Pain	2	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Nightmare	2	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Nightmare	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Nightmare	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphoedema	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Insomnia	2	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Insomnia	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Insomnia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Infected dermal cyst	1	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Hyperthyroidism	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Glomerular filtration rate decreased	2	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Glomerular filtration rate decreased	2	2021	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Folliculitis	1	2021	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Dry skin	1	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	2	2021	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	2	2020	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2020	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	2	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Chronic kidney disease	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Bronchitis	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2019	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phosphokinase increased	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phosphokinase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Weight increased	3	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Seborrhoeic dermatitis	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Rash	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Rash	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Rash	3	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	2	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Hypothyroidism	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Ejection fraction abnormal	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Ear infection	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Dyspepsia	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Chills	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Chills	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Alanine aminotransferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Urinary tract infection	2	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Upper respiratory tract infection	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Upper respiratory tract infection	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Upper respiratory tract infection	2	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Tinnitus	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Solar dermatitis	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Sciatica	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo-papular	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo-papular	2	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo-papular	2	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Proteinuria	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Gastroesophageal reflux disease	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Gastroesophageal reflux disease	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Erythema	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Eczema	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Diffuse alopecia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Cough	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Colitis	2	2018	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Atezo: None
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	C-reactive protein increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phosphokinase increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Back pain	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Back pain	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Aspartate ami-notransferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Abdominal pain upper	1	2023	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Urinary tract infection	2	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Solar dermatitis	2	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Solar dermatitis	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Nausea	2	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Nasopharyngitis	1	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count increased	2	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Infection	2	2022	2022	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Hyperuricaemia	1	2023		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Hyperthyroidism	1	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Haemorrhoids	1	2020-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Haemolytic anaemia	2	2022-	2022	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Gastritis	2	2021-	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Gastritis	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltransferase increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	3	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Erythema migrans	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Eczema nummular	1	2020-	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis bullous	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Chronic kidney disease	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Chills	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phosphokinase increased	1	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	4	2019	2019	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine increased	1	2023	.	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	1	2021	.	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	1	2019	.	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2023	.	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Arthropod bite	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Arthropod bite	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Ankle fracture	2	2023	2023	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: None
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotrans-ferase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Abdominal pain	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Vasculitis	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Uveitis	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Uveitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Sensory disturbance	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Sensory disturbance	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Sarcoid-like reaction	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Sarcoid-like reaction	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Radiation skin injury	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Proteinuria	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Proteinuria	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Panniculitis	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Panniculitis	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Pain in extremity	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Pain in extremity	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Oral candidiasis	1	2020	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Myoglobin blood increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Myalgia	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	2	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2020	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	1	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Hypothyroidism	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Hypothyroidism	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Gastrointestinal pain	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltransferase increased	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltransferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis bullous	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Conjunctivitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Conjunctivitis	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2020	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phosphokinase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	2	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitätsklinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotrans- ferase increased	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotrans- ferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotrans- ferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Abdominal pain	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Hypothyroidism	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Gamma- glutamyltransferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Chronic kidney disease	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatinine increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Alanine aminotrans- ferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Alanine aminotrans- ferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Vomiting	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Viral infection	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Sunburn	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Sunburn	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Sunburn	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Sunburn	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Rhinitis allergic	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Renal failure	2	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Renal failure	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo- papular	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo- papular	3	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Rash	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Rash	3	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Radiation skin injury	1	2017		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Pruritus	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Pruritus	2	2017-	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Pneumonitis	2	2020-	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Pneumonitis	1	2017-	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Panniculitis	1	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Lymphocyte count decreased	1	2019-	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Lymphocyte count decreased	2	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Lymphocyte count decreased	1	2017-	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Lipase increased	1	2020-		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Lipase increased	1	2018-	2018	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Lipase increased	1	2017-	2018	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Ileus	2	2020-	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Hypothyroidism	1	2020-		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Hypothyroidism	1	2018-	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Hypothyroi-dism	1	2017	2018	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Hypothyroi-dism	2	2017	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Hypothyroi-dism	1	2017	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Hypophosphataemia	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Hyperthyroi-dism	1	2020		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Hyperthyroi-dism	1	2019	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Hyperthyroi-dism	1	2017	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Hyper-natraemia	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Hydro-nephrosis	3	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Herpes virus infection	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Gastroenteritis	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Frostbite	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2018		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Enteritis	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Eczema	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Conjunctivitis	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Chronic kidney disease	2	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Chronic kidney disease	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Chronic kidney disease	2	2017	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Bursitis	1	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatinine increased	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatinine increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatinine increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatinine increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatinine increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatinine increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatinine increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2021		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2020	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2018	2018	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2017	2018	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2017	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2017	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood bilirubin increased	1	2020	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood bilirubin increased	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood bilirubin increased	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood bilirubin increased	1	2017	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Blood alkaline phosphatase increased	1		2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2017	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Arthropod sting	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Anaemia	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Allergy to arthropod sting	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]	Arm B	[REDACTED]	Female	Alanine aminotrans-ferase increased	1	2017	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Essen	[REDACTED]			Male	Acute kidney injury	2	2017		No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]			Male	Radiation skin injury	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]			Male	Proteinuria	2	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]			Male	Pollakiuria	2	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Essen	[REDACTED]		[REDACTED]	Male	Pain	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]		[REDACTED]	Male	Lymphocyte count decreased	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]		[REDACTED]	Male	Intra-abdominal haemorrhage	3	2017	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Essen	[REDACTED]		[REDACTED]	Male	Hyper-uricaemia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]		[REDACTED]	Male	General physical health deterioration	2	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]		[REDACTED]	Male	Dyspnoea	2	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Essen	[REDACTED]		[REDACTED]	Male	Chronic kidney disease	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]		[REDACTED]	Male	Blood creatinine increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]		[REDACTED]	Male	Ascites	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Essen	[REDACTED]		[REDACTED]	Male	Anaemia	3	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Constipation	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Uveitis	3	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Subdural haematoma	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Rash	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Nasopharyn-gitis	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Muscle spasms	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Lymphatic malformation	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-natraemia	1	2020-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Haematoma	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Fracture	2	2019-	2019-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Fall	3	2019-	2019-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Erythema multiforme	1	2020-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Eczema	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Dyskinesia	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Dizziness	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Craniofacial fracture	2	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Back pain	2	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Vomiting	3	2017-	2017-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Vomiting	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Rash maculo-papular	3	2017-	2017-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Rash maculo-papular	3	2017-	2017-	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Nausea	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Diarrhoea	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Acute kidney injury	3	2019-	2019-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Tooth infection	3	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Renal failure	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Pterygium	3	2020	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Pneumocystis jirovecii pneumonia	3	2021	2021	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Pancreatitis	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	Cobi: None, Vem: None
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Pain in extremity	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2021	2021	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued, Atezo: Permanently Discontinued
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Immune-mediated hepatitis	3	2021	2021	Yes	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Hypertension	2	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Hypertension	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Gamma-glutamyltrans-ferase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2021	2021	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Diabetic metabolic decompensation	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Diabetes mellitus	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Diabetes mellitus	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Cystoid macular oedema	1	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Anal candidiasis	2	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Alanine aminotransferase increased	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Adrenal insufficiency	3	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Acute kidney injury	2	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Male	Angina pectoris	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Male	Uveitis	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2017	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Male	Pharyngeal inflammation	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Male	Pain in extremity	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Male	Oedema peripheral	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Male	Malaise	2	2017	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Male	Macular oedema	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Retinopathy	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Renal failure	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Pain in extremity	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Monocytosis	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Insomnia	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Hyper-uricaemia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Dysgeusia	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Dizziness	2	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Dizziness	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Chills	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Angina pectoris	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Abscess	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Weight decreased	1	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Tinea pedis	1	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Tinea pedis	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Splinter	3	2022	2022	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Solar dermatitis	1	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Solar dermatitis	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Solar dermatitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Solar dermatitis	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Restless legs syndrome	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Peripheral swelling	1	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Pain in extremity	1	2021	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Nasopharyn-gitis	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Nasopharyn-gitis	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Musculoskeletal chest pain	2	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	3	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Ligament injury	1	2022	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Ligament injury	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Keratosis pilaris	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Keratosis follicular	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Keratosis follicular	1	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Kerato-acanthoma	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Kerato-acanthoma	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Kerato-acanthoma	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Influenza like illness	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Infection	1	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Granuloma annulare	2	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Granuloma annulare	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Dyspepsia	2	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Chronic actinic dermatitis	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Chills	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	COVID-19	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Back pain	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Arthritis	1	2022	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Adrenal insufficiency	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm A	[REDACTED]	Male	Accident at work	3	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Decubitus ulcer	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Influenza like illness	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Hypo-thyroidism	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]	Arm B	[REDACTED]	Female	Dermatitis acneiform	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Abdominal pain upper	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Vomiting	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Malaise	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Eosinophilia	3	2017	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Diarrhoea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Diarrhoea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Chills	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
HELIOS Klinikum Erfurt	[REDACTED]		[REDACTED]	Female	Abdominal pain upper	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinikum Schleswig-Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Female	Anaemia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinikum Schleswig-Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Female	Sepsis	3	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinikum Schleswig-Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Female	Pyrexia	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Female	Pain in extremity	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Female	Drug reaction with eosinophilia and systemic symptoms	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2019	2019	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	White blood cell count increased	2	2019	.	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Vomiting	1	2019	.	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Red blood cell count decreased	1	2019	.	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Rash maculo- papular	1	2019	.	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Pneumonia	3	2019	.	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Photosensiti-vity reaction	1	2019	.	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Neck pain	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Nausea	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Lymph node palpable	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Lip swelling	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Left ventricular dysfunction	3	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Fatigue	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Epistaxis	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Chills	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Pneumonia	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Naso-pharyngitis	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Lymphoedema	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Fracture	3	2018	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]		[REDACTED]	Male	Dermatitis acneiform	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal pain	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Rash maculo- papular	1	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Night sweats	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Lymphoedema	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Lymph node pain	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Headache	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Hand dermatitis	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Gingival bleeding	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Feeling cold	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	2	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	2	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Erythema multiforme	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Epistaxis	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Dyshidrotic eczema	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Dry mouth	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Cough	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Alopecia	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal pain upper	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal distension	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Solar dermatitis	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Solar dermatitis	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Rash maculo- papular	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Rash maculo- papular	3	2017	2017	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Pruritus	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Pruritus	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Pruritus	1	[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Photosensiti-vity reaction	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Photosensiti-vity reaction	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Oral herpes	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	[REDACTED]	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Naso-pharyngitis	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Lymphoedema	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Keratosis pilaris	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Iris adhesions	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Influenza like illness	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Influenza like illness	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Hypo-thyroidism	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Hypo-thyroidism	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Hyper-thyroidism	1	[REDACTED]	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Hepatic enzyme increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Haematoma	1	[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Gingival bleeding	1	[REDACTED]	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Gamma- glutamyltrans-ferase increased	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Erythema multiforme	1	[REDACTED]	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Dry skin	1	[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Chills	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	COVID-19	1	2020	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Burning sensation	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Blood thyroid stimulating hormone increased	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Blood sodium decreased	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2021	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Blepharochalasis	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2021	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Alanine aminotrans-ferase increased	1	2021	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Female	Actinic keratosis	1	2019	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Male	Actinic keratosis	1		2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Male	Vitiligo	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2018	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Male	Electrocardio-gram QT prolonged	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Male	Decreased appetite	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Male	Conjunctival haemorrhage	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm A	[REDACTED]	Male	Chills	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Asthenia	1	2017	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Photosensiti-vity reaction	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Peripheral swelling	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Musculo-skeletal chest pain	1	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Hyper-thyroidism	1	2017-	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Haematoma	1	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Groin pain	1	2017-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Gamma-glutamyltrans-ferase increased	3	2017-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Fall	1	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Dizziness	2	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	2	2017-	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Alanine aminotrans-ferase increased	1	2017-	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Varicose vein	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Skin hypo- pigmentation	1	[REDACTED]	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Sinus tachycardia	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Sinus tachycardia	2	2017	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo- papular	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Pruritus	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Overdose	1	2017	2017	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Not applicable, Vem: None
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Joint injury	3	2018	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Atezo: None
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Hypertension	3	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Gingivitis	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Fracture	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Fracture	3	2018-	2018-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	2	2017-	2017-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	2	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Fall	3	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Fall	2	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Eye injury	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Eye injury	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Embolism	3	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Cystitis noninfective	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Confusional state	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	3	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Kiel	[REDACTED]	Arm B	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Köln	[REDACTED]			Female	Arrhythmia	1			No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Köln	[REDACTED]			Female	Tumour marker increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Köln	[REDACTED]			Female	Sinus disorder	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Köln	[REDACTED]			Female	Scratch	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Köln	[REDACTED]			Female	Naso-pharyngitis	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Köln	[REDACTED]		[REDACTED]	Female	Myalgia	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Köln	[REDACTED]		[REDACTED]	Female	Lymphocyte count decreased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Köln	[REDACTED]		[REDACTED]	Female	Left ventricular dysfunction	3	2019	2019-	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitäts- klinikum Köln	[REDACTED]		[REDACTED]	Female	Dyspnoea	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Köln	[REDACTED]		[REDACTED]	Female	Blood creatinine increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Köln	[REDACTED]		[REDACTED]	Female	Blood creatine phospho-kinase increased	2	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Köln	[REDACTED]		[REDACTED]	Female	Blood creatine phospho-kinase increased	3	2019	2019-	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: None
Universitäts- klinikum Köln	[REDACTED]		[REDACTED]	Female	Blood creatine phospho-kinase increased	2	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Köln	[REDACTED]		[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Arthralgia	1	2017	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Localised oedema	1	201	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
		Arm B		Male	Joint effusion	1	201		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	4	201	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
		Arm B		Male	Headache	1	201		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	201	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
		Arm B		Male	Headache	1	201		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Erysipelas	3	201	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
		Arm B		Male	Diarrhoea	1	201		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Cough	1	201	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
		Arm B		Male										

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Abdominal pain	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
		Arm A		Male	Weight decreased	1	2017		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Rash	2	2017	2017	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Pruritus	1	2017	2017	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2017		No	No	No		Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	3	2017		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	3	2017	2017	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Hyper-thyroidism	1	2017		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Gamma- glutamyltrans-ferase increased	1	2017		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Gamma- glutamyltrans-ferase increased	1	2017	2017	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Gamma- glutamyltrans-ferase increased	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2016	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Erythema	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Dry skin	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Diverticulitis	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Cataract	1	2016	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotrans-ferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotrans-ferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Autoimmune disorder	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Not applicable, Vem: Not applicable, Atezo: None
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Vision blurred	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Holstein, Campus Lübeck Universitäts-klinikum Schleswig-Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Radiation skin injury	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Holstein, Campus Lübeck Universitäts-klinikum Schleswig-Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Holstein, Campus Lübeck Universitäts-klinikum Schleswig-Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	2	2018	2018	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Holstein, Campus Lübeck Universitäts-klinikum Schleswig-Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Holstein, Campus Lübeck Universitäts-klinikum Schleswig-Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Pain	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Holstein, Campus Lübeck Universitäts-klinikum Schleswig-Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Holstein, Campus Lübeck Universitäts-klinikum Schleswig-Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-thyroidism	2	2018	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Holstein, Campus Lübeck Universitäts-klinikum Schleswig-Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Flatulence	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Holstein, Campus Lübeck Universitäts-klinikum Schleswig-Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Decreased appetite	1	2018-01-01	2019-01-01	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal pain	2	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	2	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Vision blurred	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Vertigo	2	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Urticaria	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Sunburn	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Oesophagitis	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Muscular weakness	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Mobility decreased	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Lipase increased	4	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Hypertension	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Gastro-intestinal pain	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Gallbladder polyp	1	2017- [REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2017- [REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Fall	1	2017- [REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Erysipelas	2	2017- [REDACTED]	2017- [REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Dyskinesia	1	2017- [REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2017- [REDACTED]	2017- [REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	2	2017- [REDACTED]	2017- [REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	2	2017- [REDACTED]	2017- [REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Dehydration	3	2017- [REDACTED]	2017- [REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Candida infection	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	C-reactive protein increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	C-reactive protein increased	3	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatinine increased	1	2017	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatine phospho-kinase increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatine phosphor-kinase increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatine phosphor-kinase increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Amylase increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm A	[REDACTED]	Female	Acoustic neuroma	2	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Female	Diarrhoea	2	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Female	Tumour thrombosis	2	2016-	2016-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Female	Renal failure	1	2016-	2016-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Female	Pulmonary embolism	2	2016-	2016-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Female	Pneumonia	3	2017-	2017-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Female	Pleural effusion	1	2016-	2016-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Female	Nausea	2	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Female	Insomnia	1	2016-	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Female	Hypo-thyroidism	2	2017-	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Female	Hypokalaemia	2	2017-	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Female	Diarrhoea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Acute kidney injury	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Urinary retention	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Spinal fracture	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo- papular	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo- papular	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo- papular	3	2018	2018	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Pelvic pain	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Osteoporosis	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Osteoporosis	2	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Lipase increased	3	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Hypertension	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Headache	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	General physical health deterioration	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Fall	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Dermatitis exfoliative generalised	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Contusion	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Autoimmune disorder	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Arthralgia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Vomiting	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Vomiting	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Skin papilloma	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Restless legs syndrome	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Kerato-acanthoma	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Hypo-thyroidism	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Chills	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	C-reactive protein increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]	Arm B	[REDACTED]	Male	Troponin T increased	3	2018	2018	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem:

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Blood creatine phosphor-kinase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Permanently Discontinued
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Blood creatine phosphor-kinase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Blood creatine phosphor-kinase increased	3	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Blood creatine phosphor-kinase increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Blood creatine phosphor-kinase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Blood creatine phosphor-kinase increased	3	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Solar dermatitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Solar dermatitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Solar dermatitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Arthralgia	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Rash maculo- papular	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Rash maculo- papular	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Schleswig- Holstein, Campus Lübeck	[REDACTED]		[REDACTED]	Male	Lymphocyte count decreased	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Lymphocyte count decreased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Liver injury	4	2019-	2019-	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Lipase increased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Lipase increased	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Lipase increased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Hyperthyroidism	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Gamma- glutamyltrans-ferase increased	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Gamma- glutamyltrans-ferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Encephalopathy	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Dental caries	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Constipation	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Blood thyroid stimulating hormone decreased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Blood thyroid stimulating hormone decreased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Male	Blood alkaline phosphatase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Abscess of external ear	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Vertigo	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Vertigo	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Proteinuria	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Polychondritis	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Perichondritis	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Perichondritis	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Microangiopathy	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Influenza like illness	2	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Hypothyroidism	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Hyperthyroidism	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-thyroidism	2	2019	2019	Yes	No	Yes	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	Cobi: None, Vem: None
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Gastro-oesophageal reflux disease	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Gastro-oesophageal reflux disease	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Gastro-oesophageal reflux disease	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Furuncle	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Dysaesthesia	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Dysaesthesia	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Dysaesthesia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Dysaesthesia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Cerebral atrophy	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Blood thyroid stimulating hormone increased	1	2019	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phosphor-kinase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Blood bilirubin increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Abscess of external ear	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Acute febrile neutrophilic dermatosis	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Urticaria	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Skin plaque	1	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Rash	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Proteinuria	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Pneumonitis	1	2018	[REDACTED]	Yes	No	Yes	[REDACTED]	Cobi: Yes, Vem: No, Atezo: Yes	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Nephritis	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Nasopharyngitis	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Myoglobinuria	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Myoglobin blood increased	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Myalgia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Metastases to central nervous system	4	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	2	2018		Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	1	2017	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	4	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-glycaemia	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-bilirubinaemia	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Herpes zoster	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Haematuria	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Face oedema	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Erythrasma	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Dyspnoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Drug eruption	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Dermatitis acneiform	1	2017	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Chronic kidney disease	2	2018		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Blood bilirubin increased	1	2018	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Atrioventri- cular block first degree	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Anaemia	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Anaemia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Amylase increased	1	2018	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Male	Acute febrile neutrophilic dermatosis	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]			Female	Acute kidney injury	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]			Female	Tricuspid valve disease	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]			Female	Rash maculo- papular	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitäts- klinikum Leipzig	[REDACTED]			Female	Rash maculo- papular	3	2017	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]			Female	Pulmonary hypertension	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Mitral valve disease	1	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Left ventricular hypertrophy	2	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Fatigue	1	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Exfoliation syndrome	2	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Exfoliation syndrome	2	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Diarrhoea	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Conjunctival granuloma	2	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Conjunctival granuloma	2	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Conjunctival granuloma	2	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Conjunctival granuloma	2	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Cataract	2	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Blood creatinine increased	1	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	[REDACTED]	[REDACTED]	Female	Age-related macular degeneration	2	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]		[REDACTED]	Female	Age-related macular degeneration	2	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig				Female	Acute kidney injury	1	2017-	2017	No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig		Arm B		Male	Amblyopia	1	2019-		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig		Arm B		Male	Myalgia	1	2019-	2019	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig		Arm B		Male	Macular detachment	1	2020-		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig		Arm B		Male	Lipase increased	1	2019-	2019	No	No	No		Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig		Arm B		Male	Lipase increased	3	2019-	2019	No	No	No		Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig		Arm B		Male	Lipase increased	2	2019-	2019	No	No	No		Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig		Arm B		Male	Lipase increased	1	2019-	2019	No	No	No		Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig		Arm B		Male	Lipase increased	3	2019-	2019	No	No	No		Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig		Arm B		Male	Fatigue	1	2019-	2019	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig		Arm B		Male	Dermatitis acneiform	1	2019-	2019	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig		Arm B		Male	Chronic kidney disease	1	2019-		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Amylase increased	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Urinary tract infection	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Tooth abscess	3	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Spondylo-olisthesis	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Pharyngeal swelling	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Osteoma	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Osteoma	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Nephrolithiasis	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lumbar spinal stenosis	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	2	2020	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	1	2020	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lenticular opacities	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Inguinal hernia	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Hyperthyroidism	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Haematuria	1	2019	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Haematuria	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis psoriasiform	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Dermal cyst	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Cellulitis	3	2021	2021	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Arthritis	1	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Aortic valve disease	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Animal bite	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Acute kidney injury	3	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Tumour pain	2	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Rib fracture	2	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Retinopathy	2	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Restlessness	2	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Renal cyst	1	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo- papular	1	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Platelet count decreased	2	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Osteosclerosis	1	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Nausea	2	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Monoparesis	3	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Monoparesis	3	2018-	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Atezo: None
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	2	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	1	2018		No	No	No		Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	3	2018	2018	No	No	No		Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Infection	3	2018		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Gastroenteritis	1	2017	2017	No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	2	2018		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2018	2018	No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Diverticulum intestinal	1	2017		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2018	2018	No	No	No		Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Constipation	1	2018		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Conjunctivitis	2	2018		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	1	2018		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2018		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Amylase increased	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Acute kidney injury	2	2018-	-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Acute kidney injury	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Vertigo	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Vertigo	2	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Tremor	2	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Supraventri- cular extrasystoles	1	2018-	-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Squamous cell carcinoma	2	2018-	2018-	No	No	Yes	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Skin papilloma	2	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Skin papilloma	2	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Skin papilloma	2	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Retinopathy	2	2018-	-	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Platelet count decreased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	3	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Keratosis pilaris	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Bundle branch block right	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Atrioventri-cular block first degree	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Alopecia	1	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Acute kidney injury	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Alopecia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Vomiting	2	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Vomiting	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Upper respiratory tract infection	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Thrombo-cytopenia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Skin papilloma	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Skin papilloma	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted, Atezo: None
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Rhabdo-myolysis	1	2021	2021	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted, Atezo: None
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Rhabdo-myolysis	1	2019	2019	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo- papular	2	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Yes, Vem: Temporarily interrupted
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Radiation skin injury	1	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Proteinuria	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	3	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	2	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Lymphopenia	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Lymphocyte count decreased	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Lipase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Lipase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Immune-mediated hepatitis	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Immune-mediated hepatitis	3	2019	2019	Yes	No	Yes	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Hypo-natraemia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Hypokalaemia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Hypertrichosis	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Hepatitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Gamma-glutamyltrans-ferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	2	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Eyelid function disorder	2	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Drug-induced liver injury	3	2021	2021	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem:

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2021-	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Permanently Discontinued, Atezo: None
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	2	2018-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Dermatitis psoriasiform	2	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Dermatitis	2	2021-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Dermal cyst	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Constipation	1	2021-	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Chromaturia	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Bronchitis	2	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatinine increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Blood bilirubin increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Blood bilirubin increased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm B	[REDACTED]	Female	Atrial fibrillation	2	2021-	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Acute kidney injury	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Retinopathy	2	2018-	2018-	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: None
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Retinopathy	1	2018-	2018-	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	2	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	2	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Pain in extremity	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Oropharyngeal pain	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Oropharyngeal pain	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Oral mucosa erosion	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	4	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Hypertension	3	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Hypertension	3	2018	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Hepatitis	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Hepatitis	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Hepatitis	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Hepatitis	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Hepatitis	3	2018	2018	No	No	Yes	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	Cobi: None

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	3	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Dysaesthesia	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Cough	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Chills	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Chills	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	3	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Leipzig	[REDACTED]	Arm A	[REDACTED]	Male	Amylase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Aphthous ulcer	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Plantar fasciitis	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Pain in extremity	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Lymphoedema	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Lymphocyte count decreased	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Influenza like illness	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Hyperthyroidism	1	2019		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Confusional state	2	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Male	Blood triglycerides increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	White blood cell count decreased	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	Tracheitis	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	Pruritus	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	Iron deficiency anaemia	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	Gastro-intestinal pain	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	Arthritis	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitäts- klinikum Mannheim	[REDACTED]			Male	Anaemia	1	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]			Male	Visual impairment	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]			Male	Vision blurred	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]			Male	Rash pustular	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]			Male	Lymphocyte count decreased	3	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Mannheim	[REDACTED]		[REDACTED]	Male	Hypo-albuminaemia	2	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]		[REDACTED]	Male	Fatigue	1			No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]		[REDACTED]	Male	Cataract	1	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]		[REDACTED]	Male	Blood creatinine increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]		[REDACTED]	Male	Atrophy	1	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitäts- klinikum Mannheim	[REDACTED]		[REDACTED]	Male	Anaemia	3	2019-		No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Arthralgia	2	2016-	2016	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Skin mass	1	2017-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Skin infection	2	2016-	2016	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Skin induration	1	2016-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Lip infection	2	2016-	2016	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Hypothyroidism	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Haemorrhage intracranial	5	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Fibrin D dimer increased	1	2016	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2016	2016	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	2	2016	2016	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Dermatitis acneiform	1	2016	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Chills	1	2016	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Mannheim	[REDACTED]	Arm B	[REDACTED]	Female	Arthralgia	1	2016	2016	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Abdominal pain	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Vomiting	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Vomiting	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Vitreous floaters	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Visual impairment	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Urinary tract pain	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Parosmia	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Neutrophilia	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Neutrophil count increased	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Muscle spasms	1		2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Leukocytosis	3	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Influenza like illness	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Influenza like illness	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Hypothyroidism	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Hyper-uricaemia	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Hand dermatitis	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Haematuria	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Haematuria	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Haematuria	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Gastro-intestinal tract irritation	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	3	2019	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Erythema	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Erythema	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Dyspnoea	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Dry mouth	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Chills	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Chills	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Blepharitis	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	2	2019	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Amylase increased	1	2021	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Amylase increased	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Amylase increased	1	2019	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotransferase increased	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotransferase increased	2	2019	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Acute kidney injury	3	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	Cobi: None, Vem: None
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Vomiting	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Rash	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Photosensitivity reaction	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Oedema peripheral	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Klinikum Ludwigshafen gGmbH	[REDACTED]		[REDACTED]	Male	Nausea	1	2017	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]		[REDACTED]	Male	Nausea	1	2017	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]		[REDACTED]	Male	Hypotension	1	2017	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]		[REDACTED]	Male	Haematuria	1	2017	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]		[REDACTED]	Male	Diarrhoea	2	2017	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]		[REDACTED]	Male	Anaemia	1	2017	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]		[REDACTED]	Male	Acute kidney injury	1	2017	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Klinikum Ludwigshafen gGmbH	[REDACTED]		[REDACTED]	Male	Acute kidney injury	2	2017	2017-	No	Yes	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2018	-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Vision blurred	1	2018	-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Thrombo-phlebitis	1	2019	-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Taste disorder	1	2018	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Sjogren's syndrome	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	1	2018	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Rash	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Rash	1	2018	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Pulmonary embolism	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2018	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Joint effusion	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	2	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Folliculitis	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Dysgeusia	1	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Dry eye	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Cheilitis	1	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Cheilitis	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Back pain	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum Ludwigshafen gGmbH	[REDACTED]	Arm A	[REDACTED]	Male	Autoimmune hepatitis	3	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]			Female	Diarrhoea	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]			Female	Urinary tract infection	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]			Female	Sleep disorder	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]			Female	Skin fissures	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]			Female	Skin exfoliation	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]			Female	Retinal detachment	2	2017	2017	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: None
Johannes Wesling Klinikum Minden	[REDACTED]			Female	Pruritus	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]			Female	Photosensiti-vity reaction	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]			Female	Photosensiti-vity reaction	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Johannes Wesling Klinikum Minden	[REDACTED]		[REDACTED]	Female	Peripheral swelling	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]		[REDACTED]	Female	Papule	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]		[REDACTED]	Female	Papule	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]		[REDACTED]	Female	Pain in extremity	1	2017	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	Cobi: None
Johannes Wesling Klinikum Minden	[REDACTED]		[REDACTED]	Female	Nausea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]		[REDACTED]	Female	Lipase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]		[REDACTED]	Female	Erythema multiforme	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]		[REDACTED]	Female	Dry skin	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm A	[REDACTED]	Male	Tinea pedis	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm A	[REDACTED]	Male	Skin infection	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm A	[REDACTED]	Male	Lip infection	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Johannes Wesling Klinikum Minden	[REDACTED]	Arm A	[REDACTED]	Male	Kerato-acanthoma	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm A	[REDACTED]	Male	Hyper-glycaemia	3	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm A	[REDACTED]	Male	Electrocardio-gram QT prolonged	4	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm A	[REDACTED]	Male	C-reactive protein increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Abdominal pain	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Wound infection	3	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Weight decreased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Weight decreased	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Tonsillitis	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Skin discolouration	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Sinus tachycardia	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Pruritus	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Pruritus	1	2017-	201	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Peripheral swelling	1	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Pain in extremity	1	2017-	201	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Pain in extremity	1	2017-	201	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Pain in extremity	1	2017-	201	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Myalgia	1	2017-	201	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Mucosal infection	2	2017-	201	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Melanocytic naevus	1	2017-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Melanocytic naevus	1	2017-	201	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Hyperhidrosis	1	2017-	201	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Herpes zoster	3	2018-		No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Fall	1	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Dry skin	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Dry skin	2	2017	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Dry skin	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Dry mouth	2	2017	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2017	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Dermatitis acneiform	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Chest pain	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Cardio-vascular disorder	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Bone pain	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Bone pain	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Back pain	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Back pain	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Johannes Wesling Klinikum Minden	[REDACTED]	Arm B	[REDACTED]	Female	Abscess limb	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitäts-medizin Mainz	[REDACTED]			Male	Acute kidney injury	3	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]			Male	Oedema peripheral	2	2017		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]			Male	Oedema peripheral	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]			Male	Oedema peripheral	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]			Male	Hypo-albuminaemia	3	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]			Male	Gamma-glutamyltrans-ferase increased	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]			Male	Face oedema	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]			Male	Blood urea increased	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]			Male	Blood creatinine increased	2	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Alanine aminotrans-ferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Photosensiti-vity reaction	2	2017		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Pain in extremity	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Pain	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Nausea	2	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Nausea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Nail dystrophy	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Multiple organ dysfunction syndrome	5		2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Headache	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Fatigue	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Eye pain	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-medizin Mainz	[REDACTED]		[REDACTED]	Male	Dyspnoea	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- medizin Mainz	[REDACTED]		[REDACTED]	Male	Dry mouth	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]		[REDACTED]	Male	Dizziness	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]		[REDACTED]	Male	Blood urea increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]		[REDACTED]	Male	Blood lactate dehydro-genase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]		[REDACTED]	Male	Balanoposthitis	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]		[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Acute kidney injury	2	2017	2017	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Visual impairment	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Skin infection	3	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Sinus bradycardia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Rash maculo- papular	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Pruritus	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Obstruction gastric	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Medication error	1	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Lymphocyte count decreased	3	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Intertrigo	3	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Intertrigo	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Hypo-natraemia	3	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Hypo-kalaemia	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Gamma-glutamyltrans-ferase increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Eczema	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	3	2017	2017	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Decreased appetite	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Decreased appetite	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatinine increased	3	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- medizin Mainz	[REDACTED]	Arm A	[REDACTED]	Female	Adverse event	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm A	[REDACTED]	Male	Blood thyroid stimulating hormone decreased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm A	[REDACTED]	Male	Thyroxine free increased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Klinikum der Universität München	[REDACTED]	Arm A	[REDACTED]	Male	Sepsis	4	2018	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo- papular	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo- papular	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm A	[REDACTED]	Male	Gallbladder obstruction	3	2018	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Klinikum der Universität München	[REDACTED]	Arm A	[REDACTED]	Male	Furuncle	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm A	[REDACTED]	Male	Erythema	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans- ferase increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Sepsis	4	2018	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Not changed, Vem: None
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculopapular	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Lymphocyte count decreased	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Hypophysitis	3	2018		Yes	No	Yes	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	Cobi: None, Vem: None, Atezo: None
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	3	2017	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Dyspnoea	1	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2018-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	2	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2017-	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Cataract	1	2017-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2017-	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Arthralgia	1	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Angina pectoris	1	2017-	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Anaemia	1	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Anaemia	1	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Klinikum der Universität München	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	1	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatinine increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Vomiting	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Visual impairment	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Seizure	3	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Seizure	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Rosacea	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo- papular	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo- papular	3	2017	2017	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Photophobia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Paraesthesia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Oral pustule	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Nodule	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	2	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2017-	2017	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Lentigo	2	2017-	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Joint effusion	1	2017-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Hypertension	2	2017-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Headache	1	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Headache	1	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Haemangioma	1	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued, Atezo: None
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	General physical health deterioration	3	2017-	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Erythema	1	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Female	Erythema	1	2017-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans- ferase increased	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Vitreous detachment	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Vertigo	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Uveitis	3	2020-	2020-	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Tinnitus	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Solar dermatitis	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Pollakiuria	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Orthostatic intolerance	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Night sweats	1	2019-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	2	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Naso-pharyngitis	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Muscle spasms	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Insomnia	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-thyroidism	2	2019-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	3	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-sensitivity	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	3	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Encephalitis	3	2020-	2020	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued, Atezo: None

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Dyspnoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Dysphonia	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Dermatitis acneiform	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Dermatitis acneiform	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted, Atezo: Temporarily interrupted
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Cholestasis	3	2020	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phosphor-kinase increased	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Blood bilirubin increased	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Blood bilirubin increased	2	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Blood bilirubin increased	3	2020	[REDACTED]	No	No	Yes	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Blood alkaline phosphatase increased	3	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Back pain	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Atrial fibrillation	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Tinnitus	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Skin papilloma	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Skin papilloma	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Seborrhoeic keratosis	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Renal cyst	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Renal cell carcinoma	2	2020	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Pruritus	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Nocturia	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Nasopharyngitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Melanoma recurrent	2	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Keratoacanthoma	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Joint swelling	1	2020	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Hypokalaemia	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Glomerular filtration rate decreased	2	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Electrocardio-gram QT prolonged	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Dry skin	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Decreased appetite	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Male	Arthritis	2	2021-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal pain upper	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Sunburn	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Skin infection	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Pruritus	1	2020-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Paraesthesia	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Nasopharyngitis	1	2019-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Mucosal infection	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Menstruation irregular	1	2019	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Lymph-adenopathy	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Iron deficiency	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Headache	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Headache	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Goitre	2	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Feeling cold	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Dyshidrotic eczema	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Dry skin	1	2019	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Aphthous ulcer	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Heidelberg	[REDACTED]	Arm A	[REDACTED]	Female	Alopecia	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Vision blurred	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Renal colic	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Pruritus	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hyper-keratosis	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Back pain	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Pain	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Influenza like illness	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Influenza like illness	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hypo-thyroidism	1	2017	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-thyroidism	2	2017	2017	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Eczema	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Dizziness	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Dermatitis exfoliative generalised	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Chills	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2021-	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	3	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Abdominal pain upper	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Solar dermatitis	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Retinal detachment	3	2018-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Rash pustular	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	1	2018-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Pruritus	1	2018-	2019-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Papilloma	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Pain in extremity	2	2018		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Localised oedema	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Keratosis pilaris	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Kerato-acanthoma	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hypo-thyroidism	1	2018	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-thyroidism	2	2018	2018	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hiccups	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Herpes zoster	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Flatulence	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2018		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Epistaxis	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Dysgeusia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatinine increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatinine increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatinine increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Constipation	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Abdominal pain upper	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Tinea pedis	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Stasis dermatitis	2	2023	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Skin infection	2	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Sinus tachycardia	2	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Retinal detachment	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Pulmonary hypertension	2	2024	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Pelvic pain	1	2019	2023-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Papilloma	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Pancreatitis	2	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Pain in extremity	2	2019	2023-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Osteoarthritis	3	2023	2023-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Nausea	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Myalgia	1	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Mitral valve disease	3	2023	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	4	2019	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Left ventricular dysfunction	3	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Kerato-acanthoma	1	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Influenza like illness	1	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-phosphataemia	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Epistaxis	2	2024	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Epistaxis	2	2023	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Dyspnoea	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Constipation	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2023	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	2	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	3	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2021	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	2	2020	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	3	2020	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Amylase increased	3	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Alopecia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Actinic keratosis	2	2023		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Actinic keratosis	2	2021	2022	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Actinic keratosis	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Actinic keratosis	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]			Male	Decreased appetite	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]			Male	Sunburn	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Pruritus	1	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Fatigue	1	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Dyspepsia	1	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Dry eye	1	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2017-	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Female	Anaemia	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Female	Vomiting	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Female	Solar dermatitis	3	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Female	Platelet count decreased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Female	Photosensiti-vity reaction	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Female	Infusion related reaction	2	2019	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Female	Dermatitis exfoliative generalised	2	2019	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatinine increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Female	Arthralgia	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Alanine aminotransferase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Rash maculopapular	2	2017	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Pancreatitis	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Maculopathy	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Lipase increased	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Influenza like illness	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Hyposmia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Gamma-glutamyltrans-ferase increased	1	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Erythema multiforme	1	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	2	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	2	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Conjunctivitis	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatinine decreased	1	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatine phospho-kinase increased	2	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatine phospho-kinase increased	2	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2017-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotrans-ferase increased	1	2017-01-01	2017-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Trans-aminases increased	3	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Photosensiti-vity reaction	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Insomnia	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Influenza like illness	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Hyper-thyroidism	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Fatigue	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Vomiting	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Rash pustular	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Pneumonia	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Pain in extremity	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Muscular weakness	2	2018-	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Influenza like illness	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypovolaemia	3	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypotension	3	2018-	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypotension	3	2018-	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypotension	2	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-phosphataemia	2	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-natraemia	3	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypokalaemia	2	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypertension	3	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Headache	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Cough	2	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Chills	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Abdominal pain	1	2017-	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Urinary tract infection	2	2022-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Urinary tract infection	3	2022-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Skin infection	2	2021-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Sepsis	4	2022-	2022	No	Yes	No	[REDACTED]	Cobi: None, Vem: None	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Seizure	2	2021-	2021	No	Yes	No	[REDACTED]	Cobi: None, Vem: None	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Seizure	3	2020-	2020	No	Yes	No	[REDACTED]	Cobi: None, Vem: None	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	1	2017-	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	1	2017-	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2022-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2017-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Pain in extremity	3	2020-	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Lymphoedema	1	2017-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	3	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Left ventricular dysfunction	3	2022-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Influenza like illness	1	2021-	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-thyroidism	1	2020-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypophosphataemia	3	2017-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-naatraemia	1	2022-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Goitre	2	2019-	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2017	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Erythema multiforme	1	2017	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2017	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Chills	1	2021	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	COVID-19	1	2021	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2022		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2021	2022-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	4	2021	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	2	2022	2022-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Acute kidney injury	3	2022	2022-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Acute kidney injury	3	2019	2019-	No	Yes	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	Cobi: None
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Vomiting	1	2018	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Vasculitis	1	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Sciatica	1	2020-	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Pain	1	2021-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Oesophagitis	2	2022-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Oesophageal infection	2	2021-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Nausea	1	2018-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Middle ear inflammation	2	2023-	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Localised oedema	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Left ventricular dysfunction	3	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Keratosis pilaris	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Kerato-acanthoma	1	2019-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Kerato-acanthoma	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Influenza like illness	2	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-phosphataemia	1	2021-	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-phosphataemia	2	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-natraemia	1	2021-	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-calcaemia	2	2021-	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hyper-lipidaemia	2	2023-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Headache	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Gastritis	2	2022-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Gastritis	2	2021-	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	2	2018-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Extra-pyramidal disorder	1	2021-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Erythema migrans	2	2022-	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Electrocardio-gram QT prolonged	1	2020-	2021	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Dysphagia	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Dyspepsia	2	2022	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Dysgeusia	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Duodenitis	2	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Conduction disorder	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	COVID-19	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Borrelia test positive	2	2023		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2018	2021	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Anaphylactic reaction	2	2022-	2022-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
		Arm A		Male	Anaemia	1	2021-	2022-	No	No	No		Cobi: No, Vem: No, Atezo: No	
		Arm A		Male	Amylase increased	1	2019-	2020-	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
		Arm A		Male	Vomiting	1	2019-	2019-	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
		Arm A		Male	Rash maculo-papular	3	2019-	2019-	No	No	No		Cobi: No, Vem: Yes, Atezo: No	
		Arm A		Male	Pneumonitis	2	2019-	2020-	No	Yes	No		Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A		Male	Photosensiti-vity reaction	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
		Arm A		Male	Lymph-adenopathy	1	2019-	2019-	No	No	No		Cobi: No, Vem: No, Atezo: No	
		Arm A		Male	Lipase increased	1	2019-		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
		Arm A		Male	Lipase increased	3	2019-	2019-	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
		Arm A		Male	Laryngitis	2	2019-	2019-	No	No	No		Cobi: No, Vem: No, Atezo: No	
		Arm A		Male	Hypo-phosphataemia	2	2019-	2019-	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypokalaemia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-calcemia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Headache	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Gingival bleeding	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Dyspnoea	2	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Dyspepsia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Chills	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatinine increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Back pain	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Male	Back pain	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Abdominal pain	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Tinea versicolour	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Rhinitis	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Rash pustular	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Pleural effusion	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Pancreatitis	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Influenza like illness	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Influenza like illness	1	2019-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hyperthyroidism	2	2020-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	2	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	3	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Cholelithiasis	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Cholecystitis infective	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Cholecystitis	2	2020	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	COVID-19	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatinine increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Blood bilirubin increased	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Blood alkaline phosphatase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Bile duct stenosis	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Anxiety	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	2	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	3	2019-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	3	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Abdominal pain upper	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Abdominal pain	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Alopecia	1	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Weight decreased	1	2019-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	1	2021-	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	1	2019-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Vitamin B12 deficiency	2	2021-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Vision blurred	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Urinary tract infection	2	2022-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Skin erosion	1	2019-[REDACTED]	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Retinal detachment	2	2019-[REDACTED]		No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Pruritus	1	2019-[REDACTED]		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Papilloma	1	2019-[REDACTED]	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2021-[REDACTED]	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2019-[REDACTED]	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2019-[REDACTED]	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Lipase increased	4	2019-[REDACTED]	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Iron deficiency	2	2021-[REDACTED]		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Intertrigo	1	2019-[REDACTED]	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Ileal ulcer	1	2021-[REDACTED]		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Hypo-natraemia	1	2021-[REDACTED]	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Hypo-natraemia	1	2020-[REDACTED]	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Hypo-natraemia	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Hyper-thyroidism	1	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Hyper-kalaemia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Gastritis	2	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Fall	3	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Decreased appetite	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Decreased appetite	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Craniocerebral injury	3	2022	2022	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Constipation	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Blood urea increased	1	2019-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatinine increased	1	2019-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Anaemia	1	2021-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Anaemia	1	2019-	2021-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm A	[REDACTED]	Female	Amylase increased	3	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Abscess jaw	2	2021-	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Vertigo	1	2018-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Tinea versicolour	1	2019-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Skin infection	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Skin infection	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Skin infection	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Skin hypopigmentation	1	2020-		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Pityriasis rosea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Pain in extremity	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Nail dystrophy	2	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	3	2020	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Influenza like illness	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Influenza like illness	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Influenza like illness	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hypothyroidism	1	2020	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hypo-natraemia	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	2	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Gastrointestinal pain	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2018	2023	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Eczema	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatinine increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Back pain	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Arthralgia	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Arthralgia	1	2018	2022	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Amaurosis fugax	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Amylase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Solar dermatitis	2	2019	2021	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Soft tissue infection	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Skin infection	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Sciatica	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Prurigo	2	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Pleuritic pain	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Palmar-plantar erythro-dysaesthesia syndrome	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Pain in extremity	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Neuralgia	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Myalgia	2	2019	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Localised oedema	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Keratosis pilaris	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Insomnia	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Influenza like illness	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hypo-phosphataemia	1	2020	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hypo-phosphataemia	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hypo-phosphataemia	3	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hypo-phosphataemia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hypo-kalaemia	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-thyroidism	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Headache	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Fibroma	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Erectile dysfunction	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Electrocardio-gram QT prolonged	1	2020	2021	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Dyspnoea	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Colitis	2	2020-	2020-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Atrioventri-clar block first degree	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Arthralgia	2	2020-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts-klinik Carl Gustav Carus der TU Dresden	[REDACTED]	Arm B	[REDACTED]	Male	Arthralgia	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinikum Tübingen	[REDACTED]			Female	Alanine aminotrans-ferase increased	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinikum Tübingen	[REDACTED]			Female	Syncope	3	2018-	2018-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts-klinikum Tübingen	[REDACTED]			Female	Palpitations	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinikum Tübingen	[REDACTED]			Female	Muscular weakness	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinikum Tübingen	[REDACTED]			Female	Malaise	2	2018-	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts-klinikum Tübingen	[REDACTED]			Female	Hypokalaemia	3	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts-klinikum Tübingen	[REDACTED]			Female	Gamma-glutamyltrans-ferase increased	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts-klinikum Tübingen	[REDACTED]			Female	Fatigue	2	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Fatigue	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Ejection fraction decreased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Dyspnoea	3	2018	2018	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Dyspnoea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Diarrhoea	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Diarrhoea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Dermatitis acneiform	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Cough	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Coronary artery disease	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Blood creatinine increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Female	Activated partial thromboplastin time prolonged	3	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Arm  
A

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Urinary tract infection	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Thrombosis in device	2	2020	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Sunburn	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Sunburn	1	2022	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Restlessness	1	2020	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Raynaud's phenomenon	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Plague	1	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Phlebitis	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Myalgia	1	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Muscular weakness	1	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Menopausal symptoms	1	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Menopausal symptoms	1	2021-	2022-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Melanocytic naevus	1	2021-		No	No	No		Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Malaise	1	2023-		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Insomnia	1	2020-	2020-	No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Influenza like illness	1	2020-	2020-	No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Influenza	1	2024-	2024-	No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Hypokalaemia	1	2021-	2021-	No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Hypertension	1	2019-		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Hypersensi-tivity	1	2022-	2022-	No	No	No		Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Hair texture abnormal	1	2019-		No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Fall	2	2020-	2020-	No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Erysipelas	2	2019-	2019-	No	No	No		Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Dyspnoea	1	2020-	2020-	Yes	No	No		Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021-	2023	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021-	2021	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020-	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Cough	1	2020-	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Cheilitis	2	2022-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	COVID-19	2	2023-	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatine phospho-kinase increased	2	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Basal cell carcinoma	1	2023-	2023	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Arthralgia	2	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Ankle fracture	2	2020-	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Angular cheilitis	1	2021-	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Alanine aminotrans- ferase increased	2	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Abdominal pain	2	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Upper respiratory tract infection	2	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Sunburn	1	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo- papular	1	2018-		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Palpitations	1	2018-		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2018-	2018	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	2	2018-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Hypophysitis	2	2018-		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Haemorrhage	2	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Gait disturbance	1	2018-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Flatulence	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Dyspnoea	2	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Dyspnoea	2	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Blastocystis infection	2	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Arthralgia	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Dermatitis acneiform	1	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Vertigo	1	2017-	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo-papular	2	2017-	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Alopecia	1	2019-	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Superficial vein thrombosis	2	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Sunburn	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Sunburn	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Sunburn	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Subcutaneous abscess	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Proteinuria	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Photosensiti-vity reaction	1	2020-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Peripheral swelling	1	2021-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Panniculitis	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Pain in extremity	1	2021-		Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Lymphocyte count decreased	2	2022-		Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Lymphocyte count decreased	2	2021-	2021	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Lipoma	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Influenza like illness	1	2021	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Influenza like illness	1	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Influenza like illness	1	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Hyper-thyroidism	1	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Hordeolum	1	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Headache	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Folliculitis	1	2020	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Dysphagia	1	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2020	2020-	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Dermal cyst	1	2020	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Dermal cyst	1	2020	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Demyelination	1	2020-	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Cough	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	COVID-19	1	2022-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted, Atezo: None
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Brain radiation necrosis	3	2022-	2022	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	2	2020-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Arthralgia	1	2019-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Arthralgia	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Female	Arthralgia	2	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Amylase increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Sunburn	1	2020-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Lymphoedema	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Lipase increased	3	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	1968	Female	Lipase increased	3	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	1968	Female	Influenza like illness	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	1968	Female	Hypoaesthesia	1	2020-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	1968	Female	Cauda equina syndrome	3	2020-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	1968	Female	Bronchial obstruction	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	1968	Female	Blood alkaline phosphatase increased	3	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	1964	Male	Abdominal distension	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	1964	Male	Sunburn	2	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	1964	Male	Seasonal allergy	1	2020-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued, Atezo: None
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	1964	Male	Rash maculo- papular	3	2020-	[REDACTED]	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	1964	Male	Rash maculo- papular	3	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	1964	Male	Psoriasis	1	2019-	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Oropharyngeal pain	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Oral mucosa erosion	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Middle ear inflammation	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	2	2020	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Influenza like illness	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2020		Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2020	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Flatulence	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Ear pain	1	2020-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Ear pain	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	3	2020-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	3	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Balano-posthitis	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Arthralgia	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Amylase increased	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Amylase increased	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans- ferase increased	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Abdominal pain	1	2019-	2019-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotrans- ferase increased	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Vitiligo	1	2019	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Toothache	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Tooth infection	2	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Tinea infection	1	2023	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Skin burning sensation	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Skin burning sensation	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Sinusitis	2	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Saliva altered	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo- papular	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo- papular	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Pain	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Naso-pharyngitis	1	2018-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	2	2020-01-01	2020-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	2	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Influenza like illness	1	2018-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-thyroidism	1	2018-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Hyper-thyroidism	2	2018-01-01	2018-01-01	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Hypertension	2	2018-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Hyper-glycaemia	2	2018-01-01	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Folliculitis	1	2018-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Folliculitis	1	2017-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2018-	2019-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Eczema	1	2023-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Eczema	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Dysgeusia	1	2020-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Dry mouth	1	2018-		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Cellulitis	1	2022-	2022-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	COVID-19	1	2022-	2022-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	COVID-19	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	COVID-19	2	2020-	2021-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	COVID-19	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Amylase increased	1	2020-	2020-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]			Male	Acute kidney injury	1	2018-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Male	Vomiting	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Male	Tonsillitis	1	2018-	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Male	Sunburn	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Male	Pyrexia	2	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Male	Pyrexia	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Male	Presyncope	2	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Male	General physical health deterioration	3	2018-	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Male	General physical health deterioration	3	2018-	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Male	Gamma- glutamyltrans-ferase increased	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Male	Embolism	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	[REDACTED]	[REDACTED]	Male	Diarrhoea	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]		[REDACTED]	Male	Chills	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]		[REDACTED]	Male	Candida infection	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]		[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]		[REDACTED]	Male	Alanine aminotrans- ferase increased	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Amylase increased	3	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Sepsis	4	2019	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo- papular	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Milia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Macular oedema	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Lower gastro- intestinal haemorrhage	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	3	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Lip swelling	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Intertrigo	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Infection	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Herpes virus infection	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Erysipelas	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Electrocardio-gram QT prolonged	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Dyspepsia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Dry skin	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Dry mouth	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm B	[REDACTED]	Male	Dermatitis acneiform	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Proteinuria	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Paraesthesia	1	2020		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Pain	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Hepatic pain	1	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	2	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal distension	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Vision blurred	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Rash maculo-papular	1	2017	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Oedema peripheral	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Macular degeneration	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Lipase increased	2	2017		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Large intestine perforation	3	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Temporarily interrupted, Vem: Temporarily interrupted
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Hypo-albuminaemia	3	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	2	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Dry mouth	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Cystitis	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Anaemia	2	2017		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Anaemia	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Alopecia	1	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal pain	1	2017		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Universitäts- klinikum Tübingen	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal pain	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin Berlin	[REDACTED]			Male	Abdominal pain upper	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Vision blurred	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Sinus tachycardia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Rash maculopapular	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Pyrexia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Purpura	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Purpura	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Photosensitivity reaction	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Pain in extremity	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Oedema peripheral	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Influenza like illness	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Diarrhoea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Dermatitis acneiform	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]		[REDACTED]	Male	Decreased appetite	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Charité – Universitäts- medizin B	[REDACTED]		[REDACTED]	Male	Chills	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]		[REDACTED]	Male	Arthralgia	2	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]		[REDACTED]	Male	Arthralgia	2	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]		[REDACTED]	Male	Allergy to arthropod bite	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Haemorrhage intracranial	5	2017-	2017-	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	Cobi: None, Vem: None
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Sinus tachycardia	2	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Lymphopenia	1	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Leukocytosis	3	2017-	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Hepatobiliary disease	1	.	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Male	Arterio-sclerosis	2	2017-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Male	Sepsis	4	2017-	2017-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Charité – Universitätsmedizin B	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	1	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
		Arm A		Male	Rash maculo-papular	2	2017		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitätsmedizin B	[REDACTED]	Arm A	[REDACTED]	Male	Pneumonia	4	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Charité – Universitätsmedizin B	[REDACTED]	Arm A	[REDACTED]	Male	Infection	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Charité – Universitätsmedizin B	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	4	2017	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Charité – Universitätsmedizin B	[REDACTED]	Arm A	[REDACTED]	Male	Dehydration	4	2017		No	Yes	No		Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Charité – Universitätsmedizin B	[REDACTED]	Arm A	[REDACTED]	Male	Cerebral ischaemia	2	2017	2017	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Charité – Universitätsmedizin B	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	2	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Charité – Universitätsmedizin B	[REDACTED]	Arm A	[REDACTED]	Male	Atrial fibrillation	2	2017	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Charité – Universitätsmedizin B	[REDACTED]	Arm B	[REDACTED]	Male	Amylase increased	1	2018	2018	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Skin plaque	1	2017	2017	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Skin lesion	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Skin abrasion	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Rhinitis allergic	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Nodule	1	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Metastatic malignant melanoma	2	2017	2017	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Lactose intolerance	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Headache	2	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Gastro-oesophageal reflux disease	2	2017		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2017-	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Bronchitis	2	2017-	2017-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatinine increased	1	2017-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	3	2019-	2019-	No	No	Yes	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2018-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Bronchitis	2	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Urinary incontinence	1	2018-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Toothache	2	2018-	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Sinus tachycardia	2	2018-	2018-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Sinus tachycardia	2	2018	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Photosensiti-vity reaction	1	2017	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Hypo-thyroidism	2	2018	2018-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Hyper-thyroidism	1	2017	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Hypertension	1	2017	2017-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Hot flush	1	2018	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2018	2018-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Dyspepsia	1	2018	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2017	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Cough	1	2018	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Charité – Universitäts- medizin B	[REDACTED]	Arm A	[REDACTED]	Female	Cataract	2	2017	-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Acute kidney injury	3	2019	-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	2	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	1	2019-[REDACTED]	2019-[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	1	2019-[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Skin erosion	1	2019-[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Pain in extremity	1	2019-[REDACTED]	2019-[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Oral disorder	1	2019-[REDACTED]	2019-[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	2	2019-[REDACTED]	2019-[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2019-[REDACTED]	2019-[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Memory impairment	1	2019-[REDACTED]	2019-[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Lymphoedema	1	2019-[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Lipase increased	2	2019-[REDACTED]	2019-[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Headache	1	2019-[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Haemorrhage intracranial	3	2019-[REDACTED]	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Glomerular filtration rate decreased	3	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Fall	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Electrocardio-gram QT prolonged	2	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Dyspnoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Dry skin	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Dry mouth	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	C-reactive protein increased	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Blood uric acid increased	2	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Blood urea increased	2	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatinine increased	2	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Aspartate aminotrans-ferase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Anaemia	3	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Alanine aminotransferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Female	Alanine aminotransferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Amylase increased	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Seizure	2			No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Lymphoedema	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	3	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Lipase increased	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Joint stiffness	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Hypothyroidism	1	2020		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Hypertension	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Fibroma	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Fibroma	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Dizziness	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Amylase increased	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Amylase increased	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotrans-ferase increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Tinea pedis	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Solar dermatitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Pruritus	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Hypothyroidism	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Erysipelas	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem:



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Cholelithiasis	1	2019-[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Temporarily interrupted
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Cardiac failure	3	2019-[REDACTED]	2020-[REDACTED]	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	C-reactive protein increased	1	2019-[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2019-[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2019-[REDACTED]	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Accident	2	2020-[REDACTED]	2020-[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Vitiligo	1	2021-[REDACTED]	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Tumour marker increased	1	2021-[REDACTED]	2021-[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Skin maceration	1	2020-[REDACTED]	2020-[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Skin laceration	2	2020-[REDACTED]	2020-[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Rash	3	2019-[REDACTED]	2020-[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Joint swelling	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-kalaemia	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2022	2022	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Erythema multiforme	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Body tinea	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Blood lactate	1	2021	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	dehydro-genase increased	1	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate	1	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	aminotrans-ferase increased	1	2022	2022	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate	1	2020	2021	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	1	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-f-erase increased	3	2022	2022	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	1	2020	2021	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Abdominal pain upper	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Weight decreased	1	2018-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Sinus tachycardia	2	2018-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Sensitive skin	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	3	2018-	2018	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Pain in extremity	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Pain in extremity	1			No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Oedema peripheral	1	2018-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Neck pain	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Influenza like illness	1	2018-	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-thyroidism	1	2018-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Hyperhidrosis	1	2019-	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2018-[REDACTED]	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2018-[REDACTED]	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Glomerular filtration rate decreased	1	2018-[REDACTED]		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2019-[REDACTED]	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2018-[REDACTED]	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2018-[REDACTED]		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2018-[REDACTED]	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Decreased appetite	1	2018-[REDACTED]	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	C-reactive protein increased	1	2018-[REDACTED]	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	3	2018-[REDACTED]	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Blood bilirubin increased	1	2018-[REDACTED]	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2018-[REDACTED]	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2018-[REDACTED]	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Bilirubin conjugated increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Bilirubin conjugated decreased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Back pain	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Medizinische Hochschule Hannover	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal pain	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Vulvitis	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Pruritus	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Photosensiti-vity reaction	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Oedema peripheral	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Neck pain	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Naso-pharyngitis	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Mouth ulceration	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Laryngeal pain	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Iron deficiency anaemia	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Erythema multiforme	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Ejection fraction decreased	2	2019	2019	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: None, Vem: None
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Colitis	1	2019-01-01	2019-01-01	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Arthralgia	1	2018-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Anaemia	1	2018-01-01	2018-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Female	Alopecia	1	2018-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Alanine aminotrans-ferase increased	1	2018-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo-papular	2	2018-01-01	2019-01-01	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2018-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Pruritus	2	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Lymphoedema	1	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Left ventricular dysfunction	3	2018-01-01	2019-01-01	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem:

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Influenza like illness	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Temporarily interrupted
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Dyspnoea	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	3	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotrans-ferase increased	2	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Vomiting	2	2020	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Vomiting	2	2020	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Pain	1	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Myalgia	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Hyper-glycaemia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Hepatitis viral	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Gastroenteritis	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Erythema multiforme	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Dermo-hypodermatitis	2	2019	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: None, Vem: None
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Ventricular tachycardia	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Sinus bradycardia	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Sepsis	4	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Pruritus	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-thyroidism	3	2019	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Folliculitis	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Enterococcal infection	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted, Atezo: None
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	2	2019	2019	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Cheilitis	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Atrial pressure	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Atrial fibrillation	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Atrial fibrillation	2	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Atrial fibrillation	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Atezo: None
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	2	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm B	[REDACTED]	Male	Arthralgia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Tooth abscess	3	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Testicular pain	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Pneumonia	2	2020	2021	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Pain in extremity	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Lymphoedema	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Lung abscess	3	2021	2021	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Intertrigo	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Insomnia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Hand dermatitis	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Gastro-intestinal pain	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Furuncle	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Folliculitis	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Eczema	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Dermal cyst	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Constipation	1	2019-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Bronchitis	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hôpital de la Timone, Marseille Cedex 05	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Blepharitis	1	2019-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Vomiting	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Visual impairment	1	2020-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Vaginal haemorrhage	1	2022-	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Tricuspid valve incompetence	1	2022-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Thyroxine decreased	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Skin lesion	1	2022-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Skin lesion	1	2021-	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Sensory disturbance	1	2021-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo-papular	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo-papular	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo-papular	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Photosensiti-vity reaction	1	2021	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Palmoplantar keratoderma	1	2020	2023	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Pain in extremity	1	2020	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Pain in extremity	1	2020	2021	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Neutrophil count decreased	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Muscle spasms	1	2022	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Muscle spasms	1	2020	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Lymph-adenopathy	1	2022	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Lymph-adenopathy	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Intertrigo	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Intertrigo	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Insomnia	1	2021	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Hypo-calcemia	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Hot flush	1	2022		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Flatulence	1	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2021		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	2	2020	2021	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Dry skin	1	2021	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2020	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2020	2020	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Depressed mood	1	2021-	2023-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Decreased appetite	1	2020-	2022-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Cataract	1	2020-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	COVID-19	1	2022-	2022-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Burning sensation	1	2021-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Burning sensation	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Bronchitis	1	2022-	2022-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Blood thyroid stimulating hormone increased	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2022-	2022-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	2	2022-	2022-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2022-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm B	[REDACTED]	Female	Blepharitis	1	2020-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
CHU de Nantes	[REDACTED]		[REDACTED]	Male	Alanine aminotrans-ferase increased	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]			Male	Rash maculo-papular	3	2019	2019	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
CHU de Nantes	[REDACTED]			Male	Eosinophilia	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]			Male	Cough	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]			Male	Bone pain	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]			Male	Blood lactate dehydro-genase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]			Male	Aspartate aminotrans-ferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A		Female	Alanine aminotrans-ferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A		Female	Vomiting	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A		Female	Visual impairment	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A		Female	Pruritus	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A		Female	Photosensiti-vity reaction	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Photosensiti-vity reaction	2	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Neutrophil count increased	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Gamma-glutamyltrans-ferase increased	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Gamma-glutamyltrans-ferase increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Dizziness	2	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Blood lactate dehydro-genase increased	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Blood lactate dehydro-genase increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatinine increased	1	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatinine increased	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
CHU de Nantes	[REDACTED]	Arm A	[REDACTED]	Female	Alanine aminotrans-ferase increased	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
SLK-Kliniken Heilbronn GmbH	[REDACTED]	Arm B	[REDACTED]	Female	Alopecia	2	2018		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
SLK-Kliniken Heilbronn GmbH	[REDACTED]	Arm B	[REDACTED]	Female	Sunburn	1	2018	2018-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
SLK-Kliniken Heilbronn GmbH	[REDACTED]	Arm B	[REDACTED]	Female	Skin infection	3	2018	2018-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
SLK-Kliniken Heilbronn GmbH	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo-papular	3	2018	2018-	No	No	Yes	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
SLK-Kliniken Heilbronn GmbH	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2018		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
SLK-Kliniken Heilbronn GmbH	[REDACTED]	Arm B	[REDACTED]	Female	Constipation	1	2018		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
SLK-Kliniken Heilbronn GmbH	[REDACTED]		[REDACTED]	Female	Dizziness	1	2018	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
SLK-Kliniken Heilbronn GmbH	[REDACTED]		[REDACTED]	Female	Pneumonia	3	2019	2019-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
SLK-Kliniken Heilbronn GmbH	[REDACTED]		[REDACTED]	Female	Pain	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
SLK-Kliniken Heilbronn GmbH	[REDACTED]		[REDACTED]	Female	Gastro-intestinal pain	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
SLK-Kliniken Heilbronn GmbH	[REDACTED]		[REDACTED]	Female	Fatigue	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Stomatitis	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Stasis dermatitis	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Stasis dermatitis	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	2	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	3	2019	2019	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Platelet count decreased	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Platelet count decreased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Palmar-plantar erythron-dysaesthesia syndrome	2	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Oedema peripheral	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Hypertension	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Hypertension	2	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Electrocardio-gram QT prolonged	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Dysgeusia	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Alopecia	1	2019-	2019	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Viral infection	1	2024-	2024	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Skin oedema	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Skin mass	1	2023-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2022-	2022-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2019-	2019-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Macular degeneration	1	2024-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2023-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	2	2022-	2023-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019-	2019-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019-	2019-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Erythema	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Epistaxis	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Epistaxis	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Epistaxis	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Electrocardio-gram QT prolonged	1	2023-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Electrocardio-gram QT prolonged	1	2020-	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2024-	2024	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2024-	2024	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2023-	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2023-	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2023-	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2023-	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2023-	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2023-	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2023	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2023	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2023	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2023	2023	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2022-	2022-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021-11-01	2021-11-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Dermal cyst	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Dermal cyst	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Cheilitis	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Cheilitis	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	COVID-19	1	2024-	2024-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	COVID-19	1	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Anaemia	1	2023	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Amylase increased	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Viral infection	1	2024	2024	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Viral infection	1	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Sunburn	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Seborrhoeic keratosis	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Melanocytic naevus	1	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	3	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	2	2018	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None, Atezo: None
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Conjunctivitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Sinus tachycardia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Constipation	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal pain upper	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Vision blurred	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Viral infection	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Vertigo	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Subretinal fluid	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Photosensiti-vity reaction	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Photosensiti-vity reaction	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pharyngitis	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Paraesthesia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pain in extremity	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Nausea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Myalgia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Myalgia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Myalgia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Myalgia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Hypo-thyroidism	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Hyper-thyroidism	1	2020	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Gamma-glutamyltrans-ferase increased	1	2019	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2020	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Dry skin	1	2019	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Dry mouth	1	2019	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Version Final 1.0  
- 381 of 435 -  
10 March 2025

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Blood alkaline phosphatase increased	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Arthralgia	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Anaemia	1	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Alopecia	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal pain upper	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal pain upper	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Alopecia	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Vomiting	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Upper respiratory tract infection	2	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Solar dermatitis	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	1	2022	2022	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Sinus tachycardia	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Retinopathy	1	2022		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Rash maculo-papular	1	2019	2019	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pharyngitis	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Pain in extremity	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Oral herpes	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Nasal congestion	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Muscle spasms	1	2022		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Keratosis pilaris	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Hyper-thyroidism	2	2023		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Heavy menstrual bleeding	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Heavy menstrual bleeding	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Heavy menstrual bleeding	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Heavy menstrual bleeding	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Fibroma	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Erythema nodosum	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Erythema	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Dysphonia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Version Final 1.0  
- 387 of 435 -  
10 March 2025

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Dermatitis acneiform	1	[REDACTED]	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Breast cyst	1	2021-01-01	2021-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Basal cell carcinoma	1	2020-01-01	2021-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Arthralgia	1	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Arthralgia	1	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Anaemia	1	2023-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Anaemia	1	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotransferase increased	1	2019-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2019-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Pain in extremity	1	2018-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Oropharyngeal pain	1	2019-01-01	2019-01-01	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Oedema peripheral	1	2019-01-01	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Lip pain	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Hyper-thyroidism	1	2019	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	2	2018	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Erythema multiforme	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	C-reactive protein increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Pruritus	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Stomatitis	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Stevens-Johnson syndrome	4	2019	2019	No	No	Yes	[REDACTED]	Cobi: Permanently Discontinued, Vem: Permanently Discontinued, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]		[REDACTED]	Male	Rash maculo-papular	1	2019	[REDACTED]	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Permanently Discontinued, Vem: Permanently Discontinued
Military Medical Academy, Belgrade				Male	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade		Arm A		Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade		Arm A		Male	Skin infection	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade		Arm A		Male	Photosensiti-vity reaction	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade		Arm A		Male	Paraesthesia	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade		Arm A		Male	Oedema peripheral	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade		Arm A		Male	Nasopharyngitis	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade		Arm A		Male	Iridocyclitis	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade		Arm A		Male	Hyper-glycaemia	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade		Arm A		Male	Hemiplegia	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade		Arm A		Male	Furuncle	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotrans-ferase increased	3	2020	2020	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: None
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Skin plaque	2	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Skin mass	1	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Rash pustular	2	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2021	2021	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Oedema peripheral	1	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Folliculitis	1	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2021		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Dry skin	2	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Conjunctival oedema	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Blepharitis	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	2	2020	2020	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: None

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Hypo-thyroidism	2	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Female	Rash maculo-papular	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Female	Anaemia	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Female	Vision blurred	1	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Female	Skin hypo-pigmentation	1	2020		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Female	Sinus bradycardia	1	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo-papular	3	2019	2019	No	No	Yes	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Female	Electrocardio-gram QT prolonged	1	2021		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Female	COVID-19 pneumonia	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Female	Blood creatinine increased	1	2021		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Alopecia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Stomatitis	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Stomatitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Stomatitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	1	2019	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Pharyngitis	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Lip infection	1	2020	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-thyroidism	1	2022		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Herpes simplex	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Haematuria	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Erythema nodosum	1	2022		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Electrocardio-gram QT prolonged	1	2019	2019	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: None, Vem: None
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Cough	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-thyroidism	2	2019		Yes	No	Yes	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	Cobi: None, Vem: None, Atezo: None
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Uveitis	2	2019		Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Uveitis	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]		[REDACTED]	Male	Accident	4	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]		[REDACTED]	Male	Sepsis	4	2019		No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Military Medical Academy, Belgrade	[REDACTED]		[REDACTED]	Male	Hip fracture	3	2019		No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Military Medical Academy, Belgrade	[REDACTED]		[REDACTED]	Male	Conjunctivitis	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]		[REDACTED]	Male	Cardio-pulmonary failure	4	2019	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Military Medical Academy, Belgrade				Male	Cardiac arrest	5	2019	2019	No	Yes	No		Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
Military Medical Academy, Belgrade		Arm B		Male	Atrial fibrillation	2	2019	2019	No	No	No		Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade		Arm B		Male	Sepsis	4	2019	2019	No	No	No		Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade		Arm B		Male	Rash maculo-papular	1	2018		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade		Arm B		Male	Pleural effusion	2	2019		No	No	No		Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade		Arm B		Male	Dry skin	1	2019		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade		Arm B		Male	Dermatitis acneiform	2	2019		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade		Arm B		Male	Dermatitis acneiform	1	2018		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade		Arm B		Male	Cystitis noninfective	1	2019		No	No	No		Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade				Male	Skin exfoliation	1	2019		No	No	No		Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade				Male	Myalgia	1	2019		No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade		Arm A		Male	Cough	1	2018	2018	No	No	No		Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Urticaria	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Skin hyperpigmentation	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Rash	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Naso-pharyngitis	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Nasal congestion	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm A	[REDACTED]	Male	Electrocardio-gram QT prolonged	1	2018	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Vomiting	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Viral infection	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Vertigo	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Vertigo	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Oedema peripheral	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Nausea	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Myalgia	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Erythema nodosum	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	2	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	2	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	Yes	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: Yes	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Back pain	1	2018	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Viral infection	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Toothache	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Seizure	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Hepatic failure	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Dermatitis acneiform	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Dental caries	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Military Medical Academy, Belgrade	[REDACTED]	Arm B	[REDACTED]	Male	Back pain	1	2018-	2018	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Acute kidney injury	2	2019-	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Not applicable, Vem: Not applicable
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Retinopathy	2	2019-	2019	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: None
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Pollakiuria	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Paraesthesia	2	2019-		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Pain	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Influenza	2	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019-	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Dehydration	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Chronic kidney disease	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Amylase increased	2	2019-	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Acute kidney injury	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Abdominal pain upper	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Vision blurred	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Paraesthesia	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Dysgeusia	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Dry skin	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Arthralgia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Alopecia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Vision blurred	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Sinus bradycardia	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Retinopathy	1	2019	[REDACTED]	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pneumonia	2	2020	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Peripheral motor neuropathy	1	2020	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pain	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pain	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pain	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Oedema peripheral	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Myalgia	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Myalgia	2	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Myalgia	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Mesenteric panniculitis	1	2019-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Joint range of motion decreased	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Hypotension	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2020-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Fall	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Eye pain	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Dyspnoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Dyspnoea	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Dry skin	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Dry mouth	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Diarrhoea	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis allergic	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Conjunctivitis	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Conjunctival haemorrhage	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2019-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Basal cell carcinoma	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Arthritis	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Hypertension	3	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Male	Alopecia	1	2022-	-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
"LAIKO" General Hospital of Athens	[REDACTED]			Male	Upper respiratory tract infection	2	2022-	2022-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Upper respiratory tract infection	2	2021-	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Upper respiratory tract infection	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Tooth infection	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Sunburn	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Scleral disorder	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Pyrexia	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-thyroidism	1	2019	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Haemolysis	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Fatigue	1	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Face oedema	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Dermatitis acneiform	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	COVID-19	1	2023	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	COVID-19	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Back pain	1	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]													Cobi: Permanently Discontinued, Vem: Permanently Discontinued
"LAIKO" General Hospital of Athens	[REDACTED]			Female	Acute kidney injury	3	2019	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Female	Rash maculo-papular	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Pyrexia	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Platelet count decreased	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Nausea	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Mucosal infection	3	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Lower gastro-intestinal haemorrhage	2	2019-	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Lower gastro-intestinal haemorrhage	3	2019-	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Hypothyroidism	2	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Fatigue	3	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Embolism	2	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Diarrhoea	3	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Anaemia	2	2019-	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Male	Dyspnoea	2	2019-	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Male	Myocardial ischaemia	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Male	Acute kidney injury	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Male	Pyrexia	2	2019	2019	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Male	Pulmonary oedema	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Male	Lymph gland infection	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Anxiety	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	White blood cell count decreased	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Soft tissue infection	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo-papular	2	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	2	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Platelet count decreased	2	2019	2019	Yes	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	Atezo: None
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Insomnia	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	2	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Dermatitis acneiform	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Male	Atrial fibrillation	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Male	Ejection fraction decreased	3	2019		No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
"LAIKO" General Hospital of Athens	[REDACTED]			Male	Atrial fibrillation	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A		Male	Anaemia	2	2020		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A		Male	Pneumonitis	2	2020	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A		Male	Pneumonia	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A		Male	Insomnia	2	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A		Male	Fatigue	2	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A		Male	Chronic kidney disease	2	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A		Male	Blood creatinine increased	2	2019	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Male	Pain	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Male	Vomiting	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Arthralgia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Rash maculo-papular	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Hypertension	3	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
"LAIKO" General Hospital of Athens	[REDACTED]		[REDACTED]	Female	Ejection fraction decreased	3	2020	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Upper respiratory tract infection	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Stoma site infection	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Rash papular	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Oedema peripheral	1	2020	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Oedema peripheral	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Keratitis	2	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Hypo-thyroidism	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Hypertension	2	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Glossitis	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Erythema nodosum	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Erythema nodosum	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Blood folate decreased	2	2020		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Arthritis	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	1961	Male	Arthralgia	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	1950	Male	Blood creatinine increased	1	2019-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	1950	Male	Tooth infection	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	1950	Male	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	1950	Male	Dermatitis acneiform	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		1942	Female	Fall	3	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		1942	Female	Fracture	3	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		1942	Female	Fatigue	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
"LAIKO" General Hospital of Athens	[REDACTED]		1954	Male	Acute kidney injury	3	2018-	2018-	No	Yes	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		1954	Male	Rash maculo-papular	2	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]		1954	Male	Pyrexia	1	2018-	2018-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	1952	Female	Alanine aminotrans-ferase increased	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Vomiting	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pain	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Dry skin	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Ocular hyperaemia	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Hypertension	2	2019-	.	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	3	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Sunburn	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Rash vesicular	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	3	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	4	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Male	Blood creatine phospho-kinase increased	2	2019-	.	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Male	Myalgia	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Female	Abdominal pain	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Female	Sunburn	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Female	Rash maculo-papular	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Female	Pyrexia	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Alanine aminotrans-ferase increased	3	2019-	2019-	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Sunburn	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Sciatica	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	3	2020	[REDACTED]	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Not changed, Vem: Not changed, Atezo: None
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Paraesthesia	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pain in extremity	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Insomnia	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Delirium	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Decreased appetite	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Constipation	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Constipation	1	2019	[REDACTED]	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Back pain	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Aspartate aminotrans-ferase increased	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Aspartate aminotrans-ferase increased	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Arthralgia	1	2019-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Anxiety	1	2020-	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Alopecia	1	2020-	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Alanine aminotrans-ferase increased	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Alanine aminotrans-ferase increased	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Alopecia	1	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Xeroderma	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Sunburn	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Stoma site infection	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Skin mass	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Retinal detachment	2	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Hyper-keratosis	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Hordeolum	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Dizziness	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Dermatitis acneiform	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Cystitis	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Conjunctivitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Female	Blepharitis	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Wound	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pain	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Pain	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Fatigue	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm A	[REDACTED]	Male	Arthralgia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Female	Anaemia	2	2019		No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: None, Vem: None
"LAIKO" General Hospital of Athens	[REDACTED]			Female	Muscular weakness	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Female	Fatigue	2	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Female	Decreased appetite	2	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]			Female	Blood creatine phospho-kinase increased	4	2019	2019	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Arthralgia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Sunburn	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Back pain	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Sciatica	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Rash maculo-papular	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Pyrexia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Enanthema	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
"LAIKO" General Hospital of Athens	[REDACTED]	Arm B	[REDACTED]	Female	Diarrhoea	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Alanine aminotransferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Renal injury	1	2019	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Renal failure	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Renal failure	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculopapular	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Platelet count decreased	1	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Platelet count decreased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Platelet count decreased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Platelet count decreased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Platelet count decreased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Photosensitivity reaction	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	3	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Microalbuminuria	1	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Hypertension	3	2019-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Erythema multiforme	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Dermatitis acneiform	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Chronic papillomatous dermatitis	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Blood bilirubin increased	1	2019-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Anaemia	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Visual impairment	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Visual impairment	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Visual impairment	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Uveitis	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Rash maculo-papular	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Photosensiti-vity reaction	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Photophobia	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Lymphocyte count decreased	1	2019-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Hyper-thyroidism	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Erythema multiforme	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Constipation	1	2019-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm A	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Female	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]		[REDACTED]	Female	Platelet count decreased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]		[REDACTED]	Female	Paronychia	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]		[REDACTED]	Female	Lymphoedema	1	2019-	.	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]		[REDACTED]	Female	Lymphocyte count decreased	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]		[REDACTED]	Female	Hypo-natraemia	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: Permanently Discontinued, Vem: Permanently Discontinued
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]		[REDACTED]	Female	Erythema multiforme	1	2019-	2019-	No	Yes	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]		[REDACTED]	Female	Diarrhoea	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotransferase increased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Urinary tract infection	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Tooth infection	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Tinnitus	2	2019-	.	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Rectal haemorrhage	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
		Arm B		Male	Pyrexia	2	2020	2020	No	No	No		Cobi: No, Vem: No, Atezo: No	
		Arm B		Male	Platelet count decreased	1	2020	2020	No	No	No		Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Pituitary tumour benign	3	2020	2020	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted, Atezo: None
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Photosensiti-vity reaction	1	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Palpitations	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Pain in extremity	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Night blindness	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Neutrophil count decreased	2	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Neutrophil count decreased	2	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	1	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	3	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	2	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	2	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Lipase increased	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Hypo-calcaemia	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-thyroidism	1	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	3	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-glycaemia	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Hyper-glycaemia	3	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Headache	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Headache	2	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Haemorrhage intracranial	2	2020	2020	No	No	Yes	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	Cobi: None, Vem: None

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	3	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Fracture	1	2020-	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Eyelid ptosis	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Eyelid ptosis	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Erythema multiforme	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Erythema multiforme	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Erythema multiforme	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Erythema multiforme	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Electrocardio-gram QT prolonged	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Diplopia	2	2019-	2019-	No	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	Cobi: Temporarily interrupted, Vem: Temporarily interrupted
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Diabetes insipidus	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Cardiac arrest	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Bone pain	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatinine increased	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatinine increased	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood creatine phospho-kinase increased	3	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood bilirubin increased	1	2020-	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood bilirubin increased	2	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood bilirubin increased	1	2019-	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Blood alkaline phosphatase increased	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	1	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Aspartate aminotrans-ferase increased	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Centre Hospitalier Lyon Sud, Pierre-Bénite	[REDACTED]	Arm B	[REDACTED]	Male	Alanine aminotrans-ferase increased	1	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Boulogne-Billancourt	[REDACTED]	Arm B	[REDACTED]	Female	Abdominal pain	3	2021-		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Boulogne-Billancourt	[REDACTED]	Arm B	[REDACTED]	Female	Hypo-thyroidism	1	2020-	2020-	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Boulogne-Billancourt	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Boulogne-Billancourt	[REDACTED]	Arm B	[REDACTED]	Female	Fatigue	1	2018-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Boulogne-Billancourt	[REDACTED]	Arm B	[REDACTED]	Female	Eczema	2	2019-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Boulogne-Billancourt	[REDACTED]	Arm B	[REDACTED]	Female	Dysgeusia	1	2019-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Boulogne-Billancourt	[REDACTED]	Arm B	[REDACTED]	Female	Colitis	3	2021-	2021-	Yes	Yes	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	Cobi: None, Vem: None, Atezo: None

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Boulogne-Billancourt	[REDACTED]	Arm B	[REDACTED]	Female	Arthralgia	1	2018	2018	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]			Male	Decreased appetite	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]			Male	Rash maculo-papular	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]			Male	Hepatic pain	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]			Male	Fatigue	3	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B		Male	Bronchitis	2	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B		Male	Vitamin C decreased	2	2021	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B		Male	Tooth infection	2	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B		Male	Sinusitis	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B		Male	Rhinitis	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B		Male	Renal colic	2	2020	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B		Male	Psoriasis	2	2019	2019	Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B		Male	Pruritus	1	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Naso-pharyngitis	1	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Intertrigo	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Intertrigo	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Hypo-thyroidism	1	2019		Yes	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Hypo-calcaemia	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Gastro-oesophageal reflux disease	1		2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Erythema	2	2019		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Dry eye	1	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Dermal cyst	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Cortisol decreased	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Arthralgia	1	2019	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Urinary tract infection	2	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Urinary tract infection	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Urinary tract infection	2	2021-	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Urinary tract infection	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Urinary tract infection	2	2020-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Urinary incontinence	3	2021-	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Tracheitis	2	2022-	2022-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Pyrexia	1	2021-	2021-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Pharyngitis	2	2022-	2022-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Pharyngitis	2	2021-	2021-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Hypo-thyroidism	1	2019-	2020-	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Hypertension	3	2020-		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2020-		No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Fatigue	1	2018-	2019-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Erythema nodosum	1	2021-	2022-	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Erythema nodosum	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	2	2020	2020	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Diarrhoea	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Cystitis	2	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Cystitis	2	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Cystitis	2	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Cystitis	2	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Cystitis	2	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Cystitis	2	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Cystitis	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Cystitis	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Constipation	1	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	



Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Cataract	3	2022	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	COVID-19	2	2023	2023	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Bronchitis	2	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Bronchitis	2	2022	2022	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Bronchitis	2	2021	2021	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Bronchitis	2	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Blood creatine phospho-kinase increased	1	2021	2021	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm A	[REDACTED]	Female	Back pain	1	2023		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Chills	1		2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	White blood cell count decreased	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Thyroxine decreased	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: Yes	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Rash maculo-papular	2	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Lymphoedema	1	2019		No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	

Site	Patient ID.	Arm	Year of birth	Sex	Event (PT)	Grade	Start date	End date	irAE	SAE	AESI	Outcome	Causality	Action taken
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Hypertension	2	2019	[REDACTED]	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2020	2020	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Gamma-glutamyltrans-ferase increased	1	2019	2019	No	No	No	[REDACTED]	Cobi: No, Vem: No, Atezo: No	
Hospital Claude Huriez, Lille	[REDACTED]	Arm B	[REDACTED]	Male	Diarrhoea	1	2018	2019	No	No	No	[REDACTED]	Cobi: Yes, Vem: Yes, Atezo: No	

Data source: Listing 7 of ADO\_ImmunoCobiVem\_Final\_Part 2\_v1.0\_2025MAR05

**16.2.8 Listing of Individual Laboratory Measurements (by patient), if required by regulatory authorities**

Not applicable

**16.3 Case Report Forms****16.3.1 CRFs of Deaths, Other SAEs, and Withdrawals for AEs**

Not applicable

**16.3.2 Other CRFs**

Not applicable

Abschlusszertifikat

Umschlag-ID: [REDACTED]	Status: Abgeschlossen
Betreff: ImmunoCobiVem_CSR Finalisierung	
Quellumschlag:	
Dokumentenseiten: 435	Signaturen: 3
Zertifikatsseiten: 5	Initialen: 0
Signatur mit Anleitung: Aktiviert	Umschlagersteller:
Umschlag-ID-Stempel: Aktiviert	[REDACTED]
Zeitzone: (UTC+01:00) Amsterdam, Berlin, Bern, Rom, Stockholm, Wien	Winchsterstrasse 3
	Gießen, Hessen 35394
	[REDACTED]

Eintragsverfolgung

Status: Original	Inhaber: [REDACTED]	Standort: DocuSign
10.03.2025 14:23:18		

Unterzeichnerereignisse	Signatur	Zeitstempel
-------------------------	----------	-------------

[REDACTED]	[REDACTED]	Gesendet: 10.03.2025 14:40:13
Chair & Director		Erneut gesendet: 12.03.2025 08:25:16
Sicherheitsstufe: E-Mail, Kontoauthentifizierung (keine), Digitales Zertifikat	Signaturübernahme: Auf Gerät gezeichnet	Eingesehen: 12.03.2025 09:48:37
Signaturanbieterdetails:	[REDACTED]	Signiert: 12.03.2025 09:49:47
[REDACTED]		

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Akzeptiert: 12.03.2025 09:48:37		
[REDACTED]		
[REDACTED]	[REDACTED]	Gesendet: 10.03.2025 14:40:13
Biometry		Eingesehen: 10.03.2025 14:41:03
Alcedis GmbH	Signaturübernahme: Vorgegebener Stil	Signiert: 10.03.2025 14:43:18
Sicherheitsstufe: E-Mail, Kontoauthentifizierung (keine), Digitales Zertifikat	[REDACTED]	
Signaturanbieterdetails:	[REDACTED]	

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Nicht über DocuSign angeboten		
Vor-Ort-Unterzeichner – Ereignisse	Signatur	Zeitstempel
Bearbeiterversandereignisse	Status	Zeitstempel
Beauftragtenzustellereignisse	Status	Zeitstempel
Vermittlerversandereignisse	Status	Zeitstempel
Zertifizierter Versand - Ereignisse	Status	Zeitstempel
Kopienereignisse	Status	Zeitstempel

Kopienereignisse	Status	Zeitstempel
------------------	--------	-------------

<div></div> <div>Clinical Operations Alcedis GmbH Sicherheitsstufe: E-Mail, Kontoauthentifizierung (keine) <b>Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:</b> Nicht über DocuSign angeboten</div>	<b>Kopiert</b>	Gesendet: 10.03.2025 14:40:13
--	----------------	-------------------------------

<div></div> <div>Alcedis GmbH Sicherheitsstufe: E-Mail, Kontoauthentifizierung (keine) <b>Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:</b> Nicht über DocuSign angeboten</div>	<b>Kopiert</b>	Gesendet: 10.03.2025 14:40:14
--	----------------	-------------------------------

<div></div> <div>Alcedis GmbH Sicherheitsstufe: E-Mail, Kontoauthentifizierung (keine) <b>Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:</b> Nicht über DocuSign angeboten</div>	<b>Kopiert</b>	Gesendet: 10.03.2025 14:40:14
--	----------------	-------------------------------

Zeugen-Ereignisse	Signatur	Zeitstempel
-------------------	----------	-------------

Notarereignisse	Signatur	Zeitstempel
-----------------	----------	-------------

Umschlagereignisse – Überblick	Status	Zeitstempel
--------------------------------	--------	-------------

Umschlag gesendet	Hash-codiert/verschlüsselt	10.03.2025 14:40:14
Zertifiziert zugestellt	Sicherheitsprüfung ausgeführt	10.03.2025 14:41:03
Signiervorgang abgeschlossen	Sicherheitsprüfung ausgeführt	10.03.2025 14:43:18
Abgeschlossen	Sicherheitsprüfung ausgeführt	12.03.2025 09:49:49

Zahlungen	Status	Zeitstempel
-----------	--------	-------------

<b>Vereinbarung bezüglich elektronischer Unterlagen und Signaturen</b>
--

## **ELECTRONIC RECORD AND SIGNATURE DISCLOSURE**

From time to time, Alcedis GmbH (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

### **How to contact Alcedis GmbH:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: [REDACTED]

### **To advise Alcedis GmbH of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at [REDACTED] and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

### **To request paper copies from Alcedis GmbH**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to [REDACTED] and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

### **To withdraw your consent with Alcedis GmbH**

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to [REDACTED] and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

### **Required hardware and software**

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: [REDACTED]  
[REDACTED]

### **Acknowledging your access and consent to receive and sign documents electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Alcedis GmbH as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Alcedis GmbH during the course of your relationship with Alcedis GmbH.